



# OutcomeDriven TTS2018 | MADRID SPAIN

27<sup>th</sup> International Congress of The Transplantation Society

[www.tts2018.org](http://www.tts2018.org)

## FINAL PROGRAM

as of June 12

DISCOVER & CONNECT

### Attention:

The content of this ebook reflects information received and processed by June 12, 2018. All participants are encouraged to use the congress web app which is updated in "real time" at <http://tts.guide>.



**The  
Transplantation  
Society**





# STOP! TTS GREEN VISION – REDUCE OUR ECOLOGICAL FOOTPRINT

**DON'T PRINT THIS BOOK! LOOK AT WHAT YOU COULD BE SAVING BY NOT PRINTING:**

TTS has made it its mission to reduce the environmental impact of the Congress. As such, the Final Program is available for downloading onto your electronic devices. If you still think that you need a printed copy, please print it and bring your own. A pocket guide (program overview with room numbers) will be included in the registration materials.

PHYSICAL QUANTITY	US SYSTEM	METRIC SYSTEM	INSTANCE IN EVERYDAY LIFE
Pages	600,000	600,000	
Ton of paper	2,89 tons	2,89 tons	
Wood Use	11 tons	11 tons	69 trees
Net Energy	94 million BTU's	99 GJ	1 home/year
Greenhouse Gases	16,188 pounds CO2 equiv.	16,188 pounds CO2 equiv.	1 car/year
Water Consumption	66,047 gallons	250,000 Liters	1/10 of an Olympic-sized swimming pool
Solid Waste	5,554 pounds	2.5 tons	1/4 garbage truck
Purchased Energy	64 million BTU's	68 GJ	1 home/year
Sulfur dioxide (SO2)	77 pounds	35 kg	14 18-wheelers/year
Particulates	18 pounds	8 kg	2 buses/year
Hazardous Air Pollutants (HAP)	8 pounds	3.6 kg	
Volatile Organic Compounds (VOCs)	9 pounds	4 kg	
Total Reduced Sulfur (TRS)	1 pounds	0.45 kg	
Total Suspended Solids (TSS)	50 pounds	22.7 kg	1 home/3 months
Chemical Oxygen Demand (COD)	57 pounds	26 kg	1 home/6 weeks
Biochemical Oxygen Demand (BOD)	29 pounds	13 kg	1 home/2 months



## NO DOWNLOAD REQUIRED!

To view the app, go to <http://tts.guide> and sign in using the same username/password that was sent to you by email on June 21.

### Web App Highlights:

- Browse the final program and abstracts
- See who's attending and start networking now
- Build your personalized Congress agenda with the help of easy and efficient search functions
- Connect and engage with attendees, speakers, sponsors and exhibitors before, during and after TTS 2018
- Look up colleagues and schedule meetings with your colleagues
- Note taking
- General Congress information

## WiFi Access

**SSID: TTS2018**

### How to connect in a few simple steps:

- Step 1:** Connect to the TTS2018 SSID  
**Step 2:** Log-in page should appear automatically  
**Step 3:** Click "Log In"  
**Step 4:** Open any website in any browser if splash page doesn't appear

## Troubleshooting

- Ensure cookies are enabled on your device
- Visit the staff in the registration area for help in connecting

The 27<sup>th</sup> International Congress of The Transplantation Society  
extends its appreciation to the following sponsors for their support.

## PREMIER LEVEL



## PRINCIPAL LEVEL



## MAJOR LEVEL

BASKENT ÜNİVERSİTESİ



People and Ideas for Innovation in healthcare



Comunidad de Madrid



A Thermo Fisher Scientific Brand



## CONTRIBUTOR LEVEL



## SUPPORTER LEVEL

JDRF

Beckman Coulter Life Sciences

Welcome Messages	2-4
Congress Committees List	5-6
Young Investigator Scientific Awards	7-9
Mentee-Mentor Awards	10-13
Congress Policies	14-15
Floor Plans	16-18
Congress Information	19-26
Networking Events	27
Corporate Symposia	28-30
Exhibit Information	32-33
Detailed Program	
Pre-Congress Activities	
Saturday, June 30	34-36
Sunday, July 1	38-52
Main Program	
Monday, July 2	54-71
Tuesday, July 3	72-90
Wednesday, July 4	92-110
Thursday, July 5	112-120
Poster List	122-144
Presenter Index	146-161



It is with great pleasure and anticipation that we wish to welcome you to the 27<sup>th</sup> International Congress of The Transplantation Society here in Madrid.

TTS has recognized the leading role of Spain in donation and transplantation, with the Spanish Model having become a reference worldwide. TTS and Organización Nacional de Trasplantes (ONT) were awarded the Prince of Asturias Award (considered as the Spanish equivalent of the Nobel Prize) in 2010 in the field of International Cooperation in recognition of their joint efforts in promoting ethical practices in transplantation.

Together with our partners in the Sociedad Madrileña de Trasplante (SMT) and the Sociedad Española de Trasplante (SET), we have brought together a high-profile scientific program committee with the aim of developing a broad and exciting agenda that will cover a diverse array of topics, ranging from cutting-edge science to the latest controversies in ethics and public policy. Issues relevant to developing transplant programs, organ donation and procurement will be a highlight for many participants.

The destination and host city of the congress, Madrid, is a cosmopolitan metropolis that combines modern infrastructure with extensive cultural and artistic heritage. Madrid boasts the status of a financial, administrative and corporate center, while at the same time remaining a tolerant, passionate and lively city. Its individual artistic tradition effortlessly embraces multiple external influences, both past and present, thus highlighting the city's continuing openness to new ideas. Located in the center of Spain, Madrid has excellent air and land connections with major destinations within, and outside, the peninsula.

Enjoy this unique Congress and drive your outcome!



**Nancy Ascher**  
TTS President & Congress Chair



**José Maria Morales**  
Congress Vice-Chair

On behalf of the Spanish Society of Transplantation, it is my great pleasure to welcome you to Madrid and to the 27<sup>th</sup> International Congress of the Transplantation Society in partnership with our Society and the Sociedad Madrileña de Trasplantes.

We are very excited to have won the bid to host this important congress in Madrid. By this election, TTS is recognizing the leading role of Spain in donation and transplantation, with the Spanish model being a reference worldwide. We hope to follow in the successful footsteps of the past meetings in Hong Kong and San Francisco.

The Congress has been designed to provide an innovative and comprehensive overview of the latest research developments in transplant medicine, primarily in the areas of organ donation, immunotherapy and tissue engineering and *Big Data* in transplantation medicine.

Many distinguished transplant physicians and scientists have joined the faculty and will take part in this Congress. Abstracts will be presented in the form of oral and poster sessions and will include superb scientific material that was carefully selected by the Scientific Program Committee from over 1,700 abstracts, many of them submitted by our Spanish colleagues. It's a certainty that all these studies, originating from faculties from over 60 countries, together with the plenary and state-of-the-art sessions, symposia and networking events, will assure that the meeting will be a major scientific event.

I would like to express our gratitude to the TTS Council and the TTS International Headquarter staff for their excellent arrangements in all aspects of the Congress, to their dedicated staff, colleagues, and friends, for their untiring work in planning and arranging this meeting. And of course to the pharmaceutical industry for their continuous support towards medical education.

We hope that you will enjoy the Congress and that your interaction with your colleagues from many different countries will stimulate a creative exchange of ideas and will be personally rewarding. Lastly but by no means least, we also hope and trust that you will enjoy your visit to the very beautiful and exciting city of Madrid.

Wishing you all a heartfelt welcome for what promises to be an outstanding educational and cultural event: TTS 2018.

Yours sincerely,



**Valentín Cuervas-Mons**  
President



On behalf of the Sociedad Madrileña de Trasplantes I am pleased to welcome you to Madrid, venue of the 27<sup>th</sup> International Congress of The Transplantation Society. This congress has been prepared with special attention to exchange the latest advances in the field of organ donation and transplantation, both in its clinical and research aspects and for you to enjoy our magnificent city.

Spain is a world leader in donation and transplants and Madrid is one of the most important cities in our country in this activity. Actually, the donation and transplant program pioneers in the development of uncontrolled donation after cardiac death and donation in elderly patients are from Madrid.

Madrid has a splendid cultural, historical and culinary offer that you should be enjoying during the free time of the congress. It is one of the friendliest cities in the world where nobody feels like a foreigner and where anyone you meet is willing to hear from you with the admiration of someone who is learning from your experience.

I hope that during your stay you will feel like those who inhabit this city and say, to highlight how nice and loving the city is "from Madrid to heaven".

Yours sincerely,



**Amado Andrés Belmonte**

Presidente de la Sociedad Madrileña de Trasplantes

## Executive Committee

Nancy Ascher, San Francisco, CA, USA (Congress Chair)  
 José María Morales, Madrid, Spain (Congress Vice-Chair)  
 Philip J. O'Connell, Westmead, Australia (Scientific Program Committee Chair)  
 Kyung-Suk Suh, Seoul, Korea (TTS 2020 Representative)  
 Mehmet Haberal, Ankara, Turkey (TTS President-Elect)

## Finance Committee

Nancy Ascher, San Francisco, CA, USA (Chair)	Jongwon Ha, Seoul, Korea
Amado Andrés Belmonte, Madrid, Spain	Myoung Soo Kim, Seoul, Korea
Daniel Casanova, Santander, Spain	Daniel Serón, Barcelona, Spain
Valentín Cuervas-Mons, Madrid, Spain	Stefan G. Tullius, Boston, MA, USA
Gabriel E. Gondolesi, Buenos Aires, Argentina	

## Host Country Liaison Committee (Spain)

José María Morales, Madrid	Amado Andrés Belmonte, Madrid
Josep M. Grinyo, Barcelona	Carlos Jiménez Martín, Madrid
Beatriz Domínguez-Gil, Madrid	Marcos López Hoyos, Santander
Valentín Cuervas-Mons, Madrid	

## Scientific Program Committee

Philip J. O'Connell, Westmead, Australia (Chair)	Jonwong Ha, Seoul, Korea
Carla C. Baan, Rotterdam, Netherlands	Claus Niemann, San Francisco, CA, USA
Marcelo Cantarovich, Montreal, QC, Canada	Daniel Serón, Barcelona, Spain
Shane T. Grey, Darlinghurst, Australia	Megan Sykes, New York, NY, USA
Josep M. Grinyo, Barcelona, Spain	Stefan G. Tullius, Boston, MA, USA

## Program Sub-Committee Chairs

### Postgraduate Courses

- |   |  |
|---|--|
| <ul style="list-style-type: none"> <li>• <u>Clinical Co-Chairs</u></li> </ul> | <ul style="list-style-type: none"> <li>• <u>Basic Science Co-Chairs</u></li> </ul> |
| Medhat Askar, Dallas, TX, USA   | Fadi Issa, Oxford, UK  |
| Marcelo Cantarovich, Montreal, QC, Canada                                     | Megan Levings, Vancouver, BC, Canada   |
|   | Birgit Sawitzki, Berlin, Germany   |

## Program Sub-Committee Chairs

### TTS 2018 Congress Sessions

- Anesthesia Management and Critical Care  
John Klinck, Cambridge, UK  
Claus Niemann, San Francisco, CA, USA
- Basic Science and Translational Science  
Qizhi Tang, San Francisco, USA  
James A. Hutchinson, Regensburg, Germany  
Nancy Kwan Man, Hong Kong, Hong Kong
- Cellular and Regenerative Therapies  
Maria Koulmanda, Boston, MA, USA  
Stephen Strom, Stockholm, Sweden
- Complications  
Peter J. Friend, Oxford, UK  
Hiroto Egawa, Tokyo, Japan
- Donation & Procurement  
Susan Gunderson, Minneapolis, MN, USA  
Helen Opdam, Canberra, Australia  
Eduardo Rocha, Rio de Janeiro, Brazil
- Ethics, Community, Economics and DOI  
Rudolf Garcia-Gallont, Guatemala, Guatemala  
Beatriz Domínguez-Gil, Madrid, Spain  
Elmi Muller, Cape Town, South Africa  
Peter G. Stock, San Francisco, CA, USA
- Heart & Lung  
Tobias Deuse, San Francisco, CA, USA  
Anne I. Dipchand, Toronto, ON, Canada
- Histocompatibility  
Peter W. Nickerson, Winnipeg, BC, Canada  
Elaine F. Reed, Los Angeles, CA, USA
- Infectious Diseases  
Michael G. Ison, Chicago, IL, USA  
Nassim Kamar, Toulouse, France
- Intestine and Multivisceral Transplantation  
Gabriel E. Gondolesi, Buenos Aires, Argentina  
Andreas Pascher, Berlin, Germany
- Kidney  
Christophe Legendre, Paris, France  
Robert A. Montgomery, New York, NY, USA  
Ron Shapiro, New York, NY, USA
- Transplant Immunosuppression  
Stephan Busque, Stanford, CA, USA  
Steve J. Chadban, Camperdown, Australia  
Dirk R.J. Kuypers, Leuven, Belgium
- Liver  
Jan Lerut, Brussels, Belgium  
Claus Niemann, San Francisco, CA, USA  
Kyung-Suk Suh, Seoul, Korea
- Paediatrics  
Carlos O. Esquivel, Stanford, CA, USA  
Mignon McCulloch, Cape Town, South Africa
- Pancreas & Islet  
James F. Markmann, Boston, MA, USA  
Lorenzo Piemonti, Milan, Italy
- Registries  
Curie Ahn, Seoul, Korea  
Bertram L. Kasiske, Minneapolis, MN, USA
- Sex and Gender in Transplantation  
Elaine F. Reed, Los Angeles, CA, USA  
Lorie J. West, Edmonton, AB, Canada
- Transplantation Nursing  
Sandra A. Cupples, Potomac, MD, USA  
Christiane Kugler, Freiburg, Germany
- Vascularized Composite Allograft Transplantation  
Vijay S. Gorantla, Pittsburgh, PA, USA  
Emmanuel Morelon, Lyon, France
- Xenotransplantation  
David K.C. Cooper, Birmingham, AL, USA  
Chung-Gyu Park, Seoul, Korea

The TTS Young Investigator Scientific awards are offered by The Transplantation Society to offer trainees from all regions an opportunity to attend this important Congress. Selection of the award winners is based on the scientific merit of their abstract submissions.

These awards are supported by the Roche Organ Transplantation Research Foundation (ROTRF).



**Rebeca Arroyo Hornero**, United Kingdom

424.6 CO-STIMULATORY MODULATION OF HUMAN REGULATORY T CELLS FOR ENHANCED IMMUNOTHERAPY

**Yarl Balachandran**, United States

527.5 DELINEATION OF THE VIRAL AND HOST CELL GENOMIC ALTERATIONS IN EBV-POSITIVE PTLD

**Florencia Bonisconti**, Argentina

P.382 CLINICAL UTILITY OF A MODIFIED QRT-PCR FOR TRYPANOSOMA CRUZI DETECTION IN TRANSPLANT PATIENTS

**Xiaoyong Chen**, People's Republic of China

303.3 CHARACTERIZATION OF A CD23+CD43+ REGULATORY B CELL SUBSET IN HUMAN THAT INDUCED BY MESENCHYMAL STEM CELLS

**Aravind Cherukuri**, United States

318.1 PROSPECTIVE MULTICENTER VALIDATION OF HUMAN TRANSITIONAL B CELL CYTOKINES AS A PREDICTIVE BIOMARKER IN RENAL TRANSPLANTATION

**Fang Kuan Chiou**, Singapore

627.4 POORER LONG-TERM SURVIVAL ASSOCIATED WITH MONOMORPHIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER SOLID ORGAN TRANSPLANTATION IN CHILDREN

**Dominik Chittka**, United States

316.1 DSA PLUS TCMR LEADS TO POOR OUTCOMES IN RENAL ALLOGRAFT RECIPIENTS AND THIS IS MARKEDLY EXACERBATED BY NON-ADHERENCE

**Helong Da**, People's Republic of China

421.2 DISTAL ABDOMINAL AORTA COULD SERVE AS AN OUTFLOW TRACT FOR EN BLOC KIDNEY TRANSPLANTATION FROM INFANT DONORS WITH EXTREMELY LOW BODY WEIGHT



**Nicole De La Mata**, Australia

- 620.1 STROKE MORTALITY IN KIDNEY TRANSPLANT RECIPIENTS: A RETROSPECTIVE POPULATION-BASED COHORT STUDY USING DATA LINKAGE

**Reinier de Vries**, United States

- 615.2 EXTENDING THE HUMAN LIVER PRESERVATION TIME FOR TRANSPLANTATION BY SUPERCOOLING

**Su Kah Goh**, Australia

- 420.7 DONOR-SPECIFIC CELL-FREE DNA AS AN EMERGING BIOMARKER OF ORGAN REJECTION AFTER LIVER TRANSPLANTATION

**Christian Heim**, Germany

- 626.2 BLOCKADE OF TYROSINE KINASES AS PREVENTIVE STRATEGY AGAINST CARDIAC ALLOGRAFT VASCULOPATHY IN A MURINE AORTIC TRANSPLANT MODEL

**Charlotte A. Lee**, United Kingdom

- 523.2 THE ANTI-INFLAMMATORY EFFECT OF ALPHA-1 ANTITRYPSIN IN HEPATOCYTE TRANSPLANTATION

**Xiaoqian Ma**, People's Republic of China

- 304.4 CORD BLOOD DERIVED REGULATORY MACROPHAGES (MREG) – AN ALTERNATIVE SOURCE FOR MREG-BASED CELL THERAPY IN TRANSPLANTATION

**Berenice Mbiribindi**, United States

- 518.2 NK CELL RECOGNITION OF PEPTIDES ENCODED BY EBV LATENT CYCLE PROTEINS

**Hiroyuki Ogasawara**, Japan

- 424.8 A COMPARISON OF THE TRANSPLANT EFFICIENCY BETWEEN INTRAPORTAL AND INTRASPLENIC PROCEDURES IN HEPATOCYTE TRANSPLANTATION

**Brenda Rosales**, Australia

- 302.5 CANCER MORTALITY IN TRANSPLANT RECIPIENTS IN AUSTRALIA AND NEW ZEALAND: A NATIONAL COHORT STUDY FROM 1980 TO 2013

**Akhil Sharma**, United States

- 316.6 PRO-INFLAMMATORY B CELLS PREDICT PROGRESSIVE MINIMAL EARLY RENAL ALLOGRAFT INFLAMMATION WHICH IS ASSOCIATED WITH POOR GRAFT OUTCOMES

**Nicole Shockcor**, United States

- 622.3 END STAGE RENAL DISEASE AS A COMPLICATION OF FACE TRANSPLANT

**Ashley Suah**, United States

- 303.4 ACQUIRED RESISTANCE TO TRANSPLANTATION TOLERANCE AS A RESULT OF PRIOR PREGNANCY REQUIRES B CELLS

**Patrick Trotter**, United Kingdom

- 419.4 TRANSPLANTATION OF KIDNEYS FROM DCD AND DBD DONORS WHO DIED AFTER LIGATURE ASPHYXIATION: THE UK EXPERIENCE

**Marieke van der Zwan**, The Netherlands

- 326.1 EFFICACY OF RABBIT ANTI-THYMOCYTE GLOBULIN THERAPY FOR SEVERE ACUTE REJECTION IN KIDNEY TRANSPLANT PATIENTS USING CALCINEURIN INHIBITOR AND MYCOPHENOLATE MOFETIL BASED IMMUNOSUPPRESSIVE THERAPY

**Karen Waller**, Australia

- 590.1 INCIDENCE, PREVALENCE AND RESIDUAL INFECTION RISK OF HIV IN INCREASED RISK GROUPS PRESENTING AS POTENTIAL ORGAN DONORS IN AUSTRALIA; A SYSTEMATIC REVIEW AND META-ANALYSIS

**Casey J. Ward**, United States

- 592.1 REVERSAL OF DIABETES AND PRESERVATION OF PANCREATIC ISLET GRAFTS IN THE EXTRAHEPATIC SPACE WITH NOVEL PARATHYROID GLAND CO-TRANSPLANTATION

**Cheng Yang**, People's Republic of China

- 516.4 PREDICTION OF RENAL ALLOGRAFT CHRONIC REJECTION USING A MODEL BASED ON CONTRAST ENHANCED ULTRASONOGRAPHY

**Yuanfei Zhao**, Australia

- 608.3 IN-VIVO COSTIMULATION-BLOCKADE INDUCED FOXP3 TREGS FROM DEREGLATED MICE WITH NEONATAL ISLET CELL CLUSTER TOLERANT XENOGRAPHS EXIST MEMORY TREGS PHENOTYPE

The Transplantation Society (TTS) along with the collaboration of its Affiliated Societies celebrates the contributions of basic science to the field of transplantation with the International Transplantation Science Mentee-Mentor Awards by recognizing the efforts of basic scientists who have advanced our understanding of transplant science/immunobiology and/or treatment of transplant recipients, and the young investigators who will be the future leaders in transplantation.

The Awards will be given on **Monday, July 2, during the International Transplantation Science Mentee-Mentor Networking Event** to be held from 17:45 to 18:45 in the North Convention Centre, 1<sup>st</sup> floor (attendance by invitation only).



## TTS-Canadian Society of Transplantation Awards

**Mentee:** Ibrahim Adam

**Mentor:** Lori J. West

318.6 ANTIBODY RESPONSE TO NON-SELF BLOOD GROUP A-ANTIGEN DEPENDS ON CD4 T CELLS, FORIGEN PROTEIN AND CD22 INTERACTION

**Mentee:** Minal Borkar

**Mentor:** Lee Anne Tibbles

316.8 EPIGENETIC INHIBITORS AS POTENTIAL ANTI-VIRAL TREATMENT AGAINST BK POLYOMA VIRUS ASSOCIATED NEPHROPATHY: AN ELUCIDATION OF MECHANISM

**Mentee:** Nicholas Dawson

**Mentor:** Megan Levings

C494.6 HUMANIZATION AND PRE-CLINICAL VALIDATION OF AN ANTI-HLA-A\*02:01 CHIMERIC ANTIGEN RECEPTOR FOR USE WITH REGULATORY T CELLS TO ENHANCE TRANSPLANT TOLERANCE

**Mentee:** Avery Lam

**Mentor:** Megan Levings

586.5 HUMAN REGULATORY T CELL POTENTIAL FOR TISSUE REPAIR VIA IL-33/ST2 AND AMPHIREGULIN

## TTS-Indian Society of Organ Transplantation Awards

**Mentee:** Sahil Bagai

**Mentor:** Manish Rath

P.348 CORRELATION OF PRETRANSPLANT GLUCOSE METABOLISM AND NONALCOHOLIC FATTY LIVER DISEASE WITH THE DEVELOPMENT OF POST TRANSPLANTATION DIABETES MELLITUS

**Mentee:** Manish Balwani

**Mentor:** Pankaj Shah

P.681 KNOWLEDGE REGARDING BRAIN DEATH AND ORGAN DONATION LAWS AMONG MEDICAL STUDENTS

**Mentee:** Akhilesh Jaiswal

**Mentor:** Narayan Prasad

P.256 INTER-INDIVIDUAL VARIABILITY OF TACROLIMUS TOUGH LEVEL MAY BE DUE TO DIFFERENTIAL P-GLYCOPROTEIN EXPRESSION ON PBMCS IN RENAL TRANSPLANT RECIPIENT

**Mentee:** Sonia Mehrotra

**Mentor:** Raj Kumar Sharma

P.233 PHARMACO-DYNAMICS OF CSA AND TACROLIMUS AND ITS EFFECT ON ANTIVIRAL DRUGS IN HCV POSITIVE KIDNEY TRANSPLANT RECIPIENTS.

**Mentee:** Mohan Patel

**Mentor:** Manoj Gumbars

C391.2 PREDICTION OF TACROLIMUS DRUG DOSING AND METABOLISM BASED ON CYP3A5 POLYMORPHISM IN INDIAN RENAL TRANSPLANT RECIPIENTS

## TTS-Japan Society for Transplantation Award

**Mentee:** Asuka Tanaka

**Mentor:** Yuka Tanaka

619.7 DONOR CONDITIONING WITH RECIPIENT-DERIVED PD-L1/PD-L2-EXPRESSING B CELLS PREVENTS LETHAL ACUTE GVHD IN A FULLY ALLOGENEIC MOUSE MODEL

## TTS-Nederlandse Transplantatie Vereniging Award

**Mentee:** Jesus M. Sierra Parraga

**Mentor:** Martin Hoogduijn

424.3 MONOCYTIC CELLS PHAGOCYTOSE THERAPEUTIC MESENCHYMAL STEM CELLS, WHICH INDUCES POLARIZATION, RELOCATION AND IMMUNE REGULATION



## TTS-Sociedad Española de Trasplante Awards

**Mentee:** Patricia Conde-Sanroman

**Mentor:** Jordi C. Ochando

P.430 TARGETING TRAINED IMMUNITY PROMOTES ORGAN TRANSPLANT ACCEPTANCE

**Mentee:** Maria Garcia-Conde Delgado

**Mentor:** Iago Justo Alonso

603.3 LIVER TRANSPLANTATION FROM DONOR AFTER CARDIAC DEATH (DCD) MAASTRICHT TYPE IIA, OUR EXPERIENCE AFTER 10 YEARS

**Mentee:** Oana Anisa Nutu

**Mentor:** Iago Justo Alonso

P.835 INFLUENCE OF GRAFT STEATOSIS ON THE OUTCOME OF LIVER TRANSPLANTATION

## TTS-Turkish Transplantation Society Award

**Mentee:** Selin Akad

**Mentor:** Feride I. Sahin

P.485 IMPACT OF MMP2, MMP9 AND TIMP2 GENE POLYMORPHISMS ON ALLOGRAFT REJECTION IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS

## TTS-Transplantation Society of Australia and New Zealand Awards

**Mentee:** Sam R. Adhikary

**Mentor:** Hong Chee Chew

C495.3 IN VIVO DEPLETION OF DIVIDING DONOR CELLS USING POST-TRANSPLANT CYCLOPHOSPHAMIDE CAN REDUCE THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN A HUMANISED MOUSE MODEL

**Mentee:** Maria Garcia-Conde Delgado

**Mentor:** Iago Justo Alonso

323.5 DONATION AFTER CIRCULATORY DEATH HEART TRANSPLANTATION: AN UPDATE OF CURRENT PRACTICES AND OUTCOMES

## The Transplantation Society Awards

**Mentee:** Jianing Fu, United States

**Mentor:** Megan Sykes, United States

619.4 CLONAL AND FUNCTIONAL ANALYSIS REVEALS THE CAPACITY OF ALLOGRAFT T CELLS TO JOIN THE CIRCULATING POOL AFTER HUMAN INTESTINAL TRANSPLANTATION

**Mentee:** Ahmer Hameed, Australia

**Mentor:** Wayne Hawthorne, Australia

593.6 A NATIONAL REGISTRY ANALYSIS OF AORTIC VERSUS DUAL IN SITU PERFUSION FOR RETRIEVAL OF THE DBD LIVER

**Mentee:** Melisa Pucci Molineris, Argentina

**Mentor:** Gabriel E. Gondolesi, Argentina

522.1 PANETH AND INTESTINAL STEM CELLS ARE DIFFERENTIALLY AFFECTED DURING WORSENING OF ACUTE CELLULAR REJECTION IN SMALL BOWEL TRANSPLANTATION COMPARED TO INTESTINAL ISCHEMIA REPERFUSION INJURY AND GRAFT VERSUS HOST DISEASE

**Mentee:** Elisa Montanari, Switzerland

**Mentor:** Leo Buhler, Switzerland

C494.2 BENEFICIAL EFFECTS OF HUMAN MESENCHYMAL STROMAL CELLS ON PORCINE HEPATOCYTE VIABILITY AND ALBUMIN SECRETION

**Mentee:** Wai Ho Oscar Yeung, Hong Kong

**Mentor:** Kwan Man, Hong Kong

500.1 DELTA PD-1 EXPRESSED M2 MACROPHAGES PROMOTE LIVER TUMOR RECURRENCE AFTER TRANSPLANTATION

All attendees must respect these policies as part of the contractual commitment that they made at the time of registration. Failure to comply may result in removal / denied access to the Congress.

## Congress Public Safety and Security

For security reasons, all delegates will be issued a badge onsite that is required to be worn at all times during the Congress and at any organized functions. Badge swapping is strictly prohibited.

All individuals entering the venue may be subject to a visual and possibly a physical body search; packages and baggage may also be searched or screened before entering the venue, and at any time during the event. All physical body searches will be done professionally, in privacy, in a courteous manner, and respectful of gender.

## Recording of Presentations is Strictly Prohibited

No individual or entity - including a presenting author - may electronically record or broadcast any portion of the TTS 2018 (including their own presentation) without prior written consent of TTS 2018. Please see the staff at the Congress Registration desk. Unauthorized recording (audio, video, still photography, etc.) of presentations during sessions, posters, workshops, tutorials, etc., without the express written consent of TTS 2018 and individual authors is strictly prohibited. TTS 2018 reserves the rights to any approved audio and video production of presentations.

Press representatives must receive a Press Pass which implies photo/recording permission from TTS 2018.

## Photo Policy

Photographing formal presentations, posters, or displays without permission of the presenter is forbidden.

## Policy on Respectful Dialogue

Participants are expected to keep criticism constructive, and avoid personal attacks in sessions, in online discussion boards and in social media. Debate of ideas is encouraged, allowing delegates to enjoy a lively and stimulating congress.


## Policy on Social Media Use and Congress Web App

We encourage the use of social media (LinkedIn, Twitter, Facebook, and Instagram) and the Congress web app before, during, and after the Congress in order to share information and to network with others. However, we ask all congress participants to adhere to the following guidelines:

- Whenever possible, use the hashtag **#tts2018** to discuss the Congress.
- Communicate with respect and consideration for others, keeping criticism constructive.
- Blog, post or tweet about what you are hearing and learning, but refrain from sharing information when the speaker explicitly requests this. Talks are tweetable and shareable by default, but speakers can request that specific details or slides not be shared.
- Provide feedback to the Congress committees, we encourage participants to post and discuss topics of interest as well as ideas for future meetings.
- Do not engage in rudeness or personal attacks.




# FLOOR PLAN - IFEMA




# FLOOR PLAN - NORTH CONVENTION CENTER

Speaker Ready Room  
Post-Graduate Courses  
Sessions



Plenary  
Exhibit Area  
Campfires & Poster Sessions



Venue

TTS 2018 will be held at the IFEMA North Convention Center and Hall 10.

All TTS 2018 events will take place at the IFEMA North Convention Centre - 1st Floor and Hall 10, unless otherwise indicated. Satellite meeting space for committee and section meetings are located on the mezzanine corridors located on top of Halls 9 and 10.

IFEMA Feria de Madrid

Avda. del Partenón, 5  
Madrid, Spain 28042  
Tel: (34) 91 722 30 00  
Fax: (34) 91 722 58 01  
e-mail: lineaifema@ifema.es  
Website: www.ifema.es

Operating Hours

Date	Registration	Speaker Ready Room (N109)	Exhibit Hall 10	Luggage Check (\$)
June 30	08:00-17:30	08:00-17:00		
July 1	08:00-20:00	08:00-18:00	19:00-20:00	
July 2	08:00-17:30	08:00-16:30	09:30-17:30	
July 3	08:00-17:30	08:00-16:30	09:30-17:30	
July 4	08:00-17:30	08:00-17:00	09:30-15:00	08:00-19:00
July 5	08:00-13:30	08:00-10:00		08:00-14:00



## Accreditation / CME

The 27<sup>th</sup> International Congress of The Transplantation Society, Madrid, Spain, 30/06/2018-05/07/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 38 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

### EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:

- 30.06.2018 - 8,00
- 01.07.2018 - 7,00
- 02.07.2018 - 7,00
- 03.07.2018 - 7,00
- 04.07.2018 - 6,00
- 05.07.2018 - 3,00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

## Business Centre

Please note that the Congress will not feature a business center. The post office located at IFEMA and accessible from the "Avenida", offers photocopy and printing services.

## Certificate of Attendance

A personalized Certificate of Attendance will be available from your dashboard when you log into your account once you have collected your badge at the Congress. Certificates of Presentation can be requested at the Speaker Ready Room starting Monday, July 2. Please note that the Certificate reflects the Presenter's name and mentions the abstract authors.

## Charging Stations

Participants can charge their devices at the TTS Booth in Hall 10 or by use of the electrical outlets in the session rooms. Please do not leave your phone unsupervised. Charging your phone is at your own risk.

## Congress Evaluation

The Congress evaluation form will be available on the dashboard of the Congress web app as of 14:00 on July 3<sup>rd</sup>. You can print your CME certificate upon completion of the Congress evaluation form. TTS and all Congress Committees will appreciate your constructive feedback.

## Emergency / First Aid

For any emergency or first aid services inside IFEMA, please contact any TTS or IFEMA staff or use a house phone.

## Information

Should you require any assistance during the Congress, please call the registration desk directly at 0917-223101.

## Language

English is the official language of the Congress. Therefore, the program will be presented in English only.

## Liability

The Organizing Committee and/or The Transplantation Society and/or any of suppliers shall not be held liable for personal accidents or losses or damage to private property of registered participants of the TTS 2018 Congress. Participants should make their own arrangements with respect to personal insurance.

## Lounge Areas

Four networking areas have been designated for registered participants in the Exhibit area (Hall 10):

- TTS Booth
- Young Members Corner
- Rewind and Unwind Lounge
- Soccer Lounge

## Lost and Found

Any lost and found items will be held at the registration desk for the duration of the Congress. Any unclaimed items will be disposed of at the end of the Congress.

### Luggage Check

The luggage check will be open during the hours listed below, at a cost of 3 Euros per item.

July 4 08:00-19:00  
July 5 08:00-14:00

### Lunch Menu

DAY	OPTION 1	OPTION 2	OPTION 3
<b>JUNE 30</b>	Turkey sandwich with lettuce, tomato, mustard and honey and fusilli side salad	Baked vegetables with rosemary on baguette and fusilli side salad	Cesar salad with chicken
<b>JULY 1</b>	Serrano ham with tomato on baguette with veggie side salad	Sweet raw onion, fresh spinach, olive oil and goat cheese sandwich with veggie side salad	Quinoa salad with nuts, modena vinegar and olive oil on mixed greens with chicken, and baby tomato with a pepper and dill sauce
<b>JULY 2</b>	Ham and brie wrap with tomato, spinach and spices and quinoa side salad	Tuna wrap with spinach, celery, walnuts and mayonnaise and quinoa side salad	Spinach salad with blueberries, onion, raisins, feta cheese, olive oil, vinegar, salt, pepper, garlic and bread bun
<b>JULY 3</b>	Turkey with lettuce, tomato, mustard and honey sandwich with veggie side salad	Smoked salmon sandwich on poppy seed bread with cream cheese and dill and veggie side salad	Spanish omelette with simple side salad
<b>JULY 4</b>	Beef pastrami sandwich on tomato bread with arugula, fried onion and mayonnaise with cesar side salad	Goat cheese wrap with gourmet lettuces, roasted peppers, honey and nuts with cesar side salad	Ham and cheese meal size salad

### Parking

IFEMA offers onsite parking opportunities at a daily maximum rate of 15 Euros, at the charge of the user.

### Press

There is no media room available during the Congress. Representatives from the press can register for a media pass at the Registration Desk. Official media credentials must be presented.

### Professional Photo Booth at TTS Booth

Come to the TTS Booth and get your portrait photo taken professionally. This is a great opportunity to update your profile photo on your social media.

### Public Notice – Smoking

IFEMA is a smoke-free environment. Smoking is forbidden in all areas.

### Public Transportation

TTS 2018 registration fees include the Madrid transportation pass. IFEMA is located on the pink line and the stop is called “Campo de las naciones”.

## Registration

For security and regulation purposes, all attendees are required to wear their name badge at all times during the Congress in order to participate in the Scientific Sessions, Networking Events and to access the Exhibit Area. Badge swapping is strictly prohibited.

### Badge Colour Identification:

Delegate Member & Delegate	Blue
Post-Graduate Course Delegate, Speaker & Chair	Pink
Pre-Congress Workshop Delegate, Speaker & Chair	Purple
Student/Fellow/Trainee	Yellow
Organizing Committee	Light Blue
TTS Leadership	Black
Congress Invited Speaker & Chair	Red
Staff & Volunteer	Orange
Sponsor	Grey
Exhibitor	Green
Media	Brown

### Lost Badges

In the event of a lost or forgotten badge, an administrative fee of \$25 USD will be charged for the reprinting of the badge after verification of identification (passport, driving license, or other recognized identification paper).

## Web Recordings

*Sponsored by Roche*

All registered attendees will have the chance to view the Congress Session recordings online through the TTS 2018 website and on the Congress web app for up to a year after the Congress. Only presentations for which TTS received pre-authorization from the presenter will be available online for viewing.



## Wellness Area

*Sponsored by the World Transplant Games Federation and Fit for Life.*

A wellness area for yoga, stretching, meditation, mindfulness, and relaxation has been designated for registered participants. Find some time to join a yoga class or simply meditate or relax during some quiet time.



TIME	MONDAY, JULY 2	TUESDAY, JULY 3	WEDNESDAY, JULY 4
08:15-09:15	Yoga	Yoga	Yoga
11:15-11:30	Stretching	Stretching	Relaxation
11:30-11:45	Mindfulness	Mindfulness	Stretching
13:15-13:30	Stretching	Stretching	Stretching
13:30-13:45	Relaxation	Relaxation	Relaxation
13:45-14:00	Mindfulness	Mindfulness	Mindfulness
14:00-14:15	Meditation	Meditation	Meditation
14:15-14:30	Stretching	Stretching	Stretching
14:30-14:45	Relaxation	Relaxation	Relaxation
14:45-15:00	Stretching	Stretching	Stretching
15:00-15:15	Relaxation	Relaxation	Relaxation
15:15-15:30	Mindfulness	Mindfulness	Mindfulness
15:30-15:45	Stretching	Stretching	Stretching
15:45-16:00	Relaxation	Relaxation	Relaxation
16:00-16:15	Mindfulness	Mindfulness	Mindfulness
16:15-16:30	Meditation	Meditation	Meditation



*Services courtesy of Yoga Center S.L. Madrid*

## Young Members Corner and Activities

The Young Members Corner is a gathering and relaxation area for trainees. This is also where trainees can sign-up to the guided poster tours.

June 30	Post-Graduate Course
July 1	Post-Graduate Course Orientation Session at 17:30
July 2	Guided Poster Tours
July 3	Guided Poster Tours YMC Event: Azotea Del Círculo C/Marqués de Casa Riera nº 2.

Attendance at Lunch & Learn Sessions is highly recommended.

## Congress Orientation Session

Sunday, July 1 - 17:30-17:50  
Room N-104

## Opening Ceremony

Sunday, July 1 - 18:00-19:00  
Plenary Hall inside Hall 10  
(included in registration fees)

## Welcome Reception

Sunday, July 1 - 19:00-20:00  
Exhibit Area - Hall 10  
(included in registration fees)

## Women in Transplantation (WIT) Networking Event

Tuesday, July 3 - 17:30-19:30  
Colón Room, 2<sup>nd</sup> Floor, North Convention Center  
(By pre-registration only)

## Young Members Networking Event

Tuesday, July 3 - 20:00-23:00  
Azotea Del Círculo, C/Marqués de Casa Riera nº 2  
(Reservation fee applies)

## Congress Networking Event

Wednesday, July 4 - starting at 20:00  
Palacete de los Duques Pastranas  
(Ticketed Event - By pre-registration only: Tickets will be available for purchase at the Registration Desk until Tuesday, July 3 at 10:00.)

## Closing Ceremony

Thursday, July 5 - 12:30-13:30  
Room N-103/N-104



**Monday, July 2, 2018****Lunch Symposium sponsored by Astellas****13:30–14:30**
**Yesterday's Intervention, Tomorrow's Outcome:  
Improving the Transplant Journey**


Chair: Stefan Schneeberger (Austria)

MONIQUE'S TRANSPLANT JOURNEY: HOW COULD WE HAVE MADE A DIFFERENCE?  
KEY CLINICAL INTERVENTIONS TO ADDRESS:

NON-ADHERENCE

- Stefan Schneeberger (Austria)

VARIABILITY

- Teun van Gelder (The Netherlands)

UNDER-IMMUNOSUPPRESSION AND DSAS

- Daniel Serón (Spain)

**Evening Symposium sponsored by Chiesi****16:30–17:30**
**Might Different Patients Need Different Approaches?  
New Concepts on Tacrolimus Metabolism and Pharmacokinetics**

Chair: Julio Pascual (Spain)

CLINICAL SENSITIVITY TO TACROLIMUS PHARMACOKINETICS

- Rainer Oberbauer (Austria)

TACROLIMUS FAST METABOLIZES: HOW TO IDENTIFY THEM BEYOND RACE AND GENOTYPE

- Klemens Budde (Germany)

**Tuesday, July 3, 2018****Lunch Symposium sponsored by Bridge to Life****13:30–14:30****Kidney & Liver Hypothermic Machine Perfusion: The Role of Oxygen**

Chair: Rutger Ploeg (United Kingdom)

THE ROLE OF OXYGEN IN HYPOTHERMIC MACHINE PERFUSION

- Philipp Dutkowski (Switzerland)

CLINICAL EXPERIENCE WITH HYPOTHERMIC OXYGENATED PERFUSION OF LIVERS AND KIDNEYS

- Matteo Ravaioli (Italy)

**Evening Symposium sponsored by Qiagen****16:30–17:30**
**Improving Management of Transplanted Patients  
with Viral Load Assays and Specific Cell-Mediated Immune Response Monitoring**

Chair: José María Aguado (Spain)

COMPARISON OF INTRACELLULAR CYTOKINE STAINING VS. QUANTIFERON-CMV FOR THE MONITORING  
OF CELL-SPECIFIC IMMUNITY AGAINST CMV IN KIDNEY TRANSPLANT RECIPIENTS

- José María Aguado (Spain)

A RANDOMIZED TRIAL OF QFN-CMV DIRECTED ANTIVIRAL PROPHYLAXIS VS. STANDARD-OF-CARE TO  
REDUCE LATE CMV REACTIVATION FOLLOWING LUNG TRANSPLANTATION

- Glen Westall (Australia)

**Wednesday, July 4, 2018****Lunch Symposium sponsored by One Lambda****13:30–14:30****The Molecular Microscope® Diagnostic System:  
Insights into Disease Mechanisms Shared By All Organ Transplants**

Chair: Philip F. Halloran (Canada)

MOLECULAR MICROSCOPE® ANALYSIS OF KIDNEY (MMDX-KIDNEY) AND LUNG (MMDX-LUNG)  
TRANSPLANT BIOPSIES

- Philip F. Halloran (Canada)

MOLECULAR DIAGNOSTICS IN SOLID ORGAN TRANSPLANT: THE 2017 BANFF PERSPECTIVE

- Alexandre Loupy (France)

THE MMDX-HEART SYSTEM: CLINICAL IMPLICATIONS AND POTENTIAL UTILITY

- Luciano Potena (Italy)

Q&amp;A

**Evening Symposium sponsored by Novartis****16:15–17:15****Transforming Transplantation: From Large Scale Clinical Trials to Daily Practice**

Chair: Julio Pascual (Spain)

WELCOME AND INTRODUCTION

- Julio Pascual (Spain)

LATEST DATA FROM THE TRANSFORM STUDY – THE EFFECT OF EVEROLIMUS ON LONG-TERM  
OUTCOMES AFTER KIDNEY TRANSPLANTATION

- Julio Pascual (Spain)


PERSPECTIVE ON RENAL FUNCTION

- Christophe Legendre (France)

INSIGHTS ON THE INTRODUCTION OF A *DE NOVO* IMMUNOSUPPRESSIVE REGIMEN

- Franco Citterio (Italy)

Q&amp;A AND CLOSING REMARKS



### Exhibit Hours

**Sunday, July 1 17:30–19:00**

- Exhibit Hall open for delegates to access the Plenary for the Opening Ceremonies only.

**Sunday, July 1 19:00–20:00**

- Welcome Reception

**Monday, July 2 09:30–17:30**

**Tuesday, July 3 09:30–17:30**

**Wednesday, July 4 09:30–15:00**

### Exhibitor

### Booth #

Aferetica	40
Astellas Pharma Europe Ltd Medical Information	8
Astellas Pharma Europe Ltd	16
Baskent University	10
Bridge to Life	2
CAST 2019 (Asian Society of Transplantation)	32
China Organ Harvest Research Center	64
CSL Behring	51
CytoSorbents Europe GmbH	39
Dr. Franz Köhler Chemie GmbH	42
European Society for Organ Transplantation	78
Glycorex Transplantation AB	7
Hansa Medical AB	30
Institut George Lopez	28
International Transplant Nurses Society	33
KOTRY / KODA / KONOS / Vitallink	70
Neovii Pharmaceuticals AG	24
Novartis Pharma AG	54
Numares	27
One Lambda, Inc.	20
Organ Assist	41
Organ Recovery Systems	6
OrganOx Ltd	38
Oxford Immunotec	53
Oxiplenish	9
Peter Morris Centre for Evidence in Transplantation	71
QIAGEN GmbH	4
QUOD, University of Oxford	72
Scanlan International Inc.	5
Sociedad Argentina de Trasplantes	73
Sociedad de Trasplantes de America Latina y del Caribe	31
TPM-DTI Foundation	69
Transplant Connect	50
Turkish Transplant Foundation	66
Wisepress Book Shop	74

# DETAILED PROGRAM

Saturday, June 30, 2018



---

**08:30-10:45 100 - Joint Session 1: Academic Survival Kit** **N-104**


---

- Chairs: *Medhat Askar, United States and Megan Levings, Canada*
- 100.1 Roadmap to the PGC  
**Medhat Askar**, United States and **Megan Levings**, Canada
  - 100.2 Transplant Educator  
**Medhat Askar**, United States
  - 100.3 Preparing an abstract and a manuscript  
**Jeremy R. Chapman**, Australia
  - 100.4 How to write a grant  
**Roslyn B. Mannon**, United States
  - 100.5 How to prepare and present slides  
**Marcelo Cantarovich**, Canada

---

**10:45-11:15 Coffee Break** **Foyer Area (NCC)**


---



---

**11:15-13:15 101 - Basic Science: Innate Immune Response & Microbiome** **N-103**


---

- Chairs: *Bernard Vanhove, France and Sarah Crome, Canada*
- 101.1 Inflammatory triggers and receptors - DAMPs and PAMPs  
**Maria Koulmanda**, United States
  - 101.2 Inflammasome-mediated inflammation  
**Carmen Peralta**, Spain
  - 101.3 Alarmins and their receptors in control of the allo-immune response  
**Avery J. Lam**, Canada
  - 101.4 Microbiome analysis  
**Jonathan S. Bromberg**, United States

---

**11:15-13:15 102 - Clinical Science: The Transplant Fitting Room** **N-104**


---

- Chairs: *Dominique E. Martin, Australia and Peter W. Nickerson, Canada*
- 102.1 Pre-transplant work-up  
**Shaifali Sandal**, Canada
  - 102.2 Histocompatibility testing (pre & post)  
**Peter W. Nickerson**, Canada
  - 102.3 Management of the highly sensitized patient  
**Robert A. Montgomery**, United States
  - 102.4 Ethical dilemmas in SOT  
**Dominique E. Martin**, Australia

---

**13:15-14:15 Lunch Break** **Foyer Area (NCC)**


---



---

**14:15-16:15 103 - Basic Science: T Cells** **N-103**


---

- Chairs: *Birgit Sawitzki, Germany and Carla C. Baan, Netherlands*
- 103.1 Allorecognition by the adaptive immune system: Direct, indirect, and semidirect  
**Gavin Pettigrew**, United Kingdom
  - 103.2 CD4 effector T cells: Activation, costimulation, Th repertoire (including TFH cells), and (Finally) exhaustion!  
**Bernard Vanhove**, France
  - 103.3 Tissue-resident immune cells  
**Sarah Crome**, Canada
  - 103.4 Utilizing TCR & BCR-Seq to study antigen-specific immune responses  
**Megan Sykes**, United States

---

**14:15-16:15 104 - Clinical Science: Dealing with the Aftermath** **N-104**


---

- Chairs: *Germaine Wong, Australia* and *Jay Fishman, United States*
- 104.1 Donor derived infections  
**Jay Fishman**, United States
  - 104.2 Transplant infectious diseases  
**Camille Kotton**, United States
  - 104.3 Transplant malignancies  
**Germaine Wong**, Australia
  - 104.4 Cardiovascular and metabolic complications  
**Gregory Alan Knoll**, Canada

---

**16:15-16:45 Coffee Break** **Foyer Area (NCC)**


---



---

**16:45-18:45 105 - Basic Science: B Cells and Innate Immune System** **N-103**


---

- Chairs: *Megan Sykes, United States* and *Gavin Pettigrew, United Kingdom*
- 105.1 Update on B cell activation, memory and antibody secreting cells  
**Olivier Thaumat**, France
  - 105.2 Targeting B cells and Ab-producing cells  
**Gavin Pettigrew**, United Kingdom
  - 105.3 Adaptive function of NK cells & macrophages  
**Jordi Ochando**, Spain
  - 105.4 Innate lymphoid cells  
**Estela Paz-Artal**, Spain

---

**16:45-18:45 106 - Clinical Science: Precision Thinking** **N-104**


---

- Chairs: *Valeria Mas, United States* and *Teun Van Gelder, Netherlands*
- 106.1 Systems biology  
**Valeria Mas**, United States
  - 106.2 Biomarkers of graft function & failure  
**Minnie M. Sarwal**, United States
  - 106.3 Immunosuppression  
**Christophe Legendre**, France
  - 106.4 Pharmacogenomics & precision medicine  
**Teun Van Gelder**, Netherlands

## WTGF: Optimizing Recovery after Solid Organ Transplant – The Role of Physical Activity, Exercise and Sport (#WTGF search on WebApp)

### 08:30-10:30 120 - Evidence for Exercise and Physical Activity in Solid Organ Transplant N-107/108

- Chair: *Chris Thomas, Australia*
- 120.1 Introductions and Opening Remarks  
**Marcelo Cantarovich**, Canada and **Chris Thomas**, Australia
  - 120.2 Physical impairments in solid organ transplant candidates and recipients – what is the impact on transplant outcomes?  
**Sunita Mathur**, Canada
  - 120.3 Evidence for pre-habilitation and rehabilitation in solid organ transplantation  
**Tania Janaudis-Ferreira**, Canada
  - 120.4 Models of integrating regular physical activity into post-transplant care  
**Ka Foon Chau**, Hong Kong

### 10:30-11:00 Coffee Break Foyer Area (NCC)

### 11:00-12:30 121 - World Transplant Games Federation – Fit for Life! N-107/108

- Chair: *Marcelo Cantarovich, Canada*
- 121.1 Launch of the fit for life toolkit: A tool for engaging transplant recipients in a physically active lifestyle  
**Chris Thomas**, Australia
  - 121.2 The role of technology in encouraging the transplant community to take the first steps to a life of movement  
**Liz Schick**, Switzerland

### 12:30-13:30 Lunch Break Foyer Area (NCC)

### 13:30-15:00 122 - Transplant Recipients Leading their Peers in Physical Activity N-107/108

- Chair: *Paul N. Harden, United Kingdom*
- 122.1 How Fit for Life and Billion Steps Challenge brings together the Canadian transplant community  
**Claude JA Laflamme**, Canada
  - 122.2 Taking exercise to the extreme – what are the limitations for transplant recipients  
**Gerardo Reyna**, Spain
  - 122.3 Patient partnerships in research and knowledge translation: Experience from the CAN-RESTORE network  
**Sunita Mathur**, Canada and **Tania Janaudis-Ferreira**, Canada

### 15:00-15:30 Coffee Break Foyer Area (NCC)

### 15:30-17:30 123 - High-Performance Athletes and Sports Participation Post-Transplantation N-107/108

- Chair: *Claude JA Laflamme, Canada*
- 123.1 Sports participation in transplant athletes  
**Sheila Leddington-Wright**, United Kingdom
  - 123.2 10 years of Transplantoux in Belgium – an integrated approach  
**Diethard Monbaliu**, Belgium
  - 123.3 Volvo Ocean Race 2017: Transplant athlete preparation and participation (ending with the BBC video)  
**Paul N. Harden**, United Kingdom
  - 123.4 Program wrap-up  
**Marcelo Cantarovich**, Canada and **Chris Thomas**, Australia

## Women in Transplantation

### Advancing Women in Transplantation through Leadership and Advocacy of Issues Related to Sex and Gender (#WIT search on WebApp)

08:30-10:00	<b>130 - Increasing Leadership of Women in Transplantation: Challenges and Solutions</b>	<b>N-111</b>
	Chairs: <i>Megan Sykes, United States</i> and <i>Christine S. Falk, Germany</i>	
130.1	Tools for leadership success <b>Lori J. West</b> , Canada	
130.2	Creating a culture of support not competition <b>Lisa A. Robinson</b> , Canada	
	Panel discussion	
10:00-10:30	Coffee Break	Foyer Area (NCC)
10:30-12:00	<b>131 - Why is Advocacy Needed? Gender Disparities in Transplantation</b>	<b>N-111</b>
	Chair: <i>Curie Ahn, Korea</i>	
131.1	Gender disparities in access to transplantation <b>Anette Melk</b> , Germany	
131.2	A Bioethics perspective on gender disparities in transplantation <b>Germaine Wong</b> , Australia	
	Panel discussion	
12:00-13:00	Lunch Break	Foyer Area (NCC)
13:00-15:00	<b>132 - Research on Issues of Sex and Gender in Transplantation</b>	<b>N-111</b>
	Chairs: <i>Roslyn B. Mannon, United States</i> and <i>Bethany Foster, Canada</i>	
132.1	Sex, drugs and pharmacology <b>TBA</b>	
132.2	Immunological consequences of pregnancy and impact of subsequent transplantation <b>Anita Chong</b> , United States	
132.3	Impact of the H-Y antigen on solid organ transplant outcomes <b>Stefan G. Tullius</b> , United States	
	Panel discussion	
15:00-15:30	Coffee Break	Foyer Area (NCC)
15:30-17:30	<b>133 - Creating a Culture of Success &amp; Steps to Improve Equity</b>	<b>N-111</b>
	Chairs: <i>Lori J. West, Canada</i> and <i>Elaine F. Reed, United States</i>	
133.1	How is the new generation tackling gender equity in transplantation? <b>Maria Irene Bellini</b> , United Kingdom	
133.2	Improving gender equity in transplantation: what can professional societies do? <b>Vassilios Papalois</b> , United Kingdom	
133.3	Gender disparities in academia—how does transplantation compare with other fields? <b>Deborah Adey</b> , United States	
	Panel discussion	



**TTS Transplantation Science Committee****Virtual Global Transplantation Laboratory (vGTL)****Overcoming Pitfalls in Immune Monitoring in Clinical Transplantation Trials: perspectives from the experts (#vGTL search on WebApp)**


---

**08:30-10:00 140 - Immune Monitoring in the Real World N-112**


---

Chairs: *Fadi Issa, United Kingdom and Shane T. Grey, Australia*

- 140.1 Introduction & experience in the ONE Study  
**Edward K. Geissler**, Germany
- 140.2 Pitfalls and lessons from the ONE Study and beyond  
**Birgit Sawitzki**, Germany
- 140.3 Designing novel mechanistic studies in clinical trials  
**Carla C. Baan**, Netherlands
- Questions and Answers  
**Shane T. Grey**, Australia

---

**10:00-10:30 Coffee Break Foyer Area (NCC)**


---



---

**10:30-12:30 141 - Standardization and Success N-112**


---

Chairs: *Shane T. Grey, Australia and Fadi Issa, United Kingdom*

- 141.1 Biobanking in transplantation  
**Maria Kaisar**, United Kingdom
- 141.2 Measuring donor-reactive T cells for clinical trials and metrics to measure success  
**Qizhi Tang**, United States
- 141.3 How reliable is your assay? Approaches to standardize and harmonize immune monitoring in clinical trials  
**Megan Levings**, Canada
- 141.4 Challenges in setting up and running a Treg trial  
**Fadi Issa**, United Kingdom
- Questions and Answers  
**Shane T. Grey**, Australia

**Cell Transplants vs Stem Cell Therapy****Organized by the Cell Transplant and Regenerative Medicine Society (CTRMS)****(#CTRMS search on WebApp)**

---

**13:30-15:00 150 - Session 1: Cellular and Regenerative Therapies N-112**

---

Chair: *Ewa Ellis, Sweden*

- 150.1 Innate vs. adaptive immunity in cell transplant tolerance

**Maria Koulmanda**, United States

- 150.2 Pros and cons of using human stem cell derived b-cells for the treatment of diabetes

**Klearchos K. Papas**, United States

- 150.3 Hepatocytes and mesenchymal stem cells as therapeutic options for the treatment of liver diseases, lessons from animal models

**Peggy Stock**, Germany

---

**15:00-15:30 Coffee Break Foyer Area (NCC)**

---

---

**15:30-17:00 151 - Session 2: Cellular and Regenerative Therapies N-112**

---

Chair: *Maria Koulmanda, United States*

- 151.1 From translational research to clinical application: where the rubber hits the road

**Giuseppe Pettinato**, United States

- 151.2 Neonatal donors for hepatocyte transplantation

**Ewa Ellis**, Sweden

- 151.3 Therapeutic potential of placenta-derived stem cells for liver diseases

**Toshio Miki**, United States

[illegible]

# DETAILED PROGRAM

Sunday, July 1, 2018



---

**09:00-10:30 200 - Basic Science: Immune Regulation & Flow Standardisation N-103**


---

- Chairs: *Qizhi Tang, United States and Fadi Issa, United Kingdom*
- 200.1 Regulatory T and B cells  
**Megan Levings**, Canada
  - 200.2 Tolerogenic function of innate immune cells  
**Xian C. Li**, United States
  - 200.3 Strategies to standardize and objectify assays e.g. flow cytometry automated gating  
**Birgit Sawitzki**, Germany
- 

---

**09:00-10:30 201 - Clinical Science: Becoming Precise N-104**


---

- Chairs: *Philip F. Halloran, Canada and Michael Mengel, Canada*
- 201.1 Transplant pathology  
**Michael Mengel**, Canada
  - 201.2 Liquid biopsy  
**Sean Agbor-Enoh**, United States
  - 201.3 Molecular microscope  
**Philip F. Halloran**, Canada
- 

---

**10:30-11:00 Coffee Break Foyer Area (NCC)**


---



---

**11:00-12:30 202 - Basic Science: The Future of Organ Transplant Replacement N-103**


---

- Chairs: *Minnie M. Sarwal, United States and Hiroto Egawa, Japan*
- 202.1 Genomics & epigenomics in transplantation  
**Daniel G. Maluf**, United States
  - 202.2 Cellular therapy for liver disease and liver regeneration  
**Anil Dhawan**, United Kingdom
  - 202.3 Gene-specific nucleases (CrispCas, TALEN...)  
**Marc Guell**, United States
- 

---

**11:00-12:30 203 - Clinical Science: Clinical Crowdsourcing N-104**


---

- Chairs: *Marcelo Cantarovich, Canada and Medhat Askar, United States*
- 203.1 TCR NGS based evidence for differential diagnosis and personalized therapy in BKV nephropathy  
**Ulrik Stervbo**, Germany
  - 203.2 Day to day decision in multi-visceral transplantation immunosuppression  
**Marina Pérez-Flecha González**, Spain
  - 203.3 The great pretender: when what you see, is not what you get. An unusual presentation of lung cancer on a post kidney transplant patient  
**Bryan Christian Gaza Ilagan**, Philippines
- 

---

**12:30-13:30 Lunch Break Foyer Area (NCC)**


---



---

**13:30-15:30 204 - Joint Session 2: Future Look at Organ Shortage N-104**


---

- Chairs: *Edward K. Geissler, Germany and David K.C. Cooper, United States*
- 204.1 Tolerance  
**Giorgio Raimondi**, United States
  - 204.2 Xenotransplantation  
**Alfred J. Tector III**, United States
  - 204.3 Bioengineering and regeneration of solid organs: Current status and future directions  
**Giuseppe Orlando**, United States
  - 204.4 Advanced biomarkers of graft function & failure  
**Nina Babel**, Germany
- 

---

**15:30-16:00 Coffee Break Foyer Area (NCC)**


---

---

**16:00-17:30 205 - Joint Session 3: Transplant Mathaton**

---

**N-104***Chairs: Marcelo Cantarovich, Canada and Birgit Sawitzki, Germany*

- 205.1 How to understand and use statistics  
**Joseph Kim**, Canada
- 205.2 Big data in transplantation  
**Dorry Segev**, United States
- 205.3 Take home message (Clinical Path)  
**Marcelo Cantarovich**, Canada
- 205.4 Take home message (Basic Science Path)  
**Birgit Sawitzki**, Germany

## Optimizing Outcomes by Prevention and Management of Post-Transplant Infections

### Organized by the Transplant Infectious Disease (TID) Section

(#TID search on WebApp)

08:30-08:40	<b>220 - Welcome Message</b>	N-105
220.1	<p>Welcome Address</p> <p><b>Nassim Kamar</b>, France</p>	
08:40-10:10	<b>221 - Donor-Derived Infections and Organ Vigilance Around the World</b>	N-105
	<p>Chair: <i>Michael G. Ison, United States</i></p> <p>221.1 Donor-derived infection cases (2 cases) <b>Nicole M. Theodoropoulos</b>, United States</p> <p>221.2 Organ vigilance: background and US perspective <b>Cameron Wolfe</b>, United States</p> <p>221.3 Organ vigilance: EU perspective <b>Sophie Lucas-Samuel</b>, France</p> <p>221.4 Organ vigilance: Australian perspective <b>Helen I. Opdam</b>, Australia</p> <p>221.5 Organ vigilance: global/WHO perspective <b>Jose Ramon Nunez</b>, Switzerland</p>	
10:15-11:00	<b>222 - Transplant ID – Lessons Learned from Current Literature</b>	N-105
	<p>Chair: <i>Clarisse Machado, Brazil</i></p> <p>222.1 Top 10 papers in transplant infectious diseases <b>Camille Kotton</b>, United States</p> <p>222.2 Case 1 <b>Michele I. Morris</b>, United States</p>	
11:00-11:30	<b>Coffee Break</b>	Foyer Area (NCC)
11:30-13:00	<b>223 - Controversies in Transplant Infectious Diseases: The Expert Showdown</b>	N-105
	<p>Facilitator: <i>Hans H. Hirsch, Switzerland</i></p> <p>223.1 Use of HCV positive donors - Pro <b>Jose Maria Morales</b>, Spain</p> <p>223.2 Use of hepatitis C positive donors - Con <b>Jay Fishman</b>, United States</p> <p>Debate Discussion</p> <p>223.3 Use of donors with multi-drug resistant organisms - Pro <b>Stephanie Pouch</b>, United States</p> <p>223.4 Use of donors with multi-drug resistant organisms - No <b>Paolo A. Grossi</b>, Italy</p> <p>Debate Discussion</p> <p>223.5 HIV transplantation <b>Elmi Muller</b>, South Africa</p>	
13:00-14:00	<b>Lunch Break</b>	Foyer Area (NCC)

---

**14:00-16:00    224 - Addressing the Threat of Infections Post-Transplant**
**N-105**


---

- Chair: *Silvia Vidal Campos, Brazil*
- 224.1 Prevention and treatment of CMV  
**Francisco M. Marty**, United States
  - 224.2 BK virus nephropathy  
**Brian J. Nankivell**, Australia
  - 224.3 New options in the management of multi-drug resistant bacteria  
**Jean Ralph Zahar**, France
  - 224.4 Parasitic infections: Prevention, diagnosis and management  
**Alice Song**, Brazil
  - 224.5 Diarrhea in transplantation  
**Diana Florescu**, United States

---

**16:00-16:30    Coffee Break**
**Foyer Area (NCC)**


---



---

**16:30-17:30    225 - Cows and Zebras: Challenging Cases in Transplantation**
**N-105**


---

- Chair: *Ban Hock Tan, Singapore*
- 225.1 Case 2  
**Edward A. Dominguez**, United States
  - 225.2 Case 3: Liver transplantation for fulminant hepatitis due to yellow fever  
**Alice Song**, Brazil
  - 225.3 Case 4  
**Stephanie Pouch**, United States

## Declaration of Istanbul 10th Anniversary Symposium

### Organized by the Declaration of Istanbul Custodian Group (DICG)

(#DOI search on WebApp)

#### 09:00-09:10 230 - Welcome and Overview of Organ Trafficking N-106

- 230.1 Welcome and overview of organ trafficking  
**Dominique E. Martin**, Australia and **Elmi Muller**, South Africa

#### 09:10-10:30 231 - Evaluating Prospective Living Donors and Transplant Recipients N-106

- Chairs: *Jacob Lavee, Israel* and *Curie Ahn, Korea*  
Case presentations: Learnings from suspected cases of attempted organ trafficking involving resident patients
- 231.1 SOUTH AFRICA  
**Elmi Muller**, South Africa
- 231.2 INDIA  
**Sanjay S. Nagral**, India
- 231.3 NEW ZEALAND  
**Ian D. Dittmer**, New Zealand
- 231.4 MEXICO  
**Rafael Reyes-Acevedo**, Mexico
- Panel Discussions  
Case presentations: Learnings from suspected cases of attempted organ trafficking involving non-resident patients
- 231.5 SPAIN  
**Beatriz Dominguez-Gil**, Spain
- 231.6 PHILIPPINES  
**Benita Padilla**, Philippines
- 231.7 COSTA RICA  
**Amalia Matamoros**, Costa Rica
- Panel Discussions

#### 10:30-11:00 232 - Suggested Strategies for Preventing and Managing Organ Trafficking in the Clinical Setting N-106

- Chairs: *Jacob Lavee, Israel* and *Curie Ahn, Korea*
- 232.1 Psychosocial evaluation-getting the essential elements right and tailoring to the local environment  
**Dominique E. Martin**, Australia
- 232.2 Communicating concerns with other transplant programs while respecting patients' rights to privacy and confidentiality  
**Mona Alrukhaimi**, United Arab Emirates

#### 11:00-11:30 Coffee Break Foyer Area (NCC)

#### 11:30-13:00 233 - Managing Patients Who Returns After Transplantation Aboard that May Have Involved Organ Trafficking N-106

- Chairs: *Adeera Levin, Canada* and *Faissal Shaheen, Saudi Arabia*
- 233.1 Potential indicators of organ trafficking  
**Jacob Lavee**, Israel
- 233.2 Clinical issues in management-medical  
**Gabriel Danovitch**, United States
- 233.3 Clinical issues in management-surgical  
**Riadh A.S. Fadhil Al Noaman**, Qatar
- 233.4 Ethical issues in management  
**Alexander M. Capron**, United States
- 233.5 Building systems to support management  
**Marta López-Fraga**, France
- General Discussion

13:00-14:00	Lunch Break	Foyer Area (NCC)
-------------	-------------	------------------

14:00-16:00	<b>234 - Welcome and Introduction to the Declaration of Istanbul Custodian Group</b>	<b>N-106</b>
-------------	--	--------------

- Chairs: *Dominique E. Martin, Australia and Elmi Muller, South Africa*
- 234.1 Welcome from DICG co-chairs  
**Elmi Muller**, South Africa and **Dominique E. Martin**, Australia
  - 234.2 A brief history of the declaration and its development  
**Jeremy R. Chapman**, Australia
  - 234.3 The Declaration of Istanbul and DICG in action- achievements and impact  
**Beatriz Dominguez-Gil**, Spain
  - 234.4 Updating the declaration- a review of the public consultation  
**Dominique E. Martin**, Australia
  - 234.5 Introducing the 2018 edition of the Declaration of Istanbul  
**Alexander M. Capron**, United States
  - 234.6 Implications of the update internationally - TTS (The Transplantation Society)  
**Nancy Ascher**, United States
  - 234.7 Implications of the update internationally - ISN (International Society of Nephrology)  
**David Harris**, Australia
  - 234.8 Implications of the update internationally - WHO (World Health Organization)  
**Jose Ramon Nunez**, Switzerland

16:00-16:30	Coffee Break	Foyer Area (NCC)
-------------	--------------	------------------

16:30-17:30	<b>235 - Implications of the Update at the Regional Level</b>	<b>N-106</b>
-------------	---	--------------

- Chairs: *Dominique E. Martin, Australia and Elmi Muller, South Africa*
- 235.1 Oceania  
**Philip J. O'Connell**, Australia
  - 235.2 Africa  
**Elmi Muller**, South Africa
  - 235.3 Asia  
**Benita Padilla**, Philippines
  - 235.4 Europe  
**Axel Rahmel**, Germany
  - 235.5 Latin America  
**Rudolf Garcia-Gallont**, Guatemala
  - 235.6 Middle-East  
**Mona Alrukhaimi**, United Arab Emirates
  - 235.7 North America  
**Gabriel Danovitch**, United States
  - 235.8 Wrap-up by DICG Co-Chairs  
**Elmi Muller**, South Africa and **Dominique E. Martin**, Australia

**Advancing to the Clinic**

**Organized by the International Xenotransplantation Association**  
**(#XENO search on WebApp)**

<b>09:00-11:00</b>	<b>240 - Xeno-Part 1</b>	<b>N-111</b>
<hr/>		
	Chairs: <i>Léo Hans Bühler, Switzerland</i> and <i>Manuel A. Pascual, Switzerland</i>	
240.1	Survival of pig organs in nonhuman primates: an update <b>David K.C. Cooper</b> , United States	
240.2	Pathology of acute and subacute/chronic xenograft rejection <b>Akira Shimizu</b> , Japan	
240.3	Treatment of acute humoral rejection: Lessons learned from allotransplantation <b>Manuel A. Pascual</b> , Switzerland	
240.4	Is PERV a real risk, and should it be eliminated? <b>Linda Scobie</b> , United Kingdom	
<b>11:00-11:30</b>	<b>Coffee Break</b>	<b>Foyer Area (NCC)</b>
<hr/>		
<b>11:30-13:00</b>	<b>241 - Xeno-Part II</b>	<b>N-111</b>
<hr/>		
	Chairs: <i>David K.C. Cooper, United States</i> and <i>Chung-Gyu Park, Korea</i>	
241.1	Production of genetically-engineered pigs using new tools <b>Eckhard Wolf</b> , Germany	
241.2	Xenotransplantation of hepatocytes, an alternative to liver transplantation for acute liver failure? <b>Léo Hans Bühler</b> , Switzerland	
241.3	China and xenotransplantation: an update <b>Shaoping Deng</b> , People's Republic of China	
<b>13:00-14:00</b>	<b>Lunch Break</b>	<b>Foyer Area (NCC)</b>
<hr/>		



## Transplantation Nursing 101

Organized by TTS Education Committee and the International Transplant Nurses Society  
(#ITNS search on WebApp)

10:00-11:00	<b>250 - Solid Organ Transplant Immunology</b>	N-112
	Chair: <i>Sukru H. Emre, United States</i>	
250.1	Basic immunology core <b>Caner Süsal</b> , Germany	
250.2	Clinical immunology core <b>Sukru H. Emre</b> , United States	
11:00-11:30	<b>251 - Intestinal Transplantation</b>	N-112
	Chair: <i>Sukru H. Emre, United States</i>	
251.1	Intestinal transplant core and patient care <b>Gabriel E. Gondolessi</b> , Argentina	
11:30-12:30	<b>252 - Kidney and Pancreas</b>	N-112
	Chair: <i>Sukru H. Emre, United States</i>	
252.1	Kidney/pancreas core <b>Peter I. Abrams</b> , United States	
252.2	Specific issues in kidney/pancreas transplant <b>Peter G. Stock</b> , United States	
12:30-14:00	Lunch Break	Foyer Area (NCC)
14:00-15:00	<b>253 - Liver Transplantation</b>	N-112
	Chair: <i>Sukru H. Emre, United States</i>	
253.1	Medical <b>AnneMarie Liapakis</b> , United States	
253.2	Surgical <b>Sukru H. Emre</b> , United States	
15:00-16:30	<b>254 - Comprehensive Care of the Transplant Patient</b>	N-112
	Chair: <i>Sukru H. Emre, United States</i>	
254.1	Psychological considerations, special population, role of transplant coordinators and social workers and multidisciplinary communications <b>Joyce A. Trompeta</b> , United States	
16:30-17:00	<b>255 - Lung Transplantation</b>	N-112
	Chair: <i>Sukru H. Emre, United States</i>	
255.1	Specific issues in lung transplant <b>Christopher Wigfield</b> , United States	

## Key Issues in Paediatric Solid Organ Transplantation

### Organized by the International Pediatric Transplant Association (IPTA)

(#IPTA search on WebApp)

14:00-15:10	<b>270 - Cutting Edge Developments in Paediatric Solid Organ Transplantation</b>	<b>N-111</b>
	Chair: <i>Mignon McCulloch, South Africa</i>	
270.1	Review of key paediatric clinical transplant papers in the last 2 years <b>Burkhard Tönshoff</b> , Germany	
270.2	Review of key basic science papers/developments in the last 2 years <b>Stephen Alexander</b> , Australia	
15:15-16:00	<b>271 - Endocrine and Metabolic Challenges following Paediatric Solid Organ Transplantation</b>	<b>N-111</b>
	Chair: <i>Anne Dipchand, Canada</i>	
271.1	Obesity, metabolic syndrome, PTDM following transplant in childhood <b>Mignon McCulloch</b> , South Africa	
16:00-16:15	<b>Coffee Break</b>	<b>Foyer Area (NCC)</b>
16:15-17:30	<b>272 - Challenges to Long Term Survival following Paediatric Solid Organ Transplantation</b>	<b>N-111</b>
	Chair: <i>Mignon McCulloch, South Africa</i>	
272.1	Adherence intervention trials <b>Anne Dipchand</b> , Canada	
272.2	Tumor risk following solid organ transplantation in childhood <b>George V. Mazariegos</b> , United States	

---

18:00-20:00 TTS 2018 CONGRESS OPENING EVENTS

---



---

17:30-17:50 Congress Orientation Session

---

N-104

---

18:00-19:00 Opening Ceremony (doors open at 17:30)

---

Hall 10 – Plenary

---

19:00-20:00 Welcome Reception

---

Hall 10 – Exhibition

---

19:15 DICG: 2018 Edition of the Declaration of Istanbul and its Role  
in the Future of Donation Practices and Policies

---

Hall 10 – TTS Innovative Studio in TTS booth

285.1 DICG

**Elmi Muller**, South Africa and **Dominique E. Martin**, Australia

[illegible]

# DETAILED PROGRAM

Monday, July 2, 2018

**08:30-09:30 Oral Abstract Session (Liver)**  
**300 - Recipient Management**

N-101

Chairs: *Kyung-Suk Suh, Korea and John J. Fung, United States*

- 300.1 Revascularization time matters in liver transplantation: Prolonged implantation of marginal grafts independently predicts inferior transplant outcomes in the short and long term  
**Bettina Buchholz**, United Kingdom
- 300.2 Evaluation of enhanced recovery program in liver transplanted patients: Can we beat the benchmarks in liver transplantation?  
**Benny Wang**, Sweden
- 300.3 Oncologic outcomes of ABO incompatible living donor liver transplantation for hepatocellular carcinoma  
**Jee Youn Lee**, Korea
- 300.4 Delisting of liver transplant candidates with chronic HCV infection after viral eradication: Outcome 2 years after delisting. A European study  
**Carmen Vinaixa**, Spain
- 300.5 Surgical categorization improve outcomes and organ utilization in liver transplantation  
**Humberto Bohorquez**, United States
- 300.6 CMV-hyperimmunoglobulin improves early outcome in critically ill liver transplant patients by a combination of antiviral, anti-inflammatory and positive immunomodulatory capabilities  
**Arno Kornberg**, Germany

**08:30-09:30 Oral Abstract Session (Kidney)**  
**301 - Antibody Mediated Rejection 1**

N-102

Chairs: *Jongwon Ha, Korea and Julio Pascual, Spain*

- 301.1 Defining response to standard of care treatment of kidney recipients with antibody-mediated rejection: Role of C1q-binding donor-specific anti-HLA antibodies  
**Yassine Bouatou**, France
- 301.2 The role of donor-derived cell-free dna in the identification of injury in kidney allografts with antibody-mediated rejection or de novo dsa: A pilot study  
**Longshan Liu**, People's Republic of China
- 301.3 C1q-binding donor-specific anti-HLA antibodies for clinical decision making in kidney recipients with antibody-mediated rejection receiving standard of care treatment  
**Carmen Lefaucheur**, France
- 301.4 Is Banff 2013 classification of renal allograft pathology superior to 2007 Banff in detecting and managing cases of antibody-mediated rejection?  
**Daniel Burguete**, United States
- 301.5 Significance of antibody-mediated vascular rejection (AMVR) on graft survival: Correlation with pure antibody-mediated rejection (AMR)  
**Nurhan Ozdemir**, Turkey
- 301.6 Divergent role of programmed death –Lig and 1 (PD-L1) in renal allografts with antibody-mediated rejection (AMR)  
**B. Handan Ozdemir**, Turkey

**08:30-09:30 Oral Abstract Session (Kidney)**  
**302 - Recurrence and Cancer**

N-105

Chairs: *Ifeoma I. Ulas, Nigeria and Oriol Bestard Matamoros, Spain*

- 302.1 Apolipoprotein A-ib as biomarker of FSGS recurrence after kidney transplantation: Diagnostic performance in a prospective cohort and assessment of its prognostic value  
**Conxita Jacobs Cachá Jr.**, Spain
- 302.2 Rituximab does not prevent focal and segmental glomerulosclerosis recurrence after renal transplantation in patients at risk  
**Pilar Auñón**, Spain
- 302.3 APRIL serum levels relate to recurrence of IgA nephropathy  
**Luis Martin-Penagos**, Spain
- 302.4 MRP2 24 CT is associated with an increased risk of neoplasia and serious infection among renal transplant recipients  
**Beatriz Rodriguez-Cubillo**, Spain
- 302.5 Cancer mortality in transplant recipients in Australia and New Zealand: A national cohort study from 1980 to 2013  
**Brenda M. Rosales**, Australia
- 302.6 Analysis of the incidence and site of post-transplant cancer in patients with pre-transplant malignancies  
**Christian Unterrainer**, Germany

**08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-106****303 - B Cell Biology**Chairs: *Anita Chong, United States* and *Nancy Kwan Man, Hong Kong*

- 303.1 Ex vivo expanded regulatory B cells promote allograft survival through IL-10-dependent pathway  
**Kang Mi Lee**, United States
- 303.2 DD9+ regulatory b lymphocytes control chronic lung inflammation by inducing effector T cell apoptosis  
**Carole Brosseau**, France
- 303.3 Characterization of a CD23+CD43+ regulatory B cell subset in human that induced by mesenchymal stem cells  
**Xiaoyong Chen**, People's Republic of China
- 303.4 Acquired resistance to transplantation tolerance as a result of prior pregnancy requires B cells  
**Ashley N. Suah**, United States
- 303.5 Lymphocytes B development after kidney transplantation  
**Maciej Zieliński**, Poland
- 303.6 Phenotypic and clonal analysis of recipient B cells and plasma cells entering graft mucosa reveals an association with rejection and evolution towards a resident memory phenotype after human intestinal transplantation  
**Megan Sykes**, United States

**08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-107/108****304 - Mononuclear Phagocytes**Chairs: *Jordi Ochando, Spain* and *James A. Hutchinson, Germany*

- 304.1 Mitochondrial damage-associated molecular patterns (MTDs) released from hepatic ischemia reperfusion induce inflammatory response  
**Qianni Hu**, Canada
- 304.2 Generation of TIGIT+ Itregs by human regulatory macrophages before kidney transplantation  
**Paloma Riquelme**, Germany
- 304.3 BTNL8 is expressed by human Mreg-induced FOXP3+ iTregs  
**Paloma Riquelme**, Germany
- 304.4 Cord blood derived regulatory macrophages (Mreg) – an alternative source for Mreg-based cell therapy in transplantation  
**Xiaoqian Ma**, People's Republic of China
- 304.5 DHRS9 is a stable marker of human regulatory macrophages  
**Florian Bitterer**, Germany

**08:30-09:30 Morning Symposium (Declaration of Istanbul)****N-111****305 - New and Emerging Issues in Organ Trafficking and Travel for Transplantation**Chairs: *Beatriz Dominguez-Gil, Spain* and *Rudolf Garcia-Gallont, Guatemala*

- 305.1 Commercial transplants in the developing world  
**Elmi Muller**, South Africa
- 305.2 Ethical concerns regarding global kidney exchanges  
**Alexander M. Capron**, United States
- 305.3 When the poor donate but only the rich receive – barriers to equitable allocation of organs in developing countries  
**Sanjay S. Nagral**, India

**08:30-09:30 Morning Symposium (Sex and Gender in Transplantation)****N-112****306 - Sex and Gender Research in Transplantation- Where Are We Now?**Chairs: *Lori J. West, Canada* and *Bethany Foster, Canada*

- 306.1 Where have we been and where are we going in sex and gender research in transplant? A scoping review  
**Ruth Sapir-Pichhadze**, Canada
- 306.2 Donor sex related factors influencing transplant outcomes  
**Amanda J. Miller**, Canada
- 306.3 Gender disparities in transplantation  
**Anette Melk**, Germany



08:30-09:30	<b>Morning Symposium (Transplantation Nursing)</b> <b>307 - Improving Patient Outcomes</b>	N-113
	Chairs: <i>Sandra A. Cupples, United States and Mara Ann McAdams DeMarco, United States</i>	
307.1	Fostering healthy lifestyles <b>Christiane Kugler</b> , Germany	
307.2	Promoting transplant adherence <b>Paolo De Simone</b> , Italy	
307.3	Improving psychosocial outcomes <b>Anna Forsberg</b> , Sweden	
08:30-09:30	<b>Morning Symposium (Education)</b> <b>308 - The Transplanter vs. The Educator - Ultimate Debate: Should Transplanters be Trained as Educators?</b>	N-114
	Chair: <i>Marcelo Cantarovich, Canada</i>	
308.1	Introduction by Chair <b>Marcelo Cantarovich</b> , Canada	
308.2	The Transplanter <b>Jeremy R. Chapman</b> , Australia	
308.3	The Educator <b>Medhat Askar</b> , United States	
	Open debate discussion	
08:30-09:30	<b>Morning Symposium (Transplant Immunosuppression)</b> <b>309 - Current Immunosuppression: "Can This Old Dog Be Taught New Tricks?"</b>	N-115/116
	Chairs: <i>Christine S. Falk, Germany and TBA</i>	
309.1	Re-targeting JAK/STAT signaling in solid organ transplantation? <b>Helio S. Tedesco Jr</b> , Brazil	
309.2	Alemtuzumab and Infliximab join forces: Together we are strong <b>Petra Reinke</b> , Germany	
309.3	Proteasome inhibition before and after transplantation <b>E. Steve Woodle</b> , United States	
09:45-11:15	<b>Oral Abstract Session (Liver)</b> <b>315 - Living Donor in Liver Transplantation</b>	N-101
	Chairs: <i>John J. Fung, United States and Kyung-Suk Suh, Korea</i>	
315.1	Long-term outcomes after living liver donation: Analysis of national data base <b>Suk Kyun Hong</b> , Korea	
315.2	Evaluation of the learning curve for pure laparoscopic donor right hepatectomy by analyzing 115 consecutive cases in an experienced adult living donor liver transplant center <b>Suk Kyun Hong</b> , Korea	
315.3	Proposal for new selection criteria considering pre-transplant muscularity and visceral adiposity in living donor liver transplantation <b>Yuhei Hamaguchi</b> , Japan	
315.4	Renal function outcomes with everolimus plus reduced-exposure tacrolimus in de novo living donor liver transplantation: 24-month results from the H2307 study <b>Kyung-Suk Suh</b> , Korea	
315.5	Living donor liver transplantation for alcoholic liver disease: The North American experience <b>Hillary J. Braun</b> , United States	
315.6	Aggressive graft volume reduction in pediatric living donor liver transplantation under one year old patients <b>Takehisa Ueno</b> , Japan	
315.7	Retransplantation after living donor liver transplantation: Analysis of data from the A2All study <b>Garrett R. Roll</b> , United States	
315.8	Liver regeneration rate analysis in living donor liver transplantation <b>Lilia Martinez de la Maza</b> , Spain	
315.9	Excellent perioperative and long-term outcomes with lower graft-to-recipient weight ratio for living donor liver transplantation <b>Tiffany CL Wong</b> , Hong Kong	

## 09:45-11:15 Oral Abstract Session (Kidney)

N-102

## 316 - Acute Cellular Rejection and Polyoma

Chairs: *Ifeoma I. Ulas, Nigeria and Peter G. Stock, United States*

- 316.1 DSA plus TCMR leads to poor outcomes in renal allograft recipients and this is markedly exacerbated by non-adherence  
**Dominik Chittka**, United States
- 316.2 Inflammation in scarred areas (i-IF/TA): Defining the response to standard treatment of T cell-mediated rejection in kidney recipients  
**Alexandre Loupy**, France
- 316.3 Application of RNA-seq derived diagnostic algorithms of T-cell mediated kidney rejection (TCMR) to publicly available DNA microarray-based gene expression datasets  
**Zijie Wang**, People's Republic of China
- 316.4 Non-invasive diagnostic of renal allograft rejection via urine metabolites using NMR-spectroscopy  
**Miriam C. Banas**, Germany
- 316.5 Genome-wide association meta-analysis for acute rejection of kidney transplants  
**William S. Oetting**, United States
- 316.6 Pro-inflammatory B cells predict progressive minimal early renal allograft inflammation which is associated with poor graft outcomes  
**Akhil Sharma**, United States
- 316.7 Immune responses in renal transplant recipients at risk of BK-virus associated nephropathy – impact of three immunosuppressive regimens  
**Rolf Weimer**, Germany
- 316.8 Epigenetic inhibitors as potential anti-viral treatment against BK polyoma virus associated nephropathy: An elucidation of mechanism  
**Minal Borkar-Tripathi**, Canada
- 316.9 Prognostic biomarkers and potential treatment for BK polyomavirus associated nephropathy  
**Minal Borkar-Tripathi**, Canada

## 09:45-11:15 Oral Abstract Session (Kidney)

N-103

## 317 - Deceased Donor Issues

Chairs: *Alejandro Niño-Murcia, Colombia and Francisco Del Río, Spain*

- 317.1 Extended case series investigating vascular remodeling following whole pancreas transplantation  
**John Moir**, United Kingdom
- 317.2 Matching graft life expectancy with patient life expectancy  
**Lisa L. Mumford**, United Kingdom
- 317.4 Early outcomes and risk factors for kidney transplantation with controlled circulatory death donor (cDCD) in a nationwide strategy. Spanish multicentre SENTRA-GEODAS-Group  
**Jose Portoles Sr.**, Spain
- 317.5 Dual kidney transplantation as a strategy to use elderly donors: A systematic review  
**Nuria Montero**, Spain
- 317.6 Two decades of Eurotransplant senior program (ESP): Time on dialysis independently impacts patient survival, allograft survival and quality of life after kidney transplantation  
**Natalie Otto**, Germany
- 317.7 Factors impacting delayed graft function from uncontrolled donors after circulatory death  
**Natividad N. Calvo Romero Sr.**, Spain
- 317.8 Kidney transplantation from uncontrolled donors after circulatory death: Data from an observational cohort  
**Natividad N. Calvo Romero Sr.**, Spain

## 09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences)

N-104

## 318 - Antibody Responses

Chairs: *Shane T. Grey, Australia and Frans HJ Claas, Netherlands*

- 318.1 Prospective multicenter validation of human transitional B cell cytokines as a predictive biomarker in renal transplantation  
**Aravind Cherukuri**, United States
- 318.2 B cell immune repertoire sequencing identifies pre-transplant rejection risk  
**Silvia Pineda**, United States
- 318.3 B-cell depletion with rituximab exacerbates anti-donor CD4+ T-Cell responses in patients with donor-specific anti-human leukocyte antigen antibodies  
**Kentaro Ide**, Japan
- 318.4 Igm immunotherapy restores immune homeostasis and reverses hyperglycemia in new-onset type 1 diabetes  
**Kenneth Brayman**, United States
- 318.5 Specific immunomodulation of alloantibody responses  
**Christian Schuetz**, United States
- 318.6 Antibody response to non-self blood group a-antigen depends on CD4 T cells, forigen protein and CD22 interaction  
**Ibrahim Adam**, Canada
- 318.7 De novo DSA in the setting of stable renal allograft function is a benign finding  
**Richard J. Knight**, United States
- 318.8 HLA-DQ specific alloantibodies modify allogenic endothelial cell immunogenicity and impair the expansion of anti-inflammatory Foxp3 high regulatory T lymphocytes  
**Amy R. Cross**, France
- 318.9 DSA with TCMR identifies high risk renal transplant recipients that can be predicted by proinflammatory transitional B cells  
**Dominik Chittka**, United States

## 09:45-11:15 Oral Abstract Session (Donation &amp; Procurement)

N-105

## 319 - Living Donation-Kidney

Chairs: *Adibul Hasan Rizvi, Pakistan and Susan Gunderson, United States*

- 319.1 Impact after live donor nephrectomy: A comparative follow-up study  
**Shiromani Janki**, Netherlands
- 319.2 Factors related to suboptimal recovery of renal function after living donor nephrectomy  
**Yuji Hidaka**, Japan
- 319.3 Obesity is associated with increased risk of mortality among living kidney donors  
**Brittany A. Shelton**, United States
- 319.4 Prevalence and impact of chronic postsurgical pain following laparoscopic donor nephrectomy: A cross-sectional cohort study  
**Maira H. Bruintjes**, Netherlands
- 319.5 Inclusion of incompatible directed deceased donor organs in kidney transplant exchanges  
**Ernesto P. Molmenti**, United States
- 319.6 3D endoscopic donor nephrectomy versus robot-assisted donor nephrectomy: A detailed comparison of two prospective cohorts  
**Evalyn E.A.P. Mulder**, Netherlands
- 319.7 Single centre experience of altruistic non-directed kidney donation  
**Katharina J. Schumacher**, United Kingdom
- 319.8 Clinical utility and interpretation of CKD stages in living kidney donors  
**Allan Massie**, United States
- 319.9 Pre-donation renal function, early post-donation renal function, and subsequent ESRD risk in living kidney donors  
**Allan Massie**, United States

## 09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences)

N-106

## 320 - Mechanisms of Allograft Rejection

Chairs: *Birgit Sawitzki, Germany and Xian C. Li, United States*

- 320.1 CD47 overcomes early loss of pancreatic islet grafts transplanted intraportally  
**Esma S. Yolcu**, United States
- 320.2 Missing-self triggers NK-mediated microvascular injuries and chronic rejection of allogenic kidney transplants  
**Alice Koenig**, France
- 320.3 Glycolytic bias in mTORC2 deficient dendritic cells potentiates antigen-specific immunity and accelerates graft rejection  
**Alicia R. Watson**, United States
- 320.4 TEMRA CD8 T cells from human kidney transplant recipients exhibit potent anti-donor reactivity and induce GVHD in humanized mouse model  
**Lola Jacquemont**, France
- 320.5 Characterization of acute cellular rejection in the different layers of rat transplanted intestines  
**Martin Rumbo**, Argentina
- 320.6 Adipose-derived stromal cells attenuate acute rejection and graft vasculopathy in rodent vascularized composite allotransplantation  
**Pranitha J. Kamat**, Switzerland
- 320.7 Immunotoxin in the absence of P-glycoprotein allows selective target cell killing in the semi-direct antigen presentation pathway following organ transplantation  
**Lucy J. Meader**, United Kingdom
- 320.8 Type-1 interferons impair the immunoregulatory activity of L-10: Understanding the mechanisms of abrogation of transplant tolerance  
**Marcos Iglesias Lozano**, United States

## 09:45-11:15 Oral Abstract Session (Infectious Diseases)

N-107/108

## 321 - Reducing the Impact of Infections on Transplant Patients

Chairs: *Hans H. Hirsch, Switzerland and Silvia Vidal Campos, Brazil*

- 321.1 A prospective multi-center observational trial to evaluate a CMV-specific ELISpot Assay in solid organ transplant (SOT) recipients: The PROTECT study  
**Camille Kotton**, United States
- 321.2 Clinical validation of a novel ELISpot-based in vitro diagnostic assay to monitor CMV-specific cell-mediated immunity in kidney transplant recipients  
**Bernhard Banas**, Germany
- 321.3 Significance of cytomegalovirus specific T lymphocytes in kidney transplant recipients  
**Maciej Zieliński**, Poland
- 321.4 High frequencies of CMV-specific CD8 and CD4 T Cell cell subsets are needed pretransplant to protect from CMV replication in kidney transplant recipients treated with thymoglobulin  
**Teresa Bellón**, Spain
- 321.5 Treatment of HBV-recurrence after liver transplantation – 30 years of experience  
**Eva M. Teegen**, Germany
- 321.6 High incidence of anal human papillomavirus infection in HIV-infected solid organ transplant recipients  
**Peter V. ChinHong**, United States
- 321.7 Risk factors for fungal infections after liver transplantation: A matched cohort analysis  
**Dieter Hoyer**, Germany
- 321.8 INH prophylaxis in renal transplant recipients: A follow-up of 5 years  
**Anwar Naqvi**, Pakistan
- 321.9 HIV, HBV, AND HCV Screening with NAT AND Serology in the OPO Setting  
**Nicole M. Theodoropoulos**, United States

## 09:45-11:15 Oral Abstract Session

N-111

## 322 - Best Abstracts from the Sociedad Española de Trasplante (SET)

Chairs: *Daniel Seron, Spain* and *Jose Maria Aguado, Spain*

- 322.1 Increase in proinflammatory CD14++CD16+ monocytes in samples from aspiration cytology compared with peripheral blood in kidney transplant patients with borderline rejection  
**Teresa Vazquez**, Spain
- 322.2 Toll-Like Receptor 9 -1486C/T genetic polymorphism is associated with hepatocarcinoma recurrence after liver transplantation  
**Maria Jesus Citores Sanchez**, Spain
- 322.3 KDPI score: A comparison with classical ECD/SCD classification in predicting outcomes  
**Carlos Arias-Cabrales**, Spain
- 322.4 Urinary miRNA as a potential biomarker in kidney transplantation  
**Francesc E. Borràs-Serres**, Spain
- 322.6 MicroRNAs in kidney hypothermic machine perfusion fluid as novel biomarkers for graft function. Have changes in normalization guidelines support previous results?  
**Victoria Gomez Dos Santos**, Spain
- 322.7 Usefulness of delayed introduction of tacrolimus in kidney transplants (KT) with Type III-DCD  
**Lara Ruiz Martínez**, Spain
- 322.8 Fosfomycin for the treatment of asymptomatic bacteriuria and cystitis in kidney transplantation: New uses of an old antibiotic in the era of multidrug-resistance  
**Jose Maria Aguado**, Spain
- 322.9 Methods used to determine brain death diagnosis among actual organ donors in Spain  
**Beatriz Mahillo**, Spain

## 09:45-11:15 Oral Abstract Session (Heart and Lung)

N-112

## 323 - Heart Transplantation

Chairs: *Christopher Wigfield, United States* and *Irene Bello, Spain*

- 323.1 Frailty predicts mortality after heart transplantation  
**Peter S. MacDonald**, Australia
- 323.2 Molecular assessment of heart transplant biopsies: Emergence of the injury dimension  
**Philip F. Halloran**, Canada
- 323.3 HLA sensitization in end-stage heart failure patients supported by extracorporeal membrane oxygenation  
**Ozgur Ersoy**, Turkey
- 323.4 Coronary angiography of potential cardiac donors increases cardiac transplantation rates  
**Andreas Zuckermann**, Austria
- 323.5 Donation after circulatory death heart transplantation: An update of current practices and outcomes  
**Hong Chee Chew**, Australia
- 323.6 The importance of the histopathological findings of surveillance biopsies in the monitoring of acute antibody-mediated rejection (AMR) in cardiac allograft recipients with or without clinical symptoms: Single center experience  
**Aysen Terzi**, Turkey
- 323.7 Mediterranean and low-fat diets reduce cardiovascular disease after both heart and lung transplantation: Results from a randomised trial with 12 month follow up  
**Timothy R. Entwistle**, United Kingdom
- 323.8 Does body size matter for continuous-flow ventricular assist device implantation for bridge to transplantation?  
**Minoru Ono**, Japan
- 323.9 ECMO use post DCD Heart Transplantation: A retrospective study  
**Arjun Iyer**, Australia

**09:45-11:15 Oral Abstract Session (Registry and Transplantation Nursing)****N-113****324 - Patient Oriented Approach and Global Status**Chairs: *Christiane Kugler, Germany* and *Curie Ahn, Korea*

- 324.1 Recovery, symptoms and well-being one to five years after lung transplantation - a multi-center study  
**Anna Forsberg**, Sweden
- 324.2 Comparing the effect of an educational course about organ donation on knowledge and attitudes of nurses and nurse supervisors  
**Omid Ghobadi**, Iran (Islamic Republic of)
- 324.3 Increasing number of pancreas transplantations in the Czech Republic  
**Lenka Nemetova**, Czech Republic
- 324.4 Immunosuppressive medication adherence and its associated factors in renal transplant recipients  
**Hongxia Liu**, People's Republic of China
- 324.5 "preventing" is a new model of application for mobile phones to assess and improve immunosuppressant's adherence in renal transplant recipients; preliminary observational study evaluating usability  
**Jorge Morales-Barria**, Chile
- 324.6 Perspective on pregnancy counseling for kidney transplant recipients  
**Yuki Yoshikawa**, Japan
- 324.7 Latin America transplantations registry. Report 2015-2016  
**Francisco Gonzalez-Martinez**, Uruguay
- 324.8 Worldwide distribution of solid organ transplantation and access of population to those practices  
**Beatriz Mahillo**, Spain

**09:45-11:15 Mini-Oral Abstract Session (Pancreas & Islet)****N-115/116****325 - Islet and Pancreas Miscellaneous**Chairs: *Thomas Kay, Australia* and *Daniel Casanova, Spain*

- 325.1 A novel subcutaneous pancreatic islet transplantation method using the new device of recombinant peptide containing human type I collagen material with RGD motif (Arg-Gly-Asp)  
**Satomi Suzuki Uematsu**, Japan
- 325.2 Human amniotic epithelial cells integrated into the islet heterospheroids enhance insulin secretion and protect islet cells from hypoxic injury  
**Vanessa Lavallard**, Switzerland
- 325.3 BETA-2 score allows for convenient and precise monitoring of islet function and early detection of islet dysfunction  
**Piotr J. Bachul**, United States
- 325.4 Comparative evaluation of simple indices using a single fasting blood sample to estimate beta cell function after total pancreatectomy with islet autotransplantation  
**Justyna E. Gołębiewska**, Poland
- 325.5 Outcomes of enteric conversion of bladder drained pancreas; over a decade of experience at a single center  
**Samy M. Riad**, United States
- 325.6 Delivery of pancreatic islets and single dose local immune suppression into subcutaneous space using injectable hydrogel provides indefinite survival of the graft in mouse model of diabetes  
**Shiva Pathak**, Korea
- 325.7 Outcomes for islet transplantation in donation after circulatory death compared with donation after brain death in Australia  
**Wayne J. Hawthorne**, Australia
- 325.8 Modification of polyurethane scaffolds for localised immunosuppression of subcutaneous islet transplantation  
**Francis Kette**, Australia
- 325.9 One-year blood glucose level is the best metabolic marker for the prediction of late pancreas graft failure  
**Diego Cantarovich**, France
- 325.10 A study of effectiveness of preceding solo-kidney transplantation for Type1 diabetes with end stage renal failure  
**Taihei Ito**, Japan
- 325.11 Decline in pancreas transplantation numbers is accompanied with lower publication rates  
**Stan Benjamens**, Netherlands
- 325.12 Incidence of de-novo donor specific anti-human leucocyte antigen (HLA antibodies (DSA) in simultaneous pancreas kidney (SPK) transplant patients: A comparison between alemtuzumab and basiliximab based immunosuppression regimes  
**John Moir**, United Kingdom

**09:45-11:15 Mini-Oral Abstract Session (Complications)****N-117/118****326 - Complications-Complications-Complications**Chairs: *Johann Pratschke, Germany and Allison Tong, Australia*

- 326.1 Efficacy of rabbit anti-thymocyte globulin therapy for severe acute rejection in kidney transplant patients using calcineurin inhibitor and mycophenolate mofetil based immunosuppressive therapy  
**Marieke van der Zwan**, Netherlands
- 326.2 Predictive factors analysis of osteoporosis and fragility fractures after liver transplantation  
**Shuji Akimoto**, Japan
- 326.3 Mechanical circulatory support before and after heart transplantation: Impact on survival  
**Calogero Falletta**, Italy
- 326.4 Establishing a core outcome measure for graft health: A standardized outcomes in nephrology – kidney transplantation (SONG-Tx) consensus workshop report  
**Allison Tong**, Australia
- 326.5 Differences in risk factors for graft and patient survival among renal transplant recipients with type 2 diabetes mellitus. Generation of a T2DM specific risk calculator  
**David J. Goodman**, Australia
- 326.6 A simple strategy for diagnosis of PTDM in stable kidney transplanted patients  
**Amin M. Ussif**, Norway
- 326.7 Intravenous immunoglobulin replacement therapy in solid organ transplantation with severe infections and secondary antibody deficiency: Proof of concept  
**Javier Carbone**, Spain
- 326.8 Cardiovascular disease after kidney transplant from uncontrolled donation after circulatory death (uDCD)  
**Maria Molina**, Spain
- 326.9 Outcomes of kidney transplantation in former non kidney solid organ transplant  
**Anders Åsberg**, Norway
- 326.10 Primary Sjögren Syndrome associated with mixed cryoglobulinaemia in kidney transplant patient: A case report  
**Oscar A. Calle Mafía**, Spain
- 326.11 Invasive fungal infection among transplant tourism patients  
**Issa Al Salmi**, Oman
- 326.12 Impact of empagliflozin for the treatment of diabetes mellitus after heart transplantation  
**Peter S. MacDonald**, Australia

**09:45-11:15 328 - Leadership Series presented by the TTS Education Committee (Education)****N-114**

- 328.1 Introduction to the TTS Leadership Series Program and Structure  
**Medhat Askar**, United States
- 328.2 Success Story - Case 1  
**TBA**
- 328.3 Success Story - Case 2  
**TBA**
- Panel Discussions

**11:15-11:45 Coffee Break / Poster Viewing / Visit Exhibitors****Hall 10 – Exhibition****11:15-11:45 330 - TTS Innovation Session****Hall 10 – TTS Innovative Studio in TTS Booth**

- 330.1 Maximizing the Visibility of your Research Paper: How can social media help  
**Carla C. Baan**, Netherlands



<b>11:45-13:15</b>	<b>Plenary Session 1</b> <b>335 - Improving Patient Outcomes - Organ Donation</b>	<b>Hall 10 – Plenary</b>
	Facilitator: <i>Nancy Ascher, United States</i>	
335.1	Challenges to improving deceased organ donation - past, present and future <b>Rafael Matesanz</b> , Spain	
335.2	Molecular therapeutic targets to minimise ischemia reperfusion injury <b>Carmen Peralta</b> , Spain	
335.3	Normothermic perfusion – will it live up to its promise <b>Peter J. Friend</b> , United Kingdom	
<b>13:15-14:45</b>	<b>Lunch Break / Poster Viewing / Visit Exhibitors</b>	<b>Hall 10 – Exhibition</b>
<b>13:30-14:30</b>	<b>Corporate Symposium</b> <b>340 - Yesterday's Intervention Tomorrow's Outcome: Improving the Transplant Journey</b>	<b>Hall 10 – Plenary</b>
	See page 28 for details.	
<b>13:30-14:15</b>	<b>Lunch and Learn (#LL1 search on WebApp)</b> <b>350 - Lunch and Learn 1 (registration required)</b>	<b>Retiro Room (NCC)</b>
350.1	Differences between adult and pediatric liver transplantation <b>Carlos O. Esquivel</b> , United States	
350.2	Significance of sarcopenia in liver transplantation <b>Toshimi Kaido</b> , Japan	
350.3	Critically ill liver transplant candidate <b>Catherine Paugam-Burtz</b> , France	
350.4	Management of the HIV positive transplant recipient <b>Peter G. Stock</b> , United States and <b>Elmi Muller</b> , South Africa	
350.5	How I desensitize an HLA incompatible kidney transplant candidate <b>Lionel Rostaing</b> , France	
350.6	Essentials of organ donor research <b>Claus Niemann</b> , United States	
350.7	Kidney paired donation (KPD) transplantation to increase donor pool <b>Vivek Kute</b> , India	
350.8	Long term complications after kidney transplantation <b>Germaine Wong</b> , Australia	
350.9	Sex at the bench and beyond: a discussion on the importance of including sex as a biological variable in research! <b>Deborah J. Clegg</b> , United States	
350.12	Technical tips in live donor hepatectomy including laparoscopic donor hepatectomy <b>Kyung-Suk Suh</b> , Korea	
350.13	PSC and LT; allocation, timing, selection <b>Christian P. Strassburg</b> , Germany	
350.14	Rejection under steroid-free belatacept therapy: What to expect and how to treat <b>E. Steve Woodle</b> , United States	
350.16	Mapping out your career - finding your road to success <b>Jayne E. Locke</b> , United States	
350.17	Kidney transplant beyond the usual anatomy (For surgeons) <b>Alejandro Niño-Murcia</b> , Colombia	
350.18	Precision transplant medicine: what's next? <b>Minnie M. Sarwal</b> , United States	
350.19	Manuscript submissions <b>Transplantation Journal Editor</b>	

13:30-13:45	<b>Plenary Speaker Interview</b>	Hall 10 – TTS Innovative Studio in TTS booth
345.1	<b>Peter J. Friend</b> , United Kingdom	
14:45-16:15	<b>State-of-the-Art Session (Liver)</b> <b>360 - Recurrent Liver Allograft Disease: How to Deal With</b>	N-101
	Chairs: <i>Philip J. O'Connell, Australia</i> and <i>Kyung-Suk Suh, Korea</i>	
360.1	Acute versus chronic alcoholic liver disease: real incidence and how to prevent recurrence <b>Christophe Moreno</b> , Belgium	
360.2	Recurrent Viral B and C disease: is the graft still salvageable? <b>Marina Berenguer</b> , Spain	
360.3	Recurrent hepatocellular cancer: is there a place for surgery? <b>Shusen Zheng</b> , People's Republic of China	
14:45-16:15	<b>State-of-the-Art Session (Paediatrics)</b> <b>361 - Paediatric Transplantation: Challenges and Potential Solutions</b>	N-102
	Chairs: <i>Mignon McCulloch, South Africa</i> and <i>Rebecca Greenberg, Canada</i>	
361.1	Ethics of transplanting the non-adherent teen <b>Grainne M. Walsh</b> , United Kingdom	
361.2	Long term outcomes of paediatric transplantation <b>Carlos O. Esquivel</b> , United States	
361.3	Biomarkers for PTLT diagnosis and therapies <b>Olivia M. Martinez</b> , United States	
14:45-16:15	<b>State-of-the-Art Session (Kidney)</b> <b>362 - Strategies for the Sensitized Patient</b>	N-103
	Chairs: <i>Ron Shapiro, United States</i> and <i>Daniel Seron, Spain</i>	
362.1	IdeS: a new approach to desensitization <b>Robert A. Montgomery</b> , United States	
362.2	Anti-IL-6R Ab for the prevention and treatment of AMR <b>Olivier Aubert</b> , France	
362.3	The role of the acceptable mismatch strategy for sensitized patients <b>Frans HJ Claas</b> , Netherlands	
14:45-16:15	<b>State-of-the-Art Session (Basic Sciences and Translational Sciences)</b> <b>363 - New Therapeutic Approaches to Transplantation</b>	N-104
	Chairs: <i>Jordi Ochando, Spain</i> and <i>Birgit Sawitzki, Germany</i>	
363.1	Mechanisms of organ injury and repair by macrophages <b>Menna R. Clatworthy</b> , United Kingdom	
363.2	Systems biology of the intragraft regional immunoregulation in tumor recurrence after liver transplantation <b>Nancy Kwan Man</b> , Hong Kong	
363.3	Nudging clinical Treg responses <b>Qizhi Tang</b> , United States	
14:45-16:15	<b>State-of-the-Art Session (Donation &amp; Procurement)</b> <b>364 - New Strategies to Increase Donation</b>	N-105
	Chairs: <i>Susan Gunderson, United States</i> and <i>Martí Manyalich, Spain</i>	
364.1	Donor intervention research - priorities and trends <b>Claus Niemann</b> , United States	
364.2	Effective family approach practices <b>Howard M. Nathan</b> , United States	
364.3	End of life care decision making impact on donation <b>Kristina Krmpotic</b> , Canada	

<b>14:45-16:15</b>	<b>State-of-the-Art Session (Cellular and Regenerative Therapies)</b>	<b>N-106</b>
	<b>365 - Inflammation and Stem Cell Transplantation</b>	
	Chairs: <i>Toshio Miki, United States and Ewa Ellis, Sweden</i>	
365.1	Stem cell therapy, hepatocytes, a source for liver regeneration <b>Anil Dhawan</b> , United Kingdom	
365.2	Pursing tolerance by blocking inflammation in islet transplantation <b>Maria Koulmanda</b> , United States	
365.3	Advances in MR cell imaging <b>Frantisek Saudek</b> , Czech Republic	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Histocompatibility)</b>	<b>N-107/108</b>
	<b>366 - Cutting Edge of Alloreognition</b>	
	Chairs: <i>Peter W. Nickerson, Canada and Elaine F. Reed, United States</i>	
366.1	Novel immune alloreognition pathways <b>Megan Sykes</b> , United States	
366.2	MHC: T-Cell receptor alloreognition interface <b>James McCluskey</b> , Australia	
366.3	MHC: B-Cell receptor alloreognition interface <b>Olivier Thaumat</b> , France	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Intestine &amp; Multivisceral Transplantation)</b>	<b>N-111</b>
	<b>367 - The Future of of Intestinal Transplantation</b>	
	Chairs: <i>George V. Mazariegos, United States and Jayme E. Locke, United States</i>	
367.1	The microbiome and its implications in ITX <b>Alexander Kroemer</b> , United States	
367.2	Current knowledge on regulation and impairment of motility after intestinal transplantation <b>Martin W. von Websky</b> , Germany	
367.3	Alloimmunity of the intestinal allotransplant <b>Martin Rumbo</b> , Argentina	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Vascularized Composite Allotransplantation)</b>	<b>N-115/116</b>
	<b>368 - Novel Technologies and Tools in VCA</b>	
	Chairs: <i>Emmanuel Morelon, France and Stefan Schneeberger, Austria</i>	
368.1	Nanomedicine Strategies for VCA - Prospects and Potential <b>Jelena M. Janjic</b> , United States	
368.2	Vascularized composite allograft engineering - the new frontier <b>Benoit Lengele</b> , Belgium	
368.3	Cortical integration after VCA-relevance in hand and face transplants <b>Angela Sirigu</b> , France	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Ethics, Community, Economics)</b>	<b>N-117/118</b>
	<b>369 - Upholding the Ethics of Transplantation: The Global View</b>	
	Chairs: <i>Beatriz Dominguez-Gil, Spain and Peter G. Stock, United States</i>	
369.1	Pakistan - the challenges and successes in transplantation <b>Adibul Hasan Rizvi</b> , Pakistan	
369.2	Establishment of a successful deceased donor program in Iran <b>Seyed Ali Malek-Hosseini</b> , Iran (Islamic Republic of)	
369.3	Achieving organ donor reform in China <b>Haibo Wang</b> , People's Republic of China	

**16:30 to 17:30 - Campfire Sessions and Poster Session 1**
**16:30-17:30 Campfire Session (Kidney) Hall 10 – Exhibition**  
**C390 - Kidney Issues**

Chairs: *E. Steve Woodle, United States and Olivier Aubert, France*

- C390.1 C1q assay to determine complement fixing of anti-human leukocyte antigen antibodies, but not immunoglobulin subclass identification, allows better prediction of kidney allograft outcomes in an Asian population  
**Rachel Teo**, Singapore
- C390.2 Development and internal validation of a prediction model for early hospital readmissions in kidney transplant recipients  
**Olusegun Famure**, Canada
- C390.3 Comparative results of transurethral incision with transurethral resection of the prostate in renal transplant recipients with benign prostate hyperplasia  
**Mehmet Sarier**, Turkey
- C390.4 Timing of double-j stent removal and occurrence of urological complications: A systematic review and meta-analysis  
**Isis J. Visser**, Netherlands
- C390.5 Patient and graft outcome among high immunologic risk renal transplant recipients  
**Jeffrey P. Mora**, Philippines
- C390.6 Higher rates of rejection in HIV-infected kidney transplant recipients on Ritonavir-boosted protease inhibitors-three-year follow up  
**Ron Shapiro**, United States

**16:30-17:30 Campfire Session (Transplant Immunosuppression) Hall 10 – Exhibition**  
**C391 - Transplant Immunosuppression**

Chairs: *Christine S. Falk, Germany and Manikkam Suthanthiran, United States*

- C391.1 A limited sampling strategy to estimate whole blood and intra-lymphocyte exposure of everolimus in renal transplant recipients using population pharmacokinetic modeling and bayesian estimators  
**Anders Åsberg**, Norway
- C391.2 Prediction of tacrolimus drug dosing and metabolism based on CYP3A5 polymorphism in Indian renal transplant recipients  
**Mohan Patel**, India
- C391.3 Acute antibody-mediated rejection and its treatment in kidney transplantation: Report from a national cohort study  
**Nancy Perrottet**, Switzerland
- C391.4 The suppressive function of the human regulatory macrophages in-vitro have more potency but not in-vivo  
**Yuanfei Zhao**, Australia
- C391.5 Tacrolimus exerts age-specific immunosuppressive effects linked to modifications of CD4+ T cells metabolism  
**Yeqi Nian**, United States
- C391.6 Effects of the de novo use of everolimus with reduced calcineurin inhibitor on wound healing events in the TRANSFORM study  
**Franco Citterio**, Italy

**16:30-17:30 Campfire Session (Complications) Hall 10 – Exhibition**  
**C392 - Infections and PTLT**

Chairs: *Olivia M. Martinez, United States and TBA*

- C392.1 Epstein-Barr virus genome variation in post-transplant lymphoproliferative disorder  
**Olivia M. Martinez**, United States
- C392.2 Genomic status of the Epstein Barr virus and virus-associated PI3K/Akt/mTOR pathway dysregulation in post-transplant lymphoproliferative disorder  
**Marla C. McPherson**, United States
- C392.3 Unusual malignancies after small bowel transplantation in children: A European single centre experience  
**Undine Gerlach**, Germany
- C392.4 Elucidation of the miRNome in EBV-positive and EBV-negative PTLT  
**Yarl Balachandran**, United States
- C392.5 The MADELEINE (coMBined tAcrolimus anD EveroLimus Early ImmuNosupprEsson) study: CMV and BKV infections over the first 6 months post-transplant  
**Thomas Jouve**, France

**16:30-17:30 Campfire Session (Infectious Diseases)****Hall 10 – Exhibition****C393 - Donor-Derived and Early Post-Transplant Infections**Chairs: *Michael G. Ison, United States and Clarisse Machado, Brazil*

- C393.1 Cut-Off of COBAS®Ampliprep/COBAS®Taqman® CMV test in transplant recipients receiving intermittent Ganciclovir (GCV) Prophylaxis  
**Silvia Vidal Campos**, Brazil
- C393.2 The use of 16s ribosomal RNA PCR to investigate donor derived transport fluid infections in patients undergoing renal transplantation: a retrospective audit of 36 deceased donors  
**John T. Black**, United Kingdom
- C393.3 Transmission of multiresistant bacteria from donor to recipient  
**María Carrillo Cobarro**, Spain
- C393.4 Utility of multi locus sequence typing (MLST) in the investigation of a cluster of candida albicans infection in recipients of solid organs from a common donor  
**Ines Ushiro-Lumb**, United Kingdom
- C393.5 Intestinal mucosal barrier disruption and microfold cells impairment were required for invasive fungal infection after living donor liver transplantation  
**Jiang Liu**, People's Republic of China
- C393.6 Tuberculosis among kidney transplant patients compared to dialysis and non-dialysis CKD patients over a decade period  
**Issa Al Salmi**, Oman

**16:30-17:30 Campfire Session (Basic Sciences and Translational Sciences)****Hall 10 – Exhibition****C394 - None Plus Ultra?**Chairs: *Qizhi Tang, United States and Menna R. Clatworthy, United Kingdom*

- C394.1 The importance of adjustment for confounding factors in biomarker studies to avoid misleading conclusions  
**Maria P. Hernandez-Fuentes**, United Kingdom
- C394.2 Standardized whole-blood immunophenotyping panels on flow cytometry for transplant recipients and clinical trials  
**Elvira Jimenez Vera**, Australia
- C394.3 Biomarkers: New tool to detect subclinical inflammation?  
**Nuria Serra**, Spain
- C394.4 Can regulatory T cells help us as a biomarker of long-term kidney graft survival?  
**Luis Humberto Galvan Espinoza**, Spain
- C394.5 Early enrichment and restitution of the peripheral blood Treg pool is associated with rejection-free stable immunosuppression after liver transplantation  
**Akinbami R. Adenugba**, Germany

**16:30-17:30 Campfire Session (Xenotransplantation)****Hall 10 – Exhibition****C395 - New Approaches in Xenotransplantation**Chairs: *David K.C. Cooper, United States and Kazuhiko Yamada, United States*

- C395.1 The value of glycated albumin for monitoring graft function in the non-human primate porcine islet transplantation model  
**Hee Jung Kang**, Korea
- C395.2 Progress in xenogeneic lung transplantation using multi-transgenic donor pigs and targeted supportive drug treatments  
**Lars Burdorf**, United States
- C395.3 Multitransgenic porcine fibroblasts are protected from immunoglobulin binding and complement deposition in a xeno-microfluidic model  
**Riccardo Sfriso**, Switzerland
- C395.4 Recent progress in pig to non-human primate (nhp) solid organ xenotransplantation in Korea  
**Ik Jin Yun**, Korea
- C395.5 A novel and effective therapeutic approach to overcome refractory transplant-related anti-glycan Ab production  
**Yuka Tanaka**, Japan
- C395.6 In vitro xenoantigen stimulated human Tr1 cells enhanced suppression of the xenogeneic T cell response with upregulated expression of CD39  
**Xi Jin**, People's Republic of China

**16:30-17:30 Campfire Session (Pancreas & Islet)**  
**C396 - Islet Transplantation**
**Hall 10 – Exhibition**Chairs: *Adam D. Barlow, United Kingdom and Lorenzo Piemonti, Italy*

- C396.1 Characterization of 3D-printed human regulatory T-cells  
**Juewan Kim**, Australia
- C396.2 Development of the total pancreatectomy and autologous islet transplantation models as the step for allogenic islet transplantation experiments in the swine  
**Kohei Miura**, Japan
- C396.3 Early infectious complications post total pancreatectomy with islet autotransplantation  
**Justyna E. Gołębiewska**, Poland
- C396.4 Shielding human islets with human amniotic epithelial cells enhances islet engraftment and revascularization  
**Fanny Lebreton**, Switzerland
- C396.5 Human mesenchymal stem cells derived exosomes enhance porcine islet resistance to hypoxia in islet transplantation  
**Wei Nie**, People's Republic of China
- C396.6 The study of the influence on hIAPP deposition and dysfunction in INS-1 cell by calcineurin inhibitors  
**Jialin Zhang**, People's Republic of China

**16:30-17:30 Campfire Session (Donation & Procurement)**  
**C397 - Knowledge and Attitudes**
**Hall 10 – Exhibition**Chairs: *Katja Empson, United Kingdom and Margaux N. Mustian, United States*

- C397.1 Revisiting transplant tourism regulations in the Philippines: How can we improve the practice?  
**Campbell Fraser**, Australia
- C397.2 Factors influencing deceased donor consent rates in Cape Town, South Africa  
**David A. Thomson**, South Africa
- C397.3 Does rapid growth in the number of donation after circulatory death donors equate to fewer brain dead donors and fewer organs transplanted?  
**Jeffrey P. Orlowski**, United States
- C397.4 The weekend effect: An Australian cohort study analysing temporal trends in solid organ donation  
**Angela C. Webster**, Australia
- C397.5 Results of kidney transplantation and re transplantation in Argentina 1998-2016  
**Liliana Bisigniano IV**, Argentina
- C397.6 Clinicians' attitudes and perspectives on ante-mortem interventions in deceased organ donation: An international interview study  
**Sara Shahrestani**, Australia

**16:30-17:30 Campfire Session (Heart and Lung)**  
**C398 - Heart and Lung**
**Hall 10 – Exhibition**Chairs: *Peter S. MacDonald, Australia and Maria G. Crespo-Leiro, Spain*

- C398.1 Dyslipidaemia after heart transplantation  
**Maria M. Simonenko**, Russian Federation
- C398.2 Head to head comparison of speckle tracking strain echocardiography with invasive hemodynamic assessment for the detection of acute cellular rejection in cardiac allograft recipients  
**Haldun Muderrisoglu**, Turkey
- C398.3 Left atrial longitudinal strain at the conduit phase: A new additional parameter in predicting elevated capillary wedge pressure in patients candidate for heart transplant  
**Calogero Falletta**, Italy
- C398.4 Early postoperative acute kidney injury among heart transplant recipients: Incidence, risk factors and impact on clinical consequences  
**Pinar Zeyneloglu**, Turkey
- C398.5 Effects of transcutaneous nerve stimulation on the autonomic balance of cardiac transplant recipients  
**Beatriz Robert Moreira**, Brazil
- C398.6 Impact of a mobile pharmaceutical and healthcare programme on therapeutical adherence in heart transplant patients  
**Mar Gomis**, Spain

---

**16:30-17:30 Campfire Session (Liver)**  
**C399 - IS and Viral Hepatitis**


---

**Hall 10 – Exhibition**Chairs: *Christian P. Strassburg, Germany and TBA*

- C399.1 Cost effectiveness of immunosuppression withdrawal after liver transplantation  
**Tommaso Maria Manzia**, Italy
- C399.2 Mycophenolate mofetil effect and trough level under 2-year old in pediatric living donor liver transplantation  
**Takehisa Ueno**, Japan
- C399.3 New insights from the SILVER study; a 50 % reduction in calcineurin inhibitors at day 30 achieves a temporary renal-sparing effect but does not impact on long-term renal function after liver transplantation  
**Bettina Buchholz**, United Kingdom
- C399.4 22 years of experience in hepatic re-transplantation: Value of predictive survival scores  
**Gabriel E. Gondolesi**, Argentina
- C399.5 Long term nucleos(t)ide analog therapy after immunoglobuline withdrawal in liver transplant recipients to prevent recurrent hepatitis B  
**Carmelo Loinaz**, Spain
- C399.6 Phase 1/2a trial of a bioartificial liver support system (LifeLiver) for acute liver failure patients  
**Seung Wook Han**, Korea
- 

**16:30-17:30 Poster Session 1 - Odd Poster Number Presentations**


---

*Detailed list of all the posters available on page 122**All poster presenters with odd poster numbers shall be at their respective poster(s).*



**16:15-17:30 Other Events**

<b>16:30-17:30</b>	<b>Corporate Symposium</b>	<b>N-103</b>
<b>380</b>	<b>Might Different Patients Need Different Approaches? New Concepts on Tacrolimus Metabolism and Pharmacokinetics</b>	

See page 28 for details.

<b>16:30-16:45</b>	<b>Interview with SOTA Speakers</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
<b>375.1</b>	<b>James McCluskey</b> , Australia <b>Howard M. Nathan</b> , United States <b>Frans HJ Claas</b> , Netherlands	

<b>16:45-17:00</b>	<b>Case Competition Presentation 1</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
<b>375.2</b>	TCR NGS based evidence for differential diagnosis and personalized therapy in BKV nephropathy <b>Ulrik Stervbo</b> , Germany	

<b>17:00-17:15</b>	<b>Case Competition Presentation 2</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
<b>375.3</b>	Day to day decision in multi-visceral transplantation immunosuppression <b>Marina Pérez-Flecha González</b> , Spain	

<b>17:45-18:45</b>	<b>International Transplantation Science Mentee-Mentor Awards Networking Event</b>	<b>N-115/116</b>
--------------------	--	------------------

# DETAILED PROGRAM

Tuesday, July 3, 2018

**08:30-09:30 Mini-Oral Abstract Session (Liver)****N-101****400 - Recipient Selection and Viral Infections**Chairs: *Marina Berenguer, Spain* and *Christian P. Strassburg, Germany*

- 400.1 Predictive factors for death on a long waiting list for liver transplantation after an episode of acute on chronic liver failure  
**Speranta Iacob**, Romania
- 400.2 Impact of recipient age on long-term after liver transplantation: A double propensity score matching analysis  
**Concepción Gómez-Gavara**, Spain
- 400.3 Aging in liver transplantation: Does the interaction of donor and recipient age matter?  
**Nicholas Gilbo**, Belgium
- 400.4 OR extubation of liver transplant (LT) patients is associated with significantly less blood transfusion during surgery, acute renal failure and bacterial infection, and shorter hospital and ICU stay  
**Martin A. Maraschio**, Argentina
- 400.5 Impact of sarcopenic obesity on outcomes after liver transplantation; does sarcopenic obesity cause poor prognosis?  
**Naoko Kamo**, Japan
- 400.6 Evaluation of the renal graft function after hepatitis C virus treatment with interferon-free directly acting antiviral: A centre experience  
**Oscar A. Calle Mafla**, Spain
- 400.7 Analysis of the association of posttransplant donor-specific HLA antibody with liver fibrosis after pediatric liver transplantation  
**Kazuaki Tokodai**, Japan
- 400.8 Benefit of anti-hepatitis B immunoglobulin(hbIg)) monotherapy compared to HBLG combined with entecavir in long term renal function  
**Sung Hoon Kim**, Korea

**08:30-09:30 Mini-Oral Abstract Session (Kidney)****N-102****401 - Immunossuppression 1**Chairs: *Amado Andres Belmonte, Spain* and *TBA*

- 401.1 The results of the PRISM (prediction of rejection in sensitized patient blood samples) trial with a novel bioassay  
**Minnie M. Sarwal**, United States
- 401.2 Significant anti-CMV/BKV effect of a modern everolimus-based regimen compared to standard tacrolimus-MPA regimen in de novo kidney transplant recipients: Athena 12 months data on infections  
**Duska Dragun**, Germany
- 401.3 Mycophenolic acid therapeutic drug monitoring in de novo renal transplant patients and the related outcomes  
**Shiong Shiong Yew**, Malaysia
- 401.4 Evaluation of cell-mediated immune response by QuantiFERON Monitor® assay in kidney transplant recipients  
**Ivan Margeta**, Croatia
- 401.5 Effect of everolimus on body composition; 1-year after kidney transplantation  
**Mikiko Yoshikawa**, Japan
- 401.6 Tacrolimus - optimization of levels in kidney transplant  
**Joseph Kim**, Canada
- 401.7 Concurrent antibody-mediated rejection in post-transplant IgA nephropathy – diagnosis using a stepwise approach of graft morphology  
**Hyeon Joo Jeong**, Korea
- 401.8 The influence of polyomavirus infected glomerular cells on the development of glomerulopathy and the graft survival  
**Aysen Terzi**, Turkey

**08:30-09:30 Mini-Oral Abstract Session (Kidney)**  
**402 - Living Donor**
**N-105**Chairs: *John S. Gill, Canada* and *Gabriel Danovitch, United States*

- 402.1 Living kidney donation in Spain, a global strategy to increase this modality of transplantation  
**Maria Oliva Valentin**, Spain
- 402.2 Prospective comparison between open and robot assisted kidney transplant: Our initial results  
**Anant Kumar**, India
- 402.3 Comparative mortality of live kidney donors in the UK: 15 year cohort study  
**Nithya S. Krishnan**, United Kingdom
- 402.4 Comparative morbidity outcomes in live kidney donors in the UK: 15 year cohort study  
**Nithya S. Krishnan**, United Kingdom
- 402.5 Retroperitoneal single port versus transperitoneal multiport donor nephrectomy: A prospective randomised control trial  
**Navdeep Singh**, India
- 402.6 Radioisotopic evaluation glomerular filtration rate (GFR) before and after kidney donation  
**Vincenzo Cantaluppi**, Italy
- 402.7 CT based visceral fat measures predict complexity, complications and low clearance in living donor nephrectomy  
**Zubir Ahmed**, United Kingdom

**08:30-09:30 Mini-Oral Abstract Session (Basic Sciences and Translational Sciences)**  
**403 - Human Immunology**
**N-106**Chairs: *Megan Levings, Canada* and *Oriol Bestard Matamoros, Spain*

- 403.1 Functional analysis of hepatic TCF7L2 gene polymorphism in glucose metabolism by allele-specific CRISPR/Cas 9 gene editing  
**Qi Ling**, People's Republic of China
- 403.2 Single-cell analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus  
**Carla C. Baan**, Netherlands
- 403.3 Pre-transplant immune markers of rejection risk in HIV-positive transplant recipients  
**Simon N. Chu**, United States
- 403.4 Identifying shared patterns in the T cell receptor repertoire specific to IE-1 CMV  
**Marc Lucia Perez**, United States
- 403.5 High numbers of donor-specific IL-21 producing cells predict rejection after kidney transplantation: A cross validation  
**Nicole M. van Besouw**, Netherlands
- 403.7 Renal allograft transcription analysis reveals similar signature of acute T cell mediated rejection in patients treated with tacrolimus or belatacept  
**Marieke van der Zwan**, Netherlands

**08:30-09:30 Mini-Oral Abstract Session (Basic Sciences and Translational Sciences)**  
**404 - T Cell Biology 1**
**N-107/108**Chairs: *Xian C. Li, United States* and *James McCluskey, Australia*

- 404.1 Th1/Th2 imbalance and early age to transplantation is associated to atopic dermatitis in heart-transplanted pediatric patients  
**Rafael Correa-Rocha**, Spain
- 404.2 Peripheral blood regulatory T cells are diminished in kidney-transplant patients with chronic allograft nephropathy  
**Marco Antonio Carmona Jr.**, Mexico
- 404.3 Evidence for intrathymic clonal deletion in tolerance induction to limb allografts  
**Wensheng Zhang**, United States
- 404.4 Alloactivation of human CD4+CD25+CD127loCD45RA-Fox3hi Treg population to induce potential alloantigen specific Treg  
**Nirupama D. Verma**, Australia
- 404.5 Immunosuppressors (CsA, MPA) and IVIg act directly upon endothelial cells and differentially alter their ability to activate allogeneic T-CD4+  
**Julien Lion**, France, Metropolitan
- 404.6 Tissue-resident memory T cells of donor origin are short-lived in renal allografts after transplantation  
**Kitty de Leur**, Netherlands

08:30-09:30	<b>Morning Symposium (Cellular and Regenerative Therapies)</b> <b>405 - Clinical Applications in Stem Cells</b>	N-111
	Chairs: <i>Maria Koulmanda, United States and Qizhi Tang, United States</i>	
405.1	Bottlenecks to clinical application of IpS <b>Martin Hoogduijn</b> , Netherlands	
405.2	Clinical trials for stem-based regenerative medicine <b>Toshio Miki</b> , United States	
08:30-09:30	<b>Morning Symposium (Heart and Lung)</b> <b>406 - The Future of Thoracic Transplantation</b>	N-112
	Chairs: <i>Anne Dipchand, Canada and Olivier Bastien, France</i>	
406.1	Assessment of frailty and comorbidities <b>Cynthia Gries</b> , United States	
406.2	Efforts to increase the lung donor pool <b>Dirk Van Raemdonck</b> , Belgium	
406.3	Efforts to increase the heart donor pool <b>Peter S. MacDonald</b> , Australia	
08:30-09:45	<b>Morning Symposium (Xenotransplantation)</b> <b>407 - Issues Relating to Clinical Xenotransplantation</b>	N-113
	Chairs: <i>Alfred J. Tector III, United States and Muhammad Mohiuddin, United States</i>	
407.1	Are low anti-pig antibody levels essential to the success of pig organ xenotransplantation? <b>Emanuele E. Cozzi C</b> , Italy	
407.2	Is encapsulated pig islet Tx preferable to free pig islet Tx? <b>Rita Bottino</b> , United States	
407.3	Is pig genetic engineering essential for the success of xenotransplantation? <b>Kazuhiko Yamada</b> , United States	
	<b>Presentation of the 2017 Carl-Gustav Groth Xeno Prize</b> <i>Article published in the Xenotransplantation Journal (May/June 2017, Volume 24, Issue 3)</i> Testing of microencapsulated porcine hepatocytes in a new model of fulminant liver failure in baboons Co-Authors: <b>Zurab Machaidze</b> and <b>Heidi Yeh</b> , United States	
08:30-09:30	<b>Morning Symposium (Intestine &amp; Multivisceral Transplantation)</b> <b>408 - Controversies in Intestinal Transplant</b>	N-114
	Facilitators: <i>Alexander Kroemer, United States and Gabriel E. Gondolesi, Argentina</i>	
408.1	Should every country have an intestinal transplant program? Yes <b>Rodrigo Vianna</b> , United States	
408.2	Should every country have an intestinal transplant program? No <b>George V. Mazariegos</b> , United States	
	Open debate discussion	
408.3	Cipo: pre-emptive transplant - Yes <b>Francisco Hernandez</b> , Spain	
408.4	CIPO: Pre-emptive transplant - No <b>Florence Lacaille</b> , France	
	Open debate discussion	

<b>08:30-09:30</b>	<b>Morning Symposium (Paediatrics)</b>	<b>N-115/116</b>
	<b>409 - Trends in Paediatric Transplantation</b>	
	Chairs: <i>Carlos O. Esquivel, United States and Olivia M. Martinez, United States</i>	
409.1	Paediatric PTLT pearls <b>Stephen D. Marks</b> , United Kingdom	
409.2	Donor specific antibodies in paediatrics <b>Burkhard Tönshoff</b> , Germany	
409.3	Ethical issues in paediatric transplantation: an update on current issues <b>Rebecca Greenberg</b> , Canada	
<b>08:30-09:30</b>	<b>Morning Symposium (Donation &amp; Procurement)</b>	<b>N-117/118</b>
	<b>410 - Opt Out - New Experiences in Presumed Consent</b>	
	Chairs: <i>Howard M. Nathan, United States and Jongwon Ha, Korea</i>	
410.1	The Wales experience <b>Katja Empson</b> , United Kingdom	
410.2	The US opt in experience <b>Susan Gunderson</b> , United States	
410.3	Opt in-opt out - the European experience <b>Bernadette BJM. Haase-Kromwijk</b> , Netherlands	
<b>09:45-11:15</b>	<b>Mini-Oral Abstract Session (Liver)</b>	<b>N-101</b>
	<b>415 - Malignancies and Complications</b>	
	Chairs: <i>John J. Fung, United States and Jan Lerut, Belgium</i>	
415.1	Validated nomogram for prediction of recurrence in HCC within Milan criteria <b>Ka-Wing Ma</b> , Hong Kong	
415.2	Hepatic artery doppler flow changes during cholangitis in liver transplantation patients <b>Funda Ulu Öztürk</b> , Turkey	
415.3	Liver transplantation and auxiliary partial orthotopic transplantation outcomes in Wilson's disease: Results of a single center <b>Ebru H. Ayvazoglu Soy</b> , Turkey	
415.4	Factors associated with the development of chronic kidney disease after liver transplantation <b>Marit Kalisvaart</b> , United Kingdom	
415.5	Prediction of outcome of donation after circulatory death liver transplantation – the concept of hypotension exposure <b>Michael A. Fink</b> , Australia	
415.6	Interventional radiology in complication management after pediatric liver transplantation <b>Artem Monakhov</b> , Russian Federation	
415.7	Technical determinants of cholangiopathy in liver transplantation <b>Josue Alvarez-Casas</b> , United States	
415.8	Liver blood flow after right lobe living donor liver transplantation with middle hepatic vein <b>Oleg Kotenko</b> , Ukraine	
415.9	Comprehensive complication index measure at moment of post-liver transplant discharge well predicts long-term survival <b>Fabio Melandro</b> , Italy	
415.10	Therapy of patient with recurrent HCC after liver transplantation with T-cells transiently expressing HBV-specific TCR <b>Zhao Qiang</b> , People's Republic of China	
415.11	Impact of sarcopenia on the outcomes after living-donor liver transplantation <b>Taiga Wakabayashi</b> , Japan	
415.12	Retrospective analysis of using the modified in pediatric recipients of left lateral segment liver graft <b>Sergey Gautier</b> , Russian Federation	

09:45-11:15 **Oral Abstract Session (Kidney)**  
**416 - Allocation & Others**

N-102

- Chairs: *Ron Shapiro, United States and Eduardo Miñambres, Spain*
- 416.1 Working towards a new deceased donor kidney offering scheme in the UK  
**Lisa L. Mumford**, United Kingdom
  - 416.2 Mortality and kidney transplantation outcomes among chronic dialysis patients who are seropositive for hepatitis C virus  
**Deirdre Sawinski**, United States
  - 416.3 Virtual crossmatch permits kidney sharing; avoiding transplant into unintended recipients  
**Garrett R. Roll**, United States
  - 416.4 Relative risk over time of donor and recipient factors on kidney graft survival  
**Ernesto P. Molmenti**, United States
  - 416.5 Sharing one, keeping one policy for kidney allocation increases inequity in kidney transplantation  
**Javier Dominguez**, Chile
  - 416.6 A novel tool to define the immunogenicity of HLA mismatches  
**Cynthia SM Kramer**, Netherlands
  - 416.7 Effect of a good oral - dental care protocol on inflammation and oral lesions in renal transplant patients: A randomized control study  
**Raj Kumar Sharma**, India
  - 416.9 Results of kidney transplantation in very old age recipients using kidneys from very old donors  
**Hernando Trujillo**, Spain

09:45-11:15 **Oral Abstract Session (Kidney)**  
**417 - Ageing in Transplantation & Others**

N-103

- Chairs: *Elmi Muller, South Africa and Jayme E. Locke, United States*
- 417.1 Successful deceased donor kidney transplantation of highly sensitized candidates across positive cross match and strong donor-specific HLA-DP antibodies without desensitization  
**Raja Rajalingam**, United States
  - 417.2 Cognitive impairment and graft loss in kidney transplant recipients  
**Mara Ann McAdams DeMarco**, United States
  - 417.3 Frailty, inflammation, and waitlist mortality among patients with end-stage renal disease on the kidney transplant waitlist  
**Mara Ann McAdams DeMarco**, United States
  - 417.4 The impact of age-matching on graft function and graft survival after living donor kidney transplantation  
**Jee Youn Lee**, Korea
  - 417.5 Validation of an integrative and dynamic prognostic score for response to therapy in solid organ transplants  
**Alexandre Loupy**, France
  - 417.6 Pre-transplant assessment of AMR risk by novel donor/recipient non-HLA variants  
**Silvia Pineda**, United States
  - 417.7 Hepatitis C virus infection in kidney transplant recipients: final results from a Spanish multicenter study  
**Carmen Gonzalez-Corvillo**, Spain
  - 417.8 Allograft outcome following retransplantation of patients with failed first kidney allograft attributed to non-adherence  
**Revathy Manickavasagar**, Australia
  - 417.9 A retrospective review of the quality of care in patients with failed kidney transplants: a single centre experience  
**Monika Ashwin**, Canada

## 09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences)

N-104

## 418 - IRI Mechanisms

Chairs: *Nancy Kwan Man, Hong Kong* and *Edward K. Geissler, Germany*

- 418.1 The intestinal-liver axis of FGF15-FGFR4-PPAR? Signal control liver ischemia reperfusion injury through regulating autophagy  
**Zhao Qiang**, People's Republic of China
- 418.2 C5AR2 deficiency shows enhanced regeneration capacity after renal ischemia reperfusion injury via AKT and FGF dependent mechanisms  
**Faikah Gueler**, Germany
- 418.3 Differential impact of autophagy on innate and adaptive immune cells characterizes alloimmune responses in aging  
**Stefan G. Tullius**, United States
- 418.4 Ischemia reperfusion injury significantly differs between lung vs. heart transplantation with respect to lead cytokines and correlation to clinical outcome  
**Christine S. Falk**, Germany
- 418.5 Hypoxia induces inflammatory response and cell death by promoting NLRP3 inflammsome activation via ROS-TXNIP axis in pancreatic  $\beta$  cells  
**Cheng Chen**, People's Republic of China
- 418.6 Neutrophil-macrophage communications via inflammasome pathway induced graft injury after LDLT  
**Hui Liu**, Hong Kong
- 418.7 Effect of prolonged cold ischemia on intragraft gene expression profiles  
**Enver Akalin**, United States
- 418.8 Expression of DAP12 and its triggering co-receptor TREM2 plays a key role in regulation of liver DC function and control of liver ischemia-reperfusion injury  
**Toshimasa Nakao**, United States
- 418.9 mTORC2 deficiency in CD11c+ dendritic cells promotes acute kidney injury  
**Helong Dai**, United States

## 09:45-11:15 Oral Abstract Session (Donation &amp; Procurement)

N-105

## 419 - Maximizing Organ Utilization

Chairs: *Kristina Krmpotic, Canada* and *Katja Empson, United Kingdom*

- 419.1 Hard-to-place kidney offers: Granular examination of donor risk factors for discard  
**Reinier Narvaez**, United States
- 419.2 Exploring the viability of kidneys discarded in the US: A comparison of kidney utilization patterns and outcomes in the US and France  
**Olivier Aubert**, France
- 419.3 Allograft and patient outcomes of a tumorectomized kidney transplant program: the Western Australia experience  
**Bulang He**, Australia
- 419.4 Transplantation of kidneys from DCD and DBD donors who died after ligature asphyxiation: The UK experience  
**Patrick B. Trotter**, United Kingdom
- 419.5 The extra corporeal membrane oxygenation (ECMO) in the deceased donors after brain death with severe hemodynamic instability allow to optimize the viability of organs procured for transplantation  
**KE Qin**, People's Republic of China
- 419.6 Does acute kidney injury contraindicate transplantation of kidneys from very small pediatric donors? Single-center analysis of 68 en bloc kidney transplants from donors  $\leq 15$  kg  
**Christoph Troppmann**, United States
- 419.7 Outcomes from livers transplanted from deceased donors with end-stage renal disease  
**Marty T. Sellers**, United States
- 419.8 High risk donor kidneys should be used in pediatric kidney transplant recipients  
**Malcolm MacConmara**, United States
- 419.9 Altered expression of inflammation genes in preimplantation kidney biopsies of extended criteria donors  
**Mario M. Abbud-Filho**, Brazil



**09:45-11:15 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-106****420 - Immune Monitoring**Chairs: *Carla C. Baan, Netherlands* and *Marcos Lopez Hoyos, Spain*

- 420.1 Plasma donor-derived cell-free DNA quantification by massively multiplex PCR distinguishes kidney transplant acute rejection  
**Minnie M. Sarwal**, United States
- 420.2 HEARTBIT: a novel biosignature for detection of acute cellular rejection of heart allografts  
**Ji-Young Kim**, Canada
- 420.3 A signature of gene expression in peripheral blood that enables earlier detection of acute rejection in kidney transplant recipients  
**Maria P. Hernandez-Fuentes**, United Kingdom
- 420.4 Inclusion of CD8 monitoring improves the prognostic capacities of the kidney transplant failure score  
**Lola Jacquemont**, France
- 420.5 Urinary TIMP-2 predicts the presence and duration of delayed graft function in DCD kidney transplant recipients  
**Johan W. de Fijter**, Netherlands
- 420.6 Urinary C-X-C motif chemokines 13 is a noninvasive biomarker of antibody-mediated renal allograft rejection  
**Dajin Chen**, People's Republic of China
- 420.7 Donor-specific cell-free DNA as an emerging biomarker of organ rejection after liver transplantation  
**Su Kah Goh**, Australia
- 420.8 Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer  
**Fleur S. Peters**, Netherlands
- 420.9 Circulating follicular helper T Cells (cTfh) in renal transplantation: Utility as rejection biomarker  
**Rocio Laguna Goya**, Spain

**09:45-11:15 Oral Abstract Session (Complications)****N-107/108****421 - Kidney Complications**Chairs: *Rafael Reyes-Acevedo, Mexico* and *Hiroto Egawa, Japan*

- 421.1 DCD and AKI allografts offer a valuable platform to study molecular pathways underlying successful adaptive repair of the kidney after damage  
**Giuseppe Orlando**, United States
- 421.2 Distal abdominal aorta could serve as an outflow tract for en bloc kidney transplantation from infant donors with extremely low body weight  
**Helong Dai**, United States
- 421.3 The effect of perioperative antiplatelet / anticoagulant therapy on the incidence of early postoperative thromboembolic complications and bleeding in kidney transplantation - a dual center retrospective cohort study of 2000 kidney transplant recipients  
**Tamar A.J. van den Berg**, Netherlands
- 421.4 Comparison of removing double-J stent with and without cystoscopy in kidney transplant patients: A randomized clinical trial  
**Mohammad Nadjafi-Semnani**, Iran (Islamic Republic of)
- 421.5 Searching for new biomarkers more specific for graft loss after renal transplantation by thrombosis: IgA aB2GPI CIC  
**Manuel Serrano Blanco**, Spain
- 421.6 Pre-transplant antibodies IgA-anti Beta 2 Glycoprotein I: A new predictor of early graft thrombosis after renal transplantation in the real medicine setting. An observational, multicenter and prospective study  
**Manuel Serrano Blanco**, Spain
- 421.7 Comparative analysis of postoperative complications after kidney transplantation: Uncontrolled DCD vs DBD grafts, are they the same?  
**Felix Guerrero-Ramos**, Spain
- 421.8 Angioplasty versus medical treatment of transplant renal artery stenosis: An observational prospective study  
**Kajohnsak Noppakun**, Thailand
- 421.9 Different Patterns of Risk Factors for Mortality according Recipient Age after Renal Transplantation. A Multicenter and Prospective Study at Ten Years in the Clinical Practice  
**Jose Maria Morales**, Spain

## 09:45-11:15 Oral Abstract Session (Education)

N-111

## 422 - Innovations in Transplant Education I

Chairs: *Ruth Sapir-Pichhadze, Canada and Christiane Kugler, Germany*

- 422.1 Latin American and Caribbean Transplantation Society (STALYC) update online interactive courses program  
**Alejandro Niño-Murcia**, Colombia
- 422.2 Integrating outreach for different aspects of chronic kidney disease care: A TTS transplantation leadership development series project  
**Kenneth J. Woodside**, United States
- 422.3 Teaching principles of deceased organ donation through a massive open online course - it's place in the world  
**David A. Thomson**, South Africa
- 422.4 Retrospective study of the training visits modality; a cooperative expertise exchange program in China between China organ transplantation development foundation and donation and transplantation institute Barcelona  
**Entela Kondi**, Spain
- 422.5 Knowledge improvement results of the European-mediterranean postgraduate program on organ donation and transplantation project (EMPODaT): A 3 years' training project in Egypt, Lebanon and Morocco  
**Chloe Ballesté**, Spain
- 422.6 Training and social awareness for increasing organ donation in the European union and neighbouring countries: EUDONORGAN  
**Martí Manyalich**, Spain
- 422.7 Efficacy of at-home transplant education on transplant knowledge and pursuit in low-income and black dialysis patients with varying educational characteristics  
**Amy Waterman**, United States
- 422.8 The impact on attitude toward organ donation of an educational intervention for teenagers involving the creation of short films  
**Javier Almela**, Spain
- 422.9 Experiences and challenges in an NGO run organ donation helpline  
**Pallavi Kumar**, India

## 09:45-11:15 Mini-Oral Abstract Session (Transplant Immunosuppression)

N-112

## 423 - Novel Aspect of IS and VCA

Chairs: *Vijay S. Gorantla, United States and TBA*

- 423.1 Evaluation of immune responses following whole eye transplantation  
**Fatih Zor**, United States
- 423.2 Application of mass cytometry for analysis of the alloimmune response in a model of vascularized composite allotransplantation  
**Sheri Krams**, United States
- 423.3 The impact of topical immunosuppressive treatment on functional characterization of skin dendritic cell subpopulations in vascularized composite allotransplantation  
**Wensheng Zhang**, United States
- 423.4 Burden of infectious complications after upper extremity allotransplantation: A matched cohort study  
**Anne Conrad**, France
- 423.5 Ex vivo expanded regulatory T cells combined with short-term costimulation blockade prevent rejection of vascularized composite allografts  
**Giorgio Raimondi**, United States
- 423.6 Monitoring of arterial vessels in upper extremity allotransplantation  
**Palmina Petruzzo**, France
- 423.7 mTOR inhibitors maintain low levels of immune activation, immune senescence and EBV load in kidney transplant patients  
**Lucrezia Furian**, Italy
- 423.8 Minocycline prolongs murine cardiac allograft survival through suppression of acute rejection.  
**Karen L. Keung**, Australia
- 423.9 Accumulated experience with sirolimus in pediatric intestinal transplantation  
**Alba Bueno**, Spain
- 423.10 Development of post-transplant DSA in adult liver transplant patients from the ITN A-WISH trial  
**Vadim Jucaud**, United States
- 423.11 Effect of steroid withdrawal on the appearance of de novo donor-specific HLA antibodies in kidney transplant recipients: A prospective, randomized, controlled, parallel group study. Preliminary results  
**Teresa Vazquez**, Spain
- 423.12 The MADELEINE (coMBined tAcrolimus anD EveroLimus Early ImmuNosupprEssion) study: Pharmacokinetic evaluation.  
**Thomas Jouve**, France

**09:45-11:15 Oral Abstract Session (Cellular and Regenerative Therapies)****N-115/116****424 - Cellular Therapies on the way to clinical application**Chairs: *Anil Dhawan, United Kingdom and Frantisek Saudek, Czech Republic*

- 424.1 "First-in-Human" clinical trial employing adoptive transfer of autologous thymus-derived Treg cells (thyTreg) to prevent graft rejection in heart-transplanted children  
**Rafael Correa-Rocha**, Spain
- 424.2 NK cells differentiated from hematopoietic stem cells exert anti-HCC and anti-HCV activities similar to those of peripheral blood-propagated NK cells  
**Yuka Tanaka**, Japan
- 424.3 Monocytic cells phagocytose therapeutic mesenchymal stem cells, which induces polarization, relocation and immune regulation  
**Jesus M. Sierra Parraga**, Netherlands
- 424.4 The results of pilot study of the mesenchymal stem cells efficiency for induction of immunosuppressive therapy in the early postoperative period after kidney transplantation.  
**Sergey Korotkov**, Belarus
- 424.5 Regulatory dendritic cell (DCreg) cell infusion in living donor liver transplantation  
**Angus W. Thomson**, United States
- 424.6 Co-stimulatory modulation of human regulatory T cells for enhanced immunotherapy  
**Rebeca C. Arroyo Hornero**, United Kingdom
- 424.7 Rapamycin-based expansion of natural CD8+Tregs for cell therapy  
**S  verine B  zie**, France
- 424.8 A comparison of the transplant efficiency between intraportal and intrasplenic procedures in hepatocyte transplantation  
**Hiroyuki Ogasawara**, Japan
- 424.9 A phase-I clinical trial of donor-derived MIC cell infusion for the induction of donor-specific hyporesponsiveness after living donor kidney transplantation (TOL-1 study)  
**Christian Morath**, Germany

**09:45-11:15 Oral Abstract Session (Histocompatibility)****N-117/118****425 - Antibodies and Allograft Outcomes**Chairs: *Olivier Thaunat, France and Estela Paz-Artal, Spain*

- 425.1 An increase in low-grade spot urine protein excretion during the first year after kidney transplantation associates with subclinical de-novo donor-specific antibodies and microvascular inflammation at 1-year surveillance biopsies  
**Gregor Mlin  sek**, Slovenia
- 425.2 Antibody-mediated rejection with and without HLA donor-specific antibodies in kidney-transplantation  
**Marta Crespo Barrio**, Spain
- 425.3 Correlation between pre-transplant bead-based screening of anti-HLA antibodies and single antigen arrays  
**Renaud Snanoudj**, France
- 425.4 Unmasking uncertain results after anti-HLA antibody screening in patients on waiting list  
**David San Segundo**, Spain
- 425.5 Broad HLA mismatches and epitope mismatches: Experience of the one transplantology centre  
**Aleksei B. Zulkarnaev**, Russian Federation
- 425.6 Human neutrophil antibodies are associated with severe early rejection in kidney transplant recipients  
**Timothy Key**, United Kingdom
- 425.7 False-positive flow-cytometric T cell crossmatch caused by blood type antigen expressed on lymphocytes in ABO incompatible kidney transplantation  
**Daiki Iwami**, Japan
- 425.8 Shortened cold ischemia time and reduced incidence of delayed graft function for kidney transplants through enhanced tissue compatibility testing  
**Jouni Lauronen**, Finland
- 425.9 Antibody analysis of 4176 candidates waiting for kidney transplantation discover the hierarchy of antibody-provoking HLA types that warrant matching in kidney transplantation  
**Raja Rajalingam**, United States

**11:15-11:45 Coffee Break / Poster Viewing / Visit Exhibitors****Hall 10 – Exhibition****11:15-11:45 Transplantation Direct****Hall 10 – TTS Innovative Studio in TTS booth**

- 430.1 **Edward K. Geissler**, Germany

11:45-13:15	<b>Plenary Session 2</b> <b>435 - Future Developments in Transplantation - From Immunotherapy to Tissue Engineering</b>	Hall 10 – Plenary
Facilitator: <i>Marcelo Cantarovich, Canada</i>		
435.1	The development and function of Treg <b>Abul K. Abbas</b> , United States	
435.2	CART cells - lesson learned from cancer immunotherapy <b>Marcela V. Maus</b> , United States	
435.3	Designing natural and synthetic immune tissues <b>Jonathan S. Bromberg</b> , United States	
13:15-14:45	<b>Lunch Break</b>	
13:30-14:30	<b>Corporate Symposium</b> <b>440 - Kidney &amp; Liver Hypothermic Machine Perfusion: The Role of Oxygen</b>	Hall 10 – Plenary
See page 29 for details.		
13:30-14:15	<b>Lunch and Learn (#LL2 search on WebApp)</b> <b>450 - Lunch and Learn 2 (registration required)</b>	Retiro Room (NCC)
450.1	Xenograft tolerance <b>Megan Sykes</b> , United States	
450.2	Different strategies for beta cell replacement for the cure of Type 1 diabetes <b>Peter G. Stock</b> , United States	
450.3	Advocacy of pancreas and islet transplantation <b>Frantisek Saudek</b> , Czech Republic	
450.4	Meeting the demand for organ availability <b>Stefan G. Tullius</b> , United States	
450.5	Cellular therapies in the management of liver disease and liver transplantation <b>Anil Dhawan</b> , United Kingdom	
450.6	Blocking inflammation for cell and organ tolerance <b>Maria Koulmanda</b> , United States	
450.7	General adolescent issues <b>Miriam Kaufman</b> , Canada	
450.8	Measuring OPO performance – What's the right denominator and parameters? <b>Howard M. Nathan</b> , United States and <b>Richard Hasz</b> , United States	
450.9	Preparation of children for renal transplantation <b>Stephen D. Marks</b> , United Kingdom	
450.10	Why commercialism is difficult to eradicate <b>Adibul Hasan Rizvi</b> , Pakistan	
450.11	Preservation by machine perfusion <b>Peter J. Friend</b> , United Kingdom	
450.12	Preparing your patient for transplant & prevention of infection after transplant: Antibiotics, antivirals, vaccines <b>Camille Kotton</b> , United States	
450.13	Toward HLA epitope matching in clinical transplantation <b>Frans HJ Claas</b> , Netherlands	
450.14	Robotic kidney transplantation: Current status, an update and future perspectives <b>Pranjal Modi</b> , India	
450.15	Immunosuppression in avoidance of recurrent malignancies after liver transplantation <b>John J. Fung</b> , United States	
450.16	Mentorship Roundtable <b>Hiroto Egawa</b> , Japan	
450.17	Mentorship Roundtable <b>Gabriel E. Gondolesi</b> , Argentina	
450.18	Manuscript Decisions <b>Transplantation Journal Editors</b>	
450.19	Immunobiogram® a novel precision medicine tool to help guidance of immunosuppression in renal transplantation. Results of "BH-Pilot" proof-of-concept clinical study <b>Isabel Portero</b> , Spain and <b>Julio Pascual</b> , Spain	

<b>13:30-13:45</b>	<b>Plenary Speaker Interviews</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
445.1	<b>Marcela V. Maus</b> , United States <b>Abul K. Abbas</b> , United States	
<b>13:45-14:00</b>	<b>Getting Motivated Post-Transplant (WTGF)</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
445.2	<b>Liz Schick</b> , Switzerland	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Liver)</b> <b>460 - Outcome Driven Liver Transplantation</b>	<b>N-101</b>
	Chairs: <i>Hiroto Egawa, Japan and Johann Pratschke, Germany</i>	
460.1	In depth cardiac Pre-It investigation: A necessity to improve outcome? <b>Samuel A. Irefin</b> , United States	
460.2	Sarcopenia and denutrition: How to tackle these major determinants of outcome <b>Toshimi Kaido</b> , Japan	
460.3	Pre-L-T antiviral treatment (HCV, HBV, and HIV): Improving outcomes with and /or without liver transplantation <b>Christian P. Strassburg</b> , Germany	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Infectious Diseases)</b> <b>461 - Improving Outcomes with Common Post-Transplant Infections</b>	<b>N-102</b>
	Chairs: <i>Clarisse Machado, Brazil and Juan F. Delgado, Spain</i>	
461.1	Prevention and management of CMV: Current guidance <b>Camille Kotton</b> , United States	
461.2	Multi-drug resistant bacterial infections: Understanding epidemiology and management of challenging infections <b>Jose Maria Aguado</b> , Spain	
461.3	Infectious complications of thoracic transplantation: The challenge of ECMO, LVAD and thoracic transplantation <b>Silvia Vidal Campos</b> , Brazil	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Kidney)</b> <b>462 - Identifying the “At Risk” Renal Graft</b>	<b>N-103</b>
	Chairs: <i>Christophe Legendre, France and Jose Maria Morales, Spain</i>	
462.1	The impact of disease recurrence on graft outcome <b>Germaine Wong</b> , Australia	
462.2	The development of DSA - who is at risk and what is the outcome <b>Alexandre Loupy</b> , France	
462.3	Histological predictors of premature graft loss <b>Brian J. Nankivell</b> , Australia	
<b>14:45-16:15</b>	<b>State-of-the-Art Session (Basic Sciences and Translational Sciences)</b> <b>463 - Engineering Immune System for Transplantation</b>	<b>N-104</b>
	Chairs: <i>Shane T. Grey, Australia and Julien Zuber, France</i>	
463.1	Trained immunity in transplantation <b>Jordi Ochando</b> , Spain	
463.2	Antigen specific tregs - what is required for translation to the clinic <b>Megan Levings</b> , Canada	
463.3	Modulation of macrophage subsets to promote transplant survival <b>Xian C. Li</b> , United States	

14:45-16:15	<b>State-of-the-Art Session (Pancreas &amp; Islet)</b> <b>464 - Beta-Cell Replacement Therapy: Current Outcomes and Future Landscape</b>	N-105
	Chairs: <i>Daniel Casanova, Spain</i> and <i>Thierry Berney, Switzerland</i>	
464.1	Islet transplantation alone vs. solitary pancreas transplantation: An outcome driven choice? <b>Peter G. Stock</b> , United States	
464.2	SPK transplantation vs. living donor kidney transplantation alone: An outcome driven choice? <b>Adam D. Barlow</b> , United Kingdom	
464.3	Future landscape: Defining a successful outcome using stem cells as a source of insulin producing cells <b>Lorenzo Piemonti</b> , Italy	
14:45-16:15	<b>State-of-the-Art Session (Transplant Immunosuppression)</b> <b>465 - Delivering Co-stimulation Blockade to the Clinic</b>	N-106
	Chairs: <i>Lionel Rostaing, France</i> and <i>TBA</i>	
465.1	The role for inhibition of the CD40-CD154 pathway in coxstimulation blockade <b>Flavio Vincenti</b> , United States	
465.2	New uses of Belatacept in kidney transplantation <b>Oriol Bestard Matamoros</b> , Spain	
465.3	Selective Anti-CD28 blockade: Finally getting there? <b>Lionel Rostaing</b> , France	
14:45-16:15	<b>State-of-the-Art Session (Declaration of Istanbul)</b> <b>466 - A Multidisciplinary Approach in the Fight Against Organ Trafficking and Human Trafficking for Organ Removal</b>	N-107/108
	Chairs: <i>Dominique E. Martin, Australia</i> and <i>Elmi Muller, South Africa</i>	
466.1	The role of clinicians in preventing and combatting organ trafficking <b>Benita Padilla</b> , Philippines	
466.2	The role of prosecutors <b>Gilad Erlich</b> , Israel	
466.3	The role of multinational organisations <b>Marta López-Fraga</b> , France	
14:45-16:15	<b>State-of-the-Art Session (Sex and Gender in Transplantation)</b> <b>467 - Why Does Sex Matter in Transplantation?</b>	N-111
	Chairs: <i>Elaine F. Reed, United States</i> and <i>Ruth Sapir-Pichhadze, Canada</i>	
467.1	Sex on the bench <b>Deborah J. Clegg</b> , United States	
467.2	Recipient sex related factors impacting transplant outcome <b>Bethany Foster</b> , Canada	
467.3	Considering sex and gender in transplantation research and clinical care <b>Christine S. Falk</b> , Germany	
14:45-16:15	<b>State-of-the-Art Session (Transplantation Nursing)</b> <b>468 - Improving Transplant Outcomes: Assessing Transplant Candidates' Risk</b>	N-115/116
	Chairs: <i>Sandra A. Cupples, United States</i> and <i>Grainne M. Walsh, United Kingdom</i>	
468.1	Assessing transplant candidates' risk: Frailty <b>Mara Ann McAdams DeMarco</b> , United States	
468.2	Assessing transplant candidates' risk: Nonadherence <b>Miriam Kaufman</b> , Canada	
468.3	Assessing transplant candidates' risk: Poor social support and health literacy <b>Fabienne Dobbels</b> , Belgium	

---

**14:45-16:15 State-of-the-Art Session (Anesthesia Management and Critical Care)****N-117/118****469 - Perioperative Management: The Missing Link**

---

Chairs: *Margaux N. Mustian, United States and Claus Niemann, United States*

469.1 Bridging the failing recipient candidate in the ICU

**Catherine Paugam-Burtz**, France

469.2 Back from the brink: Management of sepsis in the transplant recipient

**Karl K. Young**, Hong Kong

469.3 Cardiac evaluation for abdominal organ transplant: Angiography for all or overrated?

**James Findlay**, United States

**16:30 to 17:30 - Campfire Sessions and Poster Session 2**


---

**16:30-17:30 Campfire Session (Kidney) Hall 10 – Exhibition**  
**C490 - Recipient Management**


---

Chairs: *Germaine Wong, Australia and Flavio Vincenti, United States*

- C490.1 Impact of donor-specific anti-HLA antibodies on chronic-active antibody-mediated rejection histological phenotype and outcome is modulated by non-adherent behavior of kidney graft recipients  
**Jorge Anjos Malheiro**, Portugal
- C490.2 Differing opinions regarding diseased kidney allocation between patients and physicians and also among physician's specialties  
**Javier Dominguez**, Chile
- C490.3 The spanish prioritization system for highly sensitized patients: A successful tool  
**Maria Oliva Valentin**, Spain
- C490.4 Modified DFPP eliminates ABO blood type IgG antibody with preserving fibrinogen before ABO-incompatible kidney transplantation  
**Daiki Iwami**, Japan
- C490.5 Organ exchange programme based on virtual crossmatch increases access to kidney transplantation of highly sensitized patients in Andalusia. Andalusian work group for highly-sensitized patients  
**Antonia Alvarez Marquez**, Spain

---

**16:30-17:30 Campfire Session (Ethics, Community, Economics) Hall 10 – Exhibition**  
**C491 - Ethical Challenges in Donation and Transplantation – Global Perspectives**


---

Chairs: *Gabriel Danovitch, United States and Francis L. Delmonico, United States*

- C491.1 Transplantation tourism and recipients perspectives and experience  
**Issa Al Salmi**, Oman
- C491.2 Ethical dilemmas in deceased organ donation and allocation – an emerging challenge in India  
**Sunil Shroff**, India
- C491.3 Transplant volumes in China  
**David Matas**, Canada
- C491.4 10 years after Istanbul Declaration, achievements and failures  
**Mustafa S. A. Almousawi**, Kuwait
- C491.5 Full body transplantation, is it allowed?  
**Kristof Van Assche**, Canada
- C491.6 Unique challenges in the deceased donation programme in India  
**Sunil Shroff**, India

---

**16:30-17:30 Campfire Session (Complications) Hall 10 – Exhibition**  
**C492 - Infections and Malignancies**


---

Chairs: *Richard D.M. Allen, Australia and TBA*

- C492.1 Underlying renal disease with increased infection risk is associated with inferior patient survival  
**Natalie Otto**, Germany
- C492.2 The role of KIR2DS4 polymorphisms in BK virus and acute rejection following renal transplantation  
**Patrick B. Trotter**, United Kingdom
- C492.3 Cancer incidence after kidney transplantation in Saudi Arabia  
**Hassan Ali Aleid**, Saudi Arabia
- C492.4 Posttransplant malignancies in adult renal and hepatic transplant patients  
**Ebru H. Ayvazoglu Soy**, Turkey
- C492.5 Outcomes of screening for BK viraemia and BK nephropathy in renal transplant recipients: a single centre cohort study  
**Kushani C. Jayasinghe**, Australia
- C492.6 Primary central nervous system post-transplantation lymphoproliferative disorder: A case series of renal transplant recipients  
**Kushani C. Jayasinghe**, Australia



**16:30-17:30 Campfire Session (Infectious Diseases)**  
**C493 - Viral Hepatitis and BK Post-Transplant**
**Hall 10 – Exhibition**Chairs: *Hans H. Hirsch, Switzerland* and *Julián de la Torre Cisneros, Spain*

- C493.1 Reducing immunosuppression preserves graft function in patients with BKVN - a single centre study  
**Ejaz Ahmed**, Pakistan
- C493.2 Staged screening of BK virus-associated nephropathy using urine cytology and serum quantitative polymerase chain reaction: Hong Kong experience  
**Maggie K. M. Ma**, Hong Kong
- C493.3 The use of sofosbuvir (SOF)-containing direct antiviral agents (DAA)-based regimens requires increase in tacrolimus (Tac) doses in kidney transplant (KT) recipients with hepatitis C virus (HCV) infection  
**Natalia I. Polanco**, Spain
- C493.4 Effectiveness of sofosbuvir and ribavirin for eradicating hepatitis C virus in renal transplant recipients in a resource constrained country  
**Nasir Hassan Luck**, Pakistan
- C493.5 Post transplant de novo hepatitis C virus infection in renal transplant recipients: Its impact on morbidity and mortality  
**Nasir Hassan Luck**, Pakistan
- C493.6 Clinical outcomes of sofosbuvir-based direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus  
**Mohamad M. Alkadi**, Qatar

**16:30-17:30 Campfire Session (Basic Sciences and Translational Sciences)**  
**C494 - Out-of-the-Box**
**Hall 10 – Exhibition**Chairs: *Marina Berenguer, Spain* and *James A. Hutchinson, Germany*

- C494.1 Synthetic immunomodulatory biomaterials to improve islet graft survival  
**Maria M. Coronel**, United States
- C494.2 Beneficial effects of human mesenchymal stromal cells on porcine hepatocyte viability and albumin secretion  
**Elisa Montanari**, Switzerland
- C494.3 Platelets stimulate liver sinusoidal endothelial cells to secrete interleukin-6 during the early phase of liver regeneration in mice  
**Jeremy Meyer**, Switzerland
- C494.4 Sex-specific dimorphism in cellular stress response upon mTOR inhibition revealed by podocyte specific RNA sequencing  
**Angelika Kusch**, Germany
- C494.5 Ex-vivo generation of alloantigen-specific immunomodulatory cells: Elucidating the mechanistical synergy of cell components  
**Ming Han Yao**, Sweden
- C494.6 Humanization and pre-clinical validation of an anti-HLA-A\*02:01 chimeric antigen receptor for use with regulatory T cells to enhance transplant tolerance  
**Nicholas AJ Dawson**, Canada

**16:30-17:30 Campfire Session (Cellular and Regenerative Therapies)**  
**C495 - Preclinical Regenerative Medicine and Cellular Therapy**
**Hall 10 – Exhibition**Chairs: *Frantisek Saudek, Czech Republic* and *Toshio Miki, United States*

- C495.1 Effect of the isolation procedure and inflammatory cytokines on blood group antigen expression on human hepatocytes in preparation for investigating ABO-incompatible hepatocyte transplantation  
**Kazuaki Tokodai**, Japan
- C495.2 Human urine-derived stem cells could protect renal function by releasing miR-129-5p which targets high-mobility group box-1 (HMGB1) in rat ischemia reperfusion injury model  
**Longshan Liu**, People's Republic of China
- C495.3 In vivo depletion of dividing donor cells using post-transplant cyclophosphamide can reduce the development of graft-versus-host disease in a humanised mouse model  
**Sam R. Adhikary**, Australia
- C495.4 Establishment of insulin-producing cells differentiated from human adipose-derived mesenchymal stem cells using a 3D-culture system with xeno-antigen free reagents  
**Mitsuo Shimada**, Japan
- C495.5 Comparison of continuous normothermic ex vivo kidney perfusion to dynamic and static hypothermic preservation techniques in porcine kidneys donated after cardiac death  
**Matyas Hamar**, Canada

<b>16:30-17:30</b>	<b>Campfire Session (Pancreas &amp; Islet)</b>	<b>Hall 10 – Exhibition</b>
	<b>C496 - Pancreas Transplantation</b>	
	Chairs: <i>Lorenzo Piemonti, Italy and Thomas Kay, Australia</i>	
C496.1	Influence of donor and recipient sex on the outcome after pancreas transplantation <b>Franka Messner</b> , Austria	
C496.2	Challenges in calcineurin inhibitor (CNI) withdrawal in conjunction with co-stimulation blockade in simultaneous pancreas and kidney transplant (SPK) <b>Casey J. Ward</b> , United States	
C496.3	Kidney failure is associated with worse pancreas graft survival in simultaneous pancreas and kidney transplantation <b>Peter Girman</b> , Czech Republic	
C496.4	Pseudocyst of pancreas transplant allograft, a rare complication <b>Jeffrey M. Stern</b> , United States	
C496.5	Duodenal leaks after pancreas transplantation. Incidence, management and outcome <b>Oana Anisa Nutu</b> , Spain	
C496.6	Risk factors for thrombosis in simultaneous pancreas-kidney transplants performed over ten years at westmead hospital <b>Sara Shahrestani</b> , Australia	
<b>16:30-17:30</b>	<b>Campfire Session (Donation &amp; Procurement)</b>	<b>Hall 10 – Exhibition</b>
	<b>C497 - Variety of Topics</b>	
	Chairs: <i>Haibo Wang, People's Republic of China and Eduardo Rocha, Brazil</i>	
C497.1	Center variation in six-month post-donation follow-up of obese living kidney donors <b>Deirdre Sawinski</b> , United States	
C497.2	Cold preservation with a hyperbranched polyglycerol-based solution improves functional recovery of kidney transplants in a pig model <b>Caigan Du</b> , Canada	
C497.3	Novel organ transplantation technology for suturing vessels while perfusing organs <b>Syhei Yoshimoto</b> , Japan	
C497.5	Opting out and offers of 'Alibis' for potential living kidney donors in US transplant centers <b>Renata Iskander</b> , Canada	
<b>16:30-17:30</b>	<b>Campfire Session (Paediatrics)</b>	<b>Hall 10 – Exhibition</b>
	<b>C498 - Issues in Paediatric Kidney Transplantation</b>	
	Chairs: <i>Stephen D. Marks, United Kingdom and Stephen Alexander, Australia</i>	
C498.1	Superior renal allograft function with male deceased donors for paediatric renal transplant recipients <b>Nadeesha L. Mudalige</b> , United Kingdom	
C498.2	Improvement of cardiac functions after renal transplantation in patients with severe cardiac risk: Long term follow-up <b>Esra Baskin</b> , Turkey	
C498.3	The rate of BK virus infection in pediatric renal transplant patients <b>Esra Baskin</b> , Turkey	
C498.4	Living donor liver transplantation for hepatorenal fibroystic disease in children <b>Rie Irie</b> , Japan	
C498.5	Effects of early post-transplant blood transfusion on graft outcome in pediatric renal transplant recipients <b>Kaan Gulleroglu</b> , Turkey	
C498.6	Immune phenotype by flow cytometry of paediatric kidney transplant recipients and healthy adult controls <b>Elvira Jimenez Vera</b> , Australia	

---

**16:30-17:30**   **Campfire Session (Liver)**   **Hall 10 – Exhibition**
**C499 - Liver Living Donor**

Chairs: *Toshimi Kaido, Japan and TBA*

- C499.1 Development of a mobile application for living liver donors to assist their understandings of a series of preoperative tests  
**Noriyo Yamashiki**, Japan
- C499.2 Clinical outcomes of totally laparoscopic living donor right hepatectomy  
**Youngseok Han**, Korea
- C499.3 The Efficacy of an Artificial Pancreas Device for Achieving Tight Perioperative Glycemic Control in Living Donor Liver Transplantation  
**Tota Kugiyama**, Japan
- C499.4 Pegylated interferon-based versus direct-acting antiviral-based preemptive treatment of HCV after adult living donor liver transplantation  
**Sang hyun Kang**, Korea
- C499.6 Is systemic heparinization necessary during living donor hepatectomy? Short-term and long-term outcomes  
**Tae-Yoon Kim**, Korea

---

**16:30-17:30**   **Poster Session 2 - Even Poster Number Presentations**   **Hall 10 – Exhibition**

*Detailed list of all the posters available on page 122*

*All poster presenters with even poster numbers shall be at their respective poster(s).*

**16:15 to 17:30 - Other Events**

<b>16:30-17:30</b>	<b>Corporate Symposium</b>	<b>N-103</b>
	<b>480 - Improving Management of Transplanted Patients with Viral Load Assays and Specific Cell-Mediated Immune Response Monitoring</b>	
	See page 29 for details.	
<b>16:30-16:50</b>	<b>SOTA Speaker Interviews</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
475.1	<b>Megan Levings</b> , Canada <b>Alexandre Loupy</b> , France <b>Camille Kotton</b> , United States <b>Lionel Rostaing</b> , France	
<b>16:50-17:05</b>	<b>Case Competition Presentation 3</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
475.2	The Great Pretender: when what you see, is not what you get. An unusual presentation of lung cancer on a post kidney transplant patient <b>Bryan Christian Gaza Ilagan</b> , Philippines	
<b>17:30-19:00</b>	<b>Women in Transplantation Networking Event (ticketed event)</b>	<b>Colon Room (IFEMA, 2nd Floor)</b>
<b>20:00-23:00</b>	<b>Young Investigators Networking Event (ticketed event)</b>	<b>Azotea del Círculo: C/Marqués de Casa Riera nº 2</b>

[illegible]

# DETAILED PROGRAM

Wednesday, July 4, 2018

**08:30-09:30 Oral Abstract Session (Liver)****N-101****500 - Liver Recipient Selection and Malignancies**Chairs: *John P. Roberts, United States and Sukru H. Emre, United States*

- 500.1 Delta PD-1 expressed m2 macrophages promote liver tumor recurrence after transplantation  
**Wai Ho Oscar Yeung**, Hong Kong
- 500.2 Serological tumor viability risk index comprising alpha-fetoprotein and C-reactive protein identifies eligible liver transplant patients with hepatocellular carcinoma beyond milan and up-to-seven criteria  
**Arno Kornberg**, Germany
- 500.3 Proposal for a worldwide usable score for the prediction of recurrence and intention-to-treat survival after liver transplantation in patients with hepatocellular cancer: A West-East analysis on 1,903 patients  
**Quirino Lai**, Italy
- 500.4 Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: A propensity score analysis  
**Quirino Lai**, Italy
- 500.5 Utility of liquid biopsy (CTCs) after liver transplantation in cirrhotic patients with hepatocarcinoma  
**David Ferreras**, Spain
- 500.6 East vs West: Predictors of oncologic outcomes following DD and LD liver transplantation for HCC  
**Varvara A. Kirchner**, United States

**08:30-09:30 Oral Abstract Session (Kidney)****N-102****501 - Antibody-Mediated Rejection 2**Chairs: *Francesc Moreso Mateos, Spain and Carmen Lefaucheur, France*

- 501.1 Anti-angiotensin II type 1-receptor antibodies (AT1R-Ab) induce a specific phenotype of rejection distinct from HLA antibody-mediated rejection  
**Carmen Lefaucheur**, France
- 501.2 Banff survey on antibody mediated injury in kidney allografts: Diagnostic misclassification affects the treatment approach  
**Carrie A. Schinstock**, United States
- 501.3 Rearrangement of the endothelial cell cytoskeleton in glomerular and peritubular capillaries (PTCS) following antibody-mediated rejection (AMR): Its significance on the development of transplant glomerulopathy and interstitial fibrosis  
**B. Handan Ozdemir**, Turkey
- 501.4 Intimal arteritis associated with microvascular inflammation even in the absence of donor-specific antibodies might result into early chronic rejection  
**Marek Novotny**, Czech Republic
- 501.5 Do C1q-positive donor specific antibodies have prognostic effect in patients with resistant antibody-mediated rejection treated with bortezomib? Single-centre experience  
**Janka Slatinska**, Czech Republic

**08:30-09:30 Oral Abstract Session (Kidney)****N-105****502 - Recipients Issues**Chairs: *Adibul Hasan Rizvi, Pakistan and Alejandro Niño-Murcia, Colombia*

- 502.1 The role of proteinuria, paricalcitol and vitamin D in the development of post-transplant diabetes mellitus after kidney transplantation  
**Ivana Dedinska**, Slovakia (Slovak Republic)
- 502.2 A high abdominal aortic calcification score by dual x-ray absorptiometry (DXA) is associated with cardiovascular events after kidney transplantation  
**Stan Benjamens**, Netherlands
- 502.3 Significant difference between proteasome and immunoproteasome inhibition in acute kidney injury  
**Feng Han**, People's Republic of China
- 502.4 Mid-term outcome of donor specific antibody positive deceased donor kidney transplantation with peri-transplant desensitization  
**Klara Osickova**, Czech Republic
- 502.5 The clinical significance of pretransplant C1q assay status in positive crossmatch kidney transplantation  
**Soo Jin Kim**, Korea
- 502.6 Partial immunological tolerance induction with extracorporeal photopheresis  
**Aleksei B. Zulkarnaev**, Russian Federation

**08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-106****503 - Preclinical Studies**Chairs: *Wayne J. Hawthorne, Australia* and *Lionel Rostaing, France*

- 503.1 Induction of tolerance for long-term liver allograft survival without immunosuppression in cynomolgus monkeys  
**Erik Berglund**, United States
- 503.2 Tomotherapy and hematopoietic stem cells for tolerance to kidney transplants in rhesus macaques  
**Dixon B. Kaufman**, United States
- 503.3 Induction of tolerance to renal allografts in non human primates by concomitant donor-matched vascularized osteomyocutaneous allotransplantation  
**Xin Xiao Zheng**, People's Republic of China
- 503.4 Megadose bone marrow and regulatory t cells for the induction of immune tolerance in non-human primates through durable mixed hematopoietic chimerism across MHC-barriers  
**Paula Alonso Gualart**, United States
- 503.5 Enhancement of intrinsic apoptosis via Bcl-2 inhibition promotes induction of robust mixed chimerism and renal allograft tolerance without myelosuppression in nonhuman primates  
**Tatsuo Kawai**, United States
- 503.6 Long-term nonhuman primate renal allograft survival without ongoing immunosuppression in recipients of delayed donor bone marrow transplantation  
**Kiyohiko Hotta**, Japan

**08:30-09:30 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-107/108****504 - Kidney Biopsy**Chairs: *Stefan G. Tullius, United States* and *Alexandre Loupy, France*

- 504.1 Overexpression of BAX, NOL3, and XIAP apoptotic genes participates in calcineurin inhibitors nephrotoxicity: New insights into chronic allograft dysfunction  
**Gloria Queipo**, Mexico
- 504.2 Isolated V-lesion early after kidney transplantation may not truly represent a rejection  
**Mariana Wohlfahrtova**, Czech Republic
- 504.3 In kidney allografts inflammation in scarred areas is not a reflection of chronic active T cell-mediated rejection  
**Philip F. Halloran**, Canada
- 504.4 Transcriptional factor FOXP3 in renal allograft biopsies predicts tolerance in non-human primates  
**Masatoshi Matsunami**, United States
- 504.5 Surveillance biopsy: Boon or bust?  
**Roslyn B. Mannon**, United States
- 504.6 A molecular approach to chronic T-cell mediated rejection  
**Enver Akalin**, United States

**08:30-09:30 Morning Symposium (Anesthesia Management and Critical Care)****N-111****505 - Organ Donor Management - Impact of Critical Care and Outcome**Chairs: *Axel Rahmel, Germany* and *Claus Niemann, United States*

- 505.1 Organ donation: Changing perspectives in critical care - donor management goals  
**Darren Malinoski**, United States
- 505.2 Critical care training and education for donor coordinators  
**Sharon Swain**, United States
- 505.3 Donation after cardiac death- the role of critical care  
**Martí Manyalich**, Spain

**08:30-09:30 Morning Symposium (Registries)****N-112****506 - What is New in the World of Transplant Registries?**Chairs: *Caner Süsal, Germany* and *Jongwon Ha, Korea*

- 506.1 National Transplant Registry of India  
**Vivek Kute**, India
- 506.2 China  
**Haibo Wang**, People's Republic of China
- 506.3 Korean Organ Transplant Registry (KOTRY)  
**Curie Ahn**, Korea



08:30-09:30	<b>Morning Symposium (Vascularized Composite Allotransplantation) 507 - Innovation and Insights in VCA</b>	<b>N-113</b>
	Chairs: <i>Benoit Lengele, Belgium</i> and <i>Vijay S. Gorantla, United States</i>	
507.1	Whole Eye Transplantation - Hope or Hype? <b>Fatih Zor</b> , United States	
507.2	Immunopathology of VCA Rejection - Knowns and Unknowns <b>Alice Koenig</b> , France	
	Panel discussions	
08:30-09:30	<b>Morning Symposium (Ethics, Community, Economics) 508 - A Discussion of Informed Consent with Living and Deceased Donation</b>	<b>N-114</b>
	Chairs: <i>Francis L. Delmonico, United States</i> and <i>Peter G. Stock, United States</i>	
508.1	The discretionary living kidney donor <b>Gabriel Danovitch</b> , United States	
508.2	Marginal deceased donor <b>John S. Gill</b> , Canada	
508.3	High risk donors <b>Paolo A. Grossi</b> , Italy	
	Panel discussions	
08:30-09:30	<b>Morning Symposium (Pancreas &amp; Islet) 509 - Beta Cell Replacement of the Future</b>	<b>N-115/116</b>
	Chairs: <i>Peter J. Friend, United Kingdom</i> and <i>Thierry Berney, Switzerland</i>	
509.1	Will gene editing carry pig islets to the clinic <b>Marc Guell</b> , United States	
509.2	Advanced insulin delivery systems can they cure patients <b>Thomas Kay</b> , Australia	
509.3	Developing delivery approaches for stem cell transplantation <b>Shane T. Grey</b> , Australia	
08:30-09:30	<b>Morning Symposium (Infectious Diseases) 510 - Challenging Cases in Transplant Infectious Diseases: Pushing the Boundaries of Donor and Recipient Outcomes</b>	<b>N-117/118</b>
	Chairs: <i>Nassim Kamar, France</i> and <i>Michael G. Ison, United States</i>	
510.1	Polyoma viruses (BK) - Case presenter <b>Diana Florescu</b> , United States	
510.2	Polyoma viruses (BK) - Case discussant <b>Hans H. Hirsch</b> , Switzerland	
510.3	Marginal donor - Case presenter <b>Hannah Kaminski</b> , France	
510.4	Marginal donor - Case discussant <b>Francisco M. Marty</b> , United States	
510.5	Nocardia - Case presenter <b>Edward A. Dominguez</b> , United States	
510.6	Nocardia - Case discussant <b>Cameron Wolfe</b> , United States	

**09:45-10:45 Oral Abstract Session (Liver)****N-101****515 - Allocation and Access**Chairs: *Valentín Cuervas-Mons, Spain and John P. Roberts, United States*

- 515.1 Survival benefit of liver transplantation in the MELD-Na era  
**Lucy C. Chau**, United States
- 515.2 Introduction of share 35 interregional allocation for high MELD liver transplant waiting list patients in Australia and New Zealand  
**Michael A. Fink**, Australia
- 515.3 Hospitalization and life support before liver transplantation – easily available predictors for post-transplant patient survival  
**Leke Wiering**, Germany
- 515.4 Trends in transplantation with older liver donors in the United States  
**Christine E. Haugen**, United States
- 515.5 MELD based allocation deteriorates patient survival without improving waiting list mortality in a low donor area  
**Paul Viktor Ritschl**, Germany
- 515.6 Ethnic and age disparities in outcomes among liver transplant waitlist candidates  
**Margaux N. Mustian**, United States

**09:45-10:45 Oral Abstract Session (Kidney)****N-102****516 - Chronic Kidney Dysfunction**Chairs: *Marcelo Cantarovich, Canada and Francesc Moreso Mateos, Spain*

- 516.1 Identifying the specific causes of kidney allograft loss: A population based study  
**Charlotte Loheac**, France
- 516.2 Role of C1q-binding donor-specific anti-HLA antibodies in premature and accelerated kidney allograft interstitial fibrosis  
**Denis Glotz**, France
- 516.3 Inflammation in fibrotic areas (i-IF/TA) identifies a T cell-mediated rejection component of IF/TA with poor kidney allograft outcome  
**Yassine Bouatou**, France
- 516.4 Prediction of renal allograft chronic rejection using a model based on contrast enhanced ultrasonography  
**Cheng Yang**, People's Republic of China
- 516.5 Identifying the specific causes and the determinants of outcome in kidney recipients with transplant glomerulopathy: A multicenter study  
**Olivier Aubert**, France
- 516.6 Potential novel proteomic biomarkers for acute T cell-mediated rejection in kidney transplant recipients  
**Jeong-Hoon Lim**, Korea

**09:45-10:45 Oral Abstract Session (Kidney)****N-103****517 - Immunosuppression 2**Chairs: *Julio Pascual, Spain and TBA*

- 517.1 The Athena Study: 12 months safety and efficacy data for everolimus combined with tacrolimus or cyclosporine compared to a standard tacrolimus-mycophenolate regimen in de novo kidney transplant patients  
**Bjoern Nashan**, Germany
- 517.2 Different effects on transitional B lymphocytes after conversion to mTOR inhibitors or steroid withdrawal in renal transplant recipients  
**Laura Llinàs Mallol**, Spain
- 517.3 Outcomes on allograft function after 12 months with everolimus plus either tacrolimus or cyclosporine compared to a standard tacrolimus-MPA regimen in de novo renal transplant recipients: The Athena Study  
**Peter Schenker**, Germany
- 517.4 Long term exposure to high variability of tacrolimus trough levels and exposure to sub therapeutic drug levels predicts worse survival after kidney transplantation  
**Ruth Rahamimov**, Israel
- 517.5 Pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19 and their influence on tacrolimus pharmacokinetics in renal transplant recipients  
**Zijie Wang**, People's Republic of China
- 517.6 Adherence to immunosuppressive medications in renal transplant recipients – different tools capture different patients  
**Marte Theie Gustavsen**, Norway

**09:45-10:45 Mini-Oral Abstract Session (Basic Sciences and Translational Sciences)****N-104****518 - Non-Classical Leucocytes**Chairs: *Julien Zuber, France* and *Minnie M. Sarwal, United States*

- 518.1 mTOR inhibitors enhance antitumor activity of liver resident NK cells  
**Jamiliya Saparbay**, Japan
- 518.2 NK cell recognition of peptides encoded by EBV latent cycle proteins  
**Berenice Mbiribindi**, United States
- 518.3 Helper innate lymphoid cells (hILC) resist immunosuppressive therapy: An observation from kidney and liver transplantation  
**Elena Gómez Massa**, Spain
- 518.4 Mast cells regulate CD4+ T Cell differentiation in absence of antigen presentation  
**Hector Rodriguez Cetina Biefer**, Switzerland
- 518.5 Transplantation of tissue-resident lymphocytes  
**Amy C. Prosser**, Australia
- 518.6 Dendritic cells as a non-invasive immunological biomarker of the late cellular rejection after kidney transplantation  
**Sergey Korotkov**, Belarus
- 518.7 High levels of monocyte-myeloid-derived suppressor cell frequencies prior kidney transplantation are related with risk of acute rejection  
**Maria Iglesias Escudero**, Spain
- 518.8 Dynamics of CD25 positive myeloid derived suppressor cells in solid organ transplanted patients and relationship with rejection  
**Alberto Utrero-Rico**, Spain

**09:45-10:45 Oral Abstract Session (Donation & Procurement)****N-105****519 - Increasing Deceased Donation**Chairs: *Helen I. Opdam, Australia* and *Darren Malinoski, United States*

- 519.1 A systems-based approach to increasing organs transplanted: One organ procurement organization's experience  
**Liz Lehr**, United States
- 519.2 Risk factors of primary non-function using uncontrolled donors after cardiac arrest (uDCD)  
**Iago Justo**, Spain
- 519.3 Family attitudes, actions, decisions and experiences following implementation of deemed consent and the human transplantation act (Wales) 2013  
**Leah Mc Laughlin**, United Kingdom
- 519.4 Non-immunologic pairing of kidney transplant donors and recipients: How important is HLA match status?  
**Amanda J. Miller**, Canada
- 519.5 Success of a "Multicultural Donation Education Program" to increase African-American organ donation in a donor service area with a high African-American population  
**Ruth D. Bell**, United States
- 519.6 Hard-to-place kidney offers: System-level predictors of discard  
**Reinier Narvaez**, United States

**09:45-10:45 Mini-Oral Abstract Session (Basic Sciences and Translational Sciences)****N-106****520 - Regulation and Tolerance**Chairs: *Megan Levings, Canada* and *Adrian E. Morelli, United States*

- 520.1 Immunomodulation with SA-FasL-engineered microgels achieves long-term survival of allogeneic islet grafts  
**Haval Shirwan**, United States
- 520.2 CD48 blockade hindered tolerance induction in a Treg dependent allograft tolerance model  
**Stephen Alexander**, Australia
- 520.3 Use of splenocytes as stimulators for the ex vivo expansion of T regulatory cells using costimulatory blockade for adoptive transfer to solid organ transplant recipients  
**Laura Contreras-Ruiz**, United States
- 520.4 MHC-matched a-expressing blood cells induce ABO tolerance in infant and adult mice  
**Ibrahim Adam**, Canada
- 520.5 Leukocytes from lung transplant recipients with severe primary graft dysfunction adoptively transfer alloreactivity to vessel grafts trans vivo  
**Ann-Kathrin Knoefel**, Germany
- 520.6 Deletion of the M33 receptor gene in murine cytomegalovirus reduces levels of cardiac allograft vasculopathy in a murine aortic transplant model  
**Christian Heim**, Germany
- 520.8 Donor T cells undermine the protective effect of DST + Anti-CD 154 in transplant rejection  
**Marcos Iglesias Lozano**, United States

**09:45-10:45 Oral Abstract Session (Paediatrics)****N-107/108****521 - Miscellaneous Issues in Paediatric Transplant**Chairs: *Bethany Foster, Canada* and *Eduardo Miñambres, Spain*

- 521.1 CDC high risk livers should be used more frequently in pediatric liver transplantation  
**Christine S. Hwang**, United States
- 521.2 Combined en-bloc heart liver transplantation in children with congenital heart disease complicated by cardiac cirrhosis  
**Waldo Concepcion**, United States
- 521.3 Results of kidney transplantation in small children  
**Sigal Aizner**, Israel
- 521.4 Large volume intraoperative fluid use in small (<20kg) renal transplant recipients is safe?  
**Natasha Liow**, United Kingdom
- 521.5 Bridge to heart transplant in pediatric patients. Successful mechanical cardiac support with ventricular assist devices (VAD)  
**Gerardo Naiman**, Argentina
- 521.6 Our experience of patients with juvenile nephronophthisis after renal transplantation  
**Kaan Gulleroglu**, Turkey

**09:45-10:45 Oral Abstract Session (Intestine & Multivisceral Transplantation)****N-111****522 - Intestinal Failure, Rehabilitation and Transplant**Chairs: *Martin Rumbo, Argentina* and *Rodrigo Vianna, United States*

- 522.1 Paneth and intestinal stem cells are differentially affected during worsening of acute cellular rejection in small bowel transplantation compared to intestinal ischemia reperfusion injury and graft versus host disease  
**Melisa E. Pucci Molineris**, Argentina
- 522.2 The effect of hepatocyte growth factor on intestinal adaption in an experimental model of short bowel syndrome  
**Georgios Bagias**, Germany
- 522.3 Excellent outcomes of children with short bowel syndrome and intestinal failure associated liver disease (IFALD) at children's national health system (CNHS), Washington DC  
**Clarivet Torres**, United States
- 522.4 Intestinal transplantation: From rescue therapy to standard of care for intestinal failure?  
**Emilio Canovai**, Belgium
- 522.5 Ubiquitin ligase MARCH8 attenuates graft versus host disease via regulation of gut epithelial cell surface MHC II expression  
**Katie E. Lineburg**, Australia
- 522.6 Comparison of induction and maintenance immunosuppression regimens in intestinal and multivisceral transplant: An analysis of the UNOS registry  
**Shunji Nagai**, United States

**09:45-10:45 Oral Abstract Session (Cellular and Regenerative Therapies)****N-112****523 - Regenerative Medicine- New Approaches**Chairs: *Eiji Kobayashi, Japan and Anil Dhawan, United States*

- 523.1 Neonatal cardiovascular progenitor cell clones expressing islet-1 stimulate cardiovascular regeneration in vivo  
**Mary Kearns-Jonker**, United States
- 523.2 The anti-inflammatory effect of alpha-1 antitrypsin in hepatocyte transplantation  
**Charlotte A. Lee**, United Kingdom
- 523.3 Chimeric human liver reconstruction within the spleen of adult pigs  
**Eiji Kobayashi**, Japan
- 523.4 The potential of repairing ischemically damaged human kidneys during acellular warm perfusion  
**Lauren Brasile**, United States
- 523.5 Optimization of a polycaprolactone (PCL) scaffold for islet and cellular transplantation  
**Steven Wisel**, United States
- 523.6 Evaluation of the efficiency of allogenic adipose tissue mesenchymal stem cells therapy for tacrolimus dose minimisation in patients with acute kidney injury after liver transplantation  
**Aliaksei Shcherba**, Belarus

**09:45-10:45 Oral Abstract Session (Sex and Gender in Transplantation)****N-113****524 - Sex and Gender in Transplant Disparities and Outcomes**Chairs: *Lori J. West, Canada and Karen Dwyer, Australia*

- 524.1 Prospective trial on sexual dysfunction in male Chinese liver transplant recipients  
**Kenneth Siu Ho Chok**, Hong Kong
- 524.2 Sexual dysfunction and risk factors in females patients on renal replacement therapy  
**Abdulmecit Yildiz**, Turkey
- 524.3 Female Hispanic health disparities in orthotopic liver transplantation during ischemia-reperfusion injury  
**Rebecca A. Sosa**, United States
- 524.4 Understanding race and gender disparities in living donor kidney transplant readiness, actions, knowledge, and socioeconomic barriers prior to transplant evaluation  
**Amy Waterman**, United States
- 524.5 Gender and racial disparities in provision of transplant information in elderly dialysis patients  
**Silvi Shah**, United States
- 524.6 Donor-recipient gender-mismatches correlate with survival outcome after lung transplantation  
**Johanna M. Kwakkel-van Erp**, Netherlands

**09:45-10:45 Oral Abstract Session (Ethics, Community, Economics)****N-114****525 - Global Ethical Dilemmas in Donation and Transplantation**Chairs: *Dominique E. Martin, Australia and Rudolf Garcia-Gallont, Guatemala*

- 525.1 Assessing the impact of an online support group on the emotional health of transplant caregivers  
**Talia Giordano**, United States
- 525.2 A first nation-wide survey of public attitudes towards socio-economic incentives to increase willingness to donate organs in Japan  
**Tomoko Asai**, Japan
- 525.3 Decision making factors of commercial donors and recipients in live unrelated kidney transplantation in the Philippines  
**Campbell Fraser**, Australia
- 525.4 Comprehensive study of an attitude of medical professionals towards organ donation in Russia  
**Oleg Reznik**, Russian Federation
- 525.5 Accuracy of promis-57 depression and anxiety scales compared to legacy instruments among kidney transplant recipients  
**Aarushi Bansal**, Canada
- 525.6 Awareness of medical students in Sudan towards organ donation and its barriers, intellectual, cultural or ethical?  
**Alaa A.S.E Dafallah**, Sudan

**09:45-10:45 Oral Abstract Session (Xenotransplantation)****N-115/116****526 - Xenotransplantation - Solid Organ**Chairs: *Léo Hans Bühler, Switzerland and Chung-Gyu Park, Korea*

- 526.1 Study for comparison of CD40-mAb and CD40L-Ab costimulation blockade after life-supporting orthotopic cardiac xenotransplantation of multi-transgenic pig hearts into baboons with a worldwide first successful long-term survival  
**Paolo Brenner**, Germany
- 526.2 B-cell depletion prevents humoral sensitization after pig-to-baboon lung xenotransplantation  
**Agnes Azimzadeh**, United States
- 526.3 Transgenic expression of hCD47 on vessels in porcine GalTKO lung grafts in baboons may mitigate acute vascular rejection in baboons: Up to 13 days graft survival in baboons  
**Hironosuke Watanabe**, United States
- 526.4 Transgenic expression of hCD47 minimizes the development of proteinuria following pig-to-baboon kidney transplantation and reduces phagocytosis of porcine endothelial cells and podocytes  
**Kazuhiko Yamada**, United States
- 526.5 Insights into the development of a life-sustaining orthotopic cardiac xenotransplant model  
**Laura DiChiacchio**, United States
- 526.6 Reducing immunogenicity of porcine bioprosthetic heart valves via GGTA1/ $\beta$ 4GalNT2/CMAH gene targeting  
**Yifan Dai**, People's Republic of China

**09:45-10:45 Oral Abstract Session (Complications)****N-117/118****527 - Complications Infections & Malignancies**Chairs: *Oscar Len Abad, Spain and Olivia M. Martinez, United States*

- 527.1 Natural history and determinants of Infectious complications after kidney transplantation: A nationwide prospective population based cohort  
**Anne Scemla**, France
- 527.2 Impact of complement fixing antibodies in murine cytomegalovirus infected renal allografts  
**Masako Shimamura**, United States
- 527.3 A ten year retrospective review of infections in the first 12 months post paediatric liver and liver-kidney transplantation at a single centre in Johannesburg, South Africa  
**Eleanor M. Duncan**, South Africa
- 527.4 Prospective analysis of EBV+ PTLD in a multi-center study of pediatric transplant recipients  
**Olivia M. Martinez**, United States
- 527.5 Delineation of the viral and host cell genomic alterations in EBV-positive PTLD  
**Yarl Balachandran**, United States
- 527.6 Clinical and immunological response to sublingual vaccination for the prevention of recurrent urinary tract infections in kidney transplant patients: Results after 1 year of follow-up  
**Amir Shabaka**, Spain

**10:45-11:15 Coffee Break / Visit Exhibitors****Hall 10 – Exhibition**

---

**11:15-13:15 535 - TTS President's Plenary and Awards** **Hall 10 – Plenary**


---

- 535.1 Welcome from the Congress Chair and TTS President  
**Nancy Ascher**, United States
  - 535.2 Presidential Address  
**Nancy Ascher**, United States  
Medawar Prize Lecture Presentation
  - 535.3 The transformation of TTS by the DOI  
**Francis L. Delmonico**, United States
  - 535.4 The Spanish model on organ donation and transplantation, and its expansion to the world  
**Beatriz Dominguez-Gil**, Spain
  - 535.5 Presentation of TTS Young Investigator, TTS Recognition and WIT Awards  
**Nancy Ascher**, United States
  - 535.6 Introduction of Incoming TTS President (Mehmet Haberal) and Closing Remarks  
**Nancy Ascher**, United States
- 

**13:15-14:30 Lunch Break / Last chance to visit Exhibitors**


---



---

**13:30-14:30 Corporate Symposium** **Hall 10 – Plenary**


---

**540 - The Molecular Microscope® Diagnostic System:  
Insights into Disease Mechanisms Shared by all Organ Transplants**

---

See page 30 for details.

<b>13:30-14:15</b>	<b>Lunch and Learn (#LL3 search on WebApp) 550 - Lunch and Learn 3 (registration required)</b>	<b>Retiro Room (NCC)</b>
550.1	Promoting medication adherence in kidney transplant recipients <b>Bethany Foster</b> , Canada	
550.2	Targeting metabolism to regulating immune responses <b>Jonathan Powell</b> , United States	
550.3	Building a serious research career in transplant surgery <b>Dorry Segev</b> , United States	
550.4	Pitfalls in Graft Survival Analysis (explaining the most frequently made mistakes in the statistical analysis of survival data in the field of kidney transplantation) <b>Caner Süsal</b> , Germany and <b>Christian Unterrainer</b> , Germany	
550.5	Tailoring the Pump for Bridge to Transplant Patients <b>Simon Maltais</b> , United States	
550.6	How to use 50% of all lungs from the lung donor pool- without EVLP <b>Gregory Snell</b> , Australia	
550.7	Pre-liver transplant cardiac evaluation – not just CAD <b>James Findlay</b> , United States	
550.8	The Microbiome in Transplantation <b>Jay Fishman</b> , United States	
550.9	Trained Immunity in Organ Transplantation <b>Jordi Ochando</b> , Spain	
550.11	Living donor nephrectomy - donor or surgeon specific? <b>Gabriel C. Oniscu</b> , United Kingdom	
550.12	Liver Transplantation for Hepatocellular Carcinoma (HCC) <b>Daniel Cherqui</b> , France	
550.13	Mentorship Roundtable <b>Marcelo Cantarovich</b> , Canada	
550.14	Perioperative management of Pulmonary Hypertension in Lung Transplantation <b>Christopher Wigfield</b> , United States	
550.15	Islet auto-transplantation for non-pancreatitis indications <b>Lorenzo Piemonti</b> , Italy	
550.16	Exploiting Immunometabolism to Sustain Immune Homeostasis <b>Ping-Chih Ho</b> , Switzerland	
550.17	Manuscript Revisions <b>Transplantation Journal Editors</b>	
<b>13:30-14:00</b>	<b>Medawar Recipient Interview</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
545.1	Medawar Recipient Interview	
<b>14:00-14:30</b>	<b>ISN-TTS Sister Transplant Centers Program</b>	<b>Hall 10 – TTS Innovative Studio in TTS booth</b>
545.2	<b>Ehab H. Hammad</b> , Saudi Arabia and <b>Abdullah El-Kishawi</b> , Palestinian Territory	
<b>14:30-16:00</b>	<b>State-of-the-Art Session (Liver) 560 - Adult LDLT: Long Term Outcome Problems</b>	<b>N-101</b>
	Chairs: <i>Gabriel E. Gondolesi, Argentina and Jan Lerut, Belgium</i>	
560.1	Long term outcome of endovascular venous intra-graft stents in LDLT <b>Yu-Fan Cheng</b> , Taiwan	
560.2	Quality of life and lap donor hepatectomy <b>Daniel Cherqui</b> , France	
560.3	Can the minimal invasive surgery using laparoscopic or robotic technique replace open surgery in living donor hepatectomy in near future? <b>Kyung-Suk Suh</b> , Korea	



---

**14:30-16:00 State-of-the-Art Session (Transplant Immunosuppression) N-102**


---

**561 - Personalized Immunosuppression in 2018:  
"Which Biomarkers in Solid Organ Transplantation Will Pay Off?"**


---

Chairs: *Minnie M. Sarwal, United States* and *Helio S. Tedesco Jr, Brazil*

- 561.1 Biomarkers for acute rejection in clinic: Show time or no time?  
**Manikkam Suthanthiran**, United States
  - 561.2 Biomarkers for chronic allograft dysfunction: What mark are we aiming for?  
**Barbara Murphy**, United States
  - 561.3 CNI minimization: How to foretell a good versus bad outcome?  
**Josep M. Cruzado**, Spain
- 

**14:30-16:00 State-of-the-Art Session (Kidney) N-103**


---

**562 - Can We Solve the Discrepancy Between Demand and Supply**


---

Chairs: *Robert A. Montgomery, United States* and *Amado Andres Belmonte, Spain*

- 562.1 Increased risk and hepatitis C positive organs donors for HCV positive and negative recipients  
**Jay Fishman**, United States
  - 562.2 The challenges of older donors and recipients  
**Stefan G. Tullius**, United States
  - 562.3 The strengths and weaknesses of KDRI  
**Ron Shapiro**, United States
- 

**14:30-16:00 State-of-the-Art Session (Basic Sciences and Translational Sciences) N-104**


---

**563 - Metabolism in Transplantation**


---

Chairs: *Anita Chong, United States* and *Marcos Lopez Hoyos, Spain*

- 563.1 Preventing allograft rejection by targeting immune metabolism  
**Jonathan Powell**, United States
  - 563.2 Nutrient regulation of immune responses  
**Ping-Chih Ho**, Switzerland
  - 563.3 Manipulating macrophage responses in transplantation  
**James A. Hutchinson**, Germany
- 

**14:30-16:00 State-of-the-Art Session (Donation & Procurement) N-105**


---

**564 - Best Use of Available Organs**


---

Chairs: *Howard M. Nathan, United States* and *Eduardo Rocha, Brazil*

- 564.1 DCD organs - what does the evidence say about outcomes?  
**Eduardo Miñambres**, Spain
  - 564.2 DCD perfusion techniques and outcomes  
**Gabriel C. Oniscu**, United Kingdom
  - 564.3 DCD lung donation and lung reconditioning  
**Gregory Snell**, Australia
- 

**14:30-16:00 State-of-the-Art Session (Complications) N-106**


---

**565 - Obesity and Bone Disease – 21st Century Challenges for Transplantation**


---

Chairs: *Peter J. Friend, United Kingdom* and *Mustafa S. A. Almousawi, Kuwait*

- 565.1 Features of postoperative bone complications specific to transplanted organs  
**Meltem Zeytinoglu**, United States
  - 565.2 Mechanisms of osteoporosis after organ transplantation and treatment  
**Sara Jiménez**, Spain
  - 565.3 Indication of bariatric surgery  
**Timucin Taner**, United States
-

14:30-16:00	<b>State-of-the-Art Session (Xenotransplantation)</b> <b>566 - Clinical Xenotransplantation-How Close Are We?</b>	N-107/108
	Chairs: <i>Megan Sykes, United States and Léo Hans Bühler, Switzerland</i>	
566.1	Kidney transplantation <b>Alfred J. Tector III</b> , United States	
566.2	Islet transplantation <b>Wayne J. Hawthorne</b> , Australia	
566.3	Heart transplantation <b>Muhammad Mohiuddin</b> , United States	
14:30-16:00	<b>State-of-the-Art Session (Registries)</b> <b>567 - The What, Who, When, Where and Why of Global Transplant Registries</b>	N-111
	Chairs: <i>Jeremy R. Chapman, Australia and Haibo Wang, People's Republic of China</i>	
567.1	The collaborative transplant study <b>Caner Süsal</b> , Germany	
567.2	WHO Global Observatory managed by Organizacion Nacional de Trasplantes (ONT) <b>Beatriz Dominguez-Gil</b> , Spain	
567.3	The harmonisation of national registries to measure global outcomes <b>Stephen P. McDonald</b> , Australia	
14:30-16:00	<b>State-of-the-Art Session</b> <b>568 - Joint TTS-AST-ASTS-ESOT: Advancing Transplant Therapeutics and Innovation</b>	N-115/116
	Chairs: <i>Philip J. O'Connell, Australia and Randall E. Morris, United States</i>	
568.1	The Transplant Therapeutics Consortium: Update on progress and goals <b>Roslyn B. Mannon</b> , United States	
568.2	Solidifying endpoints in clinical trials: SONG Tx Initiative <b>Allison Tong</b> , Australia	
568.3	Challenges involved in developing new endpoints for clinical trials <b>Stefan Schneeberger</b> , Austria	
	Panel discussion	
14:30-16:00	<b>State-of-the-Art Session (Heart and Lung)</b> <b>569 - ECMO in Thoracic Transplantation</b>	N-117/118
	Chairs: <i>Anne Dipchand, Canada and Peter S. MacDonald, Australia</i>	
569.1	ECMO for heart and lung donors vs. ex vivo perfusion <b>Christopher Wigfield</b> , United States	
569.2	ECMO intra- and postop in heart & lung transplantation <b>Olivier Bastien</b> , France	
569.3	Managing ECMO complications <b>Simon Maltais</b> , United States	
16:15-16:45	<b>TTS Business Meeting</b>	N-106
16:15-17:15	<b>Corporate Symposium</b> <b>580 - Transforming Transplantation: From Large Scale Clinical Trials to Daily Practice</b>	N-103
	See page 30 for details.	
16:30-17:00	<b>Coffee Break</b>	Foyer Area (NCC)

**17:00-18:30 Mini-Oral Abstract Session (Kidney)****N-101****585 - Kidney Transplant Management**Chairs: *Deirdre Sawinski, United States* and *Olivier Aubert, France*

- 585.1 Clinical outcomes of kidney transplant recipients with positive perfusion fluid cultures: A single centre retrospective study  
**Sally R. Black**, United Kingdom
- 585.2 Posttransplant lymphoproliferative disorders in Chinese kidney transplant recipients  
**Chi Yuen Simon Cheung**, Hong Kong
- 585.3 Prevalence of anal cytological abnormalities and human papilloma virus: A cohort study in kidney transplant recipients  
**Brenda M. Rosales**, Australia
- 585.4 Renal allograft biopsy findings in HLA identical renal transplant recipients  
**Muhammad Mubarak**, Pakistan
- 585.5 Comparison of recipients with early and later presentation polyomavirus nephropathy (PVN) with regard to histological findings and graft survival: What is the influence of CD4/CD8 ration on the presenting time of PVN  
**Nurhan Ozdemir**, Turkey
- 585.6 Immune profiling in highly sensitized kidney transplant recipients  
**Sarita Negi**, Canada
- 585.7 Comparison of the incidence, risk factors and types of acute rejection between indigenous and non-indigenous Australians with kidney transplants  
**Prue E. Howson**, Australia
- 585.8 The impact of direct antiviral therapy for hepatitis C (DAA) on acute rejection and donor specific antibody formation in kidney transplant recipients, evidence from surveillance biopsies  
**Ziad Zaky**, United States
- 585.9 Renal transplantation of discolored kidneys from donors with rhabdomyolysis and acute kidney injury  
**Xiao-Peng Yuan**, People's Republic of China
- 585.10 SLPI expression on kidney biopsies correlates with better clinical outcomes  
**Eduardo Chuluyan**, Argentina
- 585.11 Successful treatment of BK nephropathy with tacrolimus and mTOR inhibitors  
**Natalia I. Polanco**, Spain

**17:00-18:30 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-102****586 - T Cell Biology 2**Chairs: *Andreas Linkermann, Germany* and *Manuel Muro, Spain*

- 586.1 The mark of Zorro: IL35-coated exosomes cross-dress and exhaust recipient T & B cells during transplant tolerance  
**William J. Burlingham**, United States
- 586.2 Use of TGF-beta plus rapamycin to induce Foxp3, promote iTreg development and suppressive function, and induce long-term allograft survival  
**Liqing Wang**, United States
- 586.3 The immune monitoring for operationally tolerant recipients following a regulatory T cell-based cell therapy  
**Ryoichi Goto**, Japan
- 586.4 A novel mechanism of human regulatory T cell function in proinflammatory conditions  
**Joanna Hester**, United Kingdom
- 586.5 Human regulatory t cell potential for tissue repair via IL-33/ST2 and amphiregulin  
**Avery J. Lam**, Canada
- 586.6 Allogenic endothelial cells differentially modulate the expansion of anti-inflammatory FoxP3 high regulatory t lymphocytes according to their state of activation  
**Amy R. Cross**, France
- 586.7 High fibre diet induces donor specific tolerance of kidney allografts through SCFA induction of Tregs  
**Huiling Wu**, Australia
- 586.8 Gut microbiota determines graft survival outcome through regulation of anti-inflammatory and pro-inflammatory responses  
**Jonathan S. Bromberg**, United States
- 586.9 The efficacy of CMV specific immune reconstitution is highly dependent on donor/recipient serostatus and type of solid organ transplanted  
**Flavia Neri**, Italy

## 17:00-18:30 Mini-Oral Abstract Session (Donation &amp; Procurement)

N-105

## 587 - Living Donation and Organ Utilization

Chairs: *Helen I. Opdam, Australia and Martí Manyalich, Spain*

- 587.1 Despite the growing impact of the American opioid epidemic on organ donation, a small percentage of drug intoxication deaths result in organ donation  
**Laura A. Hickman**, United States
- 587.2 Machine perfusion preservation for porcine split liver graft  
**Hiroyuki Takahashi**, Japan
- 587.3 Few gender differences in attitudes and experiences after live kidney donation, with minor changes over time  
**Shinji Yamamoto**, Sweden
- 587.4 Risk factors for failure to complete post-donation follow-up among obese living kidney donors  
**Jayme E. Locke**, United States
- 587.5 Comparison of pure laparo-endoscopic single-site surgery and mini-incision retroperitoneal surgery for the retrieval of a graft in living-donor kidney transplantation  
**Naoki Yokoyama**, Japan
- 587.6 Total laparoscopic live donor nephrectomy: Comparison study between robotic arm assisted 3D laparoscopy and standard 2D laparoscopic donor nephrectomy  
**Lasantha L.N. Seneviratne**, Sri Lanka
- 587.7 The use of kidneys from deceased donors over 80 years in kidney transplantation  
**Julio Pascual**, Spain
- 587.8 Low utilization rate of hearts designated as PHS increased risk and presumed infected  
**Charles E. Wright**, United States
- 587.9 Hepatitis B markers in tissue donors. National multicenter study. Preliminary results  
**Jacinto Sánchez Ibáñez**, Spain
- 587.10 The in-hospital departments dedicated to expanding the organ donation and organ procurement in China have increased significantly the number of donors and transplants  
**Liugen Lan**, People's Republic of China
- 587.11 Pre-transplant histological assessment provides a useful predictor of subsequent kidney allograft function  
**Adam Brayne**, United Kingdom
- 587.12 Experience of lung transplantation using voluntary organ donations after brain and cardiac death of citizens at Wuxi Center—report of 242 cases  
**Wenjun Mao Sr.**, People's Republic of China

**17:00-18:30 Mini-Oral Abstract Session (Kidney)****N-106****588 - Miscellaneous Kidney Issues**Chairs: *Brian J. Nankivell, Australia and Joseph Kim, Canada*

- 588.1 Utility of preoperative non-contrast computed tomography (CT) to guide perioperative management for renal transplantation  
**Evan C. Werlin**, United States
- 588.2 De novo or early conversion to Everolimus and cancer incidence in kidney transplant recipients: A trial-based ANZDATA linkage study  
**Wai Lim**, Australia
- 588.3 Laparoscopic versus finger-assisted open donor nephrectomy techniques: A safe alternative  
**Nadey Hakim**, United Kingdom
- 588.4 Comparison of IGL-1 versus UW ex vivo back table flush on early graft function after living donor kidney transplantation: Retrospective single center analysis  
**Laurie Massaad**, Belgium
- 588.5 Transition from laparoscopy to retroperitoneoscopy for live donor nephrectomy - a case control study  
**Zi Qin Ng**, Australia
- 588.6 The effect of donor-recipient weight mismatch on kidney graft function – demand defines supply  
**Andreja Figurek**, Switzerland
- 588.7 Why in Spain the kidney altruistic donation rate is lower than that of other countries of our environment?  
**Marta MG Garcia**, Spain
- 588.8 Outcome of robotic assisted laparoscopic kidney transplantation with and without regional hypothermia  
**Pranjal Modi**, India
- 588.9 Utility of surveillance biopsies in kidney transplant recipients with delayed graft function under current immunosuppressive therapy  
**Roberto C. Manfro**, Brazil
- 588.10 Malignancy complications after kidney transplantation with different immunosuppression induction protocols  
**Maria Molina**, Spain
- 588.11 Surgical complications in kidney transplant recipients in the modern era: Types, rates and impact on clinical outcomes  
**Joseph Kim**, Canada
- 588.12 Assessment of atrial fibrillation and ventricular arrhythmia risk after transplantation in patients with end stage renal disease by P Wave/QT Interval Dispersion, Tp-e Interval, Tp-e/QT Interval Ratio  
**Haldun Muderrisoglu**, Turkey

**17:00-18:30 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-107/108****589 - IRI Interventions & Tissue Repair**Chairs: *Qizhi Tang, United States and Nancy Kwan Man, Hong Kong*

- 589.1 Co-transplant of parathyroid gland and stem cell-derived insulin-producing cells enhances graft survival through release of pro-angiogenic and pro-survival factors  
**Gaetano Faleo**, United States
- 589.2 Endothelial progenitor cell-derived extracellular vesicles inhibit kidney ischemia-reperfusion injury through the transfer of specific microRNA and mRNA coding for the transcription factor NRF2: relevance for delayed kidney graft function  
**Vincenzo Cantaluppi**, Italy
- 589.3 Senolytic treatment attenuates mtDNA-mediated inflammatory injury in old donors and improves cardiac allograft survival  
**Koichiro Minami**, United States
- 589.4 Impact of different dynamic preservation strategies on early renal function and physical machine perfusion parameters in a porcine DCD auto-transplant model  
**Tom Darius**, Belgium
- 589.5 Histone deacetylase-6 inhibition is protective in liver ischemia-reperfusion injury and acetaminophen toxicity in a murine model  
**Seth J. Concors**, United States
- 589.6 Inhalation of carbon monoxide protects liver against warm ischemia-reperfusion injury in CLAWN miniature swine  
**Hisashi Sahara**, Japan
- 589.7 MicroRNAs in kidney hypothermic machine perfusion fluid as novel biomarkers for graft function. Have changes in normalization guidelines support previous results?  
**Victoria Gomez Dos Santos**, Spain
- 589.8 A novel human myoblast chimeric cells therapy for restoration of muscle function  
**Maria Siemionow**, United States
- 589.9 Blockade of the G-CSF receptor is protective in a mouse model of renal ischemia reperfusion injury  
**Jennifer L. McRae**, Australia

**17:00-18:30 Mini-Oral Abstract Session (Infectious Diseases)****N-111****590 - The Challenges of Post-Transplant Infections**Chairs: *Edward A. Dominguez, United States* and *Oscar Len Abad, Spain*

- 590.1 Incidence, prevalence and residual infection risk of HIV in increased risk groups presenting as potential organ donors in Australia; a systematic review and meta-analysis  
**Karen Waller**, Australia
- 590.2 Cryptococcal infections in kidney transplant recipients. A single center experience  
**Marcelo V. Radisic**, Argentina
- 590.3 Hepatitis C virus infected kidney wait list patients: Treat with DAA or delay?  
**Bryce A. Kiberd**, Canada
- 590.4 The choice of immunosuppressive regimen does not impact on the occurrence of primary CMV events  
**Kamilla Linhares-Silva**, Brazil
- 590.5 Cytomegalovirus infection after transplantation in pediatric liver recipients  
**Olga Tsurulnikova**, Russian Federation
- 590.6 IgG hypogammaglobulinemia is a risk factor of cytomegalovirus infection in a multicenter study in kidney transplantation  
**Ikram Ezzahouri**, Spain
- 590.7 Lower rates of death in heart recipients with secondary antibody deficiency and severe infection after therapy with intravenous immunoglobulin  
**Javier Carbone**, Spain
- 590.8 Pattern of antibiotic resistance in *E. coli* and *klebsiella* bacteremia in renal transplant recipients from developing country  
**Ejaz Ahmed**, Pakistan
- 590.9 Deceased organ donor screening for *Trypanosoma Cruzi* in the UK - a strategy in a non-endemic country  
**Ines Ushiro-Lumb**, United Kingdom
- 590.10 Screening coccidioides serology in kidney transplant recipients: A 10-year cross-sectional analysis  
**Korntip Phonphok**, Thailand
- 590.11 Risk factors for mortality among kidney transplant recipients with *Pneumocystis jirovecii* infection  
**Maristela P. Freire**, Brazil
- 590.12 A single center experience with post transplant tuberculosis in a developing country  
**Deepesh B. Kenwar**, India

**17:00-18:30 Oral Abstract Session (Transplant Immunosuppression)****N-112****591 - Minimization/ Optimization**Chairs: *Peter W. Nickerson, Canada* and *Josep M. Grinyo, Spain*

- 591.1 MANDELA study results at 18 months after heart transplantation: Superior renal function with cni-free everolimus over standard CNI-based regimen: A randomized, multi-center trial in de novo heart transplant recipients.  
**Markus J. Barten**, Germany
- 591.2 Renal function outcomes in de novo kidney transplant recipients receiving everolimus with reduced-exposure calcineurin inhibitor versus mycophenolate with standard-exposure calcineurin inhibitor: Results from the TRANSFORM study  
**Federico Oppenheimer**, Spain
- 591.3 Everolimus failure to counteract the cytotoxic response mediated by CD8+ T and NK cells in heart-transplant patients  
**Beatriz Suarez-Alvarez**, Spain
- 591.4 High tacrolimus clearance – a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney  
**Erlend J. Egeland**, Norway
- 591.5 The feasibility of organ-specific immunosuppression  
**Lauren Brasile**, United States
- 591.6 CD40 inhibition with CFZ533 - A new, fully human, non-depleting, Fc silent mAb - improves renal allograft function while demonstrating comparable efficacy vs. tacrolimus in de-novo CNI-Free kidney transplant recipients  
**Bjoern Nashan**, Germany
- 591.7 Targeting the CD40-costimulation pathway by CFZ533 prevents the cross-talk between follicular T helper cells and B cells  
**Martijn W.F. van den Hoogen**, Netherlands
- 591.8 Costimulatory blockade with CTLA4-Ig abrogates prolonged graft survival in old recipients  
**Yeqi Nian**, United States
- 591.9 Efficacy and safety of everolimus with reduced-dose calcineurin inhibitor in de novo kidney transplant recipients: Results from the TRANSFORM study  
**Julio Pascual**, Spain

**17:00-18:30 Oral Abstract Session (Pancreas & Islet)****N-113****592 - Islet Transplantation**Chairs: *Marc Guell, United States and Peter G. Stock, United States*

- 592.1 Reversal of diabetes and preservation of pancreatic islet grafts in the extrahepatic space with novel parathyroid gland co-transplantation  
**Casey J. Ward**, United States
- 592.2 Prevention of islet inflammatory stress with JAK1/JAK2 inhibitors  
**Helen Thomas**, Australia
- 592.3 Local attenuation of immunoreaction in xenogeneic islet transplantation by controlled release of a low-dose FK506 using polydopamine-coated polymeric microspheres immobilized on pancreatic islet surface  
**Tung Thanh Pham**, Korea
- 592.4 Islet heterospheroids generated from islet cells and amniotic epithelial cells reverse diabetes after marginal mass transplantation in a murine model  
**Ekaterine Berishvili**, Switzerland
- 592.5 Prevascularization of the subcutaneous space improves survival of transplanted mouse islets  
**Nicole Conkling**, United States
- 592.6 A simple and promising strategy for pancreatic islet preconditioning to reduce immunogenicity and improve islet graft longevity  
**Takayuki Anazawa**, Japan
- 592.7 Cyanidin-3-O-glucoside treatment of human islets in vitro leads to an augmentation of autophagic flux and a decreased in inflammatory cell markers  
**Gina R. Rayat**, Canada
- 592.8 Ten year insulin-independence in select islet transplant recipients receiving CNI-sparing immunosuppression with either costimulation blockade or anti-LFA1  
**James Gardner**, United States
- 592.9 Master regulator for splenic development, Tlx1 contributes the engraftment of the transplanted islets in the spleen  
**Hiroyuki Takahashi**, Japan

**17:00-18:30 Mini-Oral Abstract Session (Donation & Procurement)****N-115/116****593 - Preservation and Increasing Donation**Chairs: *Gabriel C. Oniscu, United Kingdom and Faissal Shaheen, Saudi Arabia*

- 593.1 Longitudinal molecular assessment of renal allograft and short-term outcome: Markers of injury and recovery  
**Daniel G. Maluf**, United States
- 593.2 First series of brain death organ donors in united United Arab Emirates - SEUSA Program implementation  
**Ali A. Alobaidli**, United Arab Emirates
- 593.3 Normothermic ex-vivo kidney perfusion improves function of marginal renal grafts that were subjected to prolonged ischemia prior to preservation  
**Peter Urbanellis**, Canada
- 593.4 Effects of static subnormothermic preservation on extended warm ischemic porcine kidneys assessed by normothermic machine perfusion and renal transplantation  
**Mitsuhiro Sekijima**, Japan
- 593.5 Project of support to controlled donation after circulatory death through a normothermal regional perfusion mobile equipment for hospitals of the community of Madrid, Spain. Start-up and preliminary result.  
**Marina Pérez Redondo**, Spain
- 593.6 A national registry analysis of aortic versus dual in situ perfusion for retrieval of the DBD liver  
**Ahmer M. Hameed**, Australia
- 593.7 Histidine-Tryptophan-Ketoglutarate (HTK) versus celsior in the association with heart transplant outcomes  
**Dewei Ren**, United States
- 593.8 Superior outcomes using normothermic regional perfusion in CDCD liver transplantation  
**Elisabeth Coll**, Spain
- 593.9 The customized design of hospital-level deceased organ donation quality system in china for continuous improvement  
**Wenshi Jiang**, People's Republic of China
- 593.10 Spanish non standard risk donor project (period 2013-June 2017)  
**Beatriz Mahillo**, Spain
- 593.11 In house oxygen persufflation of cold stored livers versus simple cold storage in extended criteria liver grafts: 5-year results of a randomized controlled clinical trial  
**Anja Gallinat**, Germany
- 593.12 Current status of organ donation for transplantation in Vietnam  
**Richard D.M. Allen**, Australia

**17:00-18:30 Oral Abstract Session (Liver)****N-117/118****594 - Immunosuppression and Rejection**Chairs: *Valentín Cuervas-Mons, Spain* and *Stephan Busque, United States*

- 594.1 ABO-incompatible liver transplantation using only rituximab for patients with low anti-ABO antibody titer  
**Boram Lee**, Korea
- 594.2 Donor specific antibodies are associated with more inflammation, more fibrosis and higher expression of rejection associated transcripts in subclinically rejected liver allografts  
**Richard Taubert**, Germany
- 594.3 Prospective evaluation of noninvasive cell death marker and donor specific antibodies as predictors of subclinical graft inflammation and graft fibrosis  
**Richard Taubert**, Germany
- 594.4 Are only pre-transplant rituximab and plasma exchange sufficient for pre-transplantation desensitization protocol of ABO incompatible LDLT? Single institute experience  
**Youngseok Han**, Korea
- 594.5 Ab initio everolimus-based vs. standard CNi immunosuppression-regimen in liver transplant recipients  
**Tommaso Maria Manzia**, Italy
- 594.6 Hepatic estrogen receptor expression prevents liver fibrosis through decreasing the risk of early activation of hepatic stellate cells  
**Gonca Ozgun**, Turkey
- 594.7 Tacrolimus (TAC) and single intra-operative high-dose of r-ATG induction vs. tacrolimus monotherapy as immunosuppression (IS) in adult liver transplantation (lt): one-year results of an investigator-driven, prospective, randomized, controlled trial (RCT)  
**Samuele Iesari**, Italy
- 594.8 Immunological impact of portal hypertension and splenectomy in living donor liver transplantation  
**Kazuhiro Taguchi**, Japan

**20:00-23:00 Congress Networking Event****Palacete de los Duques de Pastrana  
Paseo de la Habana, 208**

Tickets are available for purchase at \$75 US must be purchased in advance.

**No ticket sales at the door.**



[illegible]

# DETAILED PROGRAM

Thursday, July 5, 2018

08:30-09:30	<b>Morning Symposium (Kidney)</b> <b>600 - Recurrent Disease after Transplantation</b>	N-102
	Chairs: <i>Josep M. Grinyo, Spain</i> and <i>Daniel Seron, Spain</i>	
600.1	FSGS <b>Guillaume Canaud</b> , France	
600.2	aHUS <b>Christophe Legendre</b> , France	
600.3	C3 GN <b>John S. Gill</b> , Canada	
08:30-09:30	<b>Morning Symposium (Liver)</b> <b>601 - When the Liver Transplant Surgeons Need Help...</b>	N-105
	Chairs: <i>Jan Lerut, Belgium</i> and <i>Valentín Cuervas-Mons, Spain</i>	
601.1	The role of interventional endoscopist <b>Magdy El-Serafy</b> , Egypt	
601.2	The role of the interventional radiologist <b>Pierre Goffette</b> , Belgium	
601.3	The role of the liver transplant pathologist <b>Laura Rubbia-Brandt</b> , Switzerland	
08:30-09:30	<b>Morning Symposium (Basic Sciences and Translational Sciences)</b> <b>602 - Modern Reinterpretation of Classical Concepts in Transplant Immunology</b>	N-106
	Chairs: <i>Adrian E. Morelli, United States</i> and <i>TBA</i>	
602.1	Die another day: Apoptosis, necroptosis and immune activation <b>Andreas Linkermann</b> , Germany	
602.2	Tricky ways of allorecognition: Exosomes and antigen <b>Adrian E. Morelli</b> , United States	
602.3	Are we getting there? Novel mechanistic aspects of tolerance induction <b>Julien Zuber</b> , France	
08:30-09:30	<b>Oral Abstract Session (Donation &amp; Procurement)</b> <b>603 - Donation after Circulatory Death</b>	N-107/108
	Chairs: <i>Gabriel C. Oniscu, United Kingdom</i> and <i>María García-Conde Delgado, Spain</i>	
603.1	Donation after circulatory death: An updated description of the European landscape <b>Maria del Mar Lomero</b> , France	
603.2	Long-term outcomes using uncontrolled donors after circulatory death (uDCD) for liver transplantation. A 10-year single center experience <b>Iago Justo</b> , Spain	
603.3	Liver transplantation from donor after cardiac death (DCD) Maastricht type IIA: Comparative study of outcomes during the initial five years and on <b>María García-Conde Delgado</b> , Spain	
603.4	A systematic review and meta-analysis of outcomes for islet transplantation in donation after circulatory death (DCD) compared with donation after brain death (DBD) <b>Yi Vee Chew</b> , Australia	
603.5	A new technique for cannulation and external 'clamping' in the difficult DCD donor <b>Joshua F. Hollingshead</b> , United States	
603.6	Should donation after cardiac death donor organs be used in the pediatric patient population? <b>Christine S. Hwang</b> , United States	

---

**08:30-09:30 Morning Symposium (Histocompatibility) N-111**


---

**604 - Kidney Paired Exchange. Success Stories, Ongoing Challenges and What We Can Learn from Others**


---

- Chairs: *Robert A. Montgomery, United States and Bernadette BJJM. Haase-Kromwijk, Netherlands*
- 604.1 Kidney paired exchange in Canada. What works and what challenges remain. A national approach to KPD  
**Kathryn Tinckam**, Canada
- 604.2 Kidney paired exchange in Saudi Arabia. Success and lessons  
**Khalid AlMeshari**, Saudi Arabia
- 604.3 The National Kidney Registry approach to paired exchange  
**J. Michael Cecka**, United States
- 

**08:30-09:30 Oral Abstract Session (Xenotransplantation) N-112**


---

**605 - Xenotransplantation: Cell/Tissue and Immune Regulation**


---

- Chairs: *Curie Ahn, Korea and Chung-Gyu Park, Korea*
- 605.1 Long-term function of genetically modified porcine neonatal islet xenografts in baboons  
**Wayne J. Hawthorne**, Australia
- 605.2 Correlation between islet number in the small biopsy liver and blood glucose level after pig to non-human primate islet xenotransplantation model  
**Byoung-Hoon Min**, Korea
- 605.3 Effects of several genetic engineering in the graft survival of pig-to-monkey lamellar corneal xenotransplantation with minimal immunosuppression  
**Ki Cheul Shin**, Korea
- 605.4 Durable macrochimerism (>8 weeks) and pig-specific T and B Cell unresponsiveness following hCD47+ transgenic GalTKO pig intra-bone bone marrow transplantation in baboons  
**Hironosuke Watanabe**, United States
- 605.5 Human HLA-DR+CD27+ memory-type regulatory T cells show potent xenoantigen-specific suppression in vitro  
**Lu Cao**, Australia
- 605.6 Isolation of human xenospecific regulatory t cells with high suppressive function  
**Elmar Jaeckel**, Germany
- 

**08:30-09:30 Morning Symposium N-113**


---

**606 - Pearls of Wisdom – A Roadmap to Developing a Successful Career in Transplantation**


---

- Chairs: *Fadi Issa, United Kingdom and Jayme E. Locke, United States*
- 606.1 Your first real job - making yourself marketable and finding a clinical niche  
**Barbara Murphy**, United States
- 606.2 The "How to Guide" for the aspiring physician/surgeon-scientist: Funding and publications  
**Jeremy R. Chapman**, Australia
- 606.3 The "Holy Grail of Work-Life Balance": Mindfulness, emotional intelligence and well-being  
**Nancy Ascher**, United States
- 606.4 How to find a research focus – and funding – as a trainee  
**Jayme E. Locke**, United States
- Panel discussions
- 

**08:30-09:30 Morning Symposium N-115/116**


---

**607 - Tackling the Challenges Posed by Donor Intervention Research**


---

- Chairs: *Philip J. O'Connell, Australia and Elisabeth Coll, Spain*
- 607.1 Why is it difficult to conduct trials testing novel interventions in deceased donors?  
**Claus Niemann**, United States
- 607.2 Guidance delineated in the National Academies of Medicine Donor Intervention Report  
**Sandy Feng**, United States
- 607.3 Conducting donor intervention trials in my country – an international panel discussion  
**Claus Niemann**, United States  
**Axel Rahmel**, Germany  
**Christopher J. E. Watson**, United Kingdom  
**Elisabeth Coll**, Spain  
**Helen I. Opdam**, Australia
-

**08:30-09:30 Oral Abstract Session (Transplant Immunosuppression)**  
**608 - Tolerance**

N-117/118

Chairs: *Stephan Busque, United States* and *Suzanne T. Ildstad, United States*

- 608.1 Relationship between mixed chimerism and acceptance of HLA-matched and -mismatched kidney transplants after withdrawal of immunosuppressive drugs  
**Stephan Busque**, United States
- 608.2 Renal allograft tolerance for end-stage renal disease patients with hematologic malignancies  
**Megan Sykes**, United States
- 608.3 In-vivo costimulation-blockade induced Foxp3 Tregs from DREG mice with neonatal islet cell cluster tolerant xenografts exist memory Tregs phenotype  
**Yuanfei Zhao**, Australia
- 608.4 Long-term follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients  
**David Tollerud**, United States
- 608.5 Non-myeloablative conditioning with low-dose total body irradiation in place of cyclophosphamide induces mixed chimerism and long-term immunosuppression free allograft survival without acute kidney injury in HLA mismatched kidney transplantation.  
**Tatsuo Kawai**, United States
- 608.6 Does the end justify the means? An analysis of outcomes in recipients of combined kidney/hematopoietic stem cell (HSC) transplants and comparison to standard of care (SOC) patients  
**Suzanne T. Ildstad**, United States

**09:45-11:00 Oral Abstract Session (Donation & Procurement)**  
**615 - Organ Preservation and Utilization**

N-101

Chairs: *Francisco Del Río, Spain* and *Richard S. Mangus, United States*

- 615.1 Ex-vivo lung perfusion - 10 year follow-up of the first performed double LTX with marginal donor lungs evaluated using EVLP  
**Mohammed Fakhro**, Sweden
- 615.2 Extending the human liver preservation time for transplantation by supercooling  
**Reinier J. de Vries**, United States
- 615.3 Normothermic ex-vivo kidney perfusion restores the genetic profile of marginal kidney grafts subjected to warm ischemia  
**Peter Urbanellis**, Canada
- 615.4 Use of tissue plasminogen activator (tPA) and histidine-tryptophan-ketoglutarate solution (HTK) in donation after circulatory death (dcd) liver transplant prevents ischemic cholangiopathy  
**Richard S. Mangus**, United States
- 615.5 Efficacy and quality of flush-out prior to cold storage of liver and kidney in donation after circulatory death  
**Catherine Boffa**, United Kingdom
- 615.6 Expedited evaluation for liver transplantation: Does patient acuity influence processes or outcomes?  
**Hillary J. Braun**, United States
- 615.7 Explant biopsy and remuzzi scoring outperforms kidney donor profile index (KDPI) in selection of extended criteria donor kidneys for single implant  
**Hersharan K. Sran**, Singapore

**09:45-11:00 Oral Abstract Session (Kidney)**  
**616 - Immunosuppression 3**

N-102

Chairs: *Francesc Moreso Mateos, Spain* and *TBA*

- 616.1 Thymoglobulin induction decreases risk of ABMR and death in kidney recipients  
**Charlotte Loheac**, France
- 616.2 Pretransplant immunologic predictors of rejection in patients treated with belatacept  
**Jun Shoji**, United States
- 616.3 Steroid withdrawal promotes B lymphocyte phenotypes of operational tolerance predisposition in renal allograft recipients  
**Laura Llinàs Mallol**, Spain
- 616.4 Predicting mycophenolic acid area under the curve with mycophenolic acid trough in de novo renal transplantation  
**Shiong Shiong Yew**, Malaysia
- 616.5 MRP2 24 CT is associated with an increased risk of cytomegalovirus infection among renal transplant recipients  
**Beatriz Rodriguez-Cubillo**, Spain
- 616.6 Subclinical inflammation in early surveillance biopsies is associated with immunosuppression exposure and HLA-DR mismatch  
**Francesc Moreso Mateos**, Spain
- 616.7 M-CSF and TNF- $\alpha$  Induce human MDSCs that attenuate GVHD  
**Puxun Tian**, People's Republic of China

**09:45-11:00 Oral Abstract Session (Kidney)****N-103/104****617 - Deceased Donor Issues & Others**Chairs: *Brian J. Nankivell, Australia* and *Ana I. Sanchez Fructuoso, Spain*

- 617.1 Survival analysis of kidney transplants with grafts from uncontrolled DCD donors under normothermic preservation prior to organ retrieval related to DBD: Data from our 300 transplants series  
**Felix Guerrero-Ramos**, Spain
- 617.2 A new risk stratification score for deceased donor kidneys in Korea  
**Tai Yeon Koo**, Korea
- 617.3 Beneficial effect of ABO incompatibility on de novo DSA production after kidney transplantation  
**Takaaki Kobayashi**, Japan
- 617.4 Evaluation of a deceased donor kidney allocation score. The Catalan experience  
**Jordi Comas**, Spain
- 617.5 Inflammatory frailty index and mortality after kidney transplantation  
**Christine E. Haugen**, United States
- 617.6 Impact of the new kidney allocation system A2/A2B—> B policy on access to transplantation among minority candidates  
**Margaux N. Mustian**, United States
- 617.7 Kidney transplantation from uncontrolled donation after circulatory death, our outcomes compared to donation after brain death after very long time  
**Esther González Monte Sr.**, Spain

**09:45-11:00 Oral Abstract Session (Liver)****N-105****618 - Liver Complications**Chairs: *Nancy Ascher, United States* and *Gabriel C. Oniscu, United Kingdom*

- 618.1 Better graft survival with no ischemic cholangiopathy in DCD liver transplantation in the UK using normothermic regional perfusion (nrp)  
**Gabriel C. Oniscu**, United Kingdom
- 618.2 Hazard ratio trends among deceased liver transplant recipients in the United States, 2011-2016: A propensity score-matched study  
**Shunji Nagai**, United States
- 618.3 The AKI-predict-score: A new prediction model for acute kidney injury after liver transplantation  
**Marit Kalisvaart**, United Kingdom
- 618.4 Pharmacotherapy before or after liver transplantation in familial amyloidotic polyneuropathy (FAP) and domino recipients – early report from the familial amyloidotic world transplant registry (FAPWTR) and the domino liver transplant registry (DLTR).  
**Bo-Göran Ericzon**, Sweden
- 618.5 Revascularization techniques in liver transplantation for portal vein thrombosis and stenosis: Single center experience  
**Aliaksei Shcherba**, Belarus
- 618.6 Predictors for post transplant survival in patients with acute-on-chronic liver failure  
**Martina Sterneck**, Germany
- 618.7 Severe injury of common bile ducts in donation after circulatory death liver transplantation: Histological and immunohistochemical evaluation  
**Francesca Tinti**, Italy

**09:45-11:00 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-106****619 - Chimerism and GvHD**Chairs: *Jordi Ochando, Spain* and *Andreas Linkermann, Germany*

- 619.1 Durable donor hematopoietic stem cell chimerism is associated with protection from native renal disease recurrence in recipients of combined stem cell/kidney transplants  
**Suzanne T. Ildstad**, United States
- 619.2 Donor's graft ex vivo t cell depletion with fludarabine reduces GvHD signs and improves survival after intestine transplantation  
**Maria Vela**, Spain
- 619.3 Role of graft-derived graft-versus-host t cells in facilitating multilineage blood chimerism after human intestinal transplantation  
**Jianing Fu**, United States
- 619.4 Clonal and functional analysis reveals the capacity of allograft t cells to join the circulating pool after human intestinal transplantation  
**Jianing Fu**, United States
- 619.5 Bone marrow graft-versus-host disease in reduced intensity conditioned major histocompatibility complex matched murine allogeneic hematopoietic cell transplantation  
**Pablo A. Silveira**, Australia
- 619.6 Recipient t regulatory cells enhance chimerism and prolong galt-KO pig skin graft survival in baboons  
**Nathaly P. Lore**, United States
- 619.7 Donor conditioning with recipient-derived PD-L1/PD-L2-expressing B cells prevents lethal acute GVHD in a fully allogeneic mouse model  
**Asuka Tanaka**, Japan

**09:45-11:00 Oral Abstract Session (Complications)****N-107/108****620 - Cardio-Vascular & Metabolic Complications**Chairs: *Juan F. Delgado, Spain* and *TBA*

- 620.1 Stroke mortality in kidney transplant recipients: A retrospective population-based cohort study using data linkage  
**Nicole L. De La Mata**, Australia
- 620.2 Concentric left ventricular hypertrophy geometry predicts cardiovascular events after renal transplantation  
**Edoardo Melilli**, Spain
- 620.3 Prevalence and predictors of hypertension among heart transplant recipients: An analysis of Russian National Medical Research Centre of Transplantology and Artificial Organs Registry  
**Alex O. Shevchenko**, Russian Federation
- 620.4 Pulse wave velocity and augmentation index in renal transplant recipients - 4.6 years follow up  
**Jan Alatič**, Slovenia
- 620.5 Influence of immunosuppression on metabolic outcomes one year after kidney transplantation: The role of mycophenolate and mTOR inhibitors on lipid metabolism and glycemic control  
**David Cucchiari**, Spain
- 620.6 Tacrolimus activated bmp signaling acts in synergy with stress-activated FOXO1 to induce loss of beta-cell function and identity  
**Aiko PJ de Vries**, Netherlands
- 620.7 Influence of hypomagnesemia on new-onset diabetes after kidney transplantation  
**Korntip Phonphok**, Thailand

**09:45-11:00 Oral Abstract Session (Heart and Lung)****N-111****621 - Lung Transplantation**Chairs: *Gregory Snell, Australia* and *Irene Bello, Spain*

- 621.1 Ultrastructural changes in lung allografts: Endothelial changes correlate with donor specific antibody and antibody-mediated rejection  
**Mariam P. Alexander**, United States
- 621.2 Induction of tolerance to fully allogeneic pulmonary allograft by adenosine A2A receptor agonist in MHC-defined CLAWN miniature swine  
**Hisashi Sahara**, Japan
- 621.4 Obliterative bronchiolitis syndrome and outcomes of unplanned ICU readmission following lung transplantation  
**Cristopher C. Mazo Torre Sr.**, Spain
- 621.5 Is the lung allocate score associated with the decrease of the primary graft dysfunction in lung transplantation?  
**Irene Bello**, Spain
- 621.6 Clinical benefit of lung transplantation after ECMO support  
**Alessandro Bertani**, Italy
- 621.7 Impact of allograft ischemic time on short- and long-term survival in lung transplantation  
**Mohammed Fakhro**, Sweden

**09:45-11:00 Oral Abstract Session (Vascularized Composite Allotransplantation)****N-112****622 - VCA**Chairs: *Jelena M. Janjic, United States* and *David W. Mathes, United States*

- 622.1 Mayo clinic's first face transplant: One year outcome  
**Hatem Amer**, United States
- 622.2 A clinically relevant protocol induces tolerance to a vascularized composite allograft across major histocompatibility barrier in a large animal model  
**David W. Mathes**, United States
- 622.3 End stage renal disease as a complication of face transplant  
**Nicole M. Shockcor**, United States
- 622.4 Mechanisms of vascularized bone marrow graft protection of vascularized composite allografts  
**Nicole M. Shockcor**, United States
- 622.5 Quadruple therapy tacrolimus-sparing belatacept-based maintenance immunosuppression after an arm transplant  
**Luis Landin**, Spain
- 622.6 Functional reconstruction of urogenital tissue defects using vascularized composite allotransplantation: A novel microsurgical penis transplant model and clinical & histological rejection classification  
**Giorgio Raimondi**, United States
- 622.7 Optimization of an ex-vivo limb perfusion protocol for vascularized composite allograft transplantation  
**Kavit Amin**, United Kingdom

**09:45-11:00 Oral Abstract Session (Education)****N-113****623 - Innovations in Transplant Education II**Chairs: *Marcelo Cantarovich, Canada* and *Medhat Askar, United States*

- 623.1 Integration of a massive open online course on clinical kidney, pancreas and islet transplantation into a regular medical science curriculum  
**Marlies E.J. Reinders**, Netherlands
- 623.2 Knowledge transfer and leadership in organ donation from Europe to China: keTLOD  
**Chloe Ballesté**, Spain
- 623.3 Kidney transplant education using the explore transplant Ontario package: Increasing transplant knowledge in patients on maintenance dialysis and addressing ethnic disparities in transplant education  
**Dmitri Belenko**, Canada
- 623.4 Effect of TV advertisement on donor card registration  
**Katayoun Najafizadeh**, Iran (Islamic Republic of)
- 623.5 Increasing demand on Master Education for transplantation  
**Alicia Molina**, Spain
- 623.6 Donors after circulatory death - theme of present or a future? The research of west pomeranian province in Poland  
**Marek Ostrowski**, Poland
- 623.7 Minimizing risks in organ transplantation: Notify project new developments  
**Aurora Navarro**, Spain



**09:45-11:00 Oral Abstract Session (Anesthesia Management and Critical Care)****N-114****624 - Anesthesia and Critical Care Issues**Chairs: *Darren Malinoski, United States* and *TBA*

- 624.1 Intraoperative cytokine hemoabsorption treatment may prevent vasoplegic syndrome during orthotopic heart transplantation  
**Endre Nemeth**, Hungary
- 624.2 Effect of the surgical intervention of laparoscopic donor nephrectomy on proteomic changes in living kidney donors using either propofol or sevoflurane anaesthesia  
**Honglei Huang**, United Kingdom
- 624.3 Evaluation of clonidine as an adjuvant to bupivacaine in wound infiltration for providing postoperative analgesia after laparoscopic donor nephrectomy  
**Bina Butala**, India
- 624.4 PiCCO monitoring during liver transplantation for pediatric patients  
**Zeynep Ersoy**, Turkey
- 624.5 Evaluate the efficacy of epidural dexmedetomidine as postoperative analgesic in live donor renal allograft recipients for open renal transplantation surgical approach  
**Geeta P. Parikh**, India
- 624.6 Clinical significance of lactate clearance for the development of early allograft dysfunction and short-term prognosis in deceased donor liver transplantation  
**Sung Hoon Kim**, Korea
- 624.7 Hierarchical model to predict length of stay and ICU outcome according to post-operative respiratory failure after liver transplantation  
**Alfonso W. Avolio**, Italy

**09:45-11:00 Oral Abstract Session (Pancreas & Islet)****N-115/116****625 - Pancreas Transplantation**Chairs: *Wayne J. Hawthorne, Australia* and *Peter J. Friend, United Kingdom*

- 625.1 Allograft duodenal cuff biopsy as surrogate in evaluation of pancreatic transplant rejection – a multicenter data effort  
**Danni G. Holanda**, United States
- 625.2 New tool helping differentiation between rejection and graft pancreatitis  
**Malwina Bialobrzecka**, Germany
- 625.3 Antibody monitoring in pancreas transplantation: When should we do protocol biopsies?  
**Pablo D. Uva**, Argentina
- 625.4 Pancreas graft outcomes in living versus deceased kidney donor in pancreas after kidney transplant recipients  
**Pedro Ventura-Aguilar**, Spain
- 625.5 Outcomes from brain death donors with cardiac arrest accepted for pancreas transplantation  
**Pedro Ventura-Aguilar**, Spain
- 625.6 Post-transplant survival in Type 1 diabetics in Australia and New Zealand  
**Patrick Kelly**, Australia

**09:45-11:00 Oral Abstract Session (Basic Sciences and Translational Sciences)****N-117/118****626 - Innovative Approaches**Chairs: *Estela Paz-Artal, Spain* and *Manuel Muro, Spain*

- 626.1 Anti-TIRC7 antibody treatment prevents rejection of mice cardiac allografts while immune competency to viral and bacterial antigens remain normal  
**Stefan G. Tullius**, United States
- 626.2 Blockade of tyrosine kinases as preventive strategy against cardiac allograft vasculopathy in a murine aortic transplant model  
**Christian Heim**, Germany
- 626.3 Targeting lymphotoxin receptor classical NFkB signaling facilitates inflammation resolution  
**Jonathan S. Bromberg**, United States
- 626.4 Transient antibody targeting of CD45RC to prevent the development of graft versus host diseases in rat and NSG mice  
**Laetitia Boucault**, France, Metropolitan
- 626.5 In vivo perfusion of porcine kidney scaffolds re-endothelialized with human umbilical vein endothelial cells  
**Ron Shapiro**, United States
- 626.6 Low dose IL-2 and rapamycin leads to Prolongation of human islet allograft Survival by inhibition of IFN-gamma+ T cells and expansion of FOXP3+CD25+ Tregs in a humanized islet transplant mouse model  
**Min Hu**, Australia
- 626.7 The transient display of a chimeric PD-L1 protein on pancreatic islets promotes indefinite survival in allogeneic recipients  
**Esma S. Yolcu**, United States

---

**09:45-11:00 Oral Abstract Session (Paediatrics) Retiro Room (NCC)**


---

**627 - Long Term Outcomes in Paediatric Transplantation**

- Chairs: *Stephen D. Marks, United Kingdom and Douglas G. Farmer, United States*
- 627.1 The impact of donor/recipient age difference and HLA matching on graft outcome in pediatric kidney transplantation  
**Steven McTaggart**, Australia
  - 627.2 Successful ABO and HLA incompatible renal transplantation in children in the United Kingdom over the last decade  
**Stephen D. Marks**, United Kingdom
  - 627.3 Liver transplantation in children with hepatoblastoma: A single-center 30 year experience examining prognostic factors for survival and recurrence  
**Douglas G. Farmer**, United States
  - 627.4 Poorer long-term survival associated with monomorphic post-transplant lymphoproliferative disorder after solid organ transplantation in children  
**Fang Kuan Chiou**, Singapore
  - 627.5 Septic complications and graft outcome after post-transplant lymphoproliferative disorder in paediatric solid organ transplant patients in the rituximab era  
**Fang Kuan Chiou**, Singapore
  - 627.6 Improved renal allograft survival for pre-emptive paediatric renal transplant recipients in the United Kingdom  
**Matko Marlais**, United Kingdom
  - 627.7 Impact of a dedicated young adult service on risk of non-adherence and non-engagement in pediatric-adult transition transplant recipients and in young adult patients presenting directly to adult care for transplantation  
**Paul N. Harden**, United Kingdom
- 

**11:00-11:30 Coffee Break Foyer Area (NCC)**


---

**11:30-12:30 Plenary Session 3 N-103/104**


---

**630 - How Will Big Data Transform Medicine and Transplantation**

- Facilitator: *Philip O'Connell, Australia*
- 630.1 How can we use large data in medicine  
**Atul Butte**, United States
  - 630.2 What does large data tell us in transplantation  
**Dorry Segev**, United States
- 

**Closing Ceremony - 12:30 to 13:30**


---

**12:30-13:30 Closing Plenary N-103/104**


---

**635 - Over the Horizon Summary: What Is The Future for Transplantation?**

- Facilitator: *Nancy Ascher, United States*
- 635.1 Basic Science Summary  
**Stefan G. Tullius**, United States
  - 635.2 Clinical Science Summary  
**Elmi Muller**, South Africa
  - 635.3 Closing Remarks  
**Nancy Ascher**, United States
  - 635.4 Presentation of TTS 2020 Congress  
**Kyung Suk Suh**, Korea
-

[illegible]

# POSTERS

All poster presenters  
with **odd poster numbers**  
shall be at their respective  
poster(s) on July 2, 2018  
from 16:30 to 17:30.

All poster presenters with  
**even poster numbers**  
shall be at their respective  
poster(s) on July 3, 2018  
from 16:30 to 17:30.

---

## Kidney Posters – P.001 to P.245

---

- P.001 Incidence of contrast-induced nephropathy in kidney transplant patients  
**María Ovidia López-Oliva**, Spain
- P.002 Impact of delayed graft function without dialysis needed  
**Carlos Arias-Cabrales**, Spain
- P.003 Delayed graft function in kidney transplant: A pair analysis  
**Fernanda Salomao Gorayeb-Polacchini**, Brazil
- P.004 Perioperative hemoglobin and delayed graft function in kidney transplant recipients  
**Shaifali Sandal**, Canada
- P.005 Systemic free heme increases the risk for acute kidney injury (AKI) after solid organ transplantation  
**Julian Doricic**, Germany
- P.006 Clinical analysis of impact of intraoperative hepatic blood inflow on acute kidney injury following allogeneic liver transplantation  
**Jialin Zhang**, People's Republic of China
- P.007 Efficacy and safety of early mammalian target of rapamycin inhibitors with minimization of calcineurin inhibitors in kidney transplant recipients  
**Yuki Nakamura**, Japan
- P.008 Analysis of uric acid and other factors affecting renal function in the monitoring of renal transplant recipients  
**Verushka Reddy**, South Africa
- P.009 Prognostic significance of microvascular injury in kidney transplant recipients  
**Ksenija Vučur**, Croatia
- P.010 Use of electron microscopy (EM) to detect transplant glomerulopathy (TG) in patients with late-indication allograft biopsy  
**Rafael A. Maldonado**, Argentina
- P.011 The profile of kidney transplantation in Dr. Kariadi Hospital Semarang, Indonesia: A single centre experience  
**Eriawan Agung Nugroho**, Indonesia
- P.012 Is the donor age a real limitation to the use of very extended criteria donors in kidney transplantation?  
**Asuncion Sancho Calabuig**, Spain
- P.013 Kidney transplantation in recipients older than 70 years old: A good option for our patients  
**Asuncion Sancho Calabuig**, Spain
- P.014 Risk factors of graft loss in renal transplant recipients including histopathological changes present in implanted kidney  
**Joanna Pazik**, Poland
- P.016 Kidney allograft survival in oldest donors  
**Ester Casillas Sagrado**, Spain
- P.017 Distribution of anti-ABO immunoglobulin G subclass and C1q antibody in ABO incompatible kidney transplantation  
**Jeong-Hoon Lim**, Korea
- P.018 ABO incompatibility does not have an influence on kidney graft survival in living related donor transplantation  
**Agne Laucyte-Cibulskiene**, Lithuania
- P.019 The outcome of kidney transplant recipients who had combined ABO incompatibility and performed antibody against donor HLA antigen  
**In Sung Moon**, Korea
- P.020 Long-term outcomes of ABO-incompatible living donor kidney transplantation compared with ABO-compatible grafts: A single-center experience in Korea  
**Ji Il Kim**, Korea
- P.021 Is it really necessary to remove anti-A/B antibodies in ABO-incompatible kidney transplantation?  
**Yuki Nakagawa**, Japan

- P.022 Analysis of 400 ABO incompatible kidney transplantations: A single center experience  
**Jee Yeon Kim**, Korea
- P.023 The new desensitization protocol for ABO incompatible living donor kidney transplantation using low dose rituximab without plasmapheresis  
**Yoji Hyodo**, Japan
- P.024 Immunological barriers in ABO-incompatible kidney transplantation: How to overcome  
**Sonia Mehrotra**, India
- P.025 Effect of vitamin D deficiency on antibody-mediated rejection (ABMR): a comparative analysis of live-related ABO-incompatible and abo-compatible renal transplantation  
**Raj Kumar Sharma**, India
- P.026 ABO incompatible renal transplantation without anti-CD20 treatment or splenectomy: Comparison with blood group compatible renal transplantation.  
**Amit Sharma**, India
- P.027 ABO-incompatible transplantation without conventional induction immunosuppression (IL-2RB or Depleting agents )  
**Feroz Aziz**, India
- P.028 A2 to B renal transplantation: One center's experience and the implications for decreasing wait times and reducing racial disparities in organ allocation  
**Ron Shapiro**, United States
- P.029 Screening for urinary chemokines in long term renal transplant patients associates with cellular rejection, microvascular damage and falls in GFR over time  
**Georgina Irish**, Australia
- P.030 Examination of serum miRNAs as possible biomarkers for the diagnosis of acute rejection after kidney transplantation  
**Noémi Janszky**, Germany
- P.032 Early borderline changes represent a risk for T-cell mediated rejection and graft failure in kidney transplantation  
**Petra Hrubá**, Czech Republic
- P.033 Bortezomib eliminates plasma cells from the renal graft in plasma cell-rich acute rejection  
**Masayuki Tasaki**, Japan
- P.034 C4d 100% positive in renal biopsy of patient with acute graft dysfunction successfully managed with bortezomib, clinical case  
**Marco Antonio Carmona Jr.**, Mexico
- P.035 Acute rejection and short-term outcomes in highly sensitized kidney transplant recipients  
**Lucia C. Rodriguez Gayo**, Spain
- P.036 Improved diagnosis and management of paediatric renal transplant recipients using the Banff 2013 histopathological classification  
**Evgenia Preka**, United Kingdom
- P.037 Immunologic and histologic monitoring after renal transplantation a single center experience  
**Gervasio Soler Pujol Sr.**, Argentina
- P.038 Donor specific antibody shows different IgG subtype in early versus late antibody mediated renal allograft rejection  
**Alin L. Girnita**, United States
- P.041 The impact of pre-transplant donor specific antibodies (DSA) on AMR rates in HIV kidney transplant recipients inducted with IL-2 RA  
**Samira Farouk**, United States
- P.042a Soluble BAFF levels are associated with antibody mediated rejection in kidney transplant recipients  
**Juan Irure-Ventura**, Spain
- P.043 Kidney Transplant in Highly Sensitized Patients: University Malaya Medical Centre's Experience  
**Soo Jin Lim**, Malaysia
- P.044 Patient and graft outcome among high immunologic risk renal transplant recipients  
**Jeffrey P. Mora**, Philippines
- P.045 Functional outcomes of the renal transplants obtained from controlled donation following cardiopulmonary death (DCD) with compartmental normothermic extracorporeal membrane oxygenation support (NECMO)  
**Patricia Ramirez**, Spain
- P.046 Clinical and pathological analyses of cases of acute vascular rejection after kidney transplantation  
**Tomokazu Shimizu II**, Japan
- P.047 Recurrent primary hyperoxalosis despite simultaneous kidney-liver transplantation: A case report  
**Anna Haber**, United Kingdom
- P.048 Kidney allograft histology in recipients with transplantation vintage longer than 10 years  
**Tomoko Namba-Hamano**, Japan
- P.049 The effect of chronic lesions in implantation biopsy on the function and survival of renal grafts from donation after cardiac death donors  
**Xiao-Peng Yuan**, People's Republic of China
- P.050 Risk factors for transplant vasculopathy in kidney transplant  
**Nora Imperiali**, Argentina
- P.051 Glomerular abnormalities associated with chronic calcineurin inhibitor nephrotoxicity in late renal allograft biopsies  
**Daisuke Toki**, Japan
- P.052 Clinical and pathologic outcomes of incidental IgA glomerular deposits (IgAGD) in donated kidneys in an ethnically diverse region of the USA  
**A. Osama Gaber**, United States
- P.053 Kidney donor profile index: The impact on graft survival in deceased donor kidney transplant recipients  
**Veronica Lopez**, Spain
- P.054 Kidney transplantation from deceased donor with fibromuscular dysplasia  
**Soo Jin Na Choi**, Korea
- P.055 How to select the non-heartbeating donors suffering from CPR  
**Feng Han**, People's Republic of China
- P.056 Characteristics of patients with functioning allograft over 10 years in deceased donor kidney transplantation  
**Seong Sik Kang**, Korea
- P.057 The short term outcome of deceased donor kidney transplantation with a short cold ischemic time is comparable to that of living donor kidney transplantation  
**Miyeun Han**, Korea
- P.058 Kidney transplantation utilising donors after circulatory death – the first report from the African continent  
**Tinus Du Toit**, South Africa
- P.059 Kidney transplantation from circulatory death donors with abdominal normothermic oxygenated recirculation support: The impact of cold ischemia  
**Susana M. Norton**, Portugal
- P.060 Outcomes of kidney transplantation from expanded-criteria deceased donors in a single center  
**Roberto C. Manfro**, Brazil
- P.061 Perfusion parameters during hypothermic machine perfusion in expanded criteria donors (ECD) and donors after circulatory death (DCD) does comparison allow their categorization?  
**Victoria Gomez Dos Santos**, Spain
- P.062 Similar outcomes of kidney transplant program from controlled cardiac death donors compared with kidney transplant from brain dead donors after 2 years of follow up  
**Javier Juega**, Spain
- P.063 Deceased donor renal transplantation: A single tertiary care center experience  
**Kunal Kapoor**, India

- P.065 Double J is superior to externally draining ureteric stent in enhancing recovery after living donor kidney transplantation  
**Moira H. Bruintjes**, Netherlands
- P.066 Comparison of kidney extraction incisions in laparoscopic living donor nephrectomy: A single-center experience  
**Feza Yarbug Karakayali**, Turkey
- P.067 Our experience with paired kidney exchange transplantation  
**Feza Yarbug Karakayali**, Turkey
- P.068 Living kidney transplantation from marginal donors with diabetes. Report of prognosis and outcomes of 5 pairs of recipients and donors  
**Kiyokazu Akioka**, Japan
- P.069 The new crescentic incision: A good option for donor nephrectomy  
**Mahir Kirnap**, Turkey
- P.070 Clinical outcomes in recipients of living-donor kidney transplantation by donor age group  
**Takayoshi Yokoyama**, Japan
- P.071 Taking specific steps to pursue living donor kidney transplant is associated with greater odds of receiving a living donor offer  
**Abeera Ali**, Canada
- P.072 South Asian and Muslim Canadian patients are less likely to receive living donor kidney transplant offers compared to Caucasian, non-Muslim patients  
**Abeera Ali**, Canada
- P.073 Expanding the donor pool: Experience of living kidney transplantation from very old aged donor in our center  
**Hajime Hirano**, Japan
- P.074 Collaboration converts cardiac catastrophe during living donor kidney recipient surgery to long term success  
**Martin Mai**, United States
- P.075 Outcomes of living-donor kidney transplants for long-term dialysis patients  
**Yu Kihara**, Japan
- P.076 Barriers to living kidney donation: A single-center experience  
**Kyungok Min**, Korea
- P.077 Right sided laparoscopic donor nephrectomy - dream comes true  
**Rehan Mohsin**, Pakistan
- P.078 Outcomes of laparoscopic donor nephrectomy in presence of double renal arteries – an early experience in a developing country  
**Rehan Mohsin**, Pakistan
- P.079 Criteria and relevant prognostic factors in donor selection, an analysis of 266 consecutive donor nephrectomies  
**Khalid Alqasim**, Germany
- P.080 Summary of retroperitoneoscopic nephrectomy for living donor kidney transplantation in a single institution  
**Naotake Akutsu**, Japan
- P.081 Migration of the Dacron interposition graft for middle hepatic vein reconstruction in living donor liver transplantation  
**Young kyoung You**, Korea
- P.083 Kidney exchange programs in Europe (COST-ENCKEP) what can we learn from each other?  
**Bernadette B.J.J.M. Haase-Kromwijk**, Netherlands
- P.084 Adequate timing to visit transplant center for patient intending pre-emptive living–donor kidney transplantation  
**Takeshi Ishimura**, Japan
- P.085 Renal transplantation data from Iraq  
**Ala A. Ali**, Iraq
- P.086 Transplant renal artery stenosis (TRAS) in the early post-transplantation period  
**Sandra Dzwonkowska**, Poland
- P.087 Overweight kidney donors gain weight after donation  
**Ann Bugeja**, Canada
- P.088 Correlation between CT volumetry and nuclear medicine split renal function in live kidney donation - a single centre experience  
**Lina Hua**, Australia
- P.089 The condition of the transplant service in the republic of Tajikistan  
**Gulshanova F. Sitorabonu**, Tajikistan
- P.090 Establishing a living donor kidney transplant program in Sub-Saharan African country: Living kidney donor characteristics and outcomes in Ethiopia  
**Engida Abebe Gelan**, Ethiopia
- P.091 Patient characteristics and outcomes following establishment of a living donor kidney transplant program in Sub-Saharan Africa  
**Engida Abebe Gelan**, Ethiopia
- P.093 Long-term follow-up after short renal vein repair procedure in kidney transplantation  
**Sam Minh Thai**, Vietnam
- P.094 Causes of exclusion of a living kidney donor in a public hospital in a developing country  
**German A Mir Sr.**, Argentina
- P.095 Relevance between living donors 'renal reserve capacity and recipients graft function'-retrospective study of 72 cases of living donor kidney transplantation  
**Yingxin Fu**, People's Republic of China
- P.096 Importance of regular ultrasound imaging in renal allografts for early diagnosis of de novo renal cell carcinoma: A report of two rare cases  
**Funda Ulu Öztürk**, Turkey
- P.097 Whole-exome sequencing identified mutational profiles of de novo urothelial carcinoma after kidney transplantation  
**Lee-Moay Lim**, Taiwan
- P.098 Different expression patterns of exosomal miRNAs under cyclosporin A and rapamycin treatment in distinct aggressiveness colorectal carcinomas  
**Jordi Rovira**, Spain
- P.099 Tumors in native kidney and renal grafts after renal transplantation. Experience of our centre  
**Sara Jiménez**, Spain
- P.100 Malignancy prevalence in waitlisted potential kidney transplant recipients is very low relative to patients after kidney transplantation  
**Jacek Zawierucha**, Poland
- P.101 Long-term cancer incidence in kidney transplant recipients in relation to the first posttransplant year immunosuppression intensity  
**Snježana Šulc**, Croatia
- P.103 Malignancy in a potential kidney allograft recipients-how important is the problem?  
**Jacek Zawierucha**, Poland
- P.104 Prevention of hepatitis B virus reactivation in HBsAg-positive renal transplant recipients with Rituximab treatment  
**Ji Yoon Choi**, Korea
- P.105 Effect of body weight variation in kidney transplantation: A retrospective cohorts study  
**Nuria Montero**, Spain
- P.106 Fluoroscopically guided retrograde double-J Stent removal in renal transplant patients  
**Cuneyt Aytakin**, Turkey
- P.107 Biopsy-related renal allograft arteriovenous fistulas: A series of 5 cases  
**Nihal Uslu**, Turkey
- P.108 Shear wave elastography findings of achilles tendons in patients on chronic hemodialysis and patients with renal transplantation  
**Feride Kural Rahatli**, Turkey



- P.109 Associations between high serum adipocyte fatty acid binding protein and first hospitalization in kidney transplantation patients  
**Ming-Che Lee**, Taiwan
- P.110 Orthotopic renal transplantation with spleno-renal shunt  
**Zeynep Kayhan**, Turkey
- P.111 Spot urinary sodium may be an indicator for high blood pressure and metabolic syndrome in kidney transplant recipients  
**Burak Sayin**, Turkey
- P.112 Corner-saving renal artery anastomosis for renal transplantation  
**Kenan Caliskan**, Turkey
- P.113 Malnutrition in kidney allograft recipients treated with mycophenolate mofetil is associated with IMPDH1 rs2278294 polymorphism.  
**Joanna Pazik**, Poland
- P.114 Positive effects of early intervention of renal rehabilitation on kidney transplant patients  
**Kazunari Yoshida**, Japan
- P.115 Genetic associations of polymorphism located at loci relevant for kidney function in a cohort of kidney transplant recipients  
**Jose Luis Santiago**, Spain
- P.116 Outcomes of kidney transplantation by laparoscopic surgery versus open surgery  
**Bulang He**, Australia
- P.117 Features of distribution of HLA antigens in patients with chronic kidney disease in Kazakhstan  
**Indira Ramilyeva**, Kazakhstan
- P.118 Impact of induction immunosuppression on the recurrence of primary IgA nephropathy  
**Min Jung Kim**, Korea
- P.119 Chronic hypotension in dialysis is a prognostic factor in the evolution of kidney transplantation  
**Pilar Auñón**, Spain
- P.120 Identifying what aspects of the post-kidney transplant experience affect quality of life: Setting the stage for a patient-centered intervention to optimize recovery post-transplant  
**Tania Janaudis-Ferreira**, Canada
- P.121 Can we use donor and recipient neutrophil gelatinase-associated lipocalin (NGAL) to predict graft function  
**Marta Sekowska**, Poland
- P.122 Planned genetic diagnosis of atypical hemolytic uremic syndrome and successful preemptive treatment with eculizumab for recurrence after cadaveric kidney transplantation: Case report  
**Yusuke Yamada**, Japan
- P.123 Long term outcomes of kidney transplantation with primary glomerulonephritis  
**Sangmok Yeo**, Korea
- P.124 Factors associated with waiting time to deceased donor kidney transplantation in transplant recipients  
**Jiye Ha**, Korea
- P.125 Blind spots in evidence-based medicine: The lack of knowledge on imaging and kidney transplantation  
**Tamar A.J. van den Berg**, Netherlands
- P.126 Validation of the PROMIS-57 and PROMIS-29 profile questionnaires in kidney transplant recipients  
**Dmitri Belenko**, Canada
- P.127 Relationship between the histological findings obtained by 1-year protocol biopsies and kidney transplant failure score (KTFS)  
**Lara Belmar Vega**, Spain
- P.128 A retrospective study of the immunological and non-immunological factors associated with kidney allograft rejection in two transplant centres in Medellin, Columbia  
**Cristian M. Alvarez**, Colombia
- P.129 Influence of pre-kidney transplant secondary hyperparathyroidism on later evolution after renal transplantation  
**Victoria E. García**, Spain
- P.130 Increasing obesity and diabetes prevalence in the United States end-stage renal disease population  
**Brittany A. Shelton**, United States
- P.131 The impact of deceased donor simvastatin treatment on kidney transplant outcomes - Results of a double-blinded, randomized controlled trial  
**Emil Holmström**, Finland
- P.132 Returning to dialysis after kidney transplant failure does the dialysis treatment modality influence the survival prognosis?  
**Antonio S. Moreno Salazar**, Spain
- P.133 Examining shared-care models for the long-term management of stable kidney transplant recipients  
**Monika Ashwin**, Canada
- P.134 Clinical outcome after simultaneous heart and kidney transplantation  
**Joo Hee Jung**, Korea
- P.136 Comparison of sleep quality in hemodialysis vs kidney transplant recipients using Pittsburgh Sleep Quality Index (PSQI)  
**Atul Bagul**, United Kingdom
- P.137 The potential role of Klotho as a prognostic biomarker in deceased donor kidney transplantation  
**Jongwon Ha**, Korea
- P.138 Allograft trauma in transplant recipients. A case series  
**John T. Black**, United Kingdom
- P.139 Results of a pediatric transplant program in a low income country: 10 years of Guatemalan experience  
**Randall Lou-Meda**, Guatemala
- P.140 Parvovirus causing severe anaemia in kidney transplant recipient. A case report  
**Adam D. Barlow**, United Kingdom
- P.141 Single anastomosis of double ureter kidneys – Experience in 12 kidney transplant recipients  
**Vladimir Tennak**, Israel
- P.142 Monoclonal gammopathy of renal significance in kidney transplantation: De novo C3 glomerulonephritis  
**Nuria Serra**, Spain
- P.143 Safety and efficacy of robot-assisted kidney transplantation  
**Harkiran Sran**, United Kingdom
- P.144 Kidney autotransplantation: Long-term outcomes and complications. 26-years experience in a tertiary hospital  
**Mercedes M. Ruiz Hernández**, Spain
- P.145 Voiding function of kidney transplanted recipients with bladder capacity abnormality in congenital renal hypoplasia/dysplasia  
**Takeshi Ishimura**, Japan
- P.146 Effect of rat urine on ileum muscle layer of bladder reconstruction: An experimental study  
**Mahir Kirnap**, Turkey
- P.147 Morphological and functional changes of the heart six months after renal transplantation  
**Dorian H. Toledo**, Guatemala
- P.148 Renal transplant from living donor in a patient of very high surgical risks due to Takayasu disease and several course of vascular thrombosis  
**Sara Jiménez**, Spain
- P.149 Technical characteristics, optimization and outcomes of ultrasound guided biopsy performed on kidney transplant patients  
**Javier Juega**, Spain
- P.150 Renal transplantation for Vacterl syndrome  
**Sedat Yildirim**, Turkey
- P.151 Non-immunological factors in chronic kidney disease in kidney transplant  
**Mariana A. Seija II**, Uruguay

- P.152 Successful kidney re-transplantation of a transplanted kidney 9 years after the first transplant  
**Sigal Aizner**, Israel
- P.153 Utility of contrast-enhanced ultrasonography for a diagnosis of rejection after kidney transplantation  
**Kei Kurihara**, Japan
- P.154 Polypharmacy in renal transplant recipients  
**Mohamed OAEM Ahmed**, United Kingdom
- P.155 Early post-operative acute myocardial infarction in kidney transplant recipients: Incidence, risk factors, and outcomes  
**Maya Deeb**, Canada
- P.156 Renal transplantation in patients with hereditary fibrinogen amyloidosis  
**Susana M. Norton**, Portugal
- P.157 Leptin – new marker for rejection of kidney transplant?  
**Ivana Dedinska**, Slovakia (Slovak Republic)
- P.158 Do the online materials provided by United Kingdom renal transplant centres adequately answer questions asked by transplant recipients, patients on the transplant waiting list, carers and live kidney donors?  
**Katriona JM O'Donoghue**, United Kingdom
- P.160 The impact of aorto-iliac calcifications on patient and graft survival in renal transplant recipients using the TASCII classification  
**Elsaline Rijkse**, Netherlands
- P.161 Clinical characteristics and outcomes of renal transplant recipients after abdominal surgical procedures not connected with transplantation  
**Lampros Kousoulas**, Germany
- P.164 Patient's death with a functioning graft is still the most common cause of kidney transplant loss  
**Francisco Javier de Teresa Alguacil**, Spain
- P.165 Life after kidney transplant in 600 recipients in southern Spain  
**Francisco Javier de Teresa Alguacil**, Spain
- P.167 Progression of renal function after treatment with the new antivirals for hepatitis C: Is there a difference between chronic kidney disease and kidney transplant patients?  
**Ester Casillas Sagrado**, Spain
- P.168 Intraoperative renal perfusion in kidney transplantation: A retrospective study  
**Mauricio Sainz Barriga**, Belgium
- P.169 Urine levels of CCL2 and CXCL10 as potential biomarkers of kidney allograft function: A pilot study  
**Jolanta Gozdowska**, Poland
- P.170 Live donor kidney transplant outcomes till February 2018 in the first kidney transplant center in Ethiopia  
**Mekdim Tadesse Siyoum**, Ethiopia
- P.171 Resistive index of renal grafts: Its relation to systemic and renal vascular factors  
**Gabriel E. Chanta**, Argentina
- P.172 Quality of ambulatory transplant care in a tertiary transplant center  
**Fiona Chun Chi Foo**, Singapore
- P.173 Related factors of osteosarcopenia in kidney transplant recipients  
**Masaaki Yanishi**, Japan
- P.175 Renal paratransplant hernia. An uncommon variant of internal hernia. A review of the literature  
**Christos Nikolaidis**, Greece
- P.176 Evaluating the results of preemptive kidney transplantation at Cho Ray Hospital  
**Sam Minh Thai**, Vietnam
- P.178 A systems thinking approach: Barriers to implementation of an HIV-to-HIV positive transplant program in the state sector of South Africa  
**Maryn Reyneke**, South Africa
- P.179 The enhanced recovery after surgery for patients undergoing kidney transplantation surgery  
**Wenhua Lei**, People's Republic of China
- P.180 Comorbidities can predict the mortality of kidney transplant recipients: Comparison with the Charlson comorbidity index  
**Jae Yoon Park**, Korea
- P.181 Establishing a core outcome measure for life participation: A standardized outcomes in nephrology – kidney transplantation (SONG-Tx) consensus workshop report  
**Fabienne Dobbels**, Belgium
- P.182 Outcome measures for life participation in patients with kidney transplantation  
**Allison Tong**, Australia
- P.185 The role of smoking on early postoperative pulmonary complications in renal transplantation patients  
**Elif Kupeli**, Turkey
- P.186 The relationship between CMV seropositivity and fungal pneumonia in renal transplant patients  
**Elif Kupeli**, Turkey
- P.190 A pilot study of immunosuppression resumption following BK viremia resolution  
**Karl L. Womer**, United States
- P.191 Causes and consequences of poliovirus BK infection in kidney transplant recipients  
**Serena Gatiús**, Spain
- P.192 Role of the early association of a mTOR inhibitor and tacrolimus in BK polyomavirus infection in kidney transplant recipients  
**Veronica Lopez**, Spain
- P.193 Impact of viral load in polyoma-BK virus viremia on histologic findings in late protocol biopsy in kidney transplant recipients  
**Tomas Reischig**, Czech Republic
- P.195 Nephrotoxicity of calcineurin inhibitors and BK viral nephropathy in protocol biopsies of transplanted kidney – pilot study  
**Karel Krejčí**, Czech Republic
- P.196 Polyomavirus BK-associated nephropathy after kidney transplantation: A single-center retrospective analysis  
**Luis R. Leon**, Argentina
- P.197 Association between donor/recipient BK viral serostatus and risk of BK viraemia post-transplantation  
**Ciara N. Magee**, United Kingdom
- P.198 Patients undergoing peritoneal dialysis at the time of kidney transplantation are more likely to have higher LDH-cholesterol than non-dialysis dependent chronic kidney disease patients: Korean organ transplantation registry cohort study  
**Taehee Kim**, Korea
- P.199 Application of ileobladder for clinical kidney transplantation: Two case reports  
**Gokhan Moray**, Turkey
- P.200 Pretransplant nephrectomy for large polycystic kidneys in ADPKD (autosomal dominant polycystic kidney disease) patients: Is possible peritoneal dialysis recovery after surgery?  
**Giuseppe Ietto**, Italy
- P.201 Panel reactive antibody positivity and associated human leukocyte antigen antibodies in Filipino kidney transplant candidates at the national kidney and transplant institute  
**Bryan Christian Gaza Ilagan**, Philippines
- P.202 Indications and Timing of Native Nephrectomy for Renal Transplant Recipients with End-Stage Polycystic Kidney Disease. A Literature Review  
**Christos Nikolaidis**, Greece
- P.204 Shipped versus locally transplanted kidneys: No impact on early and late renal function  
**Antoine Buemi**, Belgium



- P.205 Analysis of kidney transplantation results of very highly sensitized patients included in a virtual crossmatch programme and their kidney pairs. Results of 5 years since the beginning of the protocol. Andalusian group for highly sensitized patients  
**Antonia Alvarez Marquez**, Spain
- P.206 FlowPRA screening of antiHLA antibodies in the waiting list significantly reduces the occurrence of acute rejection after kidney transplantation  
**Juraj Miklušica**, Slovakia (Slovak Republic)
- P.207 Kdpi score: A comparison with classical ECD/SCD classification in predicting outcomes  
**Carlos Arias-Cabrales**, Spain
- P.208 Safety and efficacy of third kidney transplantation in ipsilateral iliac fossa  
**Diederik H.J.A.N. Kimenai**, Netherlands
- P.209 Kidney transplantation alone in end-stage renal disease patients with hepatitis B liver cirrhosis  
**Myung Hyun Lee**, Korea
- P.210 Outcome of overseas kidney transplantation among Azerbaijani patients  
**Mahinbanu Mammadli**, Azerbaijan
- P.211 Factors associated with time to deceased donor renal transplant waitlisting or living donor transplantation in Australia  
**Matthew P. Sypek**, Australia
- P.213 Clinical observation of single kidney transplantation for adult recipients from non-heartbeating pediatric donors  
**Puxun Tian**, People's Republic of China
- P.214 Pattern of glomerular staining for C4d immunohistochemistry is useful for the diagnosis of immune complex mediated glomerulonephritis in renal allograft biopsies  
**Cynthia B. Drachenberg**, United States
- P.216 Long-term outcome of kidney transplantation for IgA nephropathy: A single-center experiences.  
**Akira Tadokoro**, Japan
- P.217 Long-term outcome of focal segmental glomerulosclerosis after renal transplantation: A single-center experience  
**Marta L. Monteverde**, Argentina
- P.218 Identification of urinary biomarkers for recurrence of IgA nephropathy after kidney transplantation using proteomic methods  
**Samuel Lee**, Korea
- P.219 IgA nephropathy with crescent formation after renal transplantation  
**Taieb Ben Abdallah**, Tunisia
- P.221 Significant survival improvement in recipients with lupus nephritis on kidney transplantation: Single center experience  
**Ken Sakai**, Japan
- P.222 Early conversion to mTOR inhibitors prevents kidney function better than late conversion  
**Burak Sayin**, Turkey
- P.223 Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients  
**Xiaobing Ju**, People's Republic of China
- P.224 Effect of interferon-gamma gene polymorphism +874 A/T on cytomegalovirus infection in kidney transplant recipients with and without prophylactic treatment with valganciclovir  
**Jose Luis Santiago**, Spain
- P.225 Conversion from cyclosporine to once-daily tacrolimus at late post-transplant stage  
**Iwai Tomoaki**, Japan
- P.226 Renal transplantation in patients with induction based in m-TOR inhibitors: early renal function and associated factors  
**Ernesto J. Fernández**, Spain
- P.227 Clinical experience of conversion from antimetabolites with standard exposure tacrolimus to everolimus with tacrolimus minimization in stable kidney transplanted recipients  
**Maria Luisa Rodríguez-Ferrero**, Spain
- P.228 Everolimus conversion in kidney transplant recipients: Is it safe?  
**Seow Yeing Yee**, Malaysia
- P.229 Donor specific antibodies after conversion from mycophenolate mofetil with standard exposure tacrolimus to everolimus with tacrolimus minimization in stable kidney transplanted recipients  
**Maria Luisa Rodríguez-Ferrero**, Spain
- P.230 Long term follow up after conversion from calcineurin inhibitors to sirolimus in a South African renal transplant population  
**Alain G. Assounga**, South Africa
- P.231 Single reduced dose thymoglobuline as induction in kidney retransplant  
**Kamilla Linhares-Silva**, Brazil
- P.232 Immunosuppression related to de novo donor-specific HLA antibody production after renal transplantation  
**Nobuhiro Fujiyama**, Japan
- P.233 Pharmacodynamics of CSA and tacrolimus and its effect on antiviral drugs in HCV positive kidney transplant recipients  
**Sonia Mehrotra**, India
- P.234 Effect of ethnicity on tacrolimus (adoport) trough concentrations in renal transplant recipients. A single centre retrospective study  
**Binay Gurung**, United Kingdom
- P.235 Late conversion to everolimus with calcineurin inhibitor minimization in stable kidney transplant recipients - analysis of factors affecting  $\Delta$ eGFR  
**Junji Uchida**, Japan
- P.236 Transplant cost reduction in a developing country: "The case of Guatemala"  
**Randall Lou-Meda**, Guatemala
- P.237 Exceptional high dose tacrolimus requirement in a twin pregnancy post kidney transplant: Review and case report  
**Fatima AlKendi**, United Arab Emirates
- P.238 A single dose thymoglobulin in non-sensitized deceased donor kidney recipients >60 years  
**Vladimir Tennak**, Israel
- P.239 Switching from Prograf® to Advagraf® in stable kidney transplant recipients- Do Asians differ?  
**Dheepa Ramasamy**, Malaysia
- P.240 High calcineurin inhibitor intra patient variability is associated with early renal allograft inflammation, chronicity and loss  
**Akhil Sharma**, United States
- P.241 Extended release tacrolimus (LCP-TAC) prolongs calcineurin activity inhibition during drug doses intervals  
**Nuria Lloberas Blanch**, Spain
- P.242 Correlation between mycophenolate dosage and occurrence of adverse effects in renal transplant patients  
**Kim Bul**, United Kingdom
- P.242a Using the Japanese KJ Ho method as a qualitative creative problem solving technique to address clinicians' and young kidney transplant patients' needs concerning treatment  
**Kim Bul**, United Kingdom
- P.243 Use of ATG FR in mode of single dose in recipients of renal transplantation. Experience of 2 transplant units of Sante Fe, Argentina  
**Luis Gaité**, Argentina
- P.244 Clinical experience of 6 years with rabbit anti-thymocyte globulin as induction therapy in renal transplant recipients  
**Jose Cruz Santiago**, Mexico
- P.245 Advagraf de novo. Use comparative of advagraf compared with prograf  
**Luis Gaité**, Argentina

## Transplant Immunosuppression Posters – P.250 to P.266

- P.250 Hyperkalemia in the early post renal transplant period  
**Emily Christie**, Canada
- P.251 Influence of tacrolimus metabolism rate on kidney graft survival  
**Bernd Döhler**, Germany
- P.252 Determination of tacrolimus concentration and protein expression of P-glycoprotein in single human renal core biopsies  
**Erlend J. Egeland**, Norway
- P.253 Bone marrow derived myeloid suppressor cell (BM-MDSCs) prolongs the graft survival in murine heart transplantation  
**Keiichi Fujimoto**, Japan
- P.254 High-dose fish oil supplementation increase tacrolimus exposure in stable renal transplant recipients  
**Marte Theie Gustavsen**, Norway
- P.255 Drug-induced CYP-induction as therapy for tacrolimus intoxication  
**John M. Hoppe**, Germany
- P.256 Inter-individual variability of tacrolimus trough level may be due to differential p-glycoprotein expression on PBMCs in renal transplant recipient  
**Akhilesh Kumar Jaiswal**, India
- P.257 Comparative study of human and cynomolgus t-cell depletion with rabbit anti-thymocyte globulin (rATG) treatment - for dose adjustment in a non-human primate transplantation model  
**Sungjoo Kim**, Korea
- P.258 Safety of induction immunosuppression in kidney transplantation: Focus on 1-year hospitalizations for infection and development of post-transplant neoplasia  
**Alicia Molina**, Spain
- P.259 Rifampin drug interactions with tacrolimus in solid organ transplant  
**Alaa A. Mously**, Saudi Arabia
- P.260 A retrospective study on effectiveness and safety of the novel once-daily melt-dose tacrolimus in a Spanish cohort of stable kidney transplant recipients converted from once or twice-daily formulations: Reconoce study  
**Juan Carlos Ruiz**, Spain
- P.261 Characterization of the new immune suppressive anti human CD83 monoclonal antibody 3C12C in non-human primates  
**Pablo A. Silveira**, Australia
- P.262 The ratio of CTLA4 to perforin and granzyme b as a potential biomarker of tolerance in chimeric renal transplant patients  
**David Tollerud**, United States
- P.263 Posttransplant lymphoproliferative disorder in liver transplant recipients  
**Ying Liu**, People's Republic of China
- P.264 Eculizumab and intravenous immunoglobulins for the treatment of acute antibody-mediated rejection after lung and liver transplantation  
**Julien Vionnet**, Switzerland
- P.265 Tolerance induction by delayed non-myeloablative irradiation in a large animal lung transplantation model  
**Karolin Hacker**, Germany
- P.266 Analysis of CCR4high CD4+ in kidney graft blood after steroid withdrawal: A prospective, randomized, controlled, parallel group study. Preliminary results  
**Teresa Vazquez**, Spain

## Ethics, Community, Economics Posters – P.270 to P.288

- P.270 Developing stronger team dynamics to improve communication internally and externally  
**Deborah Adey**, United States
- P.271 Attitudes and factors affecting organ donation in family members of kidney transplant recipients. A single centre survey  
**Atul Bagul**, United Kingdom
- P.272 Health related quality of life in post renal transplant patients: A single center study  
**Manish Ramesh Balwani**, India
- P.273 Fit for life, thanks for life donor  
**Won-Hyun Cho**, Korea
- P.274 Argentine integral protection system for transplanted persons and on the wait list: First specific legislation in Latin America  
**Eugenia Ferreira Centeno**, Argentina
- P.275 Beneficial impact of group psychotherapy on depression and quality of life in cirrhotic patients on the liver transplant waiting list  
**Beatriz B. Gómez**, Spain
- P.276 Deceased directed donation: Considering the ethical permissibility in a multi-cultural setting  
**Rebecca Greenberg**, Canada
- P.277 Physician practice patterns and barriers to counselling on physical activity in solid organ transplant recipients: A Canadian survey  
**Tania Janaudis-Ferreira**, Canada
- P.278 Psychosocial long-term impact of donation on kidney living donors - a comparative study of two major European transplant centres  
**Entela Kondi**, Spain
- P.279 Current status of overseas transplantation in Korea  
**Oh Jung Kwon**, Korea
- P.280 The great recession and the importance of Donation After Circulatory Determination of Death (DCDD)  
**Paula Y. Lawrence**, United States
- P.281 Pediatric liver transplantation outcomes: insured vs. uninsured children  
**Helen Dayan Pava Acosta**, Colombia
- P.282 Raising awareness of the importance of exercise training in solid organ transplant: Description of a Canadian knowledge dissemination project  
**Sunita Mathur**, Canada
- P.283 Ethical issues of using ECMO in organ donation  
**Oleg Reznik**, Russian Federation
- P.284 Health related quality of life (HRQOL) after donating a kidney: do kidney donors feel the same as those who lose a pathological kidney  
**Lasantha L.N. Seneviratne**, Sri Lanka
- P.285 Assessing the impact of a hospitality house on the mental and physical health of transplant patients  
**Jan L. Weinstock**, United States
- P.286 Social aspects of long-term kidney transplant outcomes  
**Viktor Denisov**, Ukraine
- P.287 Should transplant recipients participating in the World Transplant Games have cardiac stress testing before being able to participate  
**Paul N. Harden**, United Kingdom
- P.288 Adherence and alexithymia in adolescent renal transplant recipients  
**Ruben O. Schiavelli**, Argentina

## Histocompatibility Posters – P.290 to P.308

- P.290 Renal transplantation in highly sensitized patients: SIUT experience  
**Khawar Abbas**, Pakistan
- P.291 Detection of HLA donor-specific antibodies with screening and/or specificity kits and antibody-mediated rejection in kidney transplant recipients  
**Carla Burballa**, Spain
- P.292 Single center experience of desensitization for preformed HLA-related donor specific antibody in living donor liver transplantation  
**Hiroto Egawa**, Japan
- P.293 Renal transplant with positive virtual crossmatch in patients with high immunological risk  
**Sandra Elias**, Spain
- P.294 C4d deposition – an independent predictor of graft failure following liver transplantation  
**Speranta Iacob**, Romania
- P.295 Number of BAFF-receptor molecules on plasma cells prior kidney transplantation identify patients at risk of antibody-mediated rejection  
**Juan Irure-Ventura**, Spain
- P.296 The relative immunogenicity of HLA mismatches in adult liver transplant patients from the ITN A-WISH Trial  
**Vadim Jucaud**, United States
- P.297 Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry crossmatches  
**Jee Yeon Kim**, Korea
- P.298 Formalin fixed paraffin embedded tissue-based gene expression and immune cell profiling as a tool for monitoring immune response in kidney biopsies with low grade inflammation  
**Henrik H. Junger**, United States
- P.299 Comparison of new OneLambda Flow DSA-XM with conventional flow crossmatch  
**Pamela M. Kimball**, United States
- P.300 Repeated freezing and thawing does not affect HLA antibody titer  
**Myoung Hee Park**, Korea
- P.301 A method for determining based on the frequencies of HLA alleles of HLA antibodies that are often observed with single antigen bead assay  
**Younhee Park**, Korea
- P.302 High prevalence of post-transplant donor specific HLA-DQ antibody in live related renal transplantation  
**Mirza Naqi Zafar**, Pakistan
- P.303 Humoral rejection in lung transplantation: more than Anti-HLA antibodies  
**David San Segundo**, Spain
- P.304 AT1R antibody assessment: How should we interpret positive results?  
**Lori J. West**, Canada
- P.305 Pretransplant discordant sera with a negative bead-based screening test and a positive single antigen test may reveal the presence of antibodies against denatured HLA antigens  
**Renaud Snanoudj**, France
- P.307 Non-HLA antibodies in highly sensitized renal transplant candidates  
**Angeliki Vittoraki**, Greece
- P.308 Risk Factors of De Novo Sensitization and DSA in Long-Term Renal Transplant Patients with Stable Graft Function  
**Efstathios Kasimatis**, Greece

## Complications Posters – P.310 to P.378

- P.310 Surgical treatment for ureteral obstruction after kidney transplantation  
**Aydincan Akdur**, Turkey
- P.311 Recurrent glomerulonephritis after kidney transplantation in Saudi Arabia, single center retrospective study  
**Ehab H. Hammad**, Saudi Arabia
- P.312 Skin involvement in kidney allograft patients  
**Fabio Ruben Acosta**, Argentina
- P.313 Endovascular management of arterial complications following renal transplant biopsy  
**Cuneyt Aytekin**, Turkey
- P.314 Medical complications in living donor kidney transplant recipients in the developing world  
**Mukunda Prasad Kafle**, Nepal
- P.315 Juxta-anastomotic transplant renal artery pseudoaneurysm. A graft preserving option  
**Adam D. Barlow**, United Kingdom
- P.316 Importance of the dental treatment in renal-transplant recipients~single center experience~  
**Koichi Kozaki**, Japan
- P.317 Medical complications associated with renal transplantation, monitoring one year  
**Jose Cruz Santiago**, Mexico
- P.318 Complications into urinary tract following renal transplantation: Influence of bladder anastomosis technique and urinary catheters (double J Stent and urethral catheterization)  
**Jose Medina-Polo**, Spain
- P.319 Trends of mortality among renal transplant patients in Bahrain  
**Amgad E. El-Agroudy**, Bahrain
- P.320 Kidney transplantation with grafts from old donors: Is there a difference in term of urological complications?  
**Jose Medina-Polo**, Spain
- P.321 Course and outcome of renal transplant recipients admitted to the intensive care unit (ICU): long term follow-up  
**Amgad E. El-Agroudy**, Bahrain
- P.323 Intraoperative retrograde intrarenal surgery (RIRS) as a good management option for large ureteropelvic impacted stone of transplanted kidney  
**Giuseppe Ietto**, Italy
- P.324 A proposed classification system and therapeutic strategy for chyle leak after laparoscopic live donor nephrectomy: A single-centre experience and review of literature  
**Zi Qin Ng**, Australia
- P.325 The incidence and clinical significance of isolated distal deep vein thrombosis in kidney transplant recipient  
**Ji Il Kim**, Korea
- P.326 Treatment of refractory small bowel bleeding with thalidomide after living donor kidney transplantation  
**Hyung Sub Park**, Korea
- P.327 Brain computed tomography and magnetic resonance imaging in neurological complications of liver and kidney transplantation  
**Feride Kural Rahatli**, Turkey
- P.328 Long-term results of percutaneous balloon dilatation of ureteral stricture after kidney transplantation  
**Ruth Rahamimov**, Israel
- P.330 Treatment of persistent hyperparathyroidism after renal transplant: Single center experience  
**Gabriel G. Rivelli**, Brazil
- P.331 Acute rejection in kidney transplantation and early beginning of tacrolimus  
**Sergio Salcedo**, Colombia

- P.332 Combination therapy with BCAA intake and physical therapy improved leg strength in Japanese elderly kidney transplant recipients diagnosed as sarcopenia  
**Hitomi Sasaki**, Japan
- P.334 Contamination of preservation fluid in cadaveric renal transplantation  
**Ruben O. Schiavelli**, Argentina
- P.336 The coefficient of variability is the same in the mTOR-inhibitors?  
**Rosalía Valero**, Spain
- P.340 Non melanoma skin cancers in solid organ transplant recipients: A single center experience  
**Cagri A. Uysal**, Turkey
- P.341 Lung malignancy in solid organ transplant recipients: A case series  
**Sule Akcay**, Turkey
- P.342 A case of urinary bladder squamous cell carcinoma post renal transplant with a previous history of Bilharziasis  
**Ashraf Ali Attia**, Saudi Arabia
- P.344 High serum fibroblast growth factor 23 level is associated with metabolic syndrome in kidney transplantation patients  
**Ming-Che Lee**, Taiwan
- P.345 Incidence and risk factors of post transplant diabetes mellitus in kidney transplant recipients in Qatar  
**Mohamad M. Alkadi**, Qatar
- P.346 Use of empagliflozin in renal transplant recipients with post transplantation diabetes mellitus: Short term safety  
**Thea A. S. Halden**, Norway
- P.347 The effect of diabetes on serum magnesium levels after kidney transplantation  
**Gabriel Danovitch**, United States
- P.348 Correlation of pretransplant glucose metabolism and nonalcoholic fatty liver disease with the development of post transplantation diabetes mellitus  
**Sahil Bagai**, India
- P.349 Post-transplant lymphoproliferative disorders (PTLDs) after heart transplantation? Single center experience in Japan  
**Norhide Fukushima**, Japan
- P.350 Post-transplant lymphoproliferative Disorder (PTLD); a descriptive cross sectional study describing the presence of associated factors for PTLD in a cohort of first year post renal transplant patients in Sri-Lanka  
**Adhyana IK Mahanama**, Sri Lanka
- P.351 A cross-sectional prospective study of low serum L-carnitine level associated with peripheral arterial stiffness in renal transplant recipients  
**Bang-Gee Hsu**, Taiwan
- P.352 Cardiovascular disease in kidney transplant recipients: japan academic consortium of kidney transplantation (JACK) cohort study  
**Masayoshi Okumi**, Japan
- P.353 Development of recommendations for a core outcome set for clinical trials of physical rehabilitation in adults across the continuum of solid organ transplantation: a Canadian Delphi consensus study  
**Sunita Mathur**, Canada
- P.354 Early treatment with NPH insulin in renal transplantation and diabetes mellitus  
**María del Carmen de Gracia Guindo**, Spain
- P.355 Cyclosporin a aggravates the calcification of vascular smooth muscle cells under high glucose conditions with a calcifying medium  
**Sang Youb Han**, Korea
- P.357 The assessment of cardiovascular risk in renal transplant recipients  
**Zbigniew Heleniak**, Poland
- P.358 The schedule of treatment and control of hypertension in hemodialysis patients and renal transplant recipients in 2006 and 2014/2016.  
**Zbigniew Heleniak**, Poland
- P.361 Changes in vitamin D levels after kidney transplantation  
**Gabriel Danovitch**, United States
- P.362 The impact of immunosuppression on mineral metabolism one year after kidney transplantation: differences between a mycophenolate-based regimen versus an mTOR inhibitor-based one  
**David Cucchiari**, Spain
- P.363 Worsening lumbar spin bone disease among steroid maintenance kidney allograft recipients in Qatar  
**Omar Mahjoub Fituri**, Qatar
- P.364 Early-onset and late-onset bacteremias after liver transplantation  
**Sang Il Kim**, Korea
- P.365 Occult hepatitis C virus in recipients of kidney transplantation: Prevalence and clinical implications  
**Carlos Jiménez**, Spain
- P.366 Incidence of viral infections after kidney transplantation in a single pediatric center  
**Majed Aloufi**, Saudi Arabia
- P.367 Prevalence of BK viraemia among post kidney transplant patients in Sri Lanka - a single center experience  
**Buddhisha S. Mahanama**, Sri Lanka
- P.368 Infections by carbapenemase producing klebsiella pneumoniae bacteria in solid organ transplant recipients  
**Victoria E. García**, Spain
- P.369 Adenovirus nephritis followed by visceral leishmaniasis in a renal transplant recipient  
**Helen K. Zanetti**, Brazil
- P.370 The examination of hepatitis E after renal transplantation  
**Yuki Nakagawa**, Japan
- P.371 How reliable is the management of cytomegalovirus by preemptive therapy after renal transplantation?  
**Helen K. Zanetti**, Brazil
- P.372 Dengue in the renal transplant population - a single center experience  
**Navdeep Singh**, India
- P.373 Tuberculosis in living donor kidney transplant recipients  
**Mukunda Prasad Kafle**, Nepal
- P.375 Acute graft-versus host disease after liver transplantation: A case report and literature review  
**Yuichiro Mihara**, Japan
- P.377 Epidemiology of infectious complications in renal recipients in the first year after transplantation  
**Lilia Ben Fatma**, Tunisia
- P.378 Regular surveillance of BK viruria allows early detection of BK infection in kidney allograft and alleviates bk nephropathy  
**Ping Chin Lai**, Taiwan



## Infectious Disease Posters – P.380 to P.398

- P.380 Mucormycosis in Turkey  
**Hande Arslan**, Turkey
- P.381 Urinary tract infections after kidney transplantation in fourteen medical centers in Turkey  
**Hande Arslan**, Turkey
- P.382 Clinical utility of a modified qRT-PCR for *Trypanosoma cruzi* detection in transplant patients  
**Florencia Bonisconti**, Argentina
- P.383 Clinical efficacy of pretransplant vaccination for preventing herpes zoster after living donor liver transplantation in recipients aged 50 years and older  
**Chan Woo Cho**, Korea
- P.384 Adenovirus infection of the urinary tract after kidney transplantation  
**Ku Yong Chung**, Korea
- P.385 Epidemiologic study and genotyping in renal transplant recipients BK virus  
**Marisa M. Cobos**, Argentina
- P.386 Activation of the calcium sensing receptor (CASR) prevents secretagogue-induced diarrhea in the rat small intestine  
**Michele Finotti**, United States
- P.387 Elimination of chronic hepatitis B in a kidney transplantation recipient via monotherapy: A case report  
**Mun Jang**, Korea
- P.388 Candidaemia among adult solid organ transplant recipients  
**Ozlem Kurt Azap**, Turkey
- P.389 Screening of recipients prior to liver and heart transplantation  
**Ozlem Kurt Azap**, Turkey
- P.390 The selective prophylaxis does not increase the risk of pneumocystis jirovecii pneumonia (PJP) after renal transplantation.  
**Ho Lee**, Korea
- P.391 Extensive cutaneous necrosis in kidney transplant. a rare case of mucormycosis  
**Dayana Sampaio De Almeida**, Brazil
- P.392 Efficacy of direct acting antiviral agents in dialysis patients with chronic hepatitis C virus infection on the kidney transplant waiting list: a single center experience  
**Abdulmecit Yildiz**, Turkey
- P.393 Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant recipients: Risk factors and spectrum of infectious complications  
**Igor Stoma**, Belarus
- P.394 A novel generative mycobacterium tuberculosis-specific T cells method for adoptive cellular therapy  
**Juan Zhang**, People's Republic of China
- P.395 New strategy for deceased organ donor serology testing following two serious adverse occurrences  
**Aurora Navarro**, Spain
- P.397 Incidence of Mycobacterium Tuberculosis disease following renal transplant, in a tertiary care hospital in South India  
**Satish Balan**, India
- P.398 Hospital course after TAH implantation, Nebraska experience  
**Diana Florescu**, United States

## Basic and Translational Sciences Posters – P.400 to P.489

- P.400 Anti MICA antibody (major histocompatibility complex class I related chain a) whether to treat or avoid?  
**Pankaj R. Shah**, India
- P.401 Detection of donor-specific antibodies both in serum and cardiac allograft biopsy in heart transplant patients: Tissue DSA is more predictive than serum DSA  
**Bilkay Basturk**, Turkey
- P.402 Investigation of miRNA and anti HLA antibodies correlation in patients with kidney transplant  
**Bilkay Basturk**, Turkey
- P.403 Clinical importance of type 1 angiotensin II receptor (ATR1) y anti-endotelin-1 type a (ETAR) antibodies plus HLA antibodies in kidney transplantation.  
**Manuel Muro**, Spain
- P.404 Toll-like receptor 9 -1486C/T genetic polymorphism is associated with hepatocarcinoma recurrence after liver transplantation  
**Maria Jesus Citores Sanchez**, Spain
- P.405 A composite of urinary biomarkers to differentiate between tubulointerstitial inflammation and fibrosis in kidney allografts  
**Sung Shin**, Korea
- P.406 Predicting early viral control under DAA therapy for chronic HCV using pretreatment immunological markers  
**Akinbami R. Adenugba**, Germany
- P.407 Complement regulator CD46 transcripts are associated with progression of chronic antibody mediated rejection and recurrent IgA nephropathy  
**Aneta Pletkova**, Czech Republic
- P.408 CD8 T effector memory t cells as predictive biomarker of severe acute rejection in lung transplantation  
**Maria Iglesias Escudero**, Spain
- P.409 Plasma inhibition of activation of lymphocyte from kidney transplants on various immunosuppressive drugs: Possible role of plasma exchange in anti-rejection therapy?  
**Alain G. Assounga**, South Africa
- P.410 Hypoxia induced ANKRD37 promotes angiogenesis and reprograms glucose metabolism in hepatocellular carcinoma following liver transplantation  
**Chuanhui Peng**, People's Republic of China
- P.411 What's normal? Using standardized flow cytometry immunophenotyping to create comprehensive pediatric reference ranges  
**Lori J. West**, Canada
- P.412 Ex vivo lung perfusion using the portable OCS maintains endothelial integrity in the context of reduced severe PGD rates  
**Christine S. Falk**, Germany
- P.413 The synthesis of coagulation factors during normothermic machine perfusion of livers is impaired by ischemia in pigs and might predict graft viability  
**Nicholas Gilbo**, Belgium
- P.414 Presence of pre-existing HLA antibodies in renal transplant patients and its impact during the first year post transplant  
**Mariana A. Seija II**, Uruguay
- P.415 Identification of plasma protein biomarkers of acute renal allograft rejection  
**Elaine F. Reed**, United States
- P.416 Defining secondary antibody deficiency after heart transplantation  
**Elizabeth Sarmiento**, Spain
- P.418 Mannose binding lectin (mb12) genotype frequencies in solid organ transplant patients  
**Ikram Ezzahouri**, Spain

- P.419 The study of relationship between serum levels of soluble VEGF receptor-1 and soluble Fibrinogen-like protein 2 with delayed graft function after kidney transplantation  
**Hassan Nikouejad**, Iran (Islamic Republic of)
- P.420 Donor-derived cell-free DNA as minimally invasive tool to diagnose acute rejection after kidney transplantation  
**Carla C. Baan**, Netherlands
- P.423 Differential expression of metallothioneins and slc family genes in accommodation and subclinical antibody mediated rejection  
**Petra Hrubá**, Czech Republic
- P.424 VDJ gene usage among B-Cell Receptors in ABO-incompatible kidney transplantation determined by RNA-seq transcriptomic analysis  
**Hee Jung Jeon**, Korea
- P.425 Genomic changes in pediatric renal transplant patients detected by aCGH  
**Feride I. Sahin**, Turkey
- P.426 Developing a rationale for an appropriate immunosuppressive regimen in lung vs kidney transplant recipients.  
**Paloma Leticia Martin Moreno**, Spain
- P.427 Soluble fibrinogen-like protein 2 regulates myeloid-derived suppressor cells differentiation and enhances its immunosuppressive function of in allograft immunity  
**Cheng Yang**, People's Republic of China
- P.428 Association of increased peripheral transitional B cells and plasmablasts with long-term kidney graft survival  
**Aneta Pletkova**, Czech Republic
- P.429 Immune modulatory effect of thalidomide and dexamethasone co-treatment on immune cells  
**Joon Ye Kim**, Korea
- P.430 Targeting trained immunity promotes organ transplant acceptance  
**Patricia Conde-San Román**, Spain
- P.431 NKT cells in the liver are important for peripheral tolerance induction  
**Wei Li**, People's Republic of China
- P.432 NK cells regulate CD8 t cell-mediated allogeneic rejection in immunocompetent recipients across an MHC class i mismatched barrier  
**Jose Ignacio Rodriguez-Barbaso**, Spain
- P.433 Standard induction immunosuppression interferes with the role of vascularized bone marrow in vascularized composite allograft protection  
**Josue Alvarez-Casas**, United States
- P.434 The effect of bisphosphonates on dendritic cells  
**Yuri Cho**, Korea
- P.435 Effect of native spleen preservation in an experimental model of modified multivisceral transplantation  
**Martin Rumbo**, Argentina
- P.440 Ischaemic tolerance and the effect of ageing using a rodent donation after circulatory death (DCD) model  
**Hong Chee Chew**, Australia
- P.441 Underlying protective mechanisms of cortisol against the deleterious effects of brain death in both steatotic and non-steatotic liver transplantation  
**Mónica B. Jiménez-Castro**, Spain
- P.442 The protective effect of ischemic preconditioning and HMGB1 in steatotic liver grafts from brain-dead donors submitted to transplant  
**Maria Eugenia Cornide Petronio**, Spain
- P.443 Effects of cortisol-induced acetylcholine accumulation on tissue damage and regeneration in steatotic livers in the context of partial hepatectomy under vascular occlusion  
**Maria Eugenia Cornide Petronio**, Spain
- P.444 Astaxanthin prevents ischemia-reperfusion injury of the steatotic liver in mice  
**Shaowei Li**, Japan
- P.445 Impact of diabetes on renal ischemia-reperfusion injury in a non-human primate model  
**Kyo Won Lee**, Korea
- P.446 Intra-renal delivery of drugs targeting ischemia-reperfusion injury of the kidney using normothermic machine perfusion  
**Ahmer M. Hameed**, Australia
- P.447 High oxygen pressure during continuous hypothermic machine perfusion is associated with a better ex vivo renal blood flow and early graft function in a porcine DCD auto-transplant model  
**Tom Darius**, Belgium
- P.448 Potential limitation for the use of cyclosporine a as a cardioprotective agent during donor heart retrieval and storage  
**Ling Gao**, Australia
- P.449 Protective role of m-TOR system in fatty liver grafts preserved in IGL-1 and HTK solutions.  
**Arnau Panisello Rosello**, Spain
- P.450 Stereotyped molecular response during liver and kidney ischemia/reperfusion injury  
**Daniel G. Maluf**, United States
- P.451 Role of ubiquitin proteasome activation in fatty liver preservation: an IGL-1 approach  
**Joan Rosello-Catafau**, Spain
- P.452 Histone deacetylase- 11 gene deletion is protective in renal ischemia-reperfusion injury  
**Seth J. Concors**, United States
- P.453 Immune-mechanistic insights into improved lung preservation using the organ care system in a porcine transplantation model in comparison to the INSPIRE trial  
**Ann-Kathrin Knoefel**, Germany
- P.454 Effects of ulinastatin on liver warm ischemia reperfusion injury in mice  
**Wei Li**, People's Republic of China
- P.455 The polymer pro-drug APP-103 mitigates i/r injury and improves graft function in a pre-clinical renal transplant model  
**Koichiro Minami**, United States
- P.456 Prevention of ischemia-reperfusion injury and chronic rejection in a porcine vascularized composite allotransplantation model  
**Nicholas L. Robbins**, United States
- P.458 CD137L signaling is an inflammation checkpoint in renal inflammation  
**Jong Soo Lee**, Korea
- P.459 Addition of different oxygen concentrations during long-term hypothermic machine perfusion in a clinically relevant porcine donation after circulatory death model  
**Leonie H. Venema**, Netherlands
- P.460 Activation of autophagy by everolimus confers hepatoprotection against ischemia–reperfusion injury  
**Kee-Hwan Kim**, Korea
- P.461 In vivo and in vitro PPAR-γ activation decreases m1-macrophage polarization and improves liver ischemia reperfusion injury  
**Matyas Hamar**, Canada
- P.462 Prevention of ischemic injury in colon and small intestine in an ex vivo perfusion animal model: The role of l-arginine and nutraceutical nanoparticles  
**María J. Barahona**, United States
- P.463 Recombinant thrombomodulin alpha protects kidney graft from damage after long cold ischemia time in a rat kidney transplant model  
**Kazunobu Shinoda**, Japan
- P.464 Ischemia reperfusion injury (IRL) causes local release of free heme which aggravates inflammation and contributes to delayed graft function  
**Faikah Gueler**, Germany

- P.465 The prognostic implications of renal function recovery and delayed graft function in kidney transplantation  
**Shaifali Sandal**, Canada
- P.466 Changes of glycocalyx in steatotic liver graft preservation with UW, HTK and IGL-1 solutions  
**Alexandre Lopez**, France
- P.467 Protective effect of ulvan (sulfated polysaccharide) pretreatment against hepatic ischemia-reperfusion injury in mice  
**Hyuk Jai Jang**, Korea
- P.468 Targeting innate immune cells and regulated cell death in early hepatic ischemia reperfusion injury  
**Elke Eggenhofer**, Germany
- P.469 Ex-vivo hyperbaric normothermic perfusion for 24 hours mitigates reperfusion injury in porcine vascular composite allotransplantation (VCA)  
**Matthew Wordsworth**, United States
- P.471 High throughput proteomic exploration of hypothermic preservation reveals dynamic processes within the cell interconnected to cold ischemia time  
**Thierry Hauet**, France, Metropolitan
- P.472 Dietary omega-3 food supplementation to attenuate renal ischemia reperfusion injury  
**Julian Doricic**, Germany
- P.473 B-cell activating factor BAFF reflects patients' immunological risk profile after kidney transplantation  
**Antonia M. Schuster**, Germany
- P.474 Anti-CD40 antibodies do not cause thromboembolism as demonstrated by in vitro and in vivo studies  
**Tina Rubic-Schneider**, Switzerland
- P.475 Development of organized intra-graft lymphocyte clusters – role of b cell activating factor BAFF  
**Louisa Kühne**, Germany
- P.476 Human CD49dhighCD4+ T Cells have characteristics of innate-memory t cells and can help immunoglobulin production of B1 cells  
**Jae-Ghi Lee**, Korea
- P.477 CD137-CD137L interactions regulate B-cell autoimmunity during alloimmune responses  
**Jong Soo Lee**, Korea
- P.478 High intragenic methylation of SERPINB9, a regulator of cytotoxicity, in T cells as a marker for skin cancer after kidney transplantation  
**Fleur S. Peters**, Netherlands
- P.479 FK506 accelerates CoCl<sub>2</sub> - induced cytotoxicity via endoplasmic reticulum stress pathway in HepG2 cells  
**Sang Young Chung**, Korea
- P.480 The new role of HIF-1 in the development of renal fibrosis in mouse UUO model  
**Kazuya Kabei**, Japan
- P.482 Renal intra-arterial delivery of MSC to ischemic porcine kidneys: Retainment, localization and survival  
**Jesus M. Sierra Parraga**, Netherlands
- P.483 Characterization of ex vivo created human multi-chimeric cells - a novel approach for tolerance induction in vascularized composite allotransplantation  
**Maria Siemionow**, United States
- P.484 Sarcolemmal complement membrane attack complex deposits during acute rejection of myofibers in nonhuman primates  
**Daniel Skuk**, Canada
- P.485 Impact of MMP2, MMP9 and TIMP2 gene polymorphisms on allograft rejection in pediatric renal transplant recipients  
**Selin Akad**, Turkey
- P.487 Differences in the colon microbiome between patients with and without recurrence of primary sclerosing cholangitis  
**Thijmen Visseren**, Netherlands
- P.488 Use of flow cytometry to characterize the in vivo development of neonatal porcine islets  
**Jonathan Lakey**, United States
- P.489 Filtering intestinal loop model: An experimental approach as renal function substitute  
**Andrés M. García Sr.**, Colombia

## Cellular and Regenerative Therapies Posters – P.501 to P.518

- P.501 Effects of adipose-induced stem cell application on everolimus immunosuppressed rats on colon anastomosis: An experimental study  
**Aydincan Akdur**, Turkey
- P.502 Adipose-derived regenerative cells: therapeutic potential in IRI  
**Ryan Ghita**, United Kingdom
- P.504 Hepatocyte transplantation with magnet sorting after large hepatectomy for cholangiocellular carcinoma  
**Masahiro Ito**, Japan
- P.505 Gender based transcriptome expression in induced hepatocyte like cells (miHep)  
**Sun A. Ock**, Korea
- P.506 The optimization of the hepatocyte surface modification procedures in terms of heparin and apyrase for improving hepatocyte engraftment  
**Hiroyuki Ogasawara**, Japan
- P.507 Establishment of effective differentiation protocols for insulin-producing cells using a new 3D culture system from adipose-tissue derived mesenchymal stem cell  
**Yu Saito**, Japan
- P.508 Modifying renal gene expression by anti-sense oligonucleotide delivery during normothermic machine perfusion  
**Avinash Sewpaul**, United Kingdom
- P.509 Effect of SOX9 on ductular reaction and fibrogenesis  
**Keita Shimata**, Japan
- P.510 Dna memethylation agents promote pancreatic endodermal differentiation of mesenchymal stem cells  
**Kisha N. Sivanathan**, Australia
- P.511 Development of young porcine islet maturation in vitro through helper dependent adenovirus carrying INS-venus  
**Yzumi Sugahara**, Japan
- P.512 Dynamics of glucagon-like Peptide -1 in patients with Type 1 diabetes mellitus after autologous hematopoietic stem cell transplantation  
**Olga Ulyanova**, Kazakhstan
- P.513 Role of adipose tissue-derived mesenchymal stromal cells in preventing rejection in rat intestinal transplantation  
**Ane M. Andres**, Spain
- P.517 Structural modification of alginate microbeads containing human hepatocyte and mesenchymal stromal cells as a potential way to improve hepatic functions for cell transplantation in acute liver failure  
**Charlotte A. Lee**, United Kingdom
- P.518 Adoptive transfer of HVEM signal induced alloreactive regulatory T cell protect rejection in allogeneic murine cardiac transplantation model  
**Koichiro Uchida**, Japan

## Xenotransplantation Posters – P.520 to P.539

- P.520 Partial xenotransplantation from the porcine trachea to the dog trachea  
**Seok-Hwa Choi**, Korea
- P.521 Structural and expression analyses of porcine tumor necrosis factor receptor 2 variants  
**Cristina Costa**, Spain
- P.522 Genetic engineering in xenotransplantation: What human transgenes should the GTKO.hCD46 pig lung donor additionally express?  
**Lars Burdorf**, United States
- P.523 Re-endothelialization of liver xenografts utilizing human endothelial cells  
**Laura DiChiacchio**, United States
- P.524 Multivisceral xenotransplantation: The effect of different species combination  
**Flavio H F Galvao**, Brazil
- P.525 Combining enhancement of inhibitory signals and blockade of co-stimulation to modulate human anti-pig immune responses  
**Rabea Hein**, Germany
- P.526 Glycoproteomic characterization of  $\alpha$ -1,3-glycosyltransferase and isoglobotriosylceramide synthase double knock-out cells  
**Seongsoo Hwang**, Korea
- P.527 South Korean student opinions about xenotransplantation  
**Kyeonghee Jang**, United States
- P.528 Inflammatory responses in  $\alpha$ 1,3—galactosyltransferase gene-knockout (GTKO) porcine vascular retransplantation to cynomolgus monkeys  
**Eun Mi Lee**, Korea
- P.529 Porcine neonatal islet-like cell clusters cultured with EGM2 medium enhance their resistance to apoptosis in islet xenotransplantation  
**Xiaoqian Ma**, People's Republic of China
- P.529a Human CD31 suppress macrophage-mediated xenogeneic rejection  
**Akira Maeda**, Japan
- P.531 PQA-18, a novel immunosuppressant, suppresses macrophage differentiation and macrophage-mediated xenogeneic cytotoxicity  
**Akira Maeda**, Japan
- P.532 Attitude of the chronic kidney disease patients toward xenotransplantation of organs  
**Mohan Patel**, India
- P.533 Transplantation outcome after pig to mouse intra-portal islet transplantation  
**Jun-Seop Shin**, Korea
- P.534 Real time high-resolution imaging of porcine endothelial glycocalyx shedding by human serum in an in vitro microfluidic model of pig-to-human xenotransplantation  
**Riccardo Sfriso**, Switzerland
- P.535 Expression of human thrombomodulin on GTKO.CD46 donor pigs and costimulation blockade by anti CD40 antibody is critical for extending cardiac xenograft survival in non-human primates  
**Avneesh Singh**, United States
- P.536 Composite tissue xenopreservation  
**Fatih Zor**, United States
- P.538 Operational tolerance in xenotransplantation by use of regulatory T cells with a SLA-specific chimeric antigen receptor  
**Elmar Jaeckel**, Germany
- P.539 Additive expression of hTBM on hCD46 stable cell line has synergistic effect on complement regulation  
**Hwajung Kim**, Korea



## Pancreas and Islet Posters – P.545 to P.569

- P.545 Correlation of dynamic immune cell profile with individual alloresponse and outcome in type 1 diabetes islet transplantation recipients  
**Min Hu**, Australia
- P.546 Quercetin enhanced the function of mouse islets  
**Hyuk Jai Jang**, Korea
- P.547 Australian experience of total pancreatectomy and islet auto transplant (TPIAT) utilizing a remote isolation center  
**Chris J. Drogemuller**, Australia
- P.548 Pre-clinical results of islet allo-transplantation using JAK inhibitor as replacement for tacrolimus widely used immunosuppressive drug in islet transplantation in cynomolgus monkeys  
**Jong-Min Kim**, Korea
- P.549 Development of a highly effective protocol using local immune suppression strategy in pancreatic islet transplantation  
**Shiva Pathak**, Korea
- P.550 Construction of EMSC-islet co-localizing composites for xenogeneic porcine islet transplantation  
**Jung-Sik Kim**, Korea
- P.551 Improvement of metabolic function after intra-portal allogeneic islet transplantation using induction treatment of the non-hematopoietic erythropoietin analogue cibinetide in a mouse model  
**Ming Han Yao**, Sweden
- P.552 Islet identity in patients with pancreatitis  
**Omaima M. Sabek**, United States
- P.553 The effect of steroid maintenance in recipients with pancreas transplant alone: A single center experience  
**Ji Yoon Choi**, Korea
- P.554 A fatal course after combined pancreas kidney transplantation from a donor with HELLP-syndrome  
**Malwina Bialobrzecka**, Germany
- P.555 Antibody mediated rejection due to de-novo DSA causing venous thrombosis of pancreas allograft – a case report  
**Kunal Yadav**, United States
- P.556 Use of norepinephrine in pancreas donors and its influence on patient and graft survival  
**Alberto A. Marcacuzco Quinto**, Spain
- P.557 Preserved insulin sensitivity and kidney function one year after successful pancreas transplantation  
**Espen Nordheim**, Norway
- P.558 Results of pancreas transplantation in the twenty-one century: A single center experience in Spain  
**Jaime López**, Spain
- P.559 Endoscopic intervention can prevent reoperation in patients after pancreas transplantation – the advantage of the duodenoduodenal anastomosis  
**Marek Durlik**, Poland
- P.560 Complications after pancreas transplantation  
**Lea Berger**, Germany
- P.561 Update on clinical trial EMA – SPK: Everolimus versus mycophenolic acid in simultaneous pancreas and kidney transplantation to evaluate the differences in retinal neovascularisation in patients with diabetic retinopathy  
**Barbora Voglova**, Czech Republic
- P.562 De novo glomerulonephritis in simultaneous pancreas-kidney transplantation: A single center experience  
**Christian Margreiter**, Austria
- P.563 Impact of peritoneal dialysis on SPK results  
**Agnieszka Surowiecka-Pastewka**, Poland
- P.564 Pre-operative predictors of health-related quality of life for pancreas transplant recipients  
**Irene Mosca**, United Kingdom
- P.565 Pancreas graftectomy predicting markers  
**Agnieszka Surowiecka-Pastewka**, Poland
- P.566 Enteric leaks following simultaneous pancreas and kidney transplantation: Associated risk factors and management in the Westmead Hospital Transplantation Program  
**Amy Hort**, Australia
- P.567 Delayed pancreas graft function –a challenge for clinicians  
**Marta Matejak-Górska**, Poland
- P.568 Causes and risk factors of pancreas graft loss: A single center study  
**Ichiro Koyama**, Japan
- P.569 Role of intravascular interventions in simultaneous pancreas and kidney transplantation - almost 15 years of experience  
**Marta Matejak-Górska**, Poland

## Donation and Procurement Posters – P.575 to P.677

- P.575 Impact of donor with positive bacterial infections in deceased donor liver transplantation  
**Kun-Ming Chan**, Taiwan
- P.576 Influences on a culture that supports organ donation after circulatory death  
**Luke Milross**, Australia
- P.577 Increased serum sodium values in a brain-dead donor do not influence the long-term kidney function  
**Mamoru Kusaka**, Japan
- P.578 Impact of in situ cold perfusion of kidney grafts during vascular anastomosis  
**Shinji Torai**, Japan
- P.579 Causes of rejection for organ donation by family of deceased donor  
**Jinwoo Seo**, Korea
- P.580 Long term management of a deceased organ donor- an organ donor coordinator's point of view  
**Nina Seng**, Australia
- P.581 Donor brain death alters plasma protein levels and is dependent of cause of death  
**Jan Lukac**, Finland
- P.582 Opportunities to increase organ availability from neonatal donors. The United States experience  
**Thomas A. Nakagawa**, United States
- P.583 Analysis of the reasons donor families donate organs for organ transplantation  
**Eunji Lee**, Korea
- P.584 Effects of phased education on attitudes toward organ donation and willingness to donate after brain death in an Asian country  
**Young-Nam Roh**, Korea
- P.585 Role of body mass index in determining outcomes after renal transplantation: A retrospective single-centre observational study  
**Binay Gurung**, United Kingdom
- P.586 Analysis of family interviews in uncontrolled DCD in the community of Madrid  
**Alonso Mateos Rodriguez**, Spain
- P.587 Survival analysis of deceased donor organ transplantation in a third world country  
**Noble Gracious Sr.**, India
- P.588 Optimal hemodynamic monitoring in deceased donor  
**Sang Youb Han**, Korea
- P.589 Impact of extraction time during organ procurement on kidney function after transplantation  
**Erika Rademaker**, Netherlands
- P.590 A kidney with type II damage to be transplanted into a patient undergoing treatment with antiplatelet and anticoagulant medications  
**Shunri Taniguchi**, Japan
- P.591 Donor body mass index as a risk factor for delayed onset of graft function  
**Juraj Miklušica**, Slovakia (Slovak Republic)
- P.592 The preliminary experience of deceased organ transplantation in local hospital  
**Shin Do Suh**, Korea
- P.593 Experience with hypothermic machine perfusion in extended criteria donors. Functional outcomes  
**Mercedes M. Ruiz Hernández**, Spain
- P.594 Implementation of a quality management system on organ donation in the Kingdom of Saudi Arabia (KSA)  
**Besher Al-Attar**, Saudi Arabia
- P.595 Impact of logistics with the cold ischemia time of utilized deceased organs in KSA; years 2015-2016  
**Besher Al-Attar**, Saudi Arabia
- P.596 Attitudes and knowledge about donation in Catalonia  
**Jaume Tort Bardolet**, Spain
- P.597 Use of the capnometry as a renal graft evolution predictor in uncontrolled cardiac arrest death donors  
**Alicia Villar-Arias**, Spain
- P.598 PDSA cycles show improvements in key indicators in deceased donation: The Spanish experience  
**Christel Terron**, Spain
- P.599 Features of deceased kidney transplantation in KSA; 2014-2016  
**Faissal Shaheen**, Saudi Arabia
- P.604 Survival analysis after kidney-pancreas and kidney transplant in Argentina  
**Liliana Bisigniano IV**, Argentina
- P.605 Assessment of optimal liver graft size in OLT  
**Amy Hort**, Australia
- P.608 Evaluation of the foreigner brain death cases: a retrospective study in Istanbul region between the years 2011-2016  
**Ahmet Cakiroglu**, Turkey
- P.609 A successful implementation of laparoscopic living donor nephrectomy: First experience in Lithuania  
**Agne Laucyte-Cibulskiene**, Lithuania
- P.610 Long-term risks for living kidney donors  
**Solon Castillo**, Spain
- P.611 Kidney related issues leads the medical reasons to exclude potential living kidney donors from donation in Saudi Arabia  
**Hassan Ali Aleid**, Saudi Arabia
- P.612 The early effects of kidney donation in living kidney donors  
**Palash Mitra**, Bangladesh
- P.613 Standard vs modified technique of laparoscopic donor nephrectomy  
**Anant Kumar**, India
- P.614 Which Spanish living kidney donors fear post donation kidney failure?  
**Xavier Torres**, Spain
- P.615 Challenges of renal transplantation in Asia  
**Anwar Naqvi**, Pakistan
- P.616 Health information management for clinical monitoring, research, and quality assurance in living kidney donor evaluation: The comprehensive living kidney donor database  
**Olusegun Famure**, Canada
- P.617 Crossed transplant: A strategy that maximizes benefits and minimizes risks  
**Carlos E Pregno**, Argentina
- P.618 The role of teenage living donor in Korean transplantation activity  
**Jeehye Chung**, Korea
- P.619 Living unrelated kidney transplantation: Does it prevent deceased donor kidney transplantation growth?  
**Mohammad Nadjafi-Semnani**, Iran (Islamic Republic of)
- P.620 Kidney transplantation from living donor allograft with small renal cell cancer after laparoscopic partial nephrectomy: A case report  
**Young Hwa Kim**, Korea
- P.621 Comparison of formulas estimating GFR with scintigraphy-measured GFR in living kidney donor candidates  
**Julia Mróz**, Poland
- P.621a Usefulness of serum uromodulin and beta trace protein (BTP) in evaluation of glomerular filtration rate in living kidney donor candidates  
**Łukasz Bialek**, Poland

- P.623 Argentine survey on the current situation of renal transplantation living donor  
**Rafael A Maldonado**, Argentina
- P.625 Transperitoneal laparoscopic living donor nephrectomy: Are high body mass index and multiple renal arteries still risk factors for complication?  
**Tien Ngoc My Le**, Vietnam
- P.626 Retroperitoneal laparoscopic living donor nephrectomy: Experience with 400 cases at a single center  
**Tien Ngoc My Le**, Vietnam
- P.628 Total laparoscopic living donor right hepatectomy for modified extended right graft  
**Jai Young Cho**, Korea
- P.629 Long term evaluation of marginal living kidney donor  
**Deepak S Ray**, India
- P.632 The effects of short-term subnormothermic perfusion after cold preservation on liver grafts from donors after cardiac death  
**Yuta Kakizaki**, Japan
- P.633 The effects of purification perfusate during subnormothermic machine perfusion for porcine liver donated after cardiac death  
**Masahide Otani**, Japan
- P.634 The effects of preservation temperature during machine perfusion preservation for porcine liver donated after cardiac death evaluated by isolated liver perfusion model  
**Mikako Gochi**, Japan
- P.635 The combination of ultrasound and cold storage improves kidney graft viability and survival in experimental transplantation  
**Jordi Rovira**, Spain
- P.636 Transport and preservation of liver in a revolutionary medical device  
**Mónica B. Jiménez-Castro**, Spain
- P.637 Normothermic machine perfusion of ischaemically damaged porcine kidneys with autologous, allogeneic and human red blood cells  
**Merel B.F. Pool**, Netherlands
- P.638 Common hospital ingredient perfusate equivalent to standard krebs–henseleit buffer with serum albumin derived perfusate in negative pressure ventilation ex vivo lung perfusion  
**Max T. Buchko**, Canada
- P.639 Effectivity of hypothermic machine perfusion preservation for non-heart-beating donor kidney transplantation in Japan  
**Naotake Akutsu**, Japan
- P.640 Comparison of University of Wisconsin (UW) and histidine-tryptophan-ketoglutarate (HTK) solutions in pediatric liver transplantation  
**Richard S. Mangus**, United States
- P.641 Clinical outcomes of kidney transplant recipients with positive perfusion fluid cultures: A single centre retrospective study  
**Sally R Black**, United Kingdom
- P.642 Mobile cryopreservation of vascular allografts in polydimethylsiloxane.  
**Stanislav Lauk-Dubitskiy**, Russian Federation
- P.643 Tech 4X40-40: A no-pump technique for transplantation preservation procedures  
**Andrew Yeung**, Mauritius
- P.644 Impact of machine perfusion on delayed graft function and graft survival from high-risk donors  
**Larissa Guedes da Fonte Andrade**, Brazil
- P.645 Survey results following the establishment of educational program in multi-organ procurement with simulation using large animals  
**Hiroyuki Furukawa**, Japan
- P.646 Preclinical modeling of DCD class iii donation and evaluation of the most adapted preservation protocol: Paving the way for the increased use of this challenging donor type  
**Thierry Hauet**, France, Metropolitan
- P.647 Organ utilization following drug overdose death is variable by region in the United States  
**Laura A. Hickman**, United States
- P.648 Renal allografts from brain dead donors following cerebral gunshot wounds  
**Carlos Jiménez**, Spain
- P.649 The relationship between marginal and non-marginal kidney transplants  
**Ersin Elgin**, Turkey
- P.650 The use of donor with renal failure in cadaver and one-year outcome  
**Ersin Elgin**, Turkey
- P.651 Analysis of the lung donors in the Chinese mainland  
**Qianli Ma**, People's Republic of China
- P.653 The role of clinical and morphological factors in evaluation of donor liver suitability for transplantation  
**Marina Minina**, Russian Federation
- P.655 International Registry in Organ Donation and Transplantation (IRODAT) – 2016 worldwide data  
**Maria Paula Gómez**, Spain
- P.656 Self-sufficiency in organ donation and transplantation  
**Maria Paula Gómez**, Spain
- P.657 Needs for a paediatric organ and tissue donation protocol: An overview of the literature  
**Alicija Vileito**, Netherlands
- P.659 Analysis of reasons for rejection and discontinuance of tissue donation in Korea  
**Ohhyuk Yun**, Korea
- P.660 Analysis of improving effect of organ donation culture by world transplant game in Korea  
**Ik Jin Yun**, Korea
- P.661 Evolution of donation and transplantation after circulatory death activities (2012-2016): review of the newsletter Transplant of the Council of Europe  
**Jaime Marco**, Spain
- P.662 Organ donation programs and the definition of success: A scoping review preliminary results  
**Vanessa Silva e Silva**, Canada
- P.663 Understanding the influence of inter-professional relational networks within organ donation programs in Ontario: A research protocol and preliminary results  
**Vanessa Silva e Silva**, Canada
- P.664 Knowledge and attitude towards organ donation among medical residents. Lima-Peru  
**Ana Cecilia Pastor Ludeña II**, Peru
- P.665 Analysis of the incidence of brain death per functioning ventilator in the intensive care units of a general hospital  
**Hernando Trujillo**, Spain
- P.667 Change the hospital culture - make donation routine  
**Rosemary O'Meeghan**, United States
- P.668 Experience with cadaveric arterial conduits as hemodialysis access  
**Deepesh B. Kenwar**, India
- P.669 The factors affecting the awareness about transplantation and decision of organ donation in Istanbul, Turkey  
**Ali Çevik**, Turkey
- P.670 Open data on donation and transplantation in Buenos Aires City  
**Luis D. Rojas**, Argentina
- P.671 Follow-up on donor family  
**Luis D. Rojas**, Argentina

- P.672 Continuous training of critical care professional to increase organ donation rates in Yunnan province and Guangxi autonomous region in China  
**Chao Li**, People's Republic of China
- P.673 Donor risk index could be a predictor of "resistant to flow" liver grafts  
**Pablo Lozano**, Spain
- P.675 Solvable mortality in Latin America related with lack of organ for transplantation  
**Francisco Gonzalez-Martinez**, Uruguay
- P.676 Law and increasing kidney donation in Australia: Is the law complicating increasing living kidney donation?  
**Mayowa Oyeniya Ajigboye**, Australia
- P.677 Criminalliability of medical professionals who engage in organ trafficking and human trafficking for the purpose of organ removal, and their obligations to assist in preventing and curbing these crimes  
**Sylwia Gawronska**, Poland

## Education Posters – P.680 to P.694

- P.680 Attitude toward living liver donation after an audiovisual educational intervention on teenagers  
**Javier Almela**, Spain
- P.681 Knowledge regarding brain death and organ donation laws among medical students  
**Manish Ramesh Balwani**, India
- P.682 Impact on teenagers of completing a questionnaire about organ donation and transplantation  
**Beatriz B. Gómez**, Spain
- P.683 Factors affecting compliance to calcineurin inhibitors among solid organ transplant recipients  
**Chi Yuen Simon Cheung**, Hong Kong
- P.684 A joint effect to train over 1,200 Chinese medical professionals for organ donation in 5 years in China to boost up the organ donation rate  
**Wenshi Jiang**, People's Republic of China
- P.685 Impact of training volunteers for creating awareness on organ donation  
**Pallavi Kumar**, India
- P.686 Effect on each step strategy of donation by DIP in Korea  
**Jiyoun Kwon**, Korea
- P.688 Seeding life: Cooperation for innovation and exchange of good practices in education in organ donation and transplantation  
**Martí Manyalich**, Spain
- P.690 Knowledge, attitude and perception about kidney disease and renal transplantation among care givers of CKD patients  
**Masud M. Iqbal**, Bangladesh
- P.691 Using informatic education strategy to break through the dilemma of teaching transplantation in medical institutions – multidisciplinary medical team perspectives  
**Ming Hsin Hsieh**, Taiwan
- P.692 Using informatic education strategy to break through the dilemma of teaching transplantation in medical institutions – compare medical and administrative informatic team perspectives  
**Ming Hsin Hsieh**, Taiwan
- P.694 Trends in organ transplantation. DCD in West Pomeranian in Poland.  
**Marek Ostrowski**, Poland

## Transplantation Nursing Posters – P.695 to P.697

- P.695 Fatigue one to five years after lung transplantation - A significant problem  
**Anna Forsberg**, Sweden
- P.697 Postoperative nursing and nutrition support in non-human primate recipients of combined donor-matched vascularized osteomyocutaneous and renal allografts  
**Xin Xiao Zheng**, People's Republic of China

## Vascularized Composite Allotransplantation Posters – P.700 to P.707

- P.700 Results of combined penetrating keratoplasty and implantation of posterior chamber intraocular lenses  
**Leyla Asena**, Turkey
- P.701 Visual rehabilitation after penetrating keratoplasty  
**Leyla Asena**, Turkey
- P.702 Descemet's membrane endothelial keratoplasty (DKEK): 6-month clinical outcomes  
**Dilek Dursun Altinors**, Turkey
- P.703 Customizing illumination by the operating microscope aids the visualization of DMEK grafts  
**Dilek Dursun Altinors**, Turkey
- P.704 Effect of cold-preservation on the vessels of vascularized composite allografts in rats  
**Luis Landin**, Spain
- P.705 Surgical technique for pelvic floor transplantation  
**Flavio HF Galvao**, Brazil
- P.706 Foxp3+ Treg cells resident within donor bone marrow are essential for costimulation blockade-induced long-term survival of murine limb transplants  
**Liqing Wang**, United States
- P.707 Aesthetic surgery in transplantation patients: A single center experience  
**Cagri A. Uysal**, Turkey

## Heart and Lung Posters – P.710 to P.732

- P.710 Thyroid disorders in recipients after heart transplantation  
**Maria M. Simonenko**, Russian Federation
- P.711 Thirty-year dynamics of survival among heart recipients: A single center Russian experience  
**Alex O. Shevchenko**, Russian Federation
- P.712 Relationship between glycemic control and survival in heart transplant recipients.  
**Jose Manuel Sobrino-Marquez**, Spain
- P.713 IgM-enriched human intravenous immunoglobulin for treatment of early antibody mediated rejection after heart transplantation  
**Markus J. Barten**, Germany
- P.714 Early adjunctive treatment with human cytomegalus virus (CMV) immunoglobulin increased CMV-free survival after heart transplantation  
**Carolin Neumaier**, Germany
- P.715 Posterior reversible encephalopathy syndrome after pediatric heart transplantation  
**Ilkay Erdogan**, Turkey
- P.716 Results of endomyocardial biopsy in children with heart transplantation  
**Ilkay Erdogan**, Turkey
- P.717 What should be the treatment approach in patients with cardiac allograft vasculopathy?  
**Ozgur Ersoy**, Turkey
- P.718 Left ventricular assist device management strategy  
**Atilla Sezgin**, Turkey
- P.719 Impact of renal injury on survival following left ventricular assist device  
**Atilla Sezgin**, Turkey
- P.720 High cardiac output immediately after heart transplantation is an independent risk factor of seizure early posttransplant  
**Keiichiro Iwasaki**, Japan
- P.721 Extracorporeal photopheresis (ECP) and calcineurin inhibitor (CNI) delay after heart transplantation  
**Johannes Goekler**, Austria
- P.722 Lung related complications in heart transplant recipients: results of a single center experience  
**Sule Akcay**, Turkey
- P.723 The pathological analysis of underlying diseases of explanted hearts and outcome of recipients: a single center 100 cases experience  
**Hatsue Ishibashi-Ueda**, Japan
- P.724 A man of many devices. a 15 year old boy with exclusively myocardial mitochondrial disease received a LVAD, TAH, an orthotopic heart transplant and ECMO in one inpatient episode  
**Aaraby Ragavan**, United Kingdom
- P.725 Immune monitoring of regulatory CD4 t cells in heart recipients using one-single dose versus two-dose basiliximab induction  
**Elizabeth Sarmiento**, Spain
- P.726 Immunological factors associated with health status of heart transplant recipients long-term after transplantation  
**Javier Carbone**, Spain
- P.727 Is tricuspid annular plane systolic excursion (TAPSE) predictor for out patients with lvad right ventricular failure in lvad patients with preoperative low value (TAPSE) on mild-term follow up  
**Umit Kervan**, Turkey
- P.728 How long can we safely follow patients with ineffective anticoagulation after left ventricular assist device implantation  
**Umit Kervan**, Turkey
- P.729 Lower post-transplant 1 month tacrolimus level less than 10 ng/mL was associated with poor patient survival in lung transplant patients  
**JungHwa Ryu**, Korea



- P.730 Aspergillus infections in patients received lung transplantation  
**Wenhui Chen**, People's Republic of China
- P.731 Infection from lung allograft donors in lung transplantation  
**Wenhui Chen**, People's Republic of China
- P.732 First Chinese national registry report of lung transplantation in 2016  
**Wenjun Mao Sr.**, People's Republic of China

## Paediatrics Posters – P.735 to P.757

- P.735 Azathioprine versus mycophenolate mofetil in combination with tacrolimus and steroids maintenance in pediatric kidney transplantation  
**Sahar M. Al-Mowaina**, Saudi Arabia
- P.736 Meaning of positive anti-HLA antibodies in simultaneous liver-kidney transplantation  
**Ángel Alonso Melgar**, Spain
- P.737 Clinical findings and explant liver histology in Crigler Najjar disease  
**Zeren Baris**, Turkey
- P.738 Experience of post-transplant lymphoproliferative disorder (PTLD) after pediatric liver transplant: Incidence, outcomes and association with food allergy  
**Zeren Baris**, Turkey
- P.739 Cardiac function in children after kidney transplantation  
**Kenan Caliskan**, Turkey
- P.740 Catch-up growth evaluation after liver transplant...experience in Fundación Valle del Lili  
**Luis Caicedo**, Colombia
- P.741 Whole deceased donor liver transplantation in pediatric recipients less than 10 kg. retrospective analysis of outcome and surgical complications  
**Ivan Capobianco**, Germany
- P.742 The value of working together: Organ transplantation in a highly specialized pediatric transplantation center  
**Luis Garcia-Guereta**, Spain
- P.743 Transplantchild, an European Strategy to Attend "The Secondary Rare Disease" Induced by Pediatric Transplantation  
**Francisco Hernandez**, Spain
- P.744 Transplantation and resection of the liver for multimodal treatment of hepatoblastoma  
**Oleg Kotenko**, Ukraine
- P.745 Increasing obesity prevalence in the United States pediatric end-stage renal disease population  
**Jayne E. Locke**, United States
- P.746 The effects of graft weight on allograft outcomes in pediatric patients  
**Gokhan Moray**, Turkey
- P.747 Renal blood flow measurements by magnetic resonance imaging using arterial spin labelling as a novel non-invasive biomarker in paediatric renal transplant recipients  
**Stephen D. Marks**, United Kingdom
- P.748 Postoperative platelet count can predict splenic volume expansion after living donor liver transplantation in pediatric patients with biliary atresia  
**Yuki Noguchi**, Japan
- P.749 Clinical features, laboratory findings and prognosis in Fulminant Wilson's disease  
**Figen Ozcay**, Turkey
- P.750 Incidence, clinical features and prognosis of food allergy in children who underwent liver transplantation  
**Figen Ozcay**, Turkey
- P.751 Development of a pediatric liver transplant program in a developing country: From deceased to living donors. 10-year experience  
**Jairo Eduardo Rivera Baquero Sr.**, Colombia
- P.752 Double heterozygous mutation causing PFIC2 with synchronic hepatocellular carcinomas before two years of age  
**Julio J. Trentadue**, Argentina
- P.753 Impact of Kasai portoenterostomy on liver transplantation in patients with a history of biliary atresia at the Fundacion Cardioinfantil  
**Jairo Eduardo Rivera Baquero Sr.**, Colombia

- P.754 Practice patterns surrounding surveillance biopsies in pediatric kidney transplant patients  
**Katherine Twombly**, United States
- P.755 Single centre experience with the use of envarsus in pediatric kidney transplant population  
**Anna Vila-Santandreu**, Spain
- P.756 Pediatric heart transplantation in a national pediatric hospital in Argentina  
**Horacio Vogelfang**, Argentina
- P.757 Hepatocyte transplant and bridge to subsequent liver transplant in an infant with carbamoyl phosphate synthetase deficiency  
**Sojeong Yoon**, Korea

---

## Intestine & Multivisceral Transplantation Posters – P.761 to P.769

---

- P.761 Multivisceral transplantation for diffuse portomesenteric thrombosis: A case series  
**Emilio Canovai**, Belgium
- P.763 Implication of the spleen in pediatric multivisceral transplantation  
**Inmaculada Hidalgo Montes**, Spain
- P.765 Grafting's function in patients with liver intestinal and multivisceral transplantation  
**Inmaculada Hidalgo Montes**, Spain
- P.767 Postoperative infections following intestinal transplantation  
**Barbara Kern**, Germany
- P.769 Long term outcomes after intestinal transplantation from a single South American center, lessons learned  
**Julio J. Trentadue**, Argentina

---

## Anesthesia Management and Critical Care Posters – P.775 to P.783

---

- P.775 Validating the McCluskey index for the necessity for hemoderivative transfusion in our liver transplant serie  
**Pilar Del Pozo**, Spain
- P.776 Hemoderivates transfusion differences between recipients of liver grafts from donors after uncontrolled cardiac death (uDCD) and brain death donors (DBD)  
**Pilar Del Pozo**, Spain
- P.777 Incidence of acute kidney injury following liver transplantation  
**Zeynep Ersoy**, Turkey
- P.778 Anesthesiologic management for multivisceral transplant: A case report  
**Aida Fernández García**, Spain
- P.779 Anesthetic management of renal and liver transplantation recipients during cesarean section  
**Zeynep Kayhan**, Turkey
- P.780 Perioperative predictors of acute kidney injury after liver transplantation and its impact on postoperative outcome  
**Cristina J. Lisbona**, Spain
- P.781 Determinants of one-year mortality in lung transplants recipients readmitted to intensive care unit  
**Judit Sacanell**, Spain
- P.782 Early postoperative acute kidney injury among pediatric liver transplant recipients  
**Pinar Zeyneloglu**, Turkey
- P.783 Renal replacement therapy for renal transplant recipients during ICU stay  
**Adnan Torgay**, Turkey

- P.800 Postoperative tracheal extubation after pediatric liver transplantation  
**Adnan Torgay**, Turkey
- P.801 Successful living donor liver transplantation in a case of mean pulmonary arterial pressure of 52 mmhg  
**Yang Won Yang Nah**, Korea
- P.802 Do we still need a veno-venous bypass service in liver transplantation? A survey of UK practice  
**Vivienne N. Hannon**, United Kingdom
- P.803 Preemptive chest tube in liver transplantation – an unconventional way to reduce morbidity  
**Leke Wiering**, Germany
- P.804 Effect of meal intake for evaluating hepatic artery by doppler ultrasonography in liver transplantation patients: Does fasting matter for screening hepatic artery due to hemodynamic changes in splanchnic circulation?  
**Nihal Uslu**, Turkey
- P.805 Impact of the donor age and comorbidities on graft survival after liver transplant due to hepatocellular carcinoma. Experience in 100 consecutive cases  
**Luis Alberto Martinez Insfran**, Spain
- P.807 Risk factors for graft steatosis after liver transplantation using controlled attenuation parameter measurements  
**James Fung**, Hong Kong
- P.809 Association between liver perfusate natural killer cellular subset from deceased brain donors and acute cellular rejection after liver transplantation procedure: Single center analysis.  
**Calogero Ricotta**, Italy
- P.810 Liver transplantation as a feasible and definitive treatment for advanced polycystic liver disease: Our experience and outcomes  
**Cristina Cobo**, Spain
- P.810a Implications of doppler alterations on outcomes after liver transplantation. Our experience in the last seven years  
**Cristina Cobo**, Spain
- P.811 Percutaneous transhepatic tips for Budd-Chiari syndrome: Direct simultaneous puncture of portal vein and inferior vena cava  
**Fatih Boyvat**, Turkey
- P.812 Post-liver transplant (LT) early allograft dysfunction (EAD) is associated with lack of post-LT renal recovery  
**Hani M. Wadei**, United States
- P.813 Sarcopenia no longer impacts survival after LDLT managed with early enteral feeding protocols but its postoperative prevalence is still significant  
**Riccardo Pravisani**, Italy
- P.814 Liver abscesses after liver transplantation  
**Isabel Lechuga Alonso**, Spain
- P.815 The influence of AbiGA antibodies as a vascular complication marker in liver transplantation  
**Isabel Lechuga Alonso**, Spain
- P.816 Clinical course of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation  
**Digdem Ozer Etik**, Turkey
- P.817 Malnutrition is associated with poor outcomes after liver transplantation: A promising target for pre-transplantation nutritional intervention  
**Su Kah Goh**, Australia
- P.818 Hepatic venous outflow obstruction after living-donor liver transplantation using right lateral sector graft  
**Rihito Nagata**, Japan
- P.820 Report of two cases of acute pancreatitis after liver transplantation for HCC  
**Qinfen Xie**, People's Republic of China
- P.821 C-reactive protein before liver transplantation is predictive of post-transplant mortality  
**Robert M. Jones**, Australia
- P.822 Successful treatment of a case of complex bile duct stones and gastrointestinal bleeding with liver transplantation and interventional radiology  
**Qinfen Xie**, People's Republic of China
- P.823 The experience of pseudoaneurysm rupture of the hepatic artery after living donor liver transplantation  
**Masashi Kadohisa**, Japan
- P.824 Percutaneous transhepatic portal vein angioplasty for portal vein stricture after living donor liver transplantation  
**Atsuyoshi Mita**, Japan
- P.825 Single center experience on the clinical course of hepatic artery thrombosis after living donor liver transplantation using right lobe  
**Ho Joong Choi**, Korea
- P.826 Comparable levels of inflammatory mediators in portal venous blood collected from organ donors donating after circulatory death and those donating after brain death  
**Janske Reiling**, Australia
- P.827 Long-term follow-up of patients with primary sclerosing cholangitis undergoing liver transplantation with duct-to-duct biliary  
**Bijan Eghtesad**, United States
- P.828 Comparison between cadaveric whole liver and live donor partial liver transplantation in high risk patients with MELD score more than 40  
**Chul Soo Ahn**, Korea
- P.829 Post liver transplant biliary complications and management in local university hospital  
**Tae-Seok Kim**, Korea
- P.830 A hundred experiences of liver transplantation in local university hospital  
**Tae-Seok Kim**, Korea
- P.831 Liver transplantation in patients with pre-existing portal vein thrombosis: Results of a single center  
**Sedat Yildirim**, Turkey
- P.833 Adherence of immunosuppression therapy and donor-specific anti-HLA antibodies in the pediatric liver transplant recipients  
**Atsushi Yoshizawa**, Japan
- P.834 The risk factors of post-transplant bacteremia in living donor liver transplantation  
**Masahiko Kubo**, Japan
- P.835 Influence of graft steatosis on the outcome of liver transplantation  
**Oana Anisa Nutu**, Spain
- P.836 Liver transplantation due to fulminant liver failure by heat stroke  
**Felipe Alconchel**, Spain
- P.837 Liver transplantation due to fulminant liver failure secondary to acute submassive necrosis in a patient treated with orlistat  
**Felipe Alconchel**, Spain
- P.838 Is hepatic flow a predictor of early allograft dysfunction in whole-graft deceased donor liver transplantation? An observational cohort study  
**Pablo Lozano**, Spain
- P.839 Long-term outcomes after stent insertion in patients with early and late hepatic vein outflow obstruction after living donor liver transplantation  
**Kyeong Sik Kim**, Korea
- P.843 The risk factors for portal vein thrombosis after living donor liver transplantation in adults  
**Shigehito Miyagi**, Japan



- P.844 MELD score predicts survival in patients treated with transjugular intrahepatic portosystemic shunt after liver transplantation  
**Magdalena Salcedo**, Spain
- P.845 Donor specific antibody negative acute antibody-mediated rejection under the low anti-ABO antibody titer after ABO incompatible liver transplantation: A case report  
**Boram Lee**, Korea
- P.846 Higher risk of post-transplant graft failure in male recipients of female donor grafts is not due to anastomosis mismatch  
**Kyo Won Lee**, Korea
- P.847 Liver transplantation outcomes after acute liver failure: Still some questions to be asked  
**Marina Pérez-Flecha González**, Spain
- P.847a Risk factors and consequences of ischemic cholangiopathy in liver transplantation from DCD Maastricht IIA  
**Marina Pérez-Flecha González**, Spain
- P.848 Propensity score matching analysis of post-transplant outcomes in living donor liver transplantation for obese recipients (BMI $\geq$ 30)  
**Chan Woo Cho**, Korea
- P.849 Liver transplantation as curative treatment in severe pulmonary hypertension due to hepatic vascular malformations in Rendu-Osler-Weber disease  
**Javier Martínez Caballero**, Spain
- P.850 Molecular adsorbent recirculating system support followed by liver transplantation for multiorgan failure from exertional heatstroke  
**Nicole M. Shockcor**, United States
- P.852 Actual outcomes and technical feasibility of living donor-related liver re-transplantation  
**Wan-Joon Kim**, Korea
- P.854 Liver transplantation in the adult following Kasai operation in infancy  
**Undine Gerlach**, Germany
- P.855 Incidence of biliary and arterial complications using liver grafts from 70 to 94 years old  
**Carlos M. Muñoz-Arce**, Spain
- P.855a Liver Transplantation Using Nonagenarian Liver Grafts  
**Carlos M. Muñoz-Arce**, Spain
- P.856 Liver transplantation in the treatment of neuroendocrine metastatic tumors: Our experience  
**Gabriel E. Gondolessi**, Argentina
- P.857 Applicability of liver transplantation for patients with acute on chronic liver failure  
**Valeria Descalzi**, Argentina
- P.858 DR-MELD: A new concept to predict graft survival after liver transplantation with aged donors  
**Carlos Jimenez**, Spain
- P.859 Morbidly obese patients awaiting liver transplantation. Sleeve gastrectomy: Safety and efficacy from a liver transplant unit experience  
**Alberto A. Marcacuzco Quinto**, Spain
- P.860 The analysis of pathological and serological findings in the long-term pediatric liver transplantation: The achievement of clinical operational tolerance  
**Atsushi Yoshizawa**, Japan
- P.861 Donor wound satisfaction after living donor liver transplantation in the era of pure laparoscopic donor hepatectomy  
**Jeong-Moo Lee**, Korea
- P.862 Comparative study of pure laparoscopic donor right hemihepatectomy and open donor right hemihepatectomy in patients with separate right anterior and right posterior portal veins  
**Jeong-Moo Lee**, Korea
- P.863 Volumetric reevaluation of liver left lateral segment donors, which had previously been incompatible with intraoperative weight findings  
**Mehmet Coskun**, Turkey
- P.865 Manual computed tomography liver volumetry: Can it be done faster?  
**Mehmet Coskun**, Turkey
- P.866 Outcome of left lobe living-donor liver transplantation in Tokushima  
**Satoru Imura**, Japan
- P.867 The impact of minimally-invasive open donor hepatectomy on outcomes in adult living donor liver transplantation  
**Yuji Soejima**, Japan
- P.868 The anterior sector venous outflow reconstruction using recipient's superficial femoral vein in adult right lobe living donor liver transplantation  
**Shigeyuki Kawachi**, Japan
- P.869 Simultaneous splenectomy is not recommended in living-donor liver transplantation  
**Nobuhisa Akamatsu**, Japan
- P.870 The result of weight reduction program and the risk factors for failed weight reduction in patient with fatty liver during living donor liver transplantation work up  
**Mira Jung**, Korea
- P.871 A comparison of hepatic artery reconstruction using a surgical loupe and operating microscope during living donor liver transplantation  
**Tae-Yoon Kim**, Korea
- P.872 The first case of pure 3D laparoscopic living donor hepatectomy in Kazakhstan  
**Yermakhan Assylkhanuly**, Kazakhstan
- P.873 Potential effect of using ABO-compatible living-donor liver transplantation  
**Eleazar Chaib**, Brazil
- P.874 Laparoscopic approach for living donor to paediatric liver transplantation. Experience of the first 7 cases in Spain  
**Irene Gomez-Luque**, Spain
- P.877 Right extended living donor hepatectomy for double portal vein graft (type D): A case report  
**Doojin Kim**, Korea
- P.878 Outcomes of ABO compatible and DSA positive living donor liver transplantation  
**Masahiro Shinoda**, Japan
- P.880 Anastomosis bile duct and portal anomaly in living donor liver transplantation  
**Kwangsik Chun**, Korea
- P.881 ABOi live donor liver transplantation for patients with single lymph node metastasis of hepatocellular carcinoma after hepatectomy  
**Geun Hong**, Korea
- P.882 Percutaneous biopsy of hepatocellular cancer using coaxial needle system and track cauterization to prevent bleeding and seeding  
**Fatih Boyvat**, Turkey
- P.883 Baskent University expanded criteria for hepatocellular carcinoma: The importance of the histopathological features as a part of the evaluation criteria for liver transplantation  
**Gonca Ozgun**, Turkey
- P.884 Advantage of early liver transplantation whenever hepatocellular carcinoma recurrence after primary liver resection  
**Kun-Ming Chan**, Taiwan
- P.885 Living-donor liver transplantation for hepatic epithelioid hemangioendothelioma with early recurrence in an adult: A case report  
**Kee-Hwan Kim**, Korea

- P.886 Blood transfusion as an independent risk factor for recurrence after hepatocellular carcinoma resection  
**Dongdo You**, Korea
- P.887 Preoperative prognostic nutritional index as independent predictor of overall survival on hepatocellular carcinoma after liver transplantation  
**María García-Conde Delgado**, Spain
- P.888 Analysis of differentially expressed proteins in hepatocellular carcinoma  
**Angeles Baquerizo**, United States
- P.889 Can biliary papillomatosis recur after liver transplantation in the absence of infiltrative carcinoma?  
**Carlos Jimenez**, Spain
- P.892 Impact of basiliximab induction in adult recipient survival at 60 months after liver retransplantation procedure: Single center experience  
**Calogero Ricotta**, Italy
- P.894 Liver biopsy results in potential donor evaluation in living related liver transplantation  
**Fatih Hilmioglu**, Turkey
- P.895 Successful treatment with direct-acting antiviral agents of hepatitis C in the setting of end-stage renal disease  
**Digdem Ozer Etik**, Turkey
- P.896 Efficacy and tolerability of direct-acting antiviral agents for hepatitis c virus infection in kidney transplant recipients  
**Fatih Hilmioglu**, Turkey
- P.897 Results from a long term histological follow up of de novo HBV-infection in liver transplant patients unrelated to HBV-reinfection and HBV-reactivation  
**Christine Hofer**, Germany
- P.898 Sofosbuvir plus velpatasvir combination therapy for recurrent hepatitis C infection after sofosbuvir plus ribavirin combination therapy in a liver transplant recipient  
**Yang Won Yang Nah**, Korea
- P.899 Surgical aspects of split liver transplantation  
**Sergey Gautier**, Russian Federation
- P.900 Successfully in situ right-left split liver transplantation: First report of in Argentina  
**Andres Fraile**, Argentina
- P.901 Pyloric artery to segment 4 artery vascular reconstruction, a novel surgical technique developed for donor safety after LLS hepatectomy, and now proposed for extended right lobe split grafts  
**Andres Fraile**, Argentina
- P.902 The changes of pediatric liver transplantation in Seoul National University Hospital according to the changes of allocation system  
**Ok-Kyung Kim**, Korea
- P.903 Establishing a porcine model of "Small for Flow Syndrome"  
**Maitane I. Orue-Echebarria**, Spain
- P.904 Performing a right hemihepatectomy sequentially after DDLT—The solution for a large-for-size graft during liver transplantation: Case report  
**Sung Eun Park**, Korea

[illegible]

Abbas, Abul K.....	435.1, 445.1	AlMeshari, Khalid Kam.....	604.2
Abbud-Filho, Mario M.....	419.9	Alobaidli, Ali A .....	593.2
Abrams, Peter I. ....	252.1	Alonso Guallart, Paula .....	503.4
Acosta, Fabio Ruben .....	P.312	Alonso Melgar, Ángel .....	P.736
Adam, Ibrahim.....	318.6, 520.4	Aloufi, Majed .....	P.366
Adenugba, Akinbami R.....	394.5, P.406	Alqasim, Khalid .....	P.079
Adey, Deborah .....	133.3, P.270	Alrukhami, Mona.....	232.2, 235.6
Adhikary, Sam R.....	495.3	Alvarez Marquez , Antonia.....	490.5, P.205
Agbor-Enoh, Sean .....	201.2	Alvarez-Casas, Josue .....	415.7, P.433
Aguado, Jose Maria.....	322.8, 461.2	Alvarez, Cristian M. ....	P.128
Agung Nugroho , Eriawan .....	P.011	Amer, Hatem .....	622.1
Ahmed, Ejaz.....	493.1, 590.8	Amin, Kavita.....	622.7
Ahn, Chul Soo.....	P.828	Anazawa, Takayuki .....	592.6
Aizner, Sigal.....	521.3, P.152	Andrade, Larissa Guedes da Fonte .....	P.644
Ajigboye, Mayowa Oyeniya .....	P.676	Andres, Ane M.....	P.513
Akad, Selin.....	P.485	Anjos Malheiro, Jorge .....	490.1
Akalin, Enver.....	418.7, 504.6	Arias-Cabrales, Carlos.....	322.3, P.002, P.207
Akamatsu, Nobuhisa.....	P.869	Arroyo Hornero, Rebeca C.....	424.6
Akcay, Sule .....	P.341, P.722	Arslan, Hande.....	P.380, P.381
Akdur, Aydinca.....	P.310, P.501	Arvelakis, Antonios .....	P.047a
Akimoto, Shuji .....	326.2	Asai, Tomoko .....	525.2
Akioka, Kiyokazu .....	P.068	Åsberg, Anders .....	326.9, 391.1
Akutsu, Naotake.....	P.080, P.639	Ascher, Nancy .....	234.6, 535.1, 535.2, .....535.5, 535.6, 575., 606.3, 635.3
Al Salmi, Issa .....	393.6, 491.1	Asena, Leyla.....	P.700, P.701
Al-Attar, Beshar .....	P.594, P.595	Ashwin, Monika .....	417.9, P.133
Al-Mousawi, Mustafa S. A. ....	491.4	Askar, Medhat .....	100.1, 100.2, 308.3, 328.1
Al-Mowaina, Sahar M.....	P.735	Assounga, Alain G .....	P.230, P.409
Alatič, Jan .....	620.4	Assylkhanuly, Yermakhan .....	P.872
Alconchel, Felipe.....	P.836, P.837	Attia, Ashraf Ali .....	P.342
Aleid, Hassan Ali .....	492.3, P.611	Aubert, Olivier .....	362.2, 419.2, 516.5
Alexander, Mariam P .....	621.1	Auñón, Pilar.....	302.2, P.119
Ali, Abeera .....	P.071, P.072	Avolio, Alfonso W.....	624.7
Alkadi, Mohamad M.....	493.6, P.345	Aytekin, Cuneyt.....	P.106, P.313
AlKendi, Fatima .....	P.237	Ayvazoglu Soy, Ebru H.....	415.3, 492.4
Allen, Richard D.M. ....	593.12	Azimzadeh, Agnes .....	526.2
Almela, Javier.....	422.8, P.680		

Aziz, Feroz.....	P.027	Bézie, Séverine .....	424.7
Baan, Carla C. ....	140.3, 330.1, 403.2, P.420	Bialek, Łukasz .....	P.621a
Babel, Nina.....	204.4	Bialobrzecka, Malwina .....	625.2, P.554
Bachul, Piotr J.....	325.3	Bisigniano IV, Liliana .....	397.5, P.604
Bagai, Sahil .....	P.348	Bitterer, Florian.....	304.5
Bagias, Georgios .....	522.2	Black , John T .....	393.2, P.138
Bagul, Atul.....	P.136, P.271	Black, Sally R.....	585.1, P.641
Balachandran, Yarl.....	392.4, 527.5	Boffa, Catherine .....	615.5
Balan, Satish .....	P.397	Bonisconti, Florencia .....	P.382
Ballesté, Chloe .....	422.5, 623.2	Borkar-Tripathi, Minal .....	316., 316.8
Balwani, Manish Ramesh .....	P.272, P.681	Borràs-Serres, Francesc E. ....	322.4
Banas, Bernhard .....	321.2	Bottino, Rita.....	407.2
Bansal, Aarushi .....	525.5	Bouatou, Yassine.....	301.1, 516.3
Baquerizo, Angeles.....	P.888	Boucault, Laetitia.....	626.4
Barahona, María J.....	P.462	Boyvat, Fatih .....	P.811, P.882
Baris, Zeren .....	P.737, P.738	Brasile, Lauren .....	523.4, 591.5
Barlow, Adam D.....	464.2, P.140, P.315	Braun, Hillary J.....	315.5, 615.6
Barten, Markus J .....	591.1, P.713	Brayman, Kenneth.....	318.4
Baskin, Esra .....	498.2, 498.3	Brayne, Adam .....	587.11
Bastien, Olivier OB.....	569.2	Brenner, Paolo .....	526.1
Basturk, Bilkay .....	P.401, P.402	Bromberg, Jonathan S. ..101.4, 320.9, 435.3, 586.8	
Belenko, Dmitri .....	623.3, P.126	Brosseau, Carole.....	303.2
Bell, Ruth D .....	519.5	Bruintjes, Moira H.....	319.4, P.065
Bellini, Maria Irene.....	133.1	Buchholz, Bettina .....	300.1, 399.3
Bello, Irene .....	621.5	Buchko, Max T .....	P.638
Bellón , Teresa .....	321.4	Buemi, Antoine .....	P.204
Belmar Vega, Lara.....	P.127	Bueno, Alba .....	423.9
Ben Abdallah, Taieb .....	P.219	Bugeja, Ann .....	P.087
Ben Fatma, Lilia.....	P.377	Bühler, Léo Hans .....	241.2
Benjamins, Stan.....	325.11, 502.2	Bul, Kim .....	P.242, P.242a
Berenguer, Marina.....	360.2	Burballa, Carla .....	P.291
Berger, Lea .....	P.560	Burdorf, Lars.....	395.2, P.522
Berglund, Erik.....	503.1	Burguete, Daniel.....	301.4
Berishvili, Ekaterine .....	592.4	Burlingham, William J .....	586.1
Bertani, Alessandro.....	621.6	Busque, Stephan.....	608.1
Bestard Matamoros, Oriol .....	465.2	Butala, Bina.....	624.3

Butte, Atul .....	630.1
Caicedo, Luis .....	P.740
Cakiroglu, Ahmet .....	P.608
Caliskan, Kenan .....	P.112, P.739
Calle Mafla, Oscar A.....	326.10, 400.6
Calvo Romero Sr., Natividad N.....	317.7, 317.8
Canaud, Guillaume .....	600.1
Canovai, Emilio .....	522.4, P.761
Cantaluppi, Vincenzo .....	402.6, 589.2
Cantarovich, Diego .....	325.9
Cao, Lu.....	605.5
Capobianco, Ivan .....	P.741
Capron, Alexander M .....	233.4, 234.5, 305.2
Carbone, Javier .....	326.7, 590.7, P.726
Carmona Jr., Marco Antonio.....	404.2, P.034
Carrillo Cobarro , María .....	393.3
Casillas Sagrado, Ester.....	P.016, P.167
Castillo, Solon .....	P.610
Cecka, J. Michael.....	604.3
Çevik, Ali.....	P.669
Chaib, Eleazar .....	P.873
Chan, Kun-Ming .....	P.575, P.884
Chanta, Gabriel E.....	P.171
Chapman, Jeremy R.....	100.3, 234.2, 308.2, 606.2
Chau, Ka Foon.....	120.4
Chen, Cheng.....	418.5
Cheng, Yu-Fan.....	560.1
Cherqui, Daniel .....	550.12, 560.2
Cherukuri, Aravind .....	318.1
Cheung, Chi Yuen Simon.....	585.2, P.683
Chew, Hong Chee .....	323.5, P.440
ChinHong, Peter V.....	321.6
Chiou, Fang Kuan .....	627.4, 627.5
Chittka, Dominik.....	316.1, 318.9
Cho, Chan Woo .....	P.383, P.848
Choi, Ho Joong .....	P.825
Chok, Kenneth Siu Ho.....	524.1
Chong, Anita .....	132.2
Christie, Emily .....	P.250
Chu, Simon N .....	403.3
Chuluyan, Eduardo.....	585.10
Chun, Kwangsik.....	P.880
Chung, Jeehye.....	P.618
Citores Sanchez, Maria Jesus .....	322.2, P.404
Citterio, Franco .....	391.6
Claas, Frans HJ.....	362.3, 375.1, 450.13
Clatworthy, Menna R.....	363.1
Clegg, Deborah J .....	350.9, 467.1
Cobo, Cristina .....	P.810, P.810a
Cobos, Marisa M .....	P.385
Coll, Elisabeth .....	593.8, 607.
Comas, Jordi.....	617.4
Concepcion , Waldo .....	521.2
Concors, Seth J .....	589.5, P.452
Conde -San Román, Patricia.....	P.430
Conkling, Nicole.....	592.5
Conrad, Anne .....	423.4
Contreras-Ruiz, Laura.....	520.3
Cooper, David K.C.....	240.1
Cornide Petronio, Maria Eugenia .....	P.442, P.443
Coronel, Maria M .....	494.1
Correa-Rocha, Rafael .....	404.1, 424.1
Coskun, Mehmet.....	P.863, P.865
Costa, Cristina.....	P.521
Cozzi, Emanuele E .....	407.1
Crespo Barrio, Marta.....	425.2
Crome, Sarah.....	103.3
Cross, Amy R.....	318.8, 586.6
Cruz Santiago, Jose .....	P.244, P.317
Cruzado, Josep M. ....	561.3
Cucchiari, David.....	620.5, P.362
Dafallah, Alaa A.S.E .....	525.6

Dai, Helong .....	418.9, 421.2
Danovitch, Gabriel .....	233.2, 235.7, 508.1, .....
.....	P.347, P.361
Darius, Tom.....	589.4, P.447
Dawson, Nicholas AJ .....	494.6
de Fijter, Johan W.....	420.5
de Gracia Guindo, María del Carmen.....	P.354
De La Mata, Nicole L.....	620.1
de Leur, Kitty .....	404.6
De Simone, Paolo .....	307.2
De Teresa Alguacil, Javier .....	P.164, P.165
de Vries, Aiko PJ.....	620.6
Dedinska, Ivana .....	502.1, P.157
Deeb, Maya .....	P.155
Del Pozo, Pilar .....	P.775, P.776
Delmonico, Francis L. ....	535.3
Deng, Shaoping .....	241.3
Denisov, Viktor .....	P.286
Descalzi, Valeria .....	P.857
Dhawan, Anil .....	202.2, 365.1, 450.5
DiChiacchio, Laura .....	526.5, P.523
Dipchand, Anne .....	272.1
Dittmer, Ian D.....	231.3
Dobbels, Fabienne .....	468.3, P.181
Döhler, Bernd .....	P.251
Dominguez-Gil, Beatriz .....	231.5, 234.3, 535.4, 567.2
Dominguez, Edward A.....	225.1, 510.5
Doricic, Julian.....	P.005, P.472
Drachenberg, Cinthia B.....	P.214
Dragun, Duska .....	401.2
Drogemuller, Chris J.....	P.547
Du Toit, Tinus .....	P.058
Du, Caigan.....	497.2
Duncan, Eleanor M.....	527.3
Durlik, Marek .....	P.559
Dursun Altinors, Dilek .....	P.702, P.703
Dzwonkowska, Sandra.....	P.086
Egawa, Hiroto.....	450.16, P.292
Egeland, Erlend J. ....	591.4, P.252
Eggenhofer, Elke .....	P.468
Eghtesad, Bijan .....	P.827
El-Agroudy, Amgad E .....	P.319, P.321
El-Kishawi, Abdullah.....	545.2
El-Serafy, Magdy .....	601.1
Elgin, Ersin .....	P.649, P.650
Elias, Sandra .....	P.293
Ellis, Ewa.....	151.2
Empson, Katja.....	410.1
Emre, Sukru H. ....	250.2, 253.2
Entwistle, Timothy R.....	323.7
Erdogan, Ilkay .....	P.715, P.716
Ericzon, Bo-Göran .....	618.4
Erllich, Gilad.....	466.2
Ersoy, Ozgur .....	323.3, P.717
Esquivel, Carlos O. ....	350.1, 361.2
Ezzahouri, Ikram .....	590.6, P.418
Fadhil Al Noaman, Riadh A.S. ....	233.3
Fakhro, Mohammed .....	615.1, 621.7
Faleo, Gaetano.....	589.1
Falk, Christine S.....	418.4, 467.3, P.412
Falletta, Calogero.....	326.3, 398.3
Famure, Olusegun .....	390.2, P.616
Farmer, Douglas G.....	627.3
Farouk, Samira.....	P.041
Feng, Sandy .....	607.2
Fernández García, Aida .....	P.778
Fernández, Ernesto J.....	P.226
Ferreira Centeno, Eugenia .....	P.274
Ferreras, David.....	500.5
Figurek, Andreja.....	588.6
Findlay, James.....	469.3, 550.7
Fink, Michael A .....	415.5, 515.2

Finotti, Michele .....	P.386
Fishman, Jay .....	104.1, 223.2, 550.8, 562.1
Florescu, Diana.....	224.5, 510.1, P.398
Foo, Fiona Chun Chi.....	P.172
Forsberg, Anna .....	307.3, 324.1, P.695
Foster, Bethany.....	467.2, 550.1
Fraile, Andres.....	P.900, P.901
Fraser, Campbell .....	397.1, 525.3
Friend, Peter J.....	335.3, 345.1, 450.11
Fu, Jianing .....	619.3, 619.4
Fujimoto, Keiichi.....	P.253
Fujiyama, Nobuhiro .....	P.232
Fukushima, Norhide.....	P.349
Fung, James .....	P.807
Furukawa, Hiroyuki .....	P.645
Gaber, A.Osama .....	P.052
Gaité, Luis .....	P.243, P.245
Gallinat, Anja .....	593.11
Galvan Espinoza, Luis Humberto.....	394.4
Galvao, Flavio H F .....	P.524, P.705
Gao, Ling .....	P.448
García Sr., Andrés M. ....	P.489
García-Conde Delgado, María .....	603.3, P.887
Garcia-Gallont, Rudolf .....	235.5
Garcia-Guereta, Luis.....	P.742
Garcia, Marta MG.....	588.7
Gardner, James .....	592.8
Gatius, Serena .....	P.191
Gautier, Sergey .....	415.12, P.899
Gawronska, Sylwia.....	P.677
Geissler, Edward K. ....	140.1, 430.1
Gelan , Engida Abebe.....	P.090, P.091
Gerlach, Undine.....	392.3, P.854
Ghita, Ryan .....	P.502
Ghobadi, Omid.....	324.2
Gilbo, Nicholas .....	400.3, P.413
Gill, John S.....	508.2, 600.3
Giordano, Talia.....	525.1
Girman, Peter .....	496.3
Girrita, Alin L .....	P.038
Glötz, Denis .....	516.2
Gochi, Mikako.....	P.634
Goekler, Johannes .....	P.721
Goffette, Pierre .....	601.2
Goh, Su Kah.....	420.7, P.817
Gołębiewska, Justyna E. ....	325.4, 396.3
Gomez Dos Santos, Victoria .....	322.6, 589.7, P.061
Gómez Massa , Elena.....	518.3
Gómez-Gavara, Concepción.....	400.2
Gomez-Luque, Irene .....	P.874
Gómez, Beatriz B.....	P.275, P.682
Gomis, Mar .....	398.6
Gondolesi, Gabriel E. ....	251.1, 399.4, 450.17, P.856
González Monte Sr., Esther .....	617.7
Gonzalez-Corvillo, Carmen .....	417.7
Gonzalez-Martinez, Francisco .....	324.7, P.675
Goodman, David J.....	326.5
Gorayeb-Polacchini, Fernanda Salomao .....	P.003
Goto, Ryoichi.....	586.3
Gozdowska, Jolanta .....	P.169
Gracious Sr., Noble.....	P.587
Greenberg, Rebecca.....	409.3, P.276
Grey, Shane T.....	140.4, 141.5, 509.3
Gries, Cynthia .....	406.1
Grossi, Paolo A. ....	223.4, 508.3
Gueler, Faikah .....	418.2, P.464
Guell, Marc .....	202.3, 509.1
Guerrero-Ramos, Felix .....	421.7, 617.1
Gulleroglu, Kaan .....	498.5, 521.6
Gunderson, Susan.....	410.2
Gurung, Binay.....	P.234, P.585
Gustavsen, Marte Theie .....	517.6, P.254

Ha, Jiye .....	P.124
Haase-Kromwijk, Bernadette B.J.J.M.....	410.3, P.083
Haber, Anna .....	P.047
Hacker, Karolin .....	P.265
Hakim, Nadey .....	588.3
Halden, Thea A. S.....	P.346
Halloran, Philip F.....	201.3, 323.2, 504.3
Hamaguchi, Yuhei .....	315.3
Hamar, Matyas.....	495.5, P.461
Hameed, Ahmer M .....	593.6, P.446
Hammad, Ehab H. ....	545.2, P.311
Han, Feng.....	502.3, P.055
Hannon, Vivienne N .....	P.802
Harden, Paul N .....	123.3, 627.7, P.287
Harris, David .....	234.7
Hasz, Richard.....	450.8
Hauet, Thierry .....	P.471, P.646
Haugen, Christine E .....	515.4, 617.5
Hawthorne, Wayne J.....	325.7, 566.2, 605.1
He, Bulang .....	419.3, P.116
Heim, Christian.....	520.6, 626.2
Hein, Rabea .....	P.525
Heleniak, Zbigniew .....	P.357, P.358
Hernandez-Fuentes, Maria P .....	394.1, 420.3
Hernandez, Francisco .....	408.3, P.743
Hester, Joanna .....	586.4
Hickman, Laura A. ....	587.1, P.647
Hidaka, Yuji .....	319.2
Hidalgo Montes, Inmaculada .....	P.763, P.765
Hilmioglu, Fatih .....	P.894, P.896
Hirano, Hajime .....	P.073
Hirsch, Hans H. ....	510.2
Ho , Ping-Chih .....	550.16, 563.2
Hofer, Christine .....	P.897
Holanda, Danni G. ....	625.1
Hollingshead, Joshua F .....	603.5
Holmström, Emil.....	P.131
Hong, Geun .....	P.881
Hoogduijn, Martin.....	405.1
Hoppe, John M.....	P.255
Hort, Amy .....	P.566, P.605
Hotta, Kiyohiko.....	503.6
Howson , Prue E .....	585.7
Hoyer, Dieter .....	321.7
Hrubá, Petra.....	P.032, P.423
Hsieh, Ming Hsin.....	P.691, P.692
Hsu, Bang-Gee .....	P.351
Hu, Min.....	626.6, P.545
Hua, Lina .....	P.088
Huang, Honglei .....	624.2
Hutchinson, James A.....	563.3
Hwang, Christine S.....	521.1, 603.6
Hyodo, Yoji.....	P.023
Iacob, Speranta .....	400.1, P.294
Ide, Kentaro .....	318.3
Iesari, Samuele .....	594.7
Ietto, Giuseppe .....	P.200, P.323
Iglesias Escudero, Maria.....	518.7, P.408
Iglesias Lozano, Marcos .....	320.8, 520.8
Ilagan, Bryan Christian Gaza .....	203.3, 475.2, P.201
Ildstad, Suzanne T.....	608.6, 619.1
Imperiali, Nora.....	P.050
Imura, Satoru .....	P.866
Iqbal, Masud M .....	P.690
Irefin, Samuel A .....	460.1
Irie, Rie .....	498.4
Irish, Georgina .....	P.029
Irure-Ventura, Juan .....	P.042a, P.295
Ishibashi-Ueda, Hatsue .....	P.723
Ishimura, Takeshi.....	P.084, P.145
Iskander, Renata.....	497.5
Issa, Fadi.....	141.4

Ito, Masahiro .....	P.504
Iwami, Daiki .....	425.7, 490.4
Iwasaki, Keiichiro .....	P.720
Iyer, Arjun .....	323.9
Jacobs Cachá Jr., Conxita .....	302.1
Jacquemont, Lola .....	320.4, 420.4
Jaeckel, Elmar .....	605.6, P.538
Jaiswal, Akhilesh Kumar .....	P.256
Janaudis-Ferreira, Tania ..	120.3, 122.3, P.120, P.277
Jang, Hyuk Jai.....	P.467, P.546
Janjic, Jelena M. ....	368.1
Janki, Shiromani.....	319.1
Janszky, Noémi .....	P.030
Jayasinghe, Kushani C.....	492.5, 492.6
Jeon, Hee Jung.....	P.424
Jeong, Hyeon Joo.....	401.7
Jiang, Wenshi .....	593.9, P.684
Jimenez Vera, Elvira .....	394.2, 498.6
Jiménez-Castro, Mónica B .....	P.441, P.636
Jimenez, Carlos .....	P.858, P.889
Jiménez, Carlos .....	P.365, P.648
Jin, Xi .....	395.6
Jones, Robert M .....	P.821
Jouve, Thomas .....	392.5, 423.12
Ju, Xiaobing .....	P.223
Jucaud, Vadim.....	423.10, P.296
Juega, Javier .....	P.062, P.149
Jung , Joo Hee .....	P.134
Jung, Mira .....	P.870
Junger, Henrik H. ....	P.298
Justo , Iago .....	519.2, 603.2
Kabei, Kazuya .....	P.480
Kadohisa, Masashi .....	P.823
Kafle, Mukunda Prasad .....	P.314, P.373
Kaido, Toshimi.....	350.2, 460.2
Kaisar, Maria .....	141.1
Kakizaki, Yuta .....	P.632
Kalisvaart, Marit .....	415.4, 618.3
Kamar, Nassim .....	220.1
Kamat, Pranitha J .....	320.6
Kaminski, Hannah .....	510.3
Kamo, Naoko.....	400.5
Kang, Hee Jung .....	395.1
Kapoor, Kunal .....	P.063
Kasimatis, Efstratios.....	P.308
Kaufman, Dixon B.....	503.2
Kawachi, Shigeyuki .....	P.868
Kawai, Tatsuo .....	503.5, 608.5
Kay, Thomas.....	509.2
Kayhan, Zeynep .....	P.110, P.779
Kearns-Jonker, Mary .....	523.1
Kelly, Patrick .....	625.6
Kenwar, Deepesh B. ....	590.12, P.668
Kern, Barbara .....	P.767
Kervan, Umit .....	P.727, P.728
Kette, Francis .....	325.8
Keung, Karen L .....	423.8
Key, Timothy .....	425.6
Kiberd, Bryce A .....	590.3
Kihara, Yu .....	P.075
Kim, Doojin.....	P.877
Kimball, Pamela M .....	P.299
Kimenai, Diederik H.J.A.N.....	P.208
Kirchner, Varvara A .....	500.6
Kirnap, Mahir .....	P.069, P.146
Knight, Richard J .....	318.7
Knoefel, Ann-Kathrin .....	520.5, P.453
Knoll, Gregory Alan.....	104.4
Kobayashi, Eiji.....	523.3
Koenig, Alice.....	320.2, 507.2
Kondi, Entela.....	422.4, P.278
Koo, Tai Yeon .....	617.2

Kornberg, Arno.....	300.6, 500.2
Korotkov, Sergey.....	424.4, 518.6
Kotenko, Oleg.....	415.8, P.744
Kotton, Camille.....	104.2, 222.1, 321.1, 450.12, 461.1, 475.1
Koulmanda, Maria .....	101.1, 150.1, 365.2, 450.6
Kousoulas, Lampros .....	P.161
Koyama, Ichiro .....	P.568
Kozaki, Koichi .....	P.316
Kramer, Cynthia SM .....	416.6
Krams, Sheri.....	423.2
Krishnan, Nithya S .....	402.3, 402.4
Krmpotic, Kristina.....	364.3
Kroemer, Alexander .....	367.1
Kubo, Masahiko .....	P.834
Kugiyama, Tota .....	499.3
Kugler, Christiane .....	307.1
Kühne, Louisa .....	P.475
Kumar, Anant.....	402.2, P.613
Kupeli, Elif.....	P.185, P.186
Kural Rahatli, Feride .....	P.108, P.327
kurihara, kei.....	P.153
Kurt Azap, Ozlem .....	P.388, P.389
Kusaka, Mamoru.....	P.577
Kusch, Angelika.....	494.4
Kute, Vivek.....	350.7, 506.1
Kwakkel-van Erp, Johanna M .....	524.6
Kwon, Jiyoun .....	P.686
Lacaille, Florence .....	408.4
Laflamme, Claude JA.....	122.1
Laguna Goya, Rocio.....	420.9
Lai, Ping Chin.....	P.378
Lakey, Jonathan.....	P.488
Lam, Avery J .....	101.3, 586.5
Lan, Liugen.....	587.10
Landin, Luis .....	622.5, P.704
Laucyte-Cibulskiene, Agne .....	P.018, P.609
Lauk-Dubitskiy, Stanislav .....	P.642
Lauronen, Jouni .....	425.8
Lavallard, Vanessa .....	325.2
Lavee, Jacob .....	233.1
Lawrence, Paula Y .....	P.280
Le, Tien Ngoc My.....	P.625, P.626
Lebreton, Fanny .....	396.4
Lechuga Alonso, Isabel .....	P.814, P.815
Leddington-Wright, Sheila.....	123.1
Lee, Boram .....	594.1, P.845
Lefaucœur, Carmen .....	301.3, 501.1
Legendre, Christophe .....	106.3, 600.2
Lehr, Liz .....	519.1
Lei, Wenhua .....	P.179
Lengele, Benoit .....	368.2
Leon, Luis R .....	P.196
Levings, Megan ..	100.1, 141.3, 200.1, 463.2, 475.1
Li, Chao .....	P.672
Liapakis , AnneMarie.....	253.1
Lim, Jeong-Hoon.....	516.6, P.017
Lineburg, Katie E.....	522.5
Ling, Qi .....	403.1
Linhares-Silva, Kamilla.....	590.4, P.231
Linkermann, Andreas .....	602.1
Lion, Julien.....	404.5
Liow , Natasha .....	521.4
Lisbona, Cristina J .....	P.780
Liu, Hongxia .....	324.4
Llinàs Mallol, Laura.....	517.2, 616.3
Lloberas Blanch, Nuria .....	P.241
Llore, Nathaly P .....	619.6
Locke, Jayme E.....	350.16, 587.4, 606.4, P.745
Loheac, Charlotte .....	516.1, 616.1
Loinaz, Carmelo .....	399.5
Lomero, Maria del Mar ML .....	603.1



López-Fraga, Marta .....	233.5, 466.3	Marcacuzco Quinto, Alberto A.....	P.556, P.859
López-Oliva, María Ovidia.....	P.001	Marco, Jaime .....	P.661
Lopez, Alexandre .....	P.466	Margeta, Ivan .....	401.4
López, Jaime .....	P.558	Margreiter, Christian .....	P.562
Lou-Meda, Randall .....	P.139, P.236	Marks, Stephen D .....	409.1, 450.9, 627.2, P.747
Loupy, Alexandre.....	316.2, 417.5, 462.2, 475.1	Marlais, Matko .....	627.6
Lozano, Pablo.....	P.673, P.838	Martin Moreno, Paloma Leticia.....	P.426
Lucas-Samuel, Sophie.....	221.3	Martin-Penagos, Luis.....	302.3
Lucia Perez, Marc .....	403.4	Martin, Dominique E. ....	102.4, 230.1, 232.1, .....234.1, 234.4, 235.8, 285.2
Luck, Nasir Hassan.....	493.4, 493.5	Martínez Caballero, Javier.....	P.849
Lukac, Jan.....	P.581	Martinez de la Maza, Lilia .....	315.8
Ma, Ka-Wing .....	415.1	Martinez Insfran, Luis Alberto .....	P.805
MacConmara, Malcolm .....	419.8	Martinez, Olivia M. ....	361.3, 392.1, 527.4
MacDonald, Peter S. ....	323.1, 326.12, 406.3	Marty, Francisco M .....	224.1, 510.4
Machaidze, Zurab .....	407.	Mas, Valeria R. ....	106.1
Maeda, Akira .....	P.529a, P.531	Massaad, Laurie.....	588.4
Magee, Ciara N. ....	P.197	Massie, Allan.....	319.8, 319.9
Mahanama, Adhyana I K.....	P.350	Matamoras, Amalia.....	231.7
Mahillo, Beatriz .....	322.9, 324.8, 593.10	Matas, David.....	491.3
Mahjoub Fituri, Omar .....	P.363	Matejak-Górska, Marta .....	P.567, P.569
Mai, Martin .....	P.074	Mateos Rodriguez, Alonso.....	P.586
Maldonado, Rafael A .....	P.010, P.623	Matesanz, Rafael .....	335.1
Malek-Hosseini, Seyed Ali .....	369.2	Mathes, David W. ....	622.2
Malinoski, Darren .....	505.1	Mathur, Sunita .....	120.2, 122.3, P.282, P.353
Maltais, Simon .....	550.5, 569.3	Matsunami, Masatoshi .....	504.4
Maluf, Daniel G.....	202.1, 593.1, P.450	Maus, Marcela V.....	435.2, 445.1
Mammadli, Mahinbanu .....	P.210	Mazariegos, George V. ....	272.2, 408.2
Man, Nancy Kwan.....	363.2	Mazo Torre Sr., Cristopher C.....	621.4
Manfro, Roberto C .....	588.9, P.060	Mbiribindi, Berenice .....	518.2
Mangus, Richard S .....	615.4, P.640	Mc Laughlin, Leah .....	519.3
Manickavasagar, Revathy .....	417.8	McAdams DeMarco, Mara Ann.....	417.2, 417.3, 468.1
Mannon, Roslyn B.....	100.4, 504.5, 568.1	McCluskey, James.....	366.2, 375.1
Manyalich, Martí.....	422.6, 505.3, P.688	McCulloch, Mignon .....	271.1
Manzia, Tommaso Maria .....	399.1, 594.5	McDonald, Stephen P.....	567.3
Mao Sr., Wenjun.....	587.12, P.732	McPherson, Marla C.....	392.2
Maraschio, Martin A.....	400.4		

McRae, Jennifer L.....	589.9	Montgomery, Robert A. ....	102.3, 362.1
McTaggart, Steven .....	627.1	Moon, In Sung.....	P.019
Medina-Polo, Jose .....	P.318, P.320	Mora, Jeffrey P .....	390.5, P.044
Mehrotra, Sonia .....	P.024, P.233	Morales-Barría, Jorge .....	324.5
Melandro, Fabio .....	415.9	Morales, Jose Maria .....	223.1, 421.9
Melilli, Edoardo .....	620.2	Morath, Christian.....	424.9
Melk, Anette .....	131.1, 306.3	Moray, Gokhan .....	P.199, P.746
Mengel, Michael .....	201.1	Moreira, Beatriz Robert .....	398.5
Messner, Franka .....	496.1	Morelli, Adrian E.....	602.2
Meyer, Jeremy .....	494.3	Moreno Salazar, Antonio S. ....	P.132
Mihara, Yuichiro .....	P.375	Moreno, Christophe .....	360.1
Miki, Toshio .....	151.3, 405.2	Moreso Mateos, Francesc .....	616.6
Miklušica, Juraj .....	P.206, P.591	Morris, Michele I.....	222.2
Miller, Amanda J.....	306.2, 519.4	Mosca, Irene.....	P.564
Milross, Luke .....	P.576	Mously, Alaa A.....	P.259
Min, Byoung-Hoon .....	605.2	Mróz, Julia.....	P.621
Miñambres, Eduardo.....	564.1	Mubarak, Muhammad .....	585.4
Minami, Koichiro .....	589.3, P.455	Mudalige, Nadeesha L .....	498.1
Minina, Marina .....	P.653	Muderrisoglu, Haldun .....	398.2, 588.12
Mir Sr., German A .....	P.094	Mulder, Evalyn E.A.P.....	319.6
Mita, Atsuyoshi .....	P.824	Muller, Elmi .....	223.5, 230.1, 231.1, .....234.1, 235.2, 235.8, 285.1, 305.1, 350.4, 635.2
Mitra, Palash.....	P.612	Mumford, Lisa L.....	317.2, 416.1
Miura, Kohei .....	396.2	Muñoz-Arce, Carlos M.....	P.855, P.855a
Miyagi, Shigehito .....	P.843	Muro, Manuel .....	P.403
Mlinšek, Gregor.....	425.1	Murphy, Barbara .....	561.2, 606.1
Modi, Pranjal.....	450.14, 588.8	Mustian, Margaux N. ....	515.6, 617.6
Mohiuddin, Muhammad .....	566.3	Nadjafi-Semnani, Mohammad .....	421.4, P.619
Mohsin, Rehan .....	P.077, P.078	Nagai, Shunji.....	522.6, 618.2
Moir, John .....	317.1, 325.12	Nagata, Rihito.....	P.818
Molina, Alicia .....	623.5, P.258	Nagral, Sanjay S.....	231.2, 305.3
Molmenti, Ernesto P .....	319.5, 416.4	Nah, Yang Won Yang.....	P.801, P.898
Monakhov, Artem .....	415.6	Naiman, Gerardo .....	521.5
Monbaliu, Diethard .....	123.2	Najafizadeh, Katayoun.....	623.4
Montanari, Elisa.....	494.2	Nakagawa, Thomas A. ....	P.582
Montero, Nuria .....	317.5, P.105	Nakamura, Yuki.....	P.007
Monteverde, Marta L .....	P.217		

Nakao, Toshimasa .....	418.8
Namba-Hamano, Tomoko.....	P.048
Nankivell, Brian J.....	224.2, 462.3
Naqvi, Anwar .....	321.8, P.615
Narvaez, Reinier .....	419.1, 519.6
Nashan, Bjoern .....	517.1, 591.6
Nathan, Howard M .....	364.2, 375.1, 450.8
Navarro, Aurora.....	623.7, P.395
Negi, Sarita.....	585.6
Nemeth, Endre .....	624.1
Nemetova, Lenka.....	324.3
Neri, Flavia.....	423.7, 586.9
Neumaier, Carolin .....	P.714
Ng, Zi Qin .....	588.5, P.324
Nian, Yeqi.....	391.5, 591.8
Nickerson, Peter W. ....	102.2
Nie, Wei .....	396.5
Niemann, Claus .....	350.6, 364.1, 607.1, 607.3
Nikolaïdis, Christos.....	P.175, P.202
Nikoueinejad, Hassan.....	P.419
Niño-Murcia, Alejandro .....	350.17, 422.1
Noguchi, Yuki.....	P.748
Noppakun, Kajohnsak .....	421.8
Nordheim, Espen .....	P.557
Norton, Susana M.....	P.059, P.156
Novotny, Marek.....	501.4
Núñez, José Ramón .....	221.5, 234.8
Nutu, Oana Anisa .....	496.5, P.835
O'Connell, Philip J.....	235.1
O'Donoghue, Katriona JM .....	P.158
O'Meeghan, Rosemary.....	P.667
Ochando, Jordi .....	105.3, 463.1, 550.9
Ock, Sun A. ....	P.505
Oetting, William S.....	316.5
Ogasawara, Hiroyuki.....	424.8, P.506
Okumi, Masayoshi .....	P.352
Oniscu, Gabriel C.....	550.11, 564.2, 618.1
Ono, Minoru .....	323.8
Opdam, Helen I.....	221.4, 607.
Oppenheimer, Federico .....	591.2
Orlando, Giuseppe .....	204.3, 421.1
Orlowski, Jeffrey P.....	397.3
Orue-Echebarria, Maitane I. ....	P.903
Osickova, Klara .....	502.4
Ostrowski, Marek.....	623.6, P.694
Otani, Masahide .....	P.633
Otto, Natalie .....	317.6, 492.1
Ozcay, Figen.....	P.749, P.750
Ozdemir, Handan.....	301.6, 501.3
Ozer Etik, Digidem.....	P.816, P.895
Ozgun, Gonca.....	594.6, P.883
Padilla, Benita .....	231.6, 235.3, 466.1
Panisello Rosello , Arnau .....	P.449
Papalois, Vassilios .....	133.2
Papas, Klearchos K.....	150.2
Parikh, Geeta P.....	624.5
Park, Hyung Sub .....	P.326
Pascual, Julio.....	450.19, 587.7, 591.9
Pastor Ludeña II, Ana Cecilia .....	P.664
Patel, Mohan .....	391.2, P.532
Pathak, Shiva.....	325.6, P.549
Paugam-Burtz, Catherine .....	350.3, 469.1
Pava Acosta, Helen Dayan .....	P.281
Paz-Artal, Estela.....	105.4
Pazik, Joanna.....	P.014, P.113
Peng, Chuanhui .....	P.410
Peralta, Carmen.....	101.2, 335.2
Pérez Redondo , Marina .....	593.5
Pérez-Flecha González, Marina.....	203.2, 375.3, P.847, P.847a
Perrottet, Nancy.....	391.3
Peters, Fleur S .....	420.8, P.478

Petruzzo, Palmina.....	423.6
Pettigrew, Gavin.....	103.1, 105.2
Pettinato, Giuseppe .....	151.1
Pham, Tung Thanh .....	592.3
Phonphok, Korntip .....	590.10, 620.7
Piemonti, Lorenzo.....	464.3, 550.15
Pineda, Silvia .....	318.2, 417.6
Pletkova, Aneta .....	P.407, P.428
Polanco, Natalia I.....	493.3, 585.11
Pool, Merel B.F. ....	P.637
Portero, Isabel .....	450.19
Portoles Sr., Jose .....	317.4
Pouch, Stephanie .....	223.3, 225.3
Powell, Jonathan.....	550.2, 563.1
Pravisan, Riccardo.....	P.813
Pregno, Carlos E.....	P.617
Preka, Evgenia .....	P.036
Prosser, Amy C .....	518.5
Pucci Molineris, Melisa E.....	522.1
Qiang, Zhao .....	415.10
Qin, Ke .....	419.5
Queipo, Gloria.....	504.1
Rademaker, Erika.....	P.589
Radisic, Marcelo V.....	590.2
Ragavan, Aaraby.....	P.724
Rahamimov, Ruth.....	517.4, P.328
Rahmel, Axel .....	235.4, 607.
Raimondi, Giorgio .....	204.1, 423.5, 622.6
Rajalingam, Raja .....	417.1, 425.9
Ramasamy, Dheepa.....	P.239
Ramilyeva, Indira.....	P.117
Ramirez , Patricia .....	P.045
Ray, Deepak S.....	P.629
Rayat, Gina R. ....	592.7
Reddy, Verushka .....	P.008
Reed, Elaine F .....	P.415
Reiling, Janske .....	P.826
Reinders, Marlies E.J. ....	623.1
Reinke, Petra.....	309.2
Reischig, Tomas.....	P.193
Ren, Dewei.....	593.7
Reyes-Acevedo, Rafael.....	231.4
Reyna, Gerardo.....	122.2
Reyneke, Maryn .....	P.178
Reznik, Oleg .....	525.4, P.283
Riad, Samy M.....	325.5
Ricotta, Calogero .....	P.809, P.892
Rijkse, Elsaline .....	P.160
Riquelme, Paloma .....	304.2, 304.3
Ritschl, Paul Viktor .....	515.5
Rivelli, Gabriel G. ....	P.330
Rivera Baquero Sr., Jairo Eduardo .....	P.751, P.753
Rizvi, Adibul Hasan.....	369.1, 450.10
Robbins, Nicholas L.....	P.456
Robinson, Lisa A.....	130.2
Rodriguez Cetina Biefer, Hector .....	518.4
Rodriguez Gayo, Lucia C.....	P.035
Rodriguez-Barbaso , Jose Ignacio .....	P.432
Rodriguez-Cubillo, Beatriz .....	302.4, 616.5
Rodríguez-Ferrero, Maria Luisa.....	P.227, P.229
Roh, Young-Nam .....	P.584
Rojas, Luis D.....	P.670, P.671
Roll, Garrett R .....	315.7, 416.3
Rosales, Brenda M .....	302.5, 585.3
Rosello-Catafau, Joan .....	P.451
Rostaing, Lionel.....	350.5, 465.3, 475.1
Rovira, Jordi .....	P.098, P.635
Rubbia-Brandt, Laura .....	601.3
Rubic-Schneider, Tina .....	P.474
Ruiz Hernández, Mercedes M.....	P.144, P.593
Ruiz Martínez, Lara.....	322.7
Ruiz, Juan Carlos.....	P.260

Rumbo, Martin .....	320.5, 367.3, P435
Ryu, JungHwa.....	P.729
Sabek, Omaina M.....	P.552
Sacanell, Judit.....	P.781
Sahara, Hisashi.....	589.6, 621.2
Sahin, Feride I.....	P.425
Sainz Barriga, Mauricio .....	P.168
Saito, Yu.....	P.507
Sakai, Ken.....	P.221
Salcedo, Magdalena .....	P.844
Sampaio De Almeida, Dayana.....	P.391
San Segundo, David.....	425.4, P303
Sánchez Ibáñez, Jacinto.....	587.9
Sancho Calabuig , Asuncion .....	P.012, P013
Sandal, Shaifali.....	102.1, P.004, P.465
Santiago, Jose Luis .....	P.115, P.224
Saparbay, Jamilya.....	518.1
Sapir-Pichhadze, Ruth.....	306.1
Sarier, Mehmet .....	390.3
Sarmiento, Elizabeth .....	P.416, P.725
Sarwal, Minnie M.....	106.2, 350.18, 401.1, 420.1
Sasaki, Hitomi.....	P.332
Saudek, Frantisek .....	365.3, 450.3
Sawinski, Deirdre .....	416.2, 497.1
Sawitzki, Birgit .....	140.2, 200.3, 205.4
Sayin, Burak .....	P.111, P.222
Scemla, Anne .....	527.1
Schenker, Peter.....	517.3
Schiavelli, Ruben O .....	P.288, P.334
Schick, Liz.....	121.2, 445.2
Schinstock, Carrie A.....	501.2
Schneeberger, Stefan.....	568.3
Schuetz, Christian.....	318.5
Schumacher, Katharina J .....	319.7
Schuster, Antonia M.....	P.473
Scobie, Linda.....	240.4
Segev, Dorry .....	205.2, 550.3, 630.2
Seija Il, Mariana A.....	P.151, P.414
Sekijima, Mitsuhiro .....	593.4
Sekowska, Marta .....	P.121
Sellers, Marty T .....	419.7
Seneviratne, Lasantha L N.....	587.6, P.284
Seng, Nina .....	P.580
Seo, Jinwoo .....	P.579
Serra, Nuria.....	394.3, P.142
Serrano Blanco, Manuel .....	421.5, 421.6
Sewpaul, Avinash.....	P.508
Sezgin, Atilla .....	P.718, P.719
Sfriso, Riccardo.....	395.3, P.534
Shabaka, Amir.....	527.6
Shah, Pankaj R.....	P.400
Shaheen, Faissal .....	P.599
Shahrestani, Sara .....	496.6
Shapiro, Ron.....	390.6, 562.3, 626.5, P.028
Sharma, Akhil .....	316.6, P.240
Shcherba, Aliaksei .....	523.6, 618.5
Shelton, Brittany A .....	319.3, P.130
Shevchenko, Alex O .....	620.3, P.711
Shimada, Mitsuo .....	495.4
Shimamura, Masako .....	527.2
Shimata, Keita .....	P.509
Shimizu, Akira .....	240.2
Shin, Jun-Seop .....	P.533
Shinoda, Kazunobu .....	P.463
Shirwan, Haval.....	520.1
Shockcor, Nicole M .....	622.3, 622.4, P.850
Shoji, Jun .....	616.2
Shroff, Sunil.....	491.2, 491.6
Siemionow, Maria .....	589.8, P.483
Sierra Parraga, Jesus M.....	424.3, P.482
Silva e Silva, Vanessa.....	P.662, P.663
Silveira, Pablo A .....	619.5, P.261

Simonenko, Maria M.....	398.1, P.710
Singh, Avneesh .....	P.535
Sirigu, Angela.....	368.3
Sitorabonu, Gulshanova F .....	P.089
Sivanathan, Kisha N.....	P.510
Siyoun, Mekdim Tadesse.....	P.170
Skuk, Daniel .....	P.484
Slatinska, Janka .....	501.5
Snanoudj, Renaud .....	425.3, P.305
Snell, Gregory .....	550.6, 564.3
Sobrino-Marquez, Jose Manuel .....	P.712
Soejima, Yuji.....	P.867
Soler Pujol Sr., Gervasio .....	P.037
Song, Alice .....	224.4, 225.2
Sosa, Rebecca A .....	524.3
Sran, Harkiran .....	P.143
Stern, Jeffrey M.....	496.4, P.555
Sterneck, Martina .....	618.6
Stervbo, Ulrik.....	203.1, 375.2
Stock, Peggy .....	150.3
Stoma, Igor .....	P.393
Strassburg, Christian P.....	350.13, 460.3
Suah, Ashley N.....	303.4
Suarez-Alvarez, Beatriz.....	591.3
Sugahara, Yzumi.....	P.511
Suh, Kyung-Suk.....	315.4, 350.12, 560.3, 635.4
Šulc, Snježana.....	P.101
Surowiecka-Pastewka, Agnieszka.....	P.563, P.565
Süsal , Caner .....	250.1, 550.4, 567.1
Suthanthiran, Manikkam.....	561.1
Swain, Sharon .....	505.2
Sykes, Megan .....	103.4, 303.6, 366.1, 450.1, 608.2
Sypek, Matthew P.....	P.211
Tadokoro, Akira.....	P.216
Taguchi, Kazuhiro.....	594.8
Takahashi, Hiroyuki.....	592.9
Tanaka, Asuka .....	619.7
Taner, Timucin.....	565.3
Tang, Qizhi .....	141.2, 363.3
Taniguchi, Shunri .....	P.590
Tasaki, Masayuki.....	P.033
Taubert, Richard.....	594.2, 594.3
Tector III, Alfred J.....	204.2, 566.1
Tedesco Jr, Helio S.....	309.1
Teegen, Eva M.....	321.5
Tennak, Vladimir.....	P.141, P.238
Teo, Rachel.....	390.1
Terron, Christel.....	P.598
Terzi, Aysen .....	323.6, 401.8
Thai, Sam Minh.....	P.093, P.176
Thaunat, Olivier .....	105.1, 366.3
Theodoropoulos, Nicole M. ....	221.1, 321.9
Thomas, Chris .....	120.1, 121.1, 123.4
Thomson, Angus W.....	424.5
Tian, Puxun.....	616.7, P.213
Tinckam, Kathryn .....	604.1
Tinti, Francesca.....	618.7
Toki, Daisuke.....	P.051
Tokodai, Kazuaki.....	400.7, 495.1
Toledo, Dorian H.....	P.147
Tollerud, David.....	608.4, P.262
Tomoaki, Iwai.....	P.225
Tong, Allison.....	326.4, 397.6, 568.2, P.182
Tönshoff, Burkhard.....	270.1, 409.2
Torai, Shinji.....	P.578
Torgay, Adnan .....	P.783, P.800
Torres, Clarivet .....	522.3
Tort Bardolet, Jaume.....	P.596
Trentadue, Julio J.....	P.752, P.769
Trompeta, Joyce A.....	254.1
Troppmann, Christoph.....	419.6
Trotter, Patrick B.....	419.4, 492.2

Trujillo, Hernando .....	416.9, P.665	Vila-Santandreu, Anna .....	P.755
Tsirulnikova, Olga .....	590.5	Vileito, Alicija .....	P.657
Tullius, Stefan G. ....	132.3, 418.3, 450.4, 562.2, .....626.1, 635.1	Villar-Arias, Alicia .....	P.597
Twombly, Katherine.....	P.754	Vinaixa, Carmen .....	300.4
Uchida, Junji .....	P.235	Vincenti, Flavio .....	465.1
Uematsu, Satomi Suzuki .....	325.1	Vionnet, Julien .....	P.264
Ueno, Takehisa.....	315.6, 399.2	Visser, Isis J .....	390.4
Ulu Öztürk, Funda .....	415.2, P.096	Visseren, Thijmen .....	P.487
Ulyanova, Olga.....	P.512	Vittoraki, Angeliki.....	P.307
Unterrainer, Christian .....	302.6, 550.4	Vogelfang, Horacio.....	P.756
Urbanellis, Peter.....	593.3, 615.3	Voglova, Barbora .....	P.561
Ushiro-Lumb, Ines .....	393.4, 590.9	von Websky, Martin W .....	367.2
Uslu, Nihal .....	P.107, P.804	Vučur, Ksenija .....	P.009
Ussif, Amin M .....	326.6	Wadei, Hani M .....	P.812
Utrero-Rico, Alberto .....	518.8	Wakabayashi, Taiga .....	415.11
Uva, Pablo D.....	625.3	Waller, Karen .....	590.1
Uwechue, Raphael .....	402.7	Walsh, Grainne M.....	361.1
Uysal, Cagri A .....	P.340, P.707	Wang, Benny .....	300.2
Valentin, Maria Oliva .....	402.1, 490.3	Ward, Casey J .....	496.2, 592.1
Valero, Rosalia .....	P.336	Watanabe, Hironosuke .....	526.3, 605.4
Van Assche, Kristof .....	491.5	Waterman, Amy .....	422.7, 524.4
van Besouw, Nicole M.....	403.5	Watson, Alicia R.....	320.3
van den Berg, Tamar A.J.....	421.3, P.125	Webster, Angela C.....	397.4
van den Hoogen, Martijn W.F.....	591.7	Weimer, Rolf .....	316.7
van der Zwan, Marieke .....	326.1, 403.7	Weinstock, Jan L .....	P.285
Van Gelder, Teun .....	106.4	Werlin, Evan C .....	588.1
Van Raemdonck, Dirk.....	406.2	West, Lori J .....	130.1, P.304, P.411
Vanhove, Bernard .....	103.2	Wiering, Leke .....	515.3, P.803
Vazquez, Teresa .....	322.1, 423.11, P.266	Wigfield, Christopher .....	255.1, 550.14, 569.1
Vela, Maria.....	619.2	Wisel, Steven .....	523.5
Venema, Leonie H.....	P.459	Wohlfahrtova, Mariana.....	504.2
Ventura-Aguiar, Pedro .....	625.4, 625.5	Wolf, Eckhard .....	241.1
Verma, Nirupama D .....	404.4	Wolfe, Cameron.....	221.2, 510.6
Vianna, Rodrigo.....	408.1	Womer, Karl L.....	P.190
Vidal Campos, Silvia.....	393.1, 461.3	Wong, Germaine .....	104.3, 131.2, 350.8, 462.1
		Woodle, E. Steve .....	309.3, 350.14

Woodside, Kenneth J. ....	422.2	Zeyneloglu, Pinar .....	398.4, P.782
Wordsworth, Matthew .....	P.469	Zeytinoglu, Meltem .....	565.1
Wright, Charles E .....	587.8	Zhang, Jialin .....	396.6, P.006
Wu, Huiling .....	586.7	Zhao, Yuanfei.....	391.4, 608.3
Xie, Qinfen .....	P.820, P.822	Zheng, Shusen.....	360.3
Yamada, Kazuhiko .....	407.3, 526.4	Zieliński, Maciej.....	303.5, 321.3
Yamamoto, Shinji .....	587.3	Zor, Fatih.....	423.1, 507.1, P.536
Yamashiki, Noriyo.....	499.1	Zuber, Julien .....	602.3
Yang, Cheng.....	516.4, P.427	Zuckermann, Andreas .....	323.4
Yanishi, Masaaki.....	P.173	Zulkarnaev, Aleksei B. ....	425.5, 502.6
Yao, Ming Han .....	494.5, P.551		
Yarbug Karakayali, Feza .....	P.066, P.067		
Yee, Seow Yeing .....	P.228		
Yeh, Heidi.....	407.		
Yeo, Sangmok.....	P.123		
Yeung, Andrew .....	P.643		
Yew , Shiong .....	401.3, 616.4		
Yildirim, Sedat.....	P.150, P.831		
Yildiz, Abdulmecit.....	524.2, P.392		
Yokoyama, Naoki .....	587.5		
Yolcu, Esma S.....	320.1, 626.7		
Yoon, Sojeong .....	P.757		
Yoshida, Kazunari.....	P.114		
Yoshikawa , Mikiko.....	401.5		
Yoshikawa, Yuki .....	324.6		
Yoshimoto, Syhei.....	497.3		
Yoshizawa, Atsushi .....	P.833, P.860		
You, Dongdo .....	P.886		
Young, Karl K .....	469.2		
Yuan, Xiao-Peng .....	585.9, P.049		
Yun, Ik Jin .....	395.4, P.660		
Zafar, Mirza Naqi .....	P.302		
Zahar, Jean Ralph .....	224.3		
Zaky, Ziad .....	585.8		
Zanetti, Helen K.....	P.369, P.371		
Zawierucha, Jacek .....	P.100, P.103		